VIOLIN: Vaccine Investigation and Online Information Network

Brucella spp.

Table of Contents

General Information
Vaccine Related Pathogen Genes
1. RL3382
2. sadfasfd
3. surA test
4. bcsp31 from Brucella (Other)
5. cp24 from Brucella melitensis (Other)
6. groEL from Brucella abortus (Other)
7. RpsL (Other)
8. AsnC (Protective antigen)
9. B. abortus strain 19 L7/L12 (Protective antigen)
10. B. melitensis M5 P39 (Protective antigen)
11. BAB1_0278 (Protective antigen)
12. BCSP31 (Protective antigen)
13. Bfr from B. abortus S19 (Protective antigen)
14. Bfr from B. melitensis biovar Abortus 2308 (Protective antigen)
15. Bp26 (Protective antigen)
16. cobB (Protective antigen)
17. DnaK (Protective antigen)
18. Gap (Protective antigen)
19. IalB (Protective antigen)
20. L7/L12 (Protective antigen)
21. Omp16 (Protective antigen)
22. omp16 (Protective antigen)
23. Omp19 (Protective antigen)
24. Omp25 (Protective antigen, Virmugen)
25. Omp31 (Protective antigen)
26. omp31 (Protective antigen)
27. ORF (Protective antigen)
28. P39 from Brucella abortus (Protective antigen)
29. PALFn (Protective antigen)
30. RplL (Protective antigen)
31. SodC from B. abortus strain 2308 (Protective antigen)
32. SurA (Protective antigen)
33. Tig (Protective antigen)
34. asp24 (Virmugen)
35. bp26 (Virmugen)
36. exsA (Virmugen)
37. manA (Virmugen)
38. manB (Virmugen)
39. mucR (Virmugen)
40. omp31 (Virmugen)
41. pgk (Virmugen)
42. pgm (Virmugen)
43. purE (Virmugen)
44. purK (Virmugen)
45. virB2 (Virmugen)
46. VjbR (Virmugen)
47. vjbR (Virmugen)
48. znuA (Virmugen, Virmugen)
Vaccine Related Host Genes
1. ANXI
2. BAK1
3. Ccl2
4. Ccl3
5. Cxcl10
6. Cxcl9
7. Ifng (Interferon gamma)
8. IgG
9. Ighg1
10. Ighv1-9
11. Il10 (interleukin 10)
12. Il12b
13. Il18
14. Il2
15. Il4 (interleukin 4)
16. Il5
17. SIGLEC10
18. TLR10
Vaccine Information
References

I. General Information

1. NCBI Taxonomy ID:

234

2. Disease:

Brucellosis

3. Introduction

Brucella species are gram-negative, facultative intracellular bacteria that cause brucellosis (or called Malta fever, undulant fever, Bang's disease, Mediterranean fever ) in humans and a variety of animals (Corbel, 1997). B. melitensis, B. abortus, B. suis, and B. canis are pathogenic to humans. The first three species have been identified as priority agents amenable for use in biological warfare and bio-terrorism, and are listed as NIAID and CDC category B priority pathogens. To date, there is no safe, effective Brucella vaccine available for human use. The vaccine strains used in animals are considered to be too virulent and unsafe for humans (Schurig et al., 1991). Novel vaccines that are non-infectious to humans but effective in stimulating a broad protective immune response are needed.

4. Microbial Pathogenesis

The mechanism of Brucella pathogenesis and infection of natural animal hosts is not completely understood (Corbel, 1997). It is well accepted that its pathogenesis relies on its ability to live and replicate inside the vacuolar phagocytic compartment of macrophages (Kohler et al., 2002). The host macrophage-Brucella interaction is critical for establishment of chronic Brucella infections. The Type IV secretion system encoded by the virB operon and the two-component regulatory system encoded by the bvrRS operon are required for successful replication of Brucella in macrophages. Smooth Brucella strains with intact lipopolysaccharide (LPS) O-side chains are virulent and invade macrophages through lipid rafts. On entry into the macrophage, Brucella reside in an acidified compartment that fuses with components of the early endosomal pathway. The majority of Brucella die at the early infection stage. A subpopulation of virulent Brucella strains is trafficked to an intracellular compartment known as the replicative phagosome (brucellosome) through continual interactions between the Brucella-containing vacuoles and the endoplasmic reticulum of the host macrophages. Once inside the replicative phagosome, Brucella are resistant to further attack and rapidly propagate. Virulent Brucella also inhibit macrophage apoptosis that in turn favors pathogen survival and replication. Brucella also infects placental trophoblast cells where acute infection leads to abortion and disease transmission (Roop et al., 2004).

5. Host Ranges and Animal Models

Brucella has a broad host range infecting vertebrate animal species and humans. Brucella infections are most often identified in humans, cattle, swine, goats, sheep, deer, caribou, elk, dogs and coyotes. There are six Brucella species based on the preferential host specificity: B. melitensis (goats), B. abortus (cattle), B. suis (swine), B. canis (dogs), B. ovis (sheep) and B. neotomae (desert mice). The first four species are pathogenic and exhibit a decreasing order of severity in humans. Therefore, brucellosis is a zoonotic disease (Corbel, 1997). Mouse models are often used in Brucella vaccine research. BALB/c and C57BL/10 mice differ in their abilities to induce immune responses and protection against virulent Brucella infections (Fernandes et al., 1996; Li, 1991; Montaraz et al., 1986).

6. Host Protective Immunity

Both humoral and cell-mediated immune responses can influence the course of a Brucella infection, cell-mediated immune responses are essential for clearance of intracellular Brucella (Schurig et al., 2002).

II. Vaccine Related Pathogen Genes

1. AsnC

Gene Name : AsnC
Sequence Strain (Species/Organism) : Brucella abortus 2308
NCBI Gene ID : 3788213
NCBI Protein GI : 489054600
Locus Tag : BAB_RS24000
Genbank Accession : JMRZ01000003
Protein Accession : WP_002964767
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 1633929
Gene Ending Position : 1634399
Gene Strand (Orientation) : -
Protein Name : ArsR family transcriptional regulator
Protein pI : 5.32
Protein Weight : 15857.78
Protein Length : 156

DNA Sequence : Show Sequence

>NC_007618.1:1633929-1634399 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
TCTAACGCCCATCCAGCGGGACGGCTGTGGTGTCCTTGATCTCTTCCATCACGAAAGAGGCCGATACATC
CGATAGCGGTACACAGGCTATGAGGCGCTGGTAGAGCCGGTCATAAGCTCTGACATCGGAAATGCGTGCC
TTCAGCACATAGTCCAGATCGCCGGTCATGCGATAGGCGCCGACGATTTCCGGGAAGCGAGCCACGGCAG
CGCGGAATTTGTTCAGCCATTCGGGATCATGGGCGGAGGTGCGCACCAGAATGAAAACCGAGAGGCCATA
GCCGACCATTTCCGCATCCACCAGCGCCACGCGACCTTTGATGACGCCATCGTCTTCCATGCGCTTTACG
CGCCGCCAGCAGGCATTGCGCGAAAGATTCACCCGTTCGGAAAGGGAATCAACCGACAAAGTGCCGTCGT
TTTGCAACTCAGCCAGGATTTTTCGGTCTATATCGTCCATAGATGCTGTCA

Protein Sequence : Show Sequence

>WP_002964767.1 MULTISPECIES: Lrp/AsnC family transcriptional regulator [Brucella]
MTASMDDIDRKILAELQNDGTLSVDSLSERVNLSRNACWRRVKRMEDDGVIKGRVALVDAEMVGYGLSVF
ILVRTSAHDPEWLNKFRAAVARFPEIVGAYRMTGDLDYVLKARISDVRAYDRLYQRLIACVPLSDVSASF
VMEEIKDTTAVPLDGR

Molecule Role : Protective antigen
Molecule Role Annotation : Mice given BAB1_1688 (AsnC) plus adjuvant could provide protection against virulent B. abortus infection, similarly with the known protective antigen Cu-Zn SOD and the license vaccine S19 (Fu et al., 2012).
Related Vaccine(s): Recombinant B. abortus AsnC protein with CFA/IFA adjuvant

2. asp24

Gene Name : asp24
NCBI Nucleotide GI : 2352999
NCBI Protein GI : 2353000
Protein Accession : AAB69346.1
Other Database IDs : CDD:151121
Taxonomy ID : 235
Gene Strand (Orientation) : ?
Protein Name : acid shock protein
Protein Length : 184
Protein Note : Secreted protein acidic and rich in cysteine Ca binding region; pfam10591

Protein Sequence : Show Sequence

>gi|2353000|gb|AAB69346.1| acid shock protein [Brucella abortus]
MESRTMKSKTAFIAVIATSLFAIPALAQEKSNANTDKPAAEAAVSSNQDAKNKRGPIDLEKFSRMDQLKA
ADTNGDGVLSRDEIEALALKRVVSRAADRMERRLDVNGDGKVTLDEIQNQRKKEFAALDRNDDGKLDRHE
MRAAKMSHRGHKGHHEMGKHHKSGDHKGGDHKGPMKTKAQKPQE

Molecule Role : Virmugen
Molecule Role Annotation : A asp24 mutation in Brucella abortus is attenuated and provides significant protection in mice (Kahl-McDonagh et al., 2007).
Related Vaccine(s): B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA

3. B. abortus strain 19 L7/L12

Gene Name : B. abortus strain 19 L7/L12
Sequence Strain (Species/Organism) : Strain 19
VO ID : VO_0010928
NCBI Protein GI : 304271
Genbank Accession : L19101
Other Database IDs : CDD:234671
CDD:100102
Taxonomy ID : 235
Gene Strand (Orientation) : ?
Protein Name : ribosomal protein L7/L12
Protein pI : 4.49
Protein Weight : 11795.56
Protein Length : 183
Protein Note : biovar Abortus

DNA Sequence : Show Sequence

>gi|304270|gb|L19101.1|BRURPL712X Brucella abortus ribosomal protein L7/L12 gene, complete cds 
CAAGCTCGTTATTCTCGGTGGCGCAATGGGTGCAACGACGCTTAGACCGATGGCGTCAAGTCGCTTCGTT
CGCTCCCGTCGCTCGACGAACTGCGCGCAAAGCTGGTTGGTATGATCCAGACCCCGGCTCAGCGTCTTGC
AGTGCTTACCAGCGCTCCGCGGGCCAGATCGCCCGCGTTATTGCGCGCACGCCCGGAAGAACGAGGCGGC
TTAAGGCCGTTTCTCGCTGTCAACAGTTCAAACCTTAATTATAGGAAATACAAAAATGGCTGATCTCGCA
AAGATCGTTGAAGACCTTTCGGCCCTGACCGTTCTGGAAGCCGCTGAGCTGTCCAAGCTTCTCGAAGAGA
AGTGGGGCGTTTCGGCTGCTGCTCCGGTCGCTGTTGCTGCTGCCGGTGGCGCTGCCCCTGCTGCTGCCGC
AGAAGAAAAGACCGAATTCGACGTCGTTCTCGCTGACGGCGGCGCTAACAAGATCAACGTGATCAAGGAA
GTGCGCGCACTCACCGGTCTCGGCCTCAAGGAAGCCAAGGACCTGGTCGAAGGCGCTCCGAAGGCTGTCA
AGGAAGGCGCCTCGAAGGACGAAGCTGAGAAGATCAAGGCACAGCTCGAAGCTGCTGGCGCCAAGGTTGA
ACTCAAGTAAGTTTGGACTATT

Protein Sequence : Show Sequence

>AAA19863.1 ribosomal protein L7/L12 [Brucella abortus]
MADLAKIVEDLSALTVLEAAELSKLLEEKWGVSAAAPVAVAAAGGAAPAAAAEEKTEFDVVLADGGANKI
NVIKEVRALTGLGLKEAKDLVEGAPKAVKEGASKDEAEKIKAQLEAAGAKVELK

Molecule Role : Protective antigen
Related Vaccine(s): B. abortus DNA vaccine expressing BCSP31, SOD and L7/L12 , B. abortus DNA vaccine pcDNA3.1-p39-L7/L12 encoding p39-L7/L12 fusion protein , B. abortus subunit vaccine using L7/L12

4. B. melitensis M5 P39

Gene Name : B. melitensis M5 P39
Sequence Strain (Species/Organism) : B. melitensis strain M5
VO ID : VO_0010948
NCBI Protein GI : 122892474
Genbank Accession : EF189139
Protein Accession : ABM67295
Other Database IDs : CDD:224567
CDD:304360
Taxonomy ID : 1004957
Gene Strand (Orientation) : ?
Protein Name : immunogenic 39-kDa protein
Protein pI : 4.69
Protein Weight : 40682.69
Protein Length : 483
Protein Note : biovar: 1 str. M5

DNA Sequence : Show Sequence

>gi|122892473|gb|EF189139.1| Brucella melitensis strain M5 immunogenic 39-kDa protein gene, complete cds
ATGGGTACGGCTTCCTGTGGTTTGCTCGCCGGAATGGCGCCTGTTGCCAATGCGCAGGAAAAGCAGAATG
TCGAGGTTCTGCACTGGTGGACGTCCGGCGGCGAAGCGTCCGCGCTTGAAGTTTTGAAAAAAGATCTTGA
AAGCAAGGGCATTAGCTGGACCGATATGCCGGTTGCAGGTGGCGGCGGCACGGAAGCCATGACCGTTTTG
CGCGCGCGCGTTACCGCAGGCAATGCGCCAACCGCGGTGCAGATGCTGGGTTTTGACATTCGCGACTGGG
CGGAGCAGGGCGCACTCGGCAATCTCGATACGGTTGCTTCCAAGGAAGGCTGGGAAAAGGTTATTCCGGC
TCCCTTGCAGGAATTTGCCAAATATGACGGCCACTGGATTGCTGCGCCCGTCAATATTCACTCCACCAAC
TGGATGTGGATCAACAAGGCTGCTCTCGACAAGGCTGGCGGCAAGGAGCCGACCAATTGGGATGAGCTGA
TTGCGCTTCTCGACAATTTCAAGGCGCAGGGCATTACGCCGATCGCGCATGGCGGCCAGCCGTGGCAGGA
TGCAACCATTTTCGATGCGGTTGTTCTTTCATTCGGCCCGGATTTCTACAAGAAGGCCTTCATCGATCTC
GACCCGGAAGCACTGGGCAGCGATACCATGAAGCAGGCCTTCGACCGCATGTCCAAGCTTCGCACCTATG
TTGATGACAACTTCTCCGGCCGTGACTGGAACCTTGCTTCGGCCATGGTTATCGAAGGCAAGGCCGGTGT
CCAGTTCATGGGCGACTGGGCGAAGGGCGAGTTCCTCAAGGCGGGCAAGAAGCCGGGTGAGGATTTCGTC
TGCATGCGTTATCCGGGCACGCAGGGTGCTGTCACTTTCAATTCCGGCATGTTCGCCATGTTCAAGGTTT
CGGAAGACAAGGTTCCCGCACAGCTTGAAATGGCTTCGGCGATTGAAAGCCCTGCCTTCCAGTCTGCCTT
TAATGTGGAGAAGGGGTCGGCCCCGGCACGCACGGATGTGCCCGATACCGCTTTCGATGCCTGTGGCAAG
AAGACCATTGCCGATGTCAAGGAAGCAAACAGCAAGGGCACTCTGCTTGGCTCCATGGCGCATGGCTATG
CCAATCCGGCTGCCGTGAAGAATGCGATCTACGACGTCGTGACCCGCCAGTTCAACGGCCAGCTTTCTTC
GGAAGATGCCGTCAAGGAACTCGTTGTGGCGGTTGAAGCCGCAAAATAAGGCCACGCGGAAACGTCCGGG
GGAACCTCCCGGACGTTTTTCCTGCGTGCTCCAGCAGAAGCGCATAGGCGGTTGGCGCAGCTAACCGGCA
CTTACGACGGAATTGCATGCCGATATGCCCGCCTCACCATCCGAGGCGCGTTTCGTGGGACATAGAGC

Protein Sequence : Show Sequence

>ABM67295.1 immunogenic 39-kDa protein [Brucella melitensis bv. 1 str. M5]
MAPVANAQEKQNVEVLHWWTSGGEASALEVLKKDLESKGISWTDMPVAGGGGTEAMTVLRARVTAGNAPT
AVQMLGFDIRDWAEQGALGNLDTVASKEGWEKVIPAPLQEFAKYDGHWIAAPVNIHSTNWMWINKAALDK
AGGKEPTNWDELIALLDNFKAQGITPIAHGGQPWQDATIFDAVVLSFGPDFYKKAFIDLDPEALGSDTMK
QAFDRMSKLRTYVDDNFSGRDWNLASAMVIEGKAGVQFMGDWAKGEFLKAGKKPGEDFVCMRYPGTQGAV
TFNSGMFAMFKVSEDKVPAQLEMASAIESPAFQSAFNVEKGSAPARTDVPDTAFDACGKKTIADVKEANS
KGTLLGSMAHGYANPAAVKNAIYDVVTRQFNGQLSSEDAVKELVVAVEAAK

Molecule Role : Protective antigen
Molecule Role Annotation : The 39-kDa protein is immunogenic.
Related Vaccine(s): B. melitensis P39 protein vaccine

5. BAB1_0278

Gene Name : BAB1_0278
Sequence Strain (Species/Organism) : Brucella melitensis biovar Abortus 2308
NCBI Protein GI : 82615279
Other Database IDs : CDD:264424
EnsemblGenomes-Gn:BAB1_0278
EnsemblGenomes-Tr:CAJ10234
InterPro: IPR011681
UniProtKB/TrEMBL: Q2YPC5
Taxonomy ID : 359391
Gene Strand (Orientation) : ?
Protein Name : conserved hypothetical protein
Protein pI : 8.51
Protein Weight : 8787.28
Protein Length : 148
Protein Note : GcrA cell cycle regulator; cl11564

Protein Sequence : Show Sequence

>CAJ10234.1 conserved hypothetical protein [Brucella abortus 2308]
MHWKSRSPLSEALPMFDKLTSPHEGFRLADLSRRQCKWPVNRAQAGELHLFCGEAVQNGHPYCEEHCGKA
YTGKAGSR

Molecule Role : Protective antigen
Related Vaccine(s): B. abortus DNA vaccine pVF278

6. BCSP31

Gene Name : BCSP31
Sequence Strain (Species/Organism) : Brucella abortus
NCBI Nucleotide GI : 144104
NCBI Protein GI : 144105
Protein Accession : AAA22993.1
Other Database IDs : CDD:273982
Taxonomy ID : 235
Gene Strand (Orientation) : ?
Protein Name : cell surface protein
Protein pI : 7.77
Protein Weight : 32204.04
Protein Length : 397
Protein Note : biovar Abortus

DNA Sequence : Show Sequence

>gi|144104|gb|M20404.1|BRUBCSP B.abortus BCSP31 gene encoding a 31-KDa cell surface protein, complete cds
GCGCCTATACGCGCGACCTGATCCAGTCTTTTGCATCGCGGTGCCATGTGCGTCTGGTGGGGGCCGACGG
GCTGGCGGCGATTGCCGAAGCGCATATTCGCGGTGAAAGTTTCGATGAGGCGCTGGTCATGGCGCAGATC
GCGCCATGTTTTATCGAAAAGGATGGCAAGCGCACCGATATCGTGGTGCTTGCCTGTACGCATTATCCGT
TTCTCGTCAATGTATTGCGCCGTCTGGCTCCATGGCCGGTGGATTGGCTGGACCCGGCGGAAGCCATTGC
ACGACGCATGAAATCGCTTTTGCCTGCGCGAAGTGACGATGATGAATTTCATTCTCAAGATGACCTAGCA
TTCTTCACATCCAGGAAACCCGACTATGCCATTCGCCGCCTGATGCAGGGTTTTGGGCTGCGTTTTTAAT
CGTTTCAGTCGGCTCTGGCGGCGCTTGTCGGCAAGCGATTGTATTCTTTGGGAAAATCCAGAATAATGGA
ATGCGGTGGTTGACAATCGGCCTCAAGCTTCCTATGGTTTTCGGCATAATCTATGCGGGAAGAGGACTGG
TATTATGAAATTCGGAAGCAAAATCCGTCGCTTGGCTGTTGCGGCGGTGGCGGGCGCGATTGCGTTGGGA
GCGAGCTTTGCGGTTGCACAGGCCCCGACATTTTTCCGTATCGGCACTGGCGGCACAGCCGGAACCTATT
ATCCGATTGGTGGTCTGATCGCGAACGCGATTTCCGGCGCAGGCGAAAAGGGCGTGCCGGGTCTCGTCGC
GACGGCCGTTTCGTCGAATGGCTCGGTTGCCAATATCAATGCGATCAAGTCGGGCGCTCTGGAGTCCGGC
TTTACGCAGTCAGACGTTGCCTATTGGGCCTATAACGGCACCGGCCTTTATGATGGCAAGGGCAAGGTGG
AAGATTTGCGCCTTCTGGCGACGCTTTACCCGGAAACGATCCATATCGTTGCGCGTAAGGATGCAAACAT
CAAATCGGTCGCAGACCTGAAAGGCAAGCGCGTTTCGCTGGATGAGCCGGGTTCTGGCACCATCGTCGAT
GCGCGTATCGTTCTTGAAGCCTACGGCCTCACGGAAGACGATATCAAGGCTGAACACCTGAAGCCGGGAC
CGGCAGGCGAGAGGCTGAAAGATGGTGCGCTGGACGCCTATTTCTTTGTGGGCGGCTATCCGACGGGCGC
AATCTCGGAACTGGCCATCTCGAACGGTATTTCGCTCGTTCCGATCTCCGGGCCGGAAGCGGACAAGATT
CTGGAGAAATATTCCTTCTTCTCGAAGGATGTGGTTCCTGCCGGAGCCTATAAGGACGTGGCGGAAACAC
CGACCCTTGCCGTTGCCGCACAGTGGGTGACGAGCGCCAAGCAGCCGGACGACCTCATCTATAACATCAC
CAAGGTTCTCTGGAACGAGGATACACGCAAGGCACTCGATGCGGGCCATGCGAAGGGCAAGCTCATCAAG
CTCGATAGTGCGACGAGCAGCCTCGGTATTCCGCTGCATCCCGGCGCAGAACGCTTTTACAAGGAAGCGG
GCGTGCTGAAATAATCCCTCAATGATCGGTTCCTGATATCTTATTCCGAATTGAAGGGTGACATTGCGGC
AGCTCGTTATGCGCGCTGCTGCGCTCCCGTTTTCCAGAGCGGTTCCGGTTAGAACGGAATCGTTGGAACC
GCTCTATCTCTTTGTTTTTACGCATTATCCGACGCAAAACCGTTTCACGCTTTTGCTGGAAATGCTCTAG
CCTATTGAAATGCACGACCGGCAAAGTGGAGTTGGCCCGCATGACAGAAGAACAAAATGCAAAGCTT

Protein Sequence : Show Sequence

>AAA22993.1 cell surface protein precursor [Brucella abortus]
MKFGSKIRRLAVAAVAGAIALGASFAVAQAPTFFRIGTGGTAGTYYPIGGLIANAISGAGEKGVPGLVAT
AVSSNGSVANINAIKSGALESGFTQSDVAYWAYNGTGLYDGKGKVEDLRLLATLYPETIHIVARKDANIK
SVADLKGKRVSLDEPGSGTIVDARIVLEAYGLTEDDIKAEHLKPGPAGERLKDGALDAYFFVGGYPTGAI
SELAISNGISLVPISGPEADKILEKYSFFSKDVVPAGAYKDVAETPTLAVAAQWVTSAKQPDDLIYNITK
VLWNEDTRKALDAGHAKGKLIKLDSATSSLGIPLHPGAERFYKEAGVLK

Molecule Role : Protective antigen
Related Vaccine(s): B. abortus DNA vaccine expressing BCSP31, SOD and L7/L12

7. bcsp31 from Brucella

Gene Name : bcsp31 from Brucella
Sequence Strain (Species/Organism) : Brucella
NCBI Protein GI : 361049819
Other Database IDs : CDD:32505
CDD:212369
Taxonomy ID : 1095367
Gene Strand (Orientation) : ?
Protein Name : TRAP transporter solute receptor, TAXI family precursor
Protein Length : 329
Protein Note : TRAP-type uncharacterized transport system, periplasmic component [General function prediction only]; COG2358

Protein Sequence : Show Sequence

>gi|361049819|emb|CCE21619.1| TRAP transporter solute receptor, TAXI family precursor [Brucella sp. 4986/3]
MKFGSKIRRLAVAAVAGAIVLGASFAVAQAPTFFRIGTGGTAGTYYPIGGLIANAISGAGEKGVPGLVAT
AVSSNGSVANINAIKSGALESGFTQSDVAYWAYNGTGLYDGKGKVEDLRLLATLYPETIHIVARKDANIK
SVADLKGKRVSLDEPGSGTIVDARIVLEAYGLTEDDIKAEHLKPGPAGERLKDGALDAYFFVGGYPTGAI
SELAISNGISLVPISGPEADKILEKYSFFSKDVVPAGAYKDVAETPTLAVAAQWVTSAKQPDDLIYNITK
VLWNEDTRKALDAGHAKGKLIKLDSATSSLGIPLHPGAERFYKEAGVLK

Molecule Role : Other

8. Bfr from B. abortus S19

Gene Name : Bfr from B. abortus S19
Sequence Strain (Species/Organism) : Brucella abortus S19
VO ID : VO_0010907
NCBI Gene ID : 6326162
NCBI Protein GI : 189022832
Locus Tag : BAbS19_II06320
Genbank Accession : CP000888
Protein Accession : YP_001932573
Taxonomy ID : 430066
Chromosome No : 2
Gene Starting Position : 673149
Gene Ending Position : 673634
Gene Strand (Orientation) : -
Protein Name : Bacterioferritin
Protein pI : 4.42
Protein Weight : 17971.98
Protein Length : 161

DNA Sequence : Show Sequence

>NC_010740.1:673149-673634 Brucella abortus S19 chromosome 2, complete sequence
CTTACTCAGCTTCGTCGGCGGGCGCCGCGTTAAGCTGGCCATAGCGTTCTCCGCCGATCTTGGCGAGAAG
GTCAAGCTGGGTTTCAAGGAAGTCGATATGGCCTTCTTCATCGGCCAGAAGTTCGTCGAAAAGCTGCTTC
GACACATAGTCGCCGAGCTTGTCGCAGATTTCGCGCGATTCCTTATACGAAGCGCGAGCGTCATATTCAC
CCTTGAGGTCAGCTTCGAGAACTTCCTTCACATTCTGGCCAATGCGCAACGGCGAAACGGTCTGGAGGTT
CGGAAAGCCTTCAAGGAAGATAATGCGATCAATCAGCTTGTCGGCGTGATGCATTTCCTCGATGGATTCC
TCGCGTTCCTTCTTTGCAAGGCGCGTGTAACCCCAATCGTTGAGAAGACGGTAGTGCAGCCAATACTGGT
TTACCGCACCGAGCTCAAGAAACAGTGCCTCGTTAAGCCGCTCGATGACCTTTGGTTCGCCTTTCA

Protein Sequence : Show Sequence

>YP_001932573.1 Bacterioferritin [Brucella abortus S19]
MKGEPKVIERLNEALFLELGAVNQYWLHYRLLNDWGYTRLAKKEREESIEEMHHADKLIDRIIFLEGFPN
LQTVSPLRIGQNVKEVLEADLKGEYDARASYKESREICDKLGDYVSKQLFDELLADEEGHIDFLETQLDL
LAKIGGERYGQLNAAPADEAE

Molecule Role : Protective antigen
Molecule Role Annotation : Following two intragastric immunizations in BALB/c mice, the Yersinia vectors harboring a DNA vaccine encoding BFR (P39) induced antigen-specific serum immunoglobulin and Th1-type responses among splenocytes. The best protection was conferred by a serotype O:9 strain carrying pCIP39, confirming the importance of the P39 T-cell antigen in this mechanism (Al-Mariri et al., 2002).

9. Bfr from B. melitensis biovar Abortus 2308

Gene Name : Bfr from B. melitensis biovar Abortus 2308
Sequence Strain (Species/Organism) : Brucella abortus 2308
VO ID : VO_0010968
NCBI Gene ID : 3828133
NCBI Protein GI : 489055925
Locus Tag : BAB_RS29555
Genbank Accession : JMRZ01000012
Protein Accession : WP_002966069
3D structure: PDB ID : 3FVB
Taxonomy ID : 359391
Chromosome No : II
Gene Starting Position : 673934
Gene Ending Position : 674419
Gene Strand (Orientation) : -
Protein Name : bacterioferritin
Protein pI : 4.42
Protein Weight : 17971.98
Protein Length : 161

DNA Sequence : Show Sequence

>NC_007624.1:673934-674419 Brucella melitensis biovar Abortus 2308 chromosome II, complete sequence, strain 2308
CTTACTCAGCTTCGTCGGCGGGCGCCGCGTTAAGCTGGCCATAGCGTTCTCCGCCGATCTTGGCGAGAAG
GTCAAGCTGGGTTTCAAGGAAGTCGATATGGCCTTCTTCATCGGCCAGAAGTTCGTCGAAAAGCTGCTTC
GACACATAGTCGCCGAGCTTGTCGCAGATTTCGCGCGATTCCTTATACGAAGCGCGAGCGTCATATTCAC
CCTTGAGGTCAGCTTCGAGAACTTCCTTCACATTCTGGCCAATGCGCAACGGCGAAACGGTCTGGAGGTT
CGGAAAGCCTTCAAGGAAGATAATGCGATCAATCAGCTTGTCGGCGTGATGCATTTCCTCGATGGATTCC
TCGCGTTCCTTCTTTGCAAGGCGCGTGTAACCCCAATCGTTGAGAAGACGGTAGTGCAGCCAATACTGGT
TTACCGCACCGAGCTCAAGAAACAGTGCCTCGTTAAGCCGCTCGATGACCTTTGGTTCGCCTTTCA

Protein Sequence : Show Sequence

>WP_002966069.1 MULTISPECIES: bacterioferritin [Brucella]
MKGEPKVIERLNEALFLELGAVNQYWLHYRLLNDWGYTRLAKKEREESIEEMHHADKLIDRIIFLEGFPN
LQTVSPLRIGQNVKEVLEADLKGEYDARASYKESREICDKLGDYVSKQLFDELLADEEGHIDFLETQLDL
LAKIGGERYGQLNAAPADEAE

Molecule Role : Protective antigen
Molecule Role Annotation : Brucella bacterioferritin is a protective antigen (Al-Mariri et al., 2001)

10. Bp26

Gene Name : Bp26
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
VO ID : VO_0010962
NCBI Gene ID : 1196247
NCBI Protein GI : 17986819
Locus Tag : BMEI0536
Genbank Accession : AE008917
Protein Accession : NP_539453
Taxonomy ID : 224914
Chromosome No : I
Gene Starting Position : 557728
Gene Ending Position : 558480
Gene Strand (Orientation) : -
Protein Name : immunogenic protein
Protein pI : 6.97
Protein Weight : 24369.69
Protein Length : 250

DNA Sequence : Show Sequence

>NC_003317.1:557728-558480 Brucella melitensis bv. 1 str. 16M chromosome I, complete sequence
TTTACTTGATTTCAAAAACGACATTGACCGATACGTTATAGCTGTTTTCGCCTGCGGCAATCGGCACGGA
ATTGTCCGGTGCGGCTGCTAGCATGGTTCTGAACTGTCCGCGCGCAATTGGCATCGGCATGGGCGGGCGG
CTCAGTTCACTGATTTCCACCACACGGCCAAGCCCCACGCCTGCAGCGTCGGCAAGCGTCTTCGCCTTGG
CAATGGCATTGGCCACTGCGCGCTTGCGCGCCTCGTTGATCACGGCGGAGGGATTATCATTGACCAGGTT
CAAATCACCGCCCTGATTAACACCGAGCGTGACGGATTCATCCAAAATTTTTCCAACATTGGCCAGTTCG
CGCACGCGAACCGTGAGACTGGTGGATACAGAATAGCCGGTGATGGTAGGCTCTTTCAGGTTGTTCTTGT
CGTCAGGATAGACATAAATCGGCTGGATATTGATGCCGCCTGTCTGGAGATCGCGATCTTCGATGCCGGC
CTTCTTCATGGCATCGAGCACTTTTGTCATGGCTTCATTATTCGCGGTCATGGCTTCGCGCGCGGTCTTT
GCCTGGCGTAGCACCGAGAGATTGAGAATGGCCATATCGGGCGAGGCCGTCATCATGCCTTCCCCGGTGA
CGGCGATGCGCGCGGGCTGCGTCGTCATCTGATTCTCCTGTGCGAAAGCGGGCAGGCTGAAAGCGCCGAC
GAGCATGATTGTGGAAAATGAGGCTGCGAGAAAATTGCTAGCACGAGTGTTCA

Protein Sequence : Show Sequence

>NP_539453.1 immunogenic protein [Brucella melitensis bv. 1 str. 16M]
MNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPARIAVTGEGMMTASPDMAILNLSVLRQAKTARE
AMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDDKNNLKEPTITGYSVSTSLTVRVRELANV
GKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADAAGVGLGRVVEISELSRPPMP
MPIARGQFRTMLAAAPDNSVPIAAGENSYNVSVNVVFEIK

Molecule Role : Protective antigen
Molecule Role Annotation : This is a protective antigen (Yang et al., 2007).

11. bp26

Gene Name : bp26
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. Rev.1
NCBI Protein GI : 265991532
Other Database IDs : CDD:194028
Taxonomy ID : 520464
Gene Strand (Orientation) : ?
Protein Name : outer membrane protein Bp26
Protein Length : 250
Protein Note : Protein of unknown function (DUF541); cl01077

Protein Sequence : Show Sequence

>gi|265991532|ref|ZP_06104089.1| outer membrane protein Bp26 [Brucella melitensis bv. 1 str. Rev.1]
MNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPARIAVTGEGMMTASPDMAILNLSVLRQAKTARE
AMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDDKNNLKEPTITGYSVSTSLTVRVRELANV
GKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADAAGVGLGRVVEISELSRPPMP
MPIARGQFRTMLAAAPDNSVPIAAGENSYNVSVNVVFEIK

Molecule Role : Virmugen
Molecule Role Annotation : A bp26 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice (Cloeckaert et al., 2004).
Related Vaccine(s): Brucella melitensis bp26 mutant vaccine

12. cobB

Gene Name : cobB
Sequence Strain (Species/Organism) : Brucella abortus 2308
NCBI Gene ID : 3787893
NCBI Protein GI : 489054238
Locus Tag : BAB_RS22225
Genbank Accession : JMRZ01000005
Protein Accession : WP_002964414
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 1271743
Gene Ending Position : 1273053
Gene Strand (Orientation) : -
Protein Name : hydrogenobyrinate a,c-diamide synthase
Protein pI : 6.89
Protein Weight : 44156.43
Protein Length : 436
Protein Note : responsible for the amidation of carboxylic groups at position A and C of cobyrinic acid or hydrogenobrynic acid

DNA Sequence : Show Sequence

>NC_007618.1:1271743-1273053 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
CTCACGCCGCTTCTCCGCTAAAATCAATGACATGCATGAAGGAGCCGGAGACGGAACCAACCCGCAAGCC
CGCTTCGCCAAGGTTCTCGCCCGATGCATCGCGCACCCGGAACAGGCGGTCGGCCTTTTCTTCCCGCACG
ATGCTTGCATAATGGAATTCATGCGCTTTCAAAGGCATGTCCCACGGCAATCCGCCAAGCGGCTCCAGCA
GGCGATAGCCAAGATGCAGTTTCCGCCTGGCAAAGCTCGTTTCCAATGGCAAAAGCCCCAGCATGGGATG
GTGAACGCCTGCCGCATCCTCCAGTGTTTTCCCGAGGACCATATAGCCGCCGCACTCGCCATAGACCGTG
ACGCCACGCGCGGCAGCGTCCCCTATCGCCGTGCGGAAACGGGATGCACCGGCCAATCGTTGCGCATGAA
GTTCTGGATAACCACCGGGAAGATAGATTGCATCCGCATCTGCCTTCGGTGCTTCATCTGCCAGCGGGGA
AAAGAAAGAGATTTCCGCACCCCGCCTGCGCCAGCCTTCAAAAAGATGCATATAGGCAAAAGCAAAGGCA
TCGTCCCGCGCCACGGCAATGCGGTTTCCAAGCGGTTTCAGACGCGCGACATTGGCCATGGCGTCATAGC
GCTTCGGGCGTAGCCAGATGGTCTGAAGCGCATCCATGTCGATATGCGCTTCCATCACATCGGCCGCTTG
TTCGAGAAAGCTTTCAAGACCGGCATGTTCGTCCGCCTGCACCAGCCCCAGATGCCTTTCCGGCAAGGAA
AGTGCCGGATCTCGCGGCAGCGCGCCCAGAACCGGGACGCCAAGGGGTGCCAGAGCGCCCCGCAGCATGG
CTTCATGGCGGGGACTTCCGACACGATTGAGAATGACACCCTCAATCAGCACATCCTTGCGAAACTGGCT
GAAACCCCACACCAGCGCCGCGATGGAGTGGGATTGCCGGGCGCAATCCACCACCAGCACGACTGGCAAA
TCCAGAAGCCGCGCCAGATCGGCAGAAGAGCCCTTACCGTCAATCGCCCCGTCGAAAAGCCCCATCATGC
CTTCGGCGACAAGAACACGCGCGCCGCTTTCCGTCATGCGGGAGGAAAGCGCACTGATGAGTTCCGGTCG
CATGGCCCAGGGGTCGAGATTGAAACAATCCACGCCACTCGCCGCCCTGTGATAGGCGGGGTCGATATAA
TCCGGCCCGGCCTTCACCGGCGCAAGCACCTCGCCCCTGCGTTTCAGGGCGCGCAACAAACCCAAGGTCA
CGGTCGTCTTGCCCGACCCGGAGGCCGGTGCGGCAATCATGAATCCCTTCA

Protein Sequence : Show Sequence

>WP_002964414.1 MULTISPECIES: hydrogenobyrinate a,c-diamide synthase [Brucella]
MKGFMIAAPASGSGKTTVTLGLLRALKRRGEVLAPVKAGPDYIDPAYHRAASGVDCFNLDPWAMRPELIS
ALSSRMTESGARVLVAEGMMGLFDGAIDGKGSSADLARLLDLPVVLVVDCARQSHSIAALVWGFSQFRKD
VLIEGVILNRVGSPRHEAMLRGALAPLGVPVLGALPRDPALSLPERHLGLVQADEHAGLESFLEQAADVM
EAHIDMDALQTIWLRPKRYDAMANVARLKPLGNRIAVARDDAFAFAYMHLFEGWRRRGAEISFFSPLADE
APKADADAIYLPGGYPELHAQRLAGASRFRTAIGDAAARGVTVYGECGGYMVLGKTLEDAAGVHHPMLGL
LPLETSFARRKLHLGYRLLEPLGGLPWDMPLKAHEFHYASIVREEKADRLFRVRDASGENLGEAGLRVGS
VSGSFMHVIDFSGEAA

Molecule Role : Protective antigen
Molecule Role Annotation : Mice given BAB1_1316 (CobB) plus adjuvant could provide protection against virulent B. abortus infection, similarly with the known protective antigen Cu-Zn SOD and the license vaccine S19 (Fu et al., 2012).
Related Vaccine(s): Recombinant B. abortus CobB protein with CFA/IFA adjuvant

13. cp24 from Brucella melitensis

Gene Name : cp24 from Brucella melitensis
Sequence Strain (Species/Organism) : Brucella melitensis
NCBI Protein GI : 1674445
Other Database IDs : CDD:178850
CDD:29621
Taxonomy ID : 29459
Gene Strand (Orientation) : ?
Protein Name : CP24
Protein Length : 186
Protein Note : ribosome recycling factor; Reviewed; PRK00083

Protein Sequence : Show Sequence

>gi|1674445|gb|AAB19043.1| CP24 [Brucella melitensis]
MSDAFDINDLKRRMEGAVNALKHDLGGLRTGRASASLLEPITIEAYGSTMPINQVANISVPESRMLSVSV
WDKSMVGAVERAIRDSGLGLNPITDGMTLRIRLPELNEQRRKELVKIAHQYAEQGRIAARHVRRDGMDQL
KKLEKDSVISQDESRVLSEKVQKLTDDTIAEMDKIVAVKEGEIMQV

Molecule Role : Other

14. DnaK

Gene Name : DnaK
Sequence Strain (Species/Organism) : Brucella abortus bv. 1 str. 9-941
VO ID : VO_0010970
NCBI Gene ID : 3341115
NCBI Protein GI : 62290965
Locus Tag : BruAb1_2100
Genbank Accession : AE017223
Protein Accession : YP_222758
Taxonomy ID : 262698
Chromosome No : I
Gene Starting Position : 2066035
Gene Ending Position : 2067948
Gene Strand (Orientation) : +
Protein Name : molecular chaperone DnaK
Protein pI : 4.59
Protein Weight : 63035.04
Protein Length : 637
Protein Note : heat shock protein 70; assists in folding of nascent polypeptide chains; refolding of misfolded proteins; utilizes ATPase activity to help fold; co-chaperones are DnaJ and GrpE; multiple copies in some bacteria

DNA Sequence : Show Sequence

>NC_006932.1:2066035-2067948 Brucella abortus biovar 1 str. 9-941 chromosome I, complete sequence
TATGGCTAAAGTTATTGGTATCGATCTGGGAACGACCAACTCCTGCGTTGCCGTCATGGACGGAAAGAAC
GCGAAGGTCATTGAAAATGCAGAAGGTGCACGCACCACCCCTTCGATCATCGCCTTCACCGATGGTGACG
AACGCCTCGCTGGTCAGCCTGCGAAGCGTCAGGCCGTCACCAACCCGGAAGGCACCCTTTTTGCCGTCAA
GCGCCTGATTGGCCGTCGCTATGACGATCCGATGGTCACCAAGGACAAGGATCTTGTTCCTTACAAGATC
GTCAAGGGCGACAATGGCGATGCCTGGGTCGAGGTGCACGGCAAGAAATATTCTCCGTCGCAGATCTCCG
CTATGATCCTTCAGAAGATGAAGGAAACGGCTGAATCCTACCTTGGCGAAACCGTTACGCAGGCCGTCAT
CACGGTTCCGGCCTACTTCAACGACGCCCAGCGTCAGGCCACCAAGGATGCCGGCAAGATCGCCGGTCTG
GAAGTTCTGCGCATCATCAACGAGCCGACCGCGGCTGCGCTTGCCTATGGTCTCGACAAGAGCGAAGGCA
AGACCATCGCTGTCTATGACCTTGGCGGCGGTACTTTCGACGTGTCGGTTCTGGAAATCGGCGACGGCGT
TTTTGAAGTGAAGTCCACCAATGGCGACACGTTCCTTGGCGGTGAAGACTTCGATATTCGTCTGGTCGAA
TATCTGGTTGCCGAGTTCAAGAAGGAAAGTGGCATCGACCTGAAGAACGACAAGCTTGCCCTGCAGCGCC
TCAAGGAAGCTGCCGAAAAGGCCAAGATCGAACTGTCGTCCTCGCAGCAGACCGAAATCAACCTGCCGTT
CATCACGGCTGACCAGACTGGCCCGAAGCATCTGGCGATCAAGCTGTCGCGCGCCAAGTTTGAAAGCCTG
GTCGATGATCTCGTGCAGCGCACGGTCGAGCCGTGCAAGGCGGCGCTCAAGGATGCCGGCCTCAAGGCTG
GCGAAATTGACGAAGTGGTTCTGGTCGGCGGCATGACCCGCATGCCCAAGATTCAGGAAGTCGTGAAGGC
CTTCTTCGGCAAGGAACCGCACAAGGGCGTGAACCCGGATGAAGTCGTGGCCATGGGCGCGGCGATCCAG
GGCGGCGTTTTGCAGGGCGACGTCAAGGACGTGCTGCTGCTCGACGTGACCCCGCTTTCGCTCGGCATTG
AAACGCTGGGCGGCGTGTTCACCCGCCTGATCGAACGCAACACCACTATCCCGACCAAGAAGTCGCAGAC
CTTCTCCACGGCTGAGGACAACCAGTCGGCCGTGACGATCCGCGTCTTCCAGGGCGAGCGTGAAATGGCA
GCCGATAACAAGCTGCTTGGACAGTTCGACCTCGTTGGCATTCCGCCCGCACCGCGCGGTGTGCCGCAGA
TCGAAGTGACCTTCGACATCGACGCCAACGGCATCGTCAACGTTTCGGCCAAGGATAAGGGTACCGGCAA
GGAGCACCAGATCCGCATTCAGGCTTCGGGCGGCCTGAGCGATGCCGACATCGAAAAGATGGTCAAGGAC
GCCGAAGCCAATGCCGAGGCCGACAAGAAGCGTCGTGAGAGCGTCGAAGCCAAGAATCAGGCCGAAAGCC
TGGTCCATTCGACCGAAAAGTCGCTGGCCGAATATGGCGACAAGGTTTCGGCCGATGACAAGAAGGCCAT
TGAGGATGCGATCGCAGCCCTCAAGACCTCGCTTGAAGGTGAAGACGCCGAGGATATCAAGGCGAAGACC
CAGGCCCTTGCCGAAGTTTCCATGAAGCTTGGTCAGGCCATGTACGAAGCAGCGCAGGCTGCCGAAGGTG
CGGGTGCCGAGGGCGGTGAACAGGCCTCTTCGTCCAAGGACGATGTGGTCGATGCCGACTACGAAGAAAT
CGACGACAACAAGAAGTCGTCGTA

Protein Sequence : Show Sequence

>YP_222758.1 molecular chaperone DnaK [Brucella abortus bv. 1 str. 9-941]
MAKVIGIDLGTTNSCVAVMDGKNAKVIENAEGARTTPSIIAFTDGDERLAGQPAKRQAVTNPEGTLFAVK
RLIGRRYDDPMVTKDKDLVPYKIVKGDNGDAWVEVHGKKYSPSQISAMILQKMKETAESYLGETVTQAVI
TVPAYFNDAQRQATKDAGKIAGLEVLRIINEPTAAALAYGLDKSEGKTIAVYDLGGGTFDVSVLEIGDGV
FEVKSTNGDTFLGGEDFDIRLVEYLVAEFKKESGIDLKNDKLALQRLKEAAEKAKIELSSSQQTEINLPF
ITADQTGPKHLAIKLSRAKFESLVDDLVQRTVEPCKAALKDAGLKAGEIDEVVLVGGMTRMPKIQEVVKA
FFGKEPHKGVNPDEVVAMGAAIQGGVLQGDVKDVLLLDVTPLSLGIETLGGVFTRLIERNTTIPTKKSQT
FSTAEDNQSAVTIRVFQGEREMAADNKLLGQFDLVGIPPAPRGVPQIEVTFDIDANGIVNVSAKDKGTGK
EHQIRIQASGGLSDADIEKMVKDAEANAEADKKRRESVEAKNQAESLVHSTEKSLAEYGDKVSADDKKAI
EDAIAALKTSLEGEDAEDIKAKTQALAEVSMKLGQAMYEAAQAAEGAGAEGGEQASSSKDDVVDADYEEI
DDNKKSS

Molecule Role : Protective antigen
Molecule Role Annotation : Brucella DnaK is a protective antigen (Delpino et al., 2007b).

15. exsA

Gene Name : exsA
Sequence Strain (Species/Organism) : Brucella melitensis biovar Abortus 2308
NCBI Gene ID : 3787220
NCBI Protein GI : 82699354
Locus Tag : BAB1_0468
Genbank Accession : AM040264
Protein Accession : YP_413928
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 459774
Gene Ending Position : 461660
Gene Strand (Orientation) : +
Protein Name : ABC transporter ATPase
Protein pI : 7.04
Protein Weight : 65025
Protein Length : 628
Protein Note : identified by match to protein family HMM PF00005; match to protein family HMM PF00664

DNA Sequence : Show Sequence

>gi|82698932:459774-461660 Brucella melitensis biovar Abortus 2308 chromosome chromosome I, complete sequence
GATGAATGCCCCCAAGACGGTTTCTGCCGAATCCGGCGAGACGCTGAAAACATTGCGAAATCTGTGGCCC
TACATGTGGCCGTCCGACAGGCCGGACCTGCGAATGCGCGTGGTCTGGGCCACATTCTATCTGGTTCTGT
CCAAGATTGTGCTGATCCTCGTACCCTATTTCTTCAAATGGGTGACCAATGCGCTGAACGGCCAGCTTCA
TGCGCCGGATTATATTCCGGTCGTTCTGGTCGGCGCGGTCATGCTGGTGCTGGCCTATAATGCGGCGAAA
ATCGTGCAGGCTGGCCTCAACCAGCTTCGTGACGCACTTTTTGCCAGTGTTGGCCAATATGCGGTGCGCC
AGCTTGCCTACAAGACCTTTGTGCATATGCATGAGCTTTCGCTGCGCTTTCATCTGGAGCGGCGCACGGG
CGGCCTGTCGCGCGTCATCGAGCGCGGCACCAAGGGCATTGAAACCATCGTCCGTTTTACCATCCTGAAC
ACGCTGCCTACCATTCTGGAATTTGCGCTGACGGCGGTGATCTTCGCTTTCGCCTATGGCCTGTCCTATC
TCGTGGTCGTGGCGGCGACGGTCTGGCTCTATACGTGGTTCACCATCAGGGCGAGCGATTGGCGCATCAA
TATCCGTCGCGAGATGAACGATTCCGATACCGACGCCAATACCAAGGCCATCGATTCGCTTCTCAACTTC
GAGACGGTCAAATATTTCGGCAATGAAGCGATGGAGGCCAAGCGTTTCGATGGGGCTATGGCGCGATATG
AAAAGGCTGCAACCCAGACCTGGACCTCGCTTGGCTGGCTGAACTTCGGTCAGGCCGTGATTTTCGGCGC
GGGCATGGCCATTGTCATGGTCATGTCGGCCATGGAGGTGCAGAAGGGCACACAGTCGCTGGGCGATTTC
GTCTTCATCAATGCGCTTTTGATGCAGCTTTCCATCCCGCTCAATTTCATCGGCTTTATCTATCGTGAAA
TCCGTCAGGGCCTCACCGATATCGAGCAGATGTTCGACCTTCTGGACGTCAAGCAGGAAGTGAAAGACAA
GCCCGGCGCTCCTGCGCTGAAAGTCGATAGCGGCGCAATCTCCTTCAAGGATGTGCACTTTGCCTATGAT
CCGCAGCGCCCCATCCTGCGCGGCATCAGCTTCGACGTTCCCGCAGGAAAGACGGTGGCGATTGTCGGCC
CTTCGGGGGCTGGTAAATCCACCATATCGCGGCTTCTGTTCCGCTTTTACGATATCCAGTCCGGTTCGAT
CACCATCGATGGGCAGGATGTGCGCGACGTGACCCAGGAAAGCCTGCGCAAGTTTATCGGCATGGTGCCG
CAGGATACGGTCCTGTTCAACGACACCATCGCCTATAATATCCGCTATGGCCGCACCGATGCGAGCGAGG
AGGATGTGGAAAAAGCAGCCGAGCTCGCGCAGATTGCCGGCTTCATCAAGCATCTGCCGGATGGCTACAA
ATCCATGGTTGGCGAGCGCGGCCTGAAGCTTTCCGGCGGCGAAAAGCAGCGTGTGGCGATTGCCCGCACG
ATCCTCAAGGCCCCGCCTATTCTTATTCTGGACGAGGCGACCTCGGCACTCGATACCGCGACCGAGCAGG
ACATCCAGTCGGCGCTTGATATTGTCAGCCGCGGGCGCACCACGCTGGTGATCGCGCATCGCCTTTCCAC
CGTGATCGGTGCGGATGAGATCATCGTCCTGAAAGACGGCCTGATCGCCGAGTGCGGCACGCACCGCCAT
CTCCTTGACCAGAAGGGGCTTTATGCTTCCATGTGGGATCGCCAGCGCGAGGCGAGCGAGGCTGAGGAGC
GCCTGCGCCAGGTGCGTGAAAGCGACGATATGGGCGTGGTTCTGCGCGGGACGCCGGCGGCGGAATA

Protein Sequence : Show Sequence

>gi|82699354|ref|YP_413928.1| ABC transporter ATPase [Brucella melitensis biovar Abortus 2308]
MNAPKTVSAESGETLKTLRNLWPYMWPSDRPDLRMRVVWATFYLVLSKIVLILVPYFFKWVTNALNGQLH
APDYIPVVLVGAVMLVLAYNAAKIVQAGLNQLRDALFASVGQYAVRQLAYKTFVHMHELSLRFHLERRTG
GLSRVIERGTKGIETIVRFTILNTLPTILEFALTAVIFAFAYGLSYLVVVAATVWLYTWFTIRASDWRIN
IRREMNDSDTDANTKAIDSLLNFETVKYFGNEAMEAKRFDGAMARYEKAATQTWTSLGWLNFGQAVIFGA
GMAIVMVMSAMEVQKGTQSLGDFVFINALLMQLSIPLNFIGFIYREIRQGLTDIEQMFDLLDVKQEVKDK
PGAPALKVDSGAISFKDVHFAYDPQRPILRGISFDVPAGKTVAIVGPSGAGKSTISRLLFRFYDIQSGSI
TIDGQDVRDVTQESLRKFIGMVPQDTVLFNDTIAYNIRYGRTDASEEDVEKAAELAQIAGFIKHLPDGYK
SMVGERGLKLSGGEKQRVAIARTILKAPPILILDEATSALDTATEQDIQSALDIVSRGRTTLVIAHRLST
VIGADEIIVLKDGLIAECGTHRHLLDQKGLYASMWDRQREASEAEERLRQVRESDDMGVVLRGTPAAE

Molecule Role : Virmugen
Molecule Role Annotation : Brucella DeltaexsA mutant showed decreased survival in mice compared to the survival of parental strain S2308. This demonstrated that ExsA is critical for full bacterial virulence. The B. abortus exsA deletion mutant was used as a live vaccine candidate. Challenge experiments revealed that the exsA mutant strain induced superior protective immunity in BALB/c mice compared to the protective immunity induced by strain S19 or RB51 (Rosinha et al., 2002a).
Related Vaccine(s): Brucella abortus exsA mutant vaccine

16. Gap

Gene Name : Gap
Sequence Strain (Species/Organism) : Brucella abortus bv. 1 str. 9-941
VO ID : VO_0012375
NCBI Gene ID : 3340207
NCBI Protein GI : 62290600
Locus Tag : BruAb1_1713
Genbank Accession : AE017223
Protein Accession : YP_222393
Taxonomy ID : 262698
Chromosome No : I
Gene Starting Position : 1684720
Gene Ending Position : 1685727
Gene Strand (Orientation) : +
Protein Name : glyceraldehyde-3-phosphate dehydrogenase
Protein pI : 6.44
Protein Weight : 32765.28
Protein Length : 335
Protein Note : catalyzes the formation of 3-phospho-D-glyceroyl phosphate from D-glyceraldehyde 3-phosphate

DNA Sequence : Show Sequence

>NC_006932.1:1684720-1685727 Brucella abortus biovar 1 str. 9-941 chromosome I, complete sequence
AATGGCAGTTCGCGTCGCAATCAACGGTTTTGGCCGCATTGGCCGTAACATCCTTCGCGCCATCGTGGAA
TCGGGGCGCACCGACATTCAGGTCGTCGCCATCAACGATCTCGGCCCGGTCGAAACCAACGCACATCTTC
TGCGTTATGACAGCGTTCATGGCCGTTTCCCCAAGGAAGTGGAGGTTGCAGGCGATACGATCGATGTTGG
CTACGGCCCGATCAAGGTTCATGCCGTCCGCAACCCGGCCGAACTGCCGTGGAAGGAAGAAAACGTCGAT
ATCGCCCTTGAATGCACCGGCATTTTCACCTCGCGCGACAAGGCAGCACTTCATCTTGAAGCTGGCGCCA
AGCGCGTCATCGTCTCCGCTCCCGCAGACGGTGCCGATCTCACCGTCGTCTATGGTGTCAACAACGACAA
GCTGACGAAGGACCATCTGGTCATCTCCAACGCTTCGTGTACCACCAACTGCCTTGCGCCGGTGGCTCAG
GTTCTCAACGATACTATCGGTATCGAAAAGGGCTTCATGACCACGATCCACTCCTATACGGGCGACCAGC
CGACGCTGGACACCATGCACAAGGATCTCTACCGCGCCCGCGCCGCTGCCCTTTCCATGATCCCGACCTC
GACGGGTGCGGCCAAGGCCGTCGGTCTCGTTCTGCCGGAACTGAAAGGCAAGCTCGACGGCGTTGCCATT
CGCGTCCCGACCCCAAATGTCTCGGTCGTTGATCTCACCTTCATCGCCAAGCGTGAAACCACCGTTGAAG
AAGTCAACAATGCGATCCGCGAAGCCGCCAATGGCCGCCTCAAGGGCATTCTCGGCTATACCGATGAGAA
GCTCGTCTCGCACGACTTCAACCACGATTCCCATTCCTCGGTCTTCCACACCGACCAGACCAAGGTTATG
GACGGCACCATGGTGCGTATCCTGTCGTGGTACGACAATGAATGGGGCTTCTCCAGCCGCATGAGCGACA
CCGCCGTCGCTTTGGGCAAGCTGATCTG

Protein Sequence : Show Sequence

>YP_222393.1 glyceraldehyde-3-phosphate dehydrogenase [Brucella abortus bv. 1 str. 9-941]
MAVRVAINGFGRIGRNILRAIVESGRTDIQVVAINDLGPVETNAHLLRYDSVHGRFPKEVEVAGDTIDVG
YGPIKVHAVRNPAELPWKEENVDIALECTGIFTSRDKAALHLEAGAKRVIVSAPADGADLTVVYGVNNDK
LTKDHLVISNASCTTNCLAPVAQVLNDTIGIEKGFMTTIHSYTGDQPTLDTMHKDLYRARAAALSMIPTS
TGAAKAVGLVLPELKGKLDGVAIRVPTPNVSVVDLTFIAKRETTVEEVNNAIREAANGRLKGILGYTDEK
LVSHDFNHDSHSSVFHTDQTKVMDGTMVRILSWYDNEWGFSSRMSDTAVALGKLI

Molecule Role : Protective antigen
Molecule Role Annotation : GAPDH (Gap) associated with murine IL-12 gene in a DNA vaccine formulation partially protected mice against experimental infection (Rosinha et al., 2002b).

17. groEL from Brucella abortus

Gene Name : groEL from Brucella abortus
Sequence Strain (Species/Organism) : Brucella abortus bv. 1 str. 9-941
NCBI Gene ID : 3341925
NCBI Protein GI : 62317142
Locus Tag : BruAb2_0190
Genbank Accession : AE017224
Protein Accession : YP_222995
Taxonomy ID : 262698
Chromosome No : II
Gene Starting Position : 182072
Gene Ending Position : 183712
Gene Strand (Orientation) : -
Protein Name : molecular chaperone GroEL
Protein pI : 4.79
Protein Weight : 52158.47
Protein Length : 546
Protein Note : 60 kDa chaperone family; promotes refolding of misfolded polypeptides especially under stressful conditions; forms two stacked rings of heptamers to form a barrel-shaped 14mer; ends can be capped by GroES; misfolded proteins enter the barrel where they are refolded when GroES binds; many bacteria have multiple copies of the groEL gene which are active under different environmental conditions; the B.japonicum protein in this cluster is expressed constitutively; in Rhodobacter, Corynebacterium and Rhizobium this protein is essential for growth

DNA Sequence : Show Sequence

>gi|62316961:182072-183712 Brucella abortus bv. 1 str. 9-941 chromosome II, complete sequence
CTTAGAAGTCCATGCCGCCCATGCCACCCATACCGCCAGGCATGCCAGCCGGAGCTGCGTCCTTCTTCGG
CAGTTCGGCGATCATTGCTTCCGTCGTGATCAGCAGGCCGGCAACCGAAGCTGCGTTCTGCAGAGCCGTG
CGGACAACCTTGACCGGGTCAACAATGCCGAGCGAGATCAGGTCGCCATATTCGCCATTGGCCGTGTTGT
AGCCGAAGGTTTCGGACGTGTTTTCGAGGATCTTGCCAACGATTACCGAAGCTTCTTCACCGGCATTGGT
CGTGATCTGGCGGGCCGGAGCCTGGATCGCGCGACGAACGATGTTGATGCCAGCTTCCTGGTCGGCATTC
ACACCCTTTGCGGTGATCTTGGTCGAAGCGCGGAGCAGGGCGGTGCCGCCGCCGGCAACGATACCTTCTT
CAACCGCAGCGCGGGTTGCGTTCAGGGCGTCGTCAACGCGGTCCTTCTTTTCCTTCACTTCAACTTCCGT
TGCACCGCCGACGCGGATCACGGCAACGCCGCCAGCGAGCTTGGCAAGACGTTCCTGAAGCTTTTCACGG
TCGTAGTCCGAAGTGGTTTCTTCGATCTGCTGCTTGATCTGGCCAACGCGAGCGTCGATTTCGGCCTTCT
GGCCTGCACCGTCAACGATCGTCGTGTTTTCCTTGGAGATCGAAACCTTCTTGGCGCGGCCCAGCATGTC
GAGCGTAACGCTTTCAAGCTTGATGCCGAGGTCTTCGGAGATGACCTGACCGCCAGTGAGGATCGCGATG
TCTTCGAGCATGGCCTTGCGGCGATCGCCGAAGCCCGGAGCCTTGACGGCAGCAATCTTCAGGCCGCCGC
GCAGCTTGTTGACGACGAGCGTTGCAAGAGCTTCGCCTTCGACGTCTTCAGCAATGATGAGAAGCGGCTT
GGAGGTCTGGACGACAGCTTCGAGAACCGGCAGGAGAGCCTGAAGGTTCGAGAGCTTCTTTTCGTGCAGA
AGGATGTAGGCGTCTTCGAGGTCAGCAACCATCTTTTCAGGGTTGGTGACGAAGTAAGGCGACAGGTAGC
CGCGGTCGAACTGCATGCCTTCGACGACTTCGAGTTCGGTTTCGGCGGTCTTGGCTTCTTCAACCGTGAT
GACGCCTTCGTTGCCGACCTTCTGCATCGCTTCGGCGATCATCTTGCCGATTTCGGCTTCGCCGTTGGCA
GAGATGGTGCCAACCTGGGCAACTTCTTCCGAAGTGTTGATCTTTTTGGCCTTCTTCAGCAGCTCAGCCA
CAACTTCGTTGACAGCGAGGTCGATGCCGCGCTTCAGGTCCATCGGGTTCATGCCAGCGGCAACGGCCTT
GGCGCCTTCCTGAACGATGGCCTGACCGAGAACGGTCGCGGTCGTGGTGCCGTCACCGGCAGTATCGTTG
GTCTTGGAAGCCACTTCGCGCAGCATCTGTGCGCCCATGTTTTCAAACTTGTCTTCCAGTTCGACTTCCT
TGGCGACCGAAACGCCGTCCTTGGTGATGCGCGGAGCGCCGAAGGACTTCTCGATAACGACATTGCGGCC
CTTCGGGCCGAGCGTGACCTTAACAGCGTCAGCGAGGATATCGACGCCGCGCAGCATCTTTTCGCGCGCA
GTGCGGCCGAATTTTACGTCTTTTGCAGCCA

Protein Sequence : Show Sequence

>gi|62317142|ref|YP_222995.1| groEL gene product [Brucella abortus bv. 1 str. 9-941]
MAAKDVKFGRTAREKMLRGVDILADAVKVTLGPKGRNVVIEKSFGAPRITKDGVSVAKEVELEDKFENMG
AQMLREVASKTNDTAGDGTTTATVLGQAIVQEGAKAVAAGMNPMDLKRGIDLAVNEVVAELLKKAKKINT
SEEVAQVGTISANGEAEIGKMIAEAMQKVGNEGVITVEEAKTAETELEVVEGMQFDRGYLSPYFVTNPEK
MVADLEDAYILLHEKKLSNLQALLPVLEAVVQTSKPLLIIAEDVEGEALATLVVNKLRGGLKIAAVKAPG
FGDRRKAMLEDIAILTGGQVISEDLGIKLESVTLDMLGRAKKVSISKENTTIVDGAGQKAEIDARVGQIK
QQIEETTSDYDREKLQERLAKLAGGVAVIRVGGATEVEVKEKKDRVDDALNATRAAVEEGIVAGGGTALL
RASTKITAKGVNADQEAGINIVRRAIQAPARQITTNAGEEASVIVGKILENTSETFGYNTANGEYGDLIS
LGIVDPVKVVRTALQNAASVAGLLITTEAMIAELPKKDAAPAGMPGGMGGMGGMDF

Molecule Role : Other

18. IalB

Gene Name : IalB
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
VO ID : VO_0010967
NCBI Gene ID : 1197295
NCBI Protein GI : 17987867
Locus Tag : BMEI1584
Genbank Accession : AE008917
Protein Accession : NP_540501
Taxonomy ID : 224914
Chromosome No : I
Gene Starting Position : 1632893
Gene Ending Position : 1633414
Gene Strand (Orientation) : +
Protein Name : invasion protein B
Protein pI : 8.98
Protein Weight : 17016.04
Protein Length : 173

DNA Sequence : Show Sequence

>NC_003317.1:1632893-1633414 Brucella melitensis bv. 1 str. 16M chromosome I, complete sequence
TATGAAAAATTATCGTGCAATCGGTCTTGCATTCACGTTCACTGCCCTTTCCAGTCTTTCGGCCTTTGCA
GCCTCCCTGCCCGGCGGAGCAAGCACCTTGCAGGAAACCTATCAGGACTGGACCGTGTCTTGCCAGTCGC
AGAAGGATACAACAGCCTGCGTGATGCGTCAGGAGCAAAGCAGCGCCCAGGCCGGCCAGCGCGTTCTGAC
TGCCGAGCTGCGCAACGTCGCCGGCGGCAAAGTTGACGGTGTGTTGCTGATGCCGTTCGGTCTTGATCTT
GCCAAGGGCGCCTCGCTCAAGATTGATGACACCGCTGGGCCAAACCTCACCTTCTCCACCTGCCTGCCGC
AGGGCTGCCTCGCGCCAGTGAGCTTCGATGCCAAGCAGGTTGCTGCGCTGAAATCCGGCACCAACATCAA
TGTCACCACGACGGCGCTCAGCCCGAGCCAGCCGGTTGCCTTCAAGATTTCCCTGAAAGGCTTCGGTGCC
GCGCTCGACCGCATTCAGGCATTGACCAAGTA

Protein Sequence : Show Sequence

>NP_540501.1 invasion protein B [Brucella melitensis bv. 1 str. 16M]
MKNYRAIGLAFTFTALSSLSAFAASLPGGASTLQETYQDWTVSCQSQKDTTACVMRQEQSSAQAGQRVLT
AELRNVAGGKVDGVLLMPFGLDLAKGASLKIDDTAGPNLTFSTCLPQGCLAPVSFDAKQVAALKSGTNIN
VTTTALSPSQPVAFKISLKGFGAALDRIQALTK

Molecule Role : Protective antigen
Molecule Role Annotation : Brucella IalB is a protective antigen (Commander et al., 2007).
Related Vaccine(s): B. melitensis DNA vaccine p-ialB

19. L7/L12

Gene Name : L7/L12
Sequence Strain (Species/Organism) : Brucella abortus RB51-AHVLA
NCBI Protein GI : 479804332
Other Database IDs : CDD:100102
Taxonomy ID : 1198700
Gene Strand (Orientation) : ?
Protein Name : 50S ribosomal protein L7/L12
Protein pI : 4.62
Protein Weight : 12562.32
Protein Length : 198
Protein Note : vaccine strain

Protein Sequence : Show Sequence

>ENT73302.1 50S ribosomal protein L7/L12 [Brucella abortus RB51-AHVLA]
MADLAKIVEDLSALTVLEAAELSKLLEEKWGVSAAAPVAVAAAGGAAPAAAAEEKTEFDVVLADGGANKI
NVIKEVRALTGLGLKEAKDLVEGAPKAVKEGASKDEAEKIKAQLEAAGAKVELK

Molecule Role : Protective antigen
Related Vaccine(s): Divalent DNA B. abortus Vaccine pcDNA3.1-L7/L12-Omp16

20. manA

Gene Name : manA
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
NCBI Protein GI : 260563601
Locus Tag : BAB1_0562
Other Database IDs : CDD:32765
CDD:29324
Taxonomy ID : 224914
Chromosome No : I
Gene Starting Position : 550431
Gene Ending Position : 551708
Gene Strand (Orientation) : ?
Protein Name : ManA family protein
Protein Length : 390
Protein Note : N-acyl-D-glucosamine 2-epimerase [Carbohydrate transport and metabolism]

DNA Sequence : Show Sequence

>gi|82698932:550431-551708 Brucella melitensis biovar Abortus 2308 chromosome chromosome I, complete sequence
AATGAATGATGTGATACGTAAACTTCAGGTGGAAGTGGAGCGCTTATCGTCGTGGCTCCACAACGACGCT
TTGCCTCTTTGGTTGTCAGCCGGTGTGGATGCGCCGAATAGCGGTTTCTTTGAACGTATTGGACAGGACG
GCGTCGCAACGGATGCGGATAATCGTCGTTCTCGCGTGCATCCGAGACAGATCTACTGTTTCGCCAAGGC
TGGCGCCATGGGCTGGCAAGGCGAATGGAAGCAGACGGTTGAAGCCGGAATAGAATATTATGATCGCGTC
TATCGGCGAGAAGATGGTTTCTATGGCAGTCTTGCCGGTCAAAGTGGCAAGATGATTGATCACACGTTTG
ATCTCTACAATCAGGCTTTTTCCGTTTTTGCGGCCGCCCAGATCGCGGTTTCCATACCGGATCGGTTTGA
TGAAATGCGTCAGCGAGCGCTTGGTTTGATGAATACGCTCGTGGCAGATTATCACCACCCTCTCGGTGGA
TTTGAGGAAGCCAACCCGCCAAAGCTTCCCTTGTGTTCAAATCCGCACATGCATTTGTTTGAAGCAATGC
TTGCCTGGGAGACTGTCGATCCAGAAACCCAGTTCTGGTCCACATATGCCGATGAGATCGCAAATCTTGC
CTTAACGAAATTCATCGATGGCAAGACCGGTGCGTTGCGTGAATTCTTCGATCACGATTGGAAACCTTAT
CCGGGTGACAAGGGGAGGGTGGTCGAACCAGGACATCAATTCGAATGGTCCTGGCTGATGGGCCAATGGG
CGGACCGACGGCAGAATGGCGATGGCATGATGGCCGCCAAGCGTCTATTCCAGATTGCAGTGGATCGTGG
TGTATGCGAGCAGCGCAAAGTTGCCATCATGAGCTTGTATGATGATTTTTCGGTTCACGACAGTCTGGCC
CGTCTCTGGCCGCAAACTGAATGGATAAAGTCGGCTCTGTTATTTGCTTCTTTGAGCAAGGACGAAGAGC
GAGTTTACTATCTGCAATCCGCATTGCGTGCCATTGACGCCCTACGGCCATTTCTTGAAACGCCAATCAA
AGGCTTATGGTACGACAAGTGGCCGGAAGGTGGTACGCTTATCGATGAGCCCGCGCCGGCATCGACCTTT
TATCATATTCTCTGTGCCTGTTATGAAGCAGAGAAAACAATATCAGAGCTTTATGTTGTGGTGTCGAATT
TTTGGTTGTCGCCGCTGATGATGACGATCAGATGTGCCGATGATGCCGCATCTGTATTGGAGAAACATGC
GAGTTCTTCATTTTTTTA

Protein Sequence : Show Sequence

>gi|260563601|ref|ZP_05834087.1| ManA family protein [Brucella melitensis bv. 1 str. 16M]
MNDVIRKLQVEVERLSSWLHNDALPLWLSAGVDAPNSGFFERIGQDGVATDADNRRSRVHPRQIYCFAKA
GAMGWQGEWKQTVEAGIEYYDRVYRREDGFYGSLAGQSGKMIDHTFDLYNQAFSVFAAAQIAVSIPDRFD
EMRQRALGLMNTLVADYHHPLGGFEEANPPKLPLCSNPHMHLFEAMLAWETVDPETQFWSTYADEIANLA
LTKFIDGKTGALREFFDHDWKPYPGDKGRVVEPGHQFEWSWLMGQWADRRQNGDGMMAAKRLFQIAVDRG
VCEQRKVAIMSLYDDFSVHDSLARLWPQTEWIKSALLFASLSKDEERVYYLQSALRAIDALRPFLETPIK
GLWYDKWPEGGTLIDEPAPASTFYHILCACYEAEKTISEL

Molecule Role : Virmugen
Molecule Role Annotation : Unmarked rough B. abortus and B. melitensis deletion mutants of manBA (including manA and manB) were attenuated. These mutants provided protection against virulent Brucella challenge in mice (Kahl-McDonagh and Ficht, 2006).
Related Vaccine(s): B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA

21. manB

Gene Name : manB
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
NCBI Gene ID : 1198671
NCBI Protein GI : 17989244
Locus Tag : BMEII0899
Genbank Accession : AE008918
Protein Accession : NP_541877
Taxonomy ID : 224914
Chromosome No : II
Gene Starting Position : 940999
Gene Ending Position : 942432
Gene Strand (Orientation) : +
Protein Name : phosphomannomutase
Protein pI : 6.8
Protein Weight : 47237.87
Protein Length : 477
Protein Note : 5.4.2.8

DNA Sequence : Show Sequence

>gi|17988344:940999-942432 Brucella melitensis bv. 1 str. 16M chromosome II, complete sequence
CATGAGCAGCAATTCCCTCAAATTTGGCACGAGCGGCCTTCGCGGGCTGGCGGTAGAACTGAACGGCCTG
CCCGCCTATGCCTATACGATGGCCTTTGTGCAGATGCTTGCTGCAAAAGGGCAGTTGCAGAAGGGCGACA
AGGTGTTTGTCGGCAGGGATTTGCGCCCCTCCAGCCCTGATATTGCAGCCCTTGCCATGGGTGCCATCGA
AGATGCCGGCTTCACACCGGTCAATTGCGGCGTCCTGCCCACGCCTGCGCTGAGCTATTATGCGATGGGC
GCGAAAGCACCCAGCATCATGGTCACGGGAAGCCATATTCCAGATGATCGCAACGGGCTGAAATTCTATC
GCCGCGACGGTGAAATCGACAAGGATGATGAGGCGGCAATCAGTGCAGCCTATCGCAAGCTGCCTGCCAT
TCTCGCTGCCCGCAAACATGTCGGCTCCACCGAAACCGATGCGGCCTTGCAGGCTTATGCCGATCGCTAT
GCAGGTTTTCTTGGGAAAGGGAGCCTGAATGGCCTGCGGGTCGGCGTTTATCAACATTCTTCCGTGGCGC
GCGATCTTCTGATGTACCTGCTCACGACACTCGGCGTGGAACCCGTGGCGCTCGGACGATCCGATATATT
CGTGCCGGTCGATACCGAGGCATTGCGCCCCGAAGACATTGCGCTGCTTGCCCAATGGGGCAAAAGCGAC
AGGCTTGATGCCATCGTCTCCACCGACGGAGACGCGGATCGCCCGCTGATTGCCGATGAGCATGGACAAT
TCGTTCGCGGCGATCTTGCTGGCGCCATCACCGCCACATGGGTGGGGGCGGATACGCTCGTCACGCCAGT
CACCTCCAACACCGCATTGGAAAGCCGCTTTCCCAAGGTTTTGAGAACGCGCGTCGGTTCGCCTTATGTC
ATCGCAAGCATGGCACAGGTATCCACGGGCAATTCCGGCCCGGTCATCGGGTTTGAGGCCAATGGCGGCG
TTCTGCTTGGCAGCACGGTCGAGAGGAATGGACGAAGCCTGACGGCCCTGCCGACGCGCGACGCCTTGTT
GCCCATTCTGGCTTGCCTTGCCACGGTTCACGAAAAGAAAACGCCGCTTTCAACAATCGCCCGGTCCTAT
GGCTTCCGCGTCGCGCTTAGCGACCGGCTGCAAAACATTCCGCAGGAGGCGAGCACCGCCTTCCTCGCGC
TCTTGGAGGATGCGGATAAACGCGCCTCGCTCTTTCCTGCTGGCGACGCAATCGTGCGGGTGGAAACCAT
CGACGGCGTGAAGCTTTTCTTTCAATCAGGCAATGCGGTTCATTATCGGGCATCGGGCAATGCGCCGGAA
CTGCGCTGCTATGTGGAATCTTCGGATGACACACAAGCCGCCAAGCTTCAGGCGCTTGGCTTGGAAATCG
CACGCAAAGCACTAAAGGATGCGACGAGGCCATG

Protein Sequence : Show Sequence

>gi|17989244|ref|NP_541877.1| phosphomannomutase [Brucella melitensis bv. 1 str. 16M]
MSSNSLKFGTSGLRGLAVELNGLPAYAYTMAFVQMLAAKGQLQKGDKVFVGRDLRPSSPDIAALAMGAIE
DAGFTPVNCGVLPTPALSYYAMGAKAPSIMVTGSHIPDDRNGLKFYRRDGEIDKDDEAAISAAYRKLPAI
LAARKHVGSTETDAALQAYADRYAGFLGKGSLNGLRVGVYQHSSVARDLLMYLLTTLGVEPVALGRSDIF
VPVDTEALRPEDIALLAQWGKSDRLDAIVSTDGDADRPLIADEHGQFVRGDLAGAITATWVGADTLVTPV
TSNTALESRFPKVLRTRVGSPYVIASMAQVSTGNSGPVIGFEANGGVLLGSTVERNGRSLTALPTRDALL
PILACLATVHEKKTPLSTIARSYGFRVALSDRLQNIPQEASTAFLALLEDADKRASLFPAGDAIVRVETI
DGVKLFFQSGNAVHYRASGNAPELRCYVESSDDTQAAKLQALGLEIARKALKDATRP

Molecule Role : Virmugen
Molecule Role Annotation : Mutants manB and manA were attenuated in Brucella melitensis and provided protection against challenge in mice's livers (Kahl-McDonagh et al., 2007).
Related Vaccine(s): B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA

22. mucR

Gene Name : mucR
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
NCBI Gene ID : 1197075
NCBI Protein GI : 17987647
Locus Tag : BMEI1364
Genbank Accession : AE008917
Protein Accession : NP_540281
Taxonomy ID : 224914
Chromosome No : I
Gene Starting Position : 1417768
Gene Ending Position : 1418253
Gene Strand (Orientation) : -
Protein Name : transcriptional regulatory protein MUCR
Protein pI : 9.56
Protein Weight : 16771.01
Protein Length : 161

DNA Sequence : Show Sequence

>gi|17986284:1417768-1418253 Brucella melitensis bv. 1 str. 16M chromosome chromosome I, complete sequence
ATCAGGCGTCCTTCGGCTTGCGGCCGAGGCCCATCTTCTTGGCAAGGCGCGAGCGCGCTGCAGCATAGTT
CGGAGCAACCATAGGATAGTTCGGATCGAGATCCCACTTTTCGCGGTACTGCTCAGGCGTCATGTTGTAA
TGGGTCACCAGGTGACGCTTCAGCGACTTGAACTTCTTGCCGTCTTCAAGGCAGACAATATAGTCGTCAT
GAACAGACTTCTTCGGGTTCACCGCTGGCTTCGGCTTTTCAACAACGACCGGGGCCTCTTCGCGTTCGAC
GTGGCGCTTGAAAGCAGCATGAACTTCAGCAATCAGAACCGGGAGTTCGCCTGCACGAATGGAATTATTG
CCGACATAGGCTGCAACGACATCGGCGGTCAAACTCAAAAGCAGCTCGGTGCTTTCGTCGTTCGTTTCCA
GATTTTCCATAAGTTTTCCTTTTTTAATTTTTTGTTGTCCGCGCAGCGGCTGACAATGGCAACCCA

Protein Sequence : Show Sequence

>gi|17987647|ref|NP_540281.1| transcriptional regulatory protein MUCR [Brucella melitensis bv. 1 str. 16M]
MGCHCQPLRGQQKIKKGKLMENLETNDESTELLLSLTADVVAAYVGNNSIRAGELPVLIAEVHAAFKRHV
EREEAPVVVEKPKPAVNPKKSVHDDYIVCLEDGKKFKSLKRHLVTHYNMTPEQYREKWDLDPNYPMVAPN
YAAARSRLAKKMGLGRKPKDA

Molecule Role : Virmugen
Molecule Role Annotation : A mucR mutant has a significantly reduced degree of colonization in mice and protects against wild type B. melitensis 16M (Arenas-Gamboa et al., 2011).
Related Vaccine(s): Brucella melitensis mucR mutant vaccine

23. Omp16

Gene Name : Omp16
Sequence Strain (Species/Organism) : Brucella abortus 2308
VO ID : VO_0010973
NCBI Gene ID : 3788229
NCBI Protein GI : 489056820
Locus Tag : BAB_RS24085
Genbank Accession : AM040264
Protein Accession : WP_002966947
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 1654432
Gene Ending Position : 1654938
Gene Strand (Orientation) : -
Protein Name : hypothetical protein
Protein pI : 10.24
Protein Weight : 17438.15
Protein Length : 168
Protein Annotation : Synonyms: Omp16, MotY

DNA Sequence : Show Sequence

>NC_007618.1:1654432-1654938 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
TTTACCGTCCGGCCCCGTTGAGAACGGTGACGGCGCGACGGTTCTGCGACCAGCATGTGTCGGCATCGCA
GACGGCAACCGGGCGCTCATTACCGTAGGAAATGGTGCGCATGCGGTTGGTCGGCACACCGCGCGAAGCG
AGGAAGTCGCGGGTGGCGGCAGCACGGCGCTGGCCAAGGGCGAGGTTGTACTCACGCGTGCCGCGCTCGT
CGGCATGGCCTTCGATCGTGATCGAATACTGCGGATAACGCTGCAACCACTGGGCCTGCTTGGAAAGCGT
CTGCTGCGCATCGGCGCGGATCAGCGACGAATCGAGATCGAAGAAGATGCGGTCGCCGACATTAACGGTG
AAGTCCTGCGAGGAGCCCGGCGTTGCAGCGCCTGCACCGAGACCCAGATCACCGGCATTATTCGGAAGGT
TCTTCTTTGACGCACAGCCGGCAACGGCGAGCGACATGAAAAGCGCAATAGCGATCGGGCTACGTGCAAT
CGACTGGATACGGCGCA

Protein Sequence : Show Sequence

>WP_002966947.1 MULTISPECIES: hypothetical protein [Brucella]
MRRIQSIARSPIAIALFMSLAVAGCASKKNLPNNAGDLGLGAGAATPGSSQDFTVNVGDRIFFDLDSSLI
RADAQQTLSKQAQWLQRYPQYSITIEGHADERGTREYNLALGQRRAAATRDFLASRGVPTNRMRTISYGN
ERPVAVCDADTCWSQNRRAVTVLNGAGR

Molecule Role : Protective antigen
Molecule Role Annotation : Brucella Omp16 is a protective antigen (Pasquevich et al., 2009).
Related Vaccine(s): B. abortus DNA vaccine encoding RplL and Omp16

24. omp16

Gene Name : omp16
Sequence Strain (Species/Organism) : Brucella abortus RB51-AHVLA
NCBI Protein GI : 479804733
Other Database IDs : CDD:225439
CDD:143586
Taxonomy ID : 1198700
Gene Strand (Orientation) : ?
Protein Name : outer membrane lipoprotein omp16
Protein pI : 10.24
Protein Weight : 18331.05
Protein Length : 247
Protein Note : vaccine strain

Protein Sequence : Show Sequence

>ENT73703.1 outer membrane lipoprotein omp16 [Brucella abortus RB51-AHVLA]
MRRIQSIARSPIAIALFMSLAVAGCASKKNLPNNAGDLGLGAGAATPGSSQDFTVNVGDRIFFDLDSSLI
RADAQQTLSKQAQWLQRYPQYSITIEGHADERGTREYNLALGQRRAAATRDFLASRGVPTNRMRTISYGN
ERPVAVCDADTCWSQNRRAVTVLNGAGR

Molecule Role : Protective antigen
Related Vaccine(s): Divalent DNA B. abortus Vaccine pcDNA3.1-L7/L12-Omp16

25. Omp19

Gene Name : Omp19
Sequence Strain (Species/Organism) : Brucella abortus 2308
VO ID : VO_0010972
NCBI Gene ID : 3788831
NCBI Protein GI : 489054833
Locus Tag : BAB_RS25135
Genbank Accession : AM040264
Protein Accession : WP_002964998
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 1877306
Gene Ending Position : 1877839
Gene Strand (Orientation) : -
Protein Name : hypothetical protein
Protein pI : 8.86
Protein Weight : 16412.87
Protein Length : 177

DNA Sequence : Show Sequence

>NC_007618.1:1877306-1877839 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
ATCAGCGCGACAGCGTCACGGCCTGCCCGCCGGTGGTCTGGCCATCGAAGCGGCCCTGTCCTGAAGAATA
GAGCGAGGCAACCGTACCGCCGTTCGCATCGTAAAGGACGAGTTGCTTGCCATTGACGGCCCAGGAGGCA
AGATTAGCCAGTTCACCGGGGCAGCGCAGCGGGCCTGCGCGATAGCCCTGGCCATATTTGGTCTGCGGCG
TCGCGATCTTGCAGCTCTGACCACCAAGCGAGGCGTTCCAGACGCCAGCCACGGCGCCGGGCGTCAGGTC
CGGTGCGGATGCAGGCGGCAGGCTTGCGACCTGTGTGCCGGATTGCGCGCTCATATCCGTGGAGGGCGCA
TTGGGGAATTGTGTGGGAGAATCAAGATTGCCTTTCTGCACCGTGCCTGCCGGAACAGCATTGACCGGTG
CAGGCGGCGGCGGAGGCGAAACATTATCGAGATTACCAAGCCGGGAGCTCTGGCACCCGGCCAGGACAAT
GCCAGCCGCCGCGAGGCTGAGCAGACTTGCTTTTGAAATTCCCA

Protein Sequence : Show Sequence

>WP_002964998.1 MULTISPECIES: hypothetical protein [Brucella]
MGISKASLLSLAAAGIVLAGCQSSRLGNLDNVSPPPPPAPVNAVPAGTVQKGNLDSPTQFPNAPSTDMSA
QSGTQVASLPPASAPDLTPGAVAGVWNASLGGQSCKIATPQTKYGQGYRAGPLRCPGELANLASWAVNGK
QLVLYDANGGTVASLYSSGQGRFDGQTTGGQAVTLSR

Molecule Role : Protective antigen
Molecule Role Annotation : Brucella Omp19 is a protective antigen (Pasquevich et al., 2009).

26. Omp25

Gene Name : Omp25
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
VO ID : VO_0010966
NCBI Gene ID : 1196960
NCBI Protein GI : 17987532
Locus Tag : BMEI1249
Genbank Accession : AE008917
Protein Accession : NP_540166
Taxonomy ID : 224914
Chromosome No : I
Gene Starting Position : 1297524
Gene Ending Position : 1298165
Gene Strand (Orientation) : -
Protein Name : hypothetical protein
Protein pI : 9.03
Protein Weight : 21696.72
Protein Length : 213
Protein Annotation : Reference: http://www.ncbi.nlm.nih.gov/pubmed/17049676

DNA Sequence : Show Sequence

>NC_003317.1:1297524-1298165 Brucella melitensis bv. 1 str. 16M chromosome I, complete sequence
ATTAGAACTTGTAGCCGATGCCGACGCGGAAATCCTGCGTGTCCAGCTTGTTGCGAACAGTCGTACCGGC
CAGATCATAGTTCTTGTTGCCGTACTGGGTGTAACGGTACTCAACGCGGCCGAGGATGTTGTCCGTCAGC
TTGGCTTCGAGACCGGCACCAGCCGTCCAACCCACGCGGAACTTGCTTTCGTCGTCCAAGCCGTTGTTAA
GCTTGATCTGCGAACCGGCAATACCAGCCGTGAGGTACGGCATAACCGGGTTCAGGTCGTAGCCAACGCG
GGCACGCAGCGAGCCTTCAAAGCCCTGCTTGACTTCCAGGCCGTCCTTGGACTTCTTGGCCCAGGAATAA
CCTGCATCACCTTCAACACCGTATACGATCTGGTCCTGCTGGAAGTTCCAGCCAGCAAAGGCGCCAGCCT
TCCAATCGTCAGGCTTGATGCTGCCAACGGTGCTGGTCTTGGCCTTGTTCCAGCCGTAGCCAAGGTAAAG
ACCGGTATAGCCACCAGCCCAGCTATACTGGGGAGCTACTTCAACCGGAGCCGGAACCGGAGGCTGTTCC
TGGATGGCGTCGGCAGCAAAAGCGGTCGCAGAGAACGGCAGCAACGCAGCCGAGACGATTACGAGAGACT
TAAGAGTGCGCA

Protein Sequence : Show Sequence

>NP_540166.1 hypothetical protein BMEI1249 [Brucella melitensis bv. 1 str. 16M]
MRTLKSLVIVSAALLPFSATAFAADAIQEQPPVPAPVEVAPQYSWAGGYTGLYLGYGWNKAKTSTVGSIK
PDDWKAGAFAGWNFQQDQIVYGVEGDAGYSWAKKSKDGLEVKQGFEGSLRARVGYDLNPVMPYLTAGIAG
SQIKLNNGLDDESKFRVGWTAGAGLEAKLTDNILGRVEYRYTQYGNKNYDLAGTTVRNKLDTQDFRVGIG
YKF

Molecule Role : Protective antigen
Molecule Role Annotation : Brucella Omp25 is a protective antigen (Commander et al., 2007).
Additional Molecule Role : Virmugen
Additional Molecule Role Annotation : A omp25 mutant is attenuated and provides protection against challenge in mice (Edmonds et al., 2002).
Related Vaccine(s): B. melitensis DNA vaccine p-Omp25 , Brucella melitensis omp25 mutant vaccine

27. Omp31

Gene Name : Omp31
Sequence Strain (Species/Organism) : Brucella abortus 2308
VO ID : VO_0010939
NCBI Gene ID : 3788834
NCBI Protein GI : 489054549
Locus Tag : BAB_RS23735
Genbank Accession : AM040264
Protein Accession : WP_002964719
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 1583642
Gene Ending Position : 1584427
Gene Strand (Orientation) : +
Protein Name : membrane protein
Protein pI : 4.74
Protein Weight : 25591.47
Protein Length : 261

DNA Sequence : Show Sequence

>NC_007618.1:1583642-1584427 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
CATGTTTAGCTTAAAAGGGACTGTTATGAAAACCGCACTTCTTGCATCCGTCGCAATGTTGTTCACAAGC
TCGGCTATGGCTGCCGACATCATCGTTGCTGAACCGGCACCCGTTGCAGTCGACACGTTCTCTTGGACTG
GCGGCTATATTGGTATCAATGCTGGTTACGCTGGCGGCAAGTTCAAGCATCCGTTCTCAGGCATCGAGCA
GGATGGGGCCCAAGATTTTTCAGGTTCGCTCGACGTCACGGCCAGCGGCTTTGTTGGCGGCGTTCAGGCC
GGTTATAACTGGCAGCTTGCCAACGGCCTCGTGCTTGGTGGCGAAGCTGACTTCCAGGGCTCGACGGTTA
AGAGCAAGCTTGTTGACAACGGTGACCTCTCCGATATCGGCGTTGCAGGCAACCTCAGCGGCGACGAAAG
CTTCGTCCTCGAGACCAAGGTTCAGTGGTTTGGAACGGTGCGTGCGCGCCTCGGCTTCACCCCGACTGAA
CGCCTGATGGTCTATGGTACCGGTGGTTTGGCCTATGGTAAGGTCAAGACGTCGCTTAGCGCCTATGACG
ATGGTGAATCGTTCAGCGCCGGAAACTCTAAGACCAAGGCTGGCTGGACGCTTGGTGCAGGTGTAGAATA
CGCCGTCACCAACAATTGGACCCTGAAGTCGGAATACCTCTACACCGACCTCGGCAAGCGTTCCTTCAAT
TACATTGATGAAGAAAACGTCAATATTAACATGGAAAACAAGGTGAACTTCCACACCGTCCGCCTCGGTC
TGAACTACAAGTTCTA

Protein Sequence : Show Sequence

>WP_002964719.1 MULTISPECIES: porin family protein [Brucella]
MFSLKGTVMKTALLASVAMLFTSSAMAADIIVAEPAPVAVDTFSWTGGYIGINAGYAGGKFKHPFSGIEQ
DGAQDFSGSLDVTASGFVGGVQAGYNWQLANGLVLGGEADFQGSTVKSKLVDNGDLSDIGVAGNLSGDES
FVLETKVQWFGTVRARLGFTPTERLMVYGTGGLAYGKVKTSLSAYDDGESFSAGNSKTKAGWTLGAGVEY
AVTNNWTLKSEYLYTDLGKRSFNYIDEENVNINMENKVNFHTVRLGLNYKF

Molecule Role : Protective antigen
Related Vaccine(s): B. melitensis 16M DNA vaccine expressing Omp31

28. omp31

Gene Name : omp31
Sequence Strain (Species/Organism) : Brucella melitensis ATCC 23457
NCBI Gene ID : 7676420
NCBI Protein GI : 225853091
Locus Tag : BMEA_A1674
Genbank Accession : CP001488
Protein Accession : YP_002733324
Taxonomy ID : 546272
Chromosome No : I
Gene Starting Position : 1588634
Gene Ending Position : 1589242
Gene Strand (Orientation) : +
Protein Name : outer membrane protein Omp31
Protein pI : 4.8
Protein Weight : 20497.92
Protein Length : 202

DNA Sequence : Show Sequence

>gi|225851546:1588634-1589242 Brucella melitensis ATCC 23457 chromosome chromosome I, complete sequence
TGTGTTGCAATATAGTGACAGACATTGGAGCCCATATTGGGCCCAAGATTTTTCAGGTTCGCTCGACGTC
ACGGCCAGCGGCTTTGTTGGCGGCGTTCAGGCCGGTTATAACTGGCAGCTTGCCAACGGCCTCGTGCTTG
GTGGCGAAGCTGACTTCCAGGGCTCGACGGTTAAGAGCAAGCTTGTTGACAACGGTGACCTCTCCGATAT
CGGCGTTGCAGGCAACCTCAGCGGCGACGAAAGCTTCGGCCTCGAGACCAAGGTTCAGTGGTTTGGAACG
GTGCGTGCGCGCCTCGGCTTCACCCCGACTGAACGCCTGATGGTCTATGGTACCGGTGGTTTGGCCTATG
GTAAGGTCAAGACGTCGCTTAGCGCCTATGACGATGGTGAATCGTTCAGCGCCGGAAACTCTAAGACCAA
GGCTGGCTGGACGCTTGGTGCAGGTGTAGAATACGCCGTCACCAACAATTGGACCCTGAAGTCGGAATAC
CTCTACACCGACCTCGGCAAGCGTTCCTTCAATTACATTGATGAAGAAAACGTCAATATTAACATGGAAA
ACAAGGTGAACTTCCACACCGTCCGCCTCGGTCTGAACTACAAGTTCTA

Protein Sequence : Show Sequence

>gi|225853091|ref|YP_002733324.1| outer membrane protein Omp31 [Brucella melitensis ATCC 23457]
MLQYSDRHWSPYWAQDFSGSLDVTASGFVGGVQAGYNWQLANGLVLGGEADFQGSTVKSKLVDNGDLSDI
GVAGNLSGDESFGLETKVQWFGTVRARLGFTPTERLMVYGTGGLAYGKVKTSLSAYDDGESFSAGNSKTK
AGWTLGAGVEYAVTNNWTLKSEYLYTDLGKRSFNYIDEENVNINMENKVNFHTVRLGLNYKF

Molecule Role : Virmugen
Molecule Role Annotation : A omp31 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice (Cloeckaert et al., 2004).
Related Vaccine(s): B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 , Brucella melitensis omp31 mutant vaccine

29. omp31

Gene Name : omp31
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
NCBI Protein GI : 61229373
Other Database IDs : CDD:226163
Taxonomy ID : 224914
Gene Strand (Orientation) : ?
Protein Name : 31 kDa outer-membrane immunogenic protein
Protein pI : 5.06
Protein Weight : 24732.46
Protein Length : 343
Protein Note : biovar: 1 str. 16M

Protein Sequence : Show Sequence

>sp|P0A3U4.1|OM31_BRUME RecName: Full=31 kDa outer-membrane immunogenic protein; Flags: Precursor
MKSVILASIAAMFATSAMAADVVVSEPSAPTAAPVDTFSWTGGYIGINAGYAGGKFKHPFSSFDKEDNEQ
VSGSLDVTAGGFVGGVQAGYNWQLDNGVVLGAETDFQGSSVTGSISAGASGLEGKAETKVEWFGTVRARL
GYTATERLMVYGTGGLAYGKVKSAFNLGDDASALHTWSDKTKAGWTLGAGAEYAINNNWTLKSEYLYTDL
GKRNLVDVDNSFLESKVNFHTVRVGLNYKF

Molecule Role : Protective antigen
Related Vaccine(s): B. melitensis DNA vaccine pCI-Omp31 , B. melitensis DNA vaccine pCIBLSOmp31 encoding BLSOmp31 (fusion protein)

30. ORF

Gene Name : ORF
VO ID : VO_0010927
NCBI Nucleotide GI : 599653
NCBI Protein GI : 599654
Protein Accession : CAA86936.1
3D structure: PDB ID : 1DI0
Other Database IDs : CDD:237096
CDD:187741
GOA:P61711
InterPro: IPR002180
PDB: 1DI0
PDB: 1T13
PDB: 1XN1
UniProtKB/UniProt: P61711
Taxonomy ID : 235
Gene Strand (Orientation) : ?
Protein pI : 7.41
Protein Weight : 16119.15
Protein Length : 197
Protein Note : riboflavin synthase subunit beta; Provisional

DNA Sequence : Show Sequence

>gi|599653|emb|Z46864.1| B.abortus gene for open reading frame
GAATTCCGATCAGTGCATAGTTTCCGCGTGCTCGCGCAATGGTGCGCGGGCTTGTTCTCGGGGCGGGGTG
AAACTCCCCACCGGCGGTATGAAAAGCAATTTTCAAGCCCGCGAGCGCCTGAAATGGAAGCCGATTCGCA
TGCCATTTCAGGGTCAGCAGATCCGGTGAGATGCCGGAGCCGACGGTTAAAGTCCGGATGGAAGAGAGCG
AATGAGCGTCACGATTGCGCCTTCCGGCGTCGTTCTTGCGTTCTTTTGTGCGCCCTGATTCTAGTTTCGT
GAGGAACCTATGAACCAAAGCTGTCCGAACAAGACATCCTTTAAAATCGCATTCATTCAGGCCCGCTGGC
ACGCCGACATCGTTGACGAAGCGCGCAAAAGCTTTGTCGCCGAACTGGCCGCAAAGACGGGTGGCAGCGT
CGAGGTAGAGATATTCGACGTGCCGGGTGCATATGAAATTCCCCTTCACGCCAAGACATTGGCCAGAACC
GGGCGCTATGCAGCCATCGTCGGTGCGGCCTTCGTGATCGACGGCGGCATCTATCGTCATGATTTCGTGG
CGACGGCCGTTATCAACGGCATGATGCAGGTGCAGCTTGAAACGGAAGTGCCGGTGCTGAGCGTCGTGCT
GACGCCGCACCATTTCCATGAAAGCAAGGAGCATCACGACTTCTTCCATGCTCATTTCAAGGTGAAGGGC
GTGGAAGCGGCCCATGCCGCCTTGCAGATCGTGAGCGAGCGCAGCCGCATCGCCGCGCTTGTCTGACTAA
CCCTCTATAATACGCCCGCAATGGGTATAAATGTCGAATTC

Protein Sequence : Show Sequence

>CAA86936.1 ORF [Brucella abortus]
MNQSCPNKTSFKIAFIQARWHADIVDEARKSFVAELAAKTGGSVEVEIFDVPGAYEIPLHAKTLARTGRY
AAIVGAAFVIDGGIYRHDFVATAVINGMMQVQLETEVPVLSVVLTPHHFHESKEHHDFFHAHFKVKGVEA
AHAALQIVSERSRIAALV

Molecule Role : Protective antigen
Molecule Role Annotation : This gene was originally isolated from a lambda gt11 expression library probed with sera from Brucella-infected sheep. Sequence analysis of the cloned gene revealed the presence of an open reading frame of 158 amino acids encoding a protein of 17.3 kDa (Hemmen et al., 1995). It was later identified as a cytoplasmic protein lumazine synthase (Goldbaum et al., 1999). This gene can be used for diagnosis (Hemmen et al., 1995; Goldbaum et al., 1999) and vaccine development (Velikovsky et al., 2002).
Related Vaccine(s): B. abortus pcDNA-BLS , B. melitensis DNA vaccine pCIBLSOmp31 encoding BLSOmp31 (fusion protein)

31. P39 from Brucella abortus

Gene Name : P39 from Brucella abortus
Sequence Strain (Species/Organism) : Brucella abortus bv. 1 str. 9-941
NCBI Protein GI : 68067499
Other Database IDs : CDD:224567
Taxonomy ID : 262698
Gene Strand (Orientation) : ?
Protein Name : Probable sugar-binding periplasmic protein
Protein pI : 5.06
Protein Weight : 44330.68
Protein Length : 589
Protein Note : biovar: 1 str. 9-941

Protein Sequence : Show Sequence

>sp|O06875.3|SP39_BRUAB RecName: Full=Probable sugar-binding periplasmic protein; AltName: Full=Immunogenic 39 kDa protein; AltName: Full=P39; Flags: Precursor
MHKLLKLAAMGTAACALLAGMAPVANAQEKQNVEVLHWWTSGGEASALEVLKKDLESKGISWTDMPVAGG
GGTEAMTVLRARVTAGNAPTAVQMLGFDIRDWAEQGALGNLDTVASKEGWEKVIPAPLQEFAKYDGHWIA
APVNIHSTNWMWINKAALDKAGGKEPTNWDELIALLDNFKAQGITPIAHGGQPWQDATIFDAVVLSFGPD
FYKKAFIDLDPEALGSDTMKQAFDRMSKLRTYVDDNFSGRDWNLASAMVIEGKAGVQFMGDWAKGEFLKA
GKKPGEDFVCMRYPGTQGAVTFNSDMFAMFKVSEDKVPAQLEMASAIESPAFQSAFNVVKGSAPARTDVP
DTAFDACGKKAIADVKEANSKGTLLGSMAHGYANPAAVKNAIYDVVTRQFNGQLSSEDAVKELVAAVEAA
K

Molecule Role : Protective antigen
Related Vaccine(s): B. abortus DNA vaccine pcDNA3.1-p39-L7/L12 encoding p39-L7/L12 fusion protein

32. PALFn

Gene Name : PALFn
Sequence Strain (Species/Organism) : Bacillus anthracis
NCBI Protein GI : AKB95640
Other Database IDs : CDD:284994
CDD:281492
CDD:285037
CDD:286266
CDD:238144
Taxonomy ID : 32630
Protein Name : PALFn
Protein pI : 5.69
Protein Weight : 169963.43
Protein Length : 1613
Protein Note : derived from Bacillus anthracis

Protein Sequence : Show Sequence

>AKB95640.1 PALFn [synthetic construct]
MSYYHHHHHHDYDIPTTENLYFQGAMDPEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGD
LSIPSSELENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGR
LYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDRDNDG
IPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEAR
HPLVAAYPIVHVDMENIILSKNEDQSTQNTDSQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVSA
GFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLA
TIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATY
NFENGRVRVDTGSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFG
FNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNVTNIYTVLDKIKLNAKMNILIRDKRFHYDRNN
IAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDG
KTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIGGGGGSGG
GGSAGGHGDVGMHVKEKEKNKDENKRKDEERNKTQEEHLKEIMKHIVKIEVKGEEAVKKEAAEKLLEKVP
SDVLEMYKAIGGKIYIVDGDITKHISLEALSEDKKKIKDIYGKDALLHEHYVYAKEGYEPVLVIQSSEDY
VENTEKALNVYYEIGKILSRDILSKINQPYQKFLDVLNTIKNASDSDGQDLLFTNQLKEHPTDFSVEFLE
QNSNEVQEVFAKAFAYYIEPQHRDVLQLYAPEAFNYMDKFNEQEINLSLEELKDQRMLSRYEKWEKIKQH
YQHWSDSLSEEGRGLLKKLQIPIEPKKDDIIHSLSQEEKELLKRIQIDSSDFLSTEEKEFLKKLQIDIRD
SLSEEEKELLNRIQVDSSNPLSEKEKEFLKKLKLDIQPYDINQRLQDTGGLIDSPSINLDVRKQYKRDIQ
NIDALLHQSIGSTLYNKIYLYENMNINNLTATLGADLVDSTDNTKINRGIFNEFKKNFKYSISSNYMIVD
INERPALDNERLKWRIQLSPDTRAGYLENGKLILQRNIGLEIKDVQIIKQSEKEYIRIDAKVVPKSKIDT
KIQEAQLNINQEWNKALGLPKYTKLITFNVHNRYASNIVESAYLILNEWKNNIQSDLIKKVTNYLVDGNG
RFVFTDITLPNIAEQYTHQDEIYEQVHSKGLYVPESRSILLHGPSKGVELRNDSEGFIHEFGHAVDDYAG
YLLDKNQSDLVTNSKKFIDIFKEEGSNLTSYGRTNEAEFFAEAFRLMHSTDHAERLKVQKNAPKTFQFIN
DQIKFIINS

Molecule Role : Protective antigen
Molecule Role Annotation : (Suryanarayana et al., 2016)

33. pgk

Gene Name : pgk
Sequence Strain (Species/Organism) : Brucella melitensis biovar Abortus 2308
NCBI Gene ID : 3788256
NCBI Protein GI : 82700518
Locus Tag : BAB1_1742
Genbank Accession : AM040264
Protein Accession : YP_415092
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 1682955
Gene Ending Position : 1684142
Gene Strand (Orientation) : ?
Protein Name : phosphoglycerate kinase
Protein pI : 5.91
Protein Weight : 37696.73
Protein Length : 395
Protein Note : Converts 3-phospho-D-glycerate to 3-phospho-D-glyceroyl phosphate during the glycolysis pathway

DNA Sequence : Show Sequence

>gi|82698932:1682955-1684142 Brucella melitensis biovar Abortus 2308 chromosome chromosome I, complete sequence
GATGTTCCGCACCCTTGACGATGCCAATGTCCAATCCAAGCGCGTGCTGGTCCGTGTTGACCTCAACGTG
CCGATGGCAAACGGCGAAGTCACCGACCTTACCCGCATCGAACGCATCGTTCCGACCATCGCGGAACTGT
CAAGGAAGGGCGCGAAGGTCATCCTGCTCGCCCATTTCGGTCGCCCGAAGGGGGTTGCCTCGGATGAAAA
TTCGCTGAAGCATGTCGTGAAGCCGCTCTCCAAGGTTCTGGATCACAGTGTTCATTTTGCCGAAGACTGC
ATCGGCGACAAGGCGAAAGCGGCCGTCGATGCGCTGAAGGACGGCGACGTCCTGCTTCTGGAAAATACCC
GTTTCCACAAGGGCGAGGAAAAGAACGATCCTGAATTCGTGCAGGCGCTGGCCGCCAATGGCGATCTCTA
TGTGAACGATGCCTTTTCCGCCGCTCACCGCGCCCATGCCTCGACTGAAGGTCTGGCCCATGTCCTGCCT
GCCTTCGCGGGCCGCGCCATGCAGGCTGAGCTTGAAGCACTTGAAAAGGGCCTCGGCAATCCGGCCCGCC
CGGTGGTCGCCATCGTCGGCGGTGCAAAGGTTTCGACCAAGCTCGACCTCCTGTCCAACCTGATCGAAAA
GGTCGATGCGCTTGTCATCGGCGGCGGCATGGCCAACACGTTCCTTGCAGCCAAGGGTCTTGATGTCGGC
AAATCGCTCTGCGAGCATGAGCTGGCCTCGACCGCACGCGAAATCATGGCCAAGGCCGAAACCACCAAAT
GCGCCATCATCCTGCCGGTGGACGCGGTCGTGGGCTGGCACTTCGCCGCCGATACGCCACACCAGACCTA
TGGCGTGGATTCGGTTCCGGGCGACGCCATGATCCTTGACGCAGGCGAGCTTTCGACCGACCTCATTGCT
TCGGCCATCGATGATGCCGCAACATTGGTCTGGAACGGCCCGCTTGGGGCTTTCGAGTTGCGCCCCTTTG
ACACAGCAACGGTGAAGGTCGCAAGGCATGTCGCAAAGCGCACAAAGGAAGGCAAGCTTGTTTCGGTCGG
CGGCGGCGGCGATACGGTGGCAGCCCTCAACCATGCGGGCGTGGCCGACGACTTCACCTATATCTCAACC
GCTGGCGGCGCTTTCCTCGAATGGATGGAAGGCAAACCGCTTCCGGGCGTCGATGTATTGAAGAAGTG

Protein Sequence : Show Sequence

>gi|82700518|ref|YP_415092.1| phosphoglycerate kinase [Brucella melitensis biovar Abortus 2308]
MFRTLDDANVQSKRVLVRVDLNVPMANGEVTDLTRIERIVPTIAELSRKGAKVILLAHFGRPKGVASDEN
SLKHVVKPLSKVLDHSVHFAEDCIGDKAKAAVDALKDGDVLLLENTRFHKGEEKNDPEFVQALAANGDLY
VNDAFSAAHRAHASTEGLAHVLPAFAGRAMQAELEALEKGLGNPARPVVAIVGGAKVSTKLDLLSNLIEK
VDALVIGGGMANTFLAAKGLDVGKSLCEHELASTAREIMAKAETTKCAIILPVDAVVGWHFAADTPHQTY
GVDSVPGDAMILDAGELSTDLIASAIDDAATLVWNGPLGAFELRPFDTATVKVARHVAKRTKEGKLVSVG
GGGDTVAALNHAGVADDFTYISTAGGAFLEWMEGKPLPGVDVLKK

Molecule Role : Virmugen
Molecule Role Annotation : A pgk mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus (Trant et al., 2010).
Related Vaccine(s): Brucella abortus pgk mutant vaccine

34. pgm

Gene Name : pgm
Sequence Strain (Species/Organism) : Brucella melitensis biovar Abortus 2308
NCBI Gene ID : 3788847
NCBI Protein GI : 82698981
Locus Tag : BAB1_0055
Genbank Accession : AM040264
Protein Accession : YP_413555
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 60852
Gene Ending Position : 62483
Gene Strand (Orientation) : -
Protein Name : phosphoglucomutase
Protein pI : 6.52
Protein Weight : 55523.82
Protein Length : 543
Protein Note : catalyzes the interconversion of alpha-D-glucose 1-phosphate to alpha-D-glucose 6-phosphate

DNA Sequence : Show Sequence

>gi|82698932:60852-62483 Brucella melitensis biovar Abortus 2308 chromosome chromosome I, complete sequence
CTCAAGTAACCACCGACGGCTCTGTCCGCCCGCTGCGTTTTTTTACTTCGGCGATCTGTTCAGCCGCGTC
GATCAGTGGGGCCAGCGTTGCCTGCGTGTCGAGATTATGTTTTGCAGGATCGGCTTCATAGCGTTCGATA
TAGATGCGGATGGTCGCGCCTGACGTCCCGGTACCGGACAGGCGAAGCACGATGCGCGCACCTCCTTCAA
AATAGATGCGGATGCCCTGATGTTCGCTGGTCGAGCCATCAACGGGATCATGATAGGCGAAGTCGTCGGC
CTTTTCGATCCTGAGGCCATTGACGCTCGTGCCGGGCAGGCCGGCAAGCTTGCCGCGCAGGTCAGCCACC
AGCTTCGTCGCAATATCGGAATCGACGGCTTCATAGTCGTGGCGAGTGTAATAATTGCGCCCGAAACGTG
CCCAATGGTCGTCCGCGATTGCCTTCACACTTTCCTTGCGCACCGCCAGAATGTTGAGCCAGAGCAGAAC
GGCCCACAAACCATCTTTTTCGCGCACATGGTCGGAGCCGGTGCCGGAGCTTTCCTCGCCGCAGATCGTC
ACCTTGCCGCTGTCGAGAAGATTGCCGAAGAATTTCCAGCCGGTCGGGGTTTCATACATGCCGATACCGA
GTTTTTCCGCCACGCGGTCGGCGGCGGCGCTCGTCGGCATGGAACGGGCAATGCCCTTGATACCGCCTTT
ATAGCCCGGCGCCAGATGGGCATTTGCGGCCAGCATGGCAAGCGAATCTGACGGCGTGATGAAGATACCG
CGCCCGAGAATGAGGTTGCGATCGCCATCGCCGTCGGAGGCGGCGCCAAAATCCGGCGCATGGCTGGACA
TCAGAAGATCGTAGAGATCCTTGGCATAGACGAGGTTTGGATCCGGGTGATGGCCACCGAAATCCGGCAG
GGGCACGAAATTGACGACGCTGCCTTCGGGCGCACCGAGGCGGCGCTCGAAGATTTCCTTGGCATAAGGC
CCGGTCACCGCATGCATGGCGTCGAACTTCATCTGGAAGCCGCCTTTTATCATGGCGCGGATGGCGGCGA
AATCGAACAGGCTTTCCATCAATTCAGCATAATCGGCCACCGGATCGAAGATGACCACCTCGGTATCGCC
GATCTTGCTTGTGCCGATCTTGTCGATATCGATATCGGCTGCATCTGCAATTTTATACTGGTCGATCACC
TTTGAGCGGGCGAAGATCGCTTCGGTGATCTTTTCGGGTGCCGGTCCACCATTGCCGATATTGTACTTGA
TGCCGAAATCCTGCGTAGGCCCGCCCGGATTGTGGCTGGCCGAAAGGATCATGCCACCGAAGGCTTTGTA
CTTGCGGATCATGTTGGAGGCGGCTGGCGTGGAAAGAATGCCGCCCTGTCCCACCATGATACGGCCAAAA
CCGTTGGCGGCTGCGATCTTGATAAGCTTCTGGATCACCTCGCGGTTATAAAAGCGTCCGTCGCCGCCAA
CCACGAGCGTCTTGCCCTTGAACCCCTCCAGCACGTCGAAGATCGACTGGATGAAATTTTCTGCATAATT
GGGCTGCTGGAAAACCGGAACCTTCTTGCGCAAGCCCGAAGTGCCCGGCTGTTGATCCTGGTATGGCGTG
GTCGCAATGGTCTTGACGGTCA

Protein Sequence : Show Sequence

>gi|82698981|ref|YP_413555.1| phosphoglucomutase [Brucella melitensis biovar Abortus 2308]
MTVKTIATTPYQDQQPGTSGLRKKVPVFQQPNYAENFIQSIFDVLEGFKGKTLVVGGDGRFYNREVIQKL
IKIAAANGFGRIMVGQGGILSTPAASNMIRKYKAFGGMILSASHNPGGPTQDFGIKYNIGNGGPAPEKIT
EAIFARSKVIDQYKIADAADIDIDKIGTSKIGDTEVVIFDPVADYAELMESLFDFAAIRAMIKGGFQMKF
DAMHAVTGPYAKEIFERRLGAPEGSVVNFVPLPDFGGHHPDPNLVYAKDLYDLLMSSHAPDFGAASDGDG
DRNLILGRGIFITPSDSLAMLAANAHLAPGYKGGIKGIARSMPTSAAADRVAEKLGIGMYETPTGWKFFG
NLLDSGKVTICGEESSGTGSDHVREKDGLWAVLLWLNILAVRKESVKAIADDHWARFGRNYYTRHDYEAV
DSDIATKLVADLRGKLAGLPGTSVNGLRIEKADDFAYHDPVDGSTSEHQGIRIYFEGGARIVLRLSGTGT
SGATIRIYIERYEADPAKHNLDTQATLAPLIDAAEQIAEVKKRSGRTEPSVVT

Molecule Role : Virmugen
Molecule Role Annotation : A pgm mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus (Ugalde et al., 2003).
Related Vaccine(s): Brucella abortus pgm mutant vaccine

35. purE

Gene Name : purE
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
NCBI Protein GI : 600729
Locus Tag : BMEI0295
Genbank Accession : NZ_GG703781
Protein Accession : NP_539212
Other Database IDs : CDD:200634
Taxonomy ID : 29459
Chromosome No : I
Gene Starting Position : 308233
Gene Ending Position : 309321
Gene Strand (Orientation) : -
Protein Name : 5'-phosphoribosyl-5-amino-4-imidazole carboxylase
Protein pI : 5.29
Protein Weight : 36300.44
Protein Length : 161
Protein Note : AIR carboxylase; cl00310

DNA Sequence : Show Sequence

>gi|17986284:308233-309321 Brucella melitensis bv. 1 str. 16M chromosome chromosome I, complete sequence
CTTAAATTGTGCGGGGCTTTATGCGGGTCACATGGCCTATTTTCCGGCCCGCGCGAGCTTCCTTTTTACC
GTAAAGATGCAGCACGGCGTTCTTCTCGCAGAGAATCGCCGGAACCTTTTCGATATCGTCGCCAATCAGG
TTTTCCATCACACAGTCGCTATGGCGATCCGTATTGCCGAGCGGCAGTCCCGCCACAGCGCGGATATGCT
GCTCAAATTGGGAAATGGCGCAGGCTGCTTCCGTCCAGTGGCCCGAATTATGCACACGCGGGGCAAATTC
ATTGGCGAGCAGCGTGCCGTCCTTCAGCACGAAGAATTCAAGCCCCAGCACACCGACATAGTCCAGCGCG
TGCAACAGTTTTTCGGCGGCTGTGCGCGCGGCTTCTGCCGTCTGTACGCTGATCGCGGCAGGCACTGTGG
ACGTGGCGAGAATGCCATCCTTGTGGACGTTTTCCGCAAGATCGAAGATGGCGACATTGCCGCTGCGATC
GCGCGCGGCGATGACGGAGACTTCGCGCTCGAATTCCACGAAGCCTTCGAGAATCGCAGGCGCCTTGTTG
ATGGCTGCAAAAGCGTTGCAGGCCTGGGTTTCATCGAGGGAGGCAAGGCGCACCTGCCCCTTGCCGTCAT
AACCCAGACGCCGTATCTTGAGGATGCCACGCCCGCCCAGTGCGCCGAGCGCGGCGATGAGCGTTTCCTC
GTCATCCACGAGCCGCCAGGGCGCGGTTTCAATGCCGCTTTCGTTGAGAAACTGCTTTTCTGTGAAGCGG
TCCTGAGAGATTTCCAGTGCGGCGGGCGGGGGCAGAACAAGCGCCGTTTCAGCCAGCTTGTCGGCGGCGC
TGACTGGCACATTTTCAAATTCATAGGTGATGACGTCGGAAGCGGCGGCAAGTTCGGCCAGCGCCTTCGG
GTCATCATAGGCGGCGACAATCTGGCGATTGGCAACCTGTGCTGCCGGGCAACCGGCCTGCGGCTCAAGG
ATTATGGTTTCATAACCGAAGCGCGCCGCTGCCATGGCGAGCATACGGCCAAGCTGGCCCCCGCCGATAA
TGCCGATGGTGGAGCCGGGCTTGAGAGATGTCTTGTCCA

Protein Sequence : Show Sequence

>gi|600729|gb|AAA57002.1| 5'-phosphoribosyl-5-amino-4-imidazole carboxylase [Brucella melitensis]
MSVDVAIIMGSQSDWETMHHAADTLEALGISFDARIVSAHRTPDRLVAFAKGAKREGFKVIIAGAGRAHL
PGMAAAMTPLPVFGVPVQSKALSGQDSLLSIVQMPAGIPVGTLAIGRAGAVNAALLAAAVLALYDEALAA
RLDEWRKAQTESVAERPSNEA

Molecule Role : Virmugen
Molecule Role Annotation : Mice were infected with delta purE201 or wild type parent strain 16M. The number of bacteria in the spleen and spleen weight peaked for both strains between 1 and 2 weeks postinfection (p.i.), though the number of delta purE201 cells was significantly less than the number of 16M cells recovered from the spleens of infected mice (Crawford et al., 1996). Later, a purE/purK mutant demonstrated protection from challenge with wild type B. melitensis (Hoover et al., 1999).
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK)

36. purK

Gene Name : purK
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
NCBI Protein GI : 20141763
Other Database IDs : CDD:180352
CDD:200773
CDD:194530
Taxonomy ID : 224914
Chromosome No : I
Gene Strand (Orientation) : ?
Protein Name : N5-carboxyaminoimidazole ribonucleotide synthase
Protein Length : 362
Protein Note : biovar: 1 str. 16M

DNA Sequence : Show Sequence

>gi|3788877|gb|AQ262397.1|AQ262397 CITBI-E1-2502P3.TF CITBI-E1 Homo sapiens genomic clone 2502P3, DNA sequence
CACCACCCCCCAGCCTGAGACCAAAGTCACAGTTTAACTCTGTCATGGGTCATGTGCAGAGGGAAGGGAC
TGCCCCAGAATTAGCAGTTGGCTGAACACCCTGCTTAAAAACTTTTTCTTTTCCTTTTTTTGTGAGTACC
GTCCGCTTGGACTAAAGAAGTTTTGGTTCGTTGTTTTCTTAATTTTGGGCTACAGAGTCTCTACCTACAT
TTGTGTTTTGTGTTTTGGTAACCACATGTAACAGCCGGTGGAATCTTTTTTCTCTTTGCTTTCTCTGAAC
TTTTCAAAGAGTAGGCCCCTATCTTTCGGGGGATTAACTCCTTGTGGCCCCTGTGTCGTTGGTGCT

Protein Sequence : Show Sequence

>gi|20141763|sp|P52559.2|PURK_BRUME RecName: Full=N5-carboxyaminoimidazole ribonucleotide synthase; Short=N5-CAIR synthase; AltName: Full=5-(carboxyamino)imidazole ribonucleotide synthetase
MDKTSLKPGSTIGIIGGGQLGRMLAMAAARFGYETIILEPQAGCPAAQVANRQIVAAYDDPKALAELAAA
SDVITYEFENVPVSAADKLAETALVLPPPAALEISQDRFTEKQFLNESGIETAPWRLVDDEETLIAALGA
LGGRGILKIRRLGYDGKGQVRLASLDETQACNAFAAINKAPAILEGFVEFEREVSVIAARDRSGNVAIFD
LAENVHKDGILATSTVPAAISVQTAEAARTAAEKLLHALDYVGVLGLEFFVLKDGTLLANEFAPRVHNSG
HWTEAACAISQFEQHIRAVAGLPLGNTDRHSDCVMENLIGDDIEKVPAILCEKNAVLHLYGKKEARAGRK
IGHVTRIKPRTI

Molecule Role : Virmugen
Molecule Role Annotation : A purE/purK mutant of B. melitensis 16M was attenuated in mice when given intraperitoneally. Nine weeks after immunization, mice were protected from challenge with wild type B. melitensis (Drazek et al., 1995).
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK)

37. RL3382

Gene Name : RL3382
Sequence Strain (Species/Organism) : Rhizobium leguminosarum bv. viciae 3841
NCBI Gene ID : 4399754
NCBI Protein GI : 116253124
Locus Tag : RL3382
Genbank Accession : NC_008380
Protein Accession : YP_768962
Taxonomy ID : 216596
Gene Starting Position : 3553339
Gene Ending Position : 3554079
Gene Strand (Orientation) : ?
Protein Name : putative outer membrane protein related to bp26 antigen of Brucella
Protein pI : 4.91
Protein Weight : 23778
Protein Length : 246
Protein Note : similarity:fasta; with=UniProt: AB126349" target="_blank">Q5W9U9_9RHIZ (EMBL: AB126349); Brucella sp. JM13/00.; bp26; Outer membrane protein Bp26.; length=250; id 51.515; 231 aa overlap; query 20-245; subject 21-250~similarity:fasta; with=UniProt: SME591790" target="_blank">Q92NA6_RHIME (EMBL: SME591790); Rhizobium meliloti (Sinorhizobium meliloti).; Hypothetical protein SMc01556.; length=262; id 58.594; 256 aa overlap; query 7-246; subject 8-262

DNA Sequence : Show Sequence

>gi|4399754|gb|AI501903.1|AI501903 UI-R-C2p-sd-g-11-0-UI.s1 UI-R-C2p Rattus norvegicus cDNA clone UI-R-C2p-sd-g-11-0-UI 3', mRNA sequence
TTTTTTTTTTTTTTATTCGGTTTTATTTATTTATTTTTGGTGCAGACAAGAAACATAACAGTAACATGTC
TTTCCTTCGAGCACAAAGAAGACAGAGGACTAAGATCCTCATGTAGTTGCTAAGCAGTTCTAGTCCTCAC
ACTGGTTAAGAACAAAATGTCAAGTATTACTACAGCAAGAAATATCAGTAAGACAAGTTACATTTGTCTT
TTTGAAACCACTTTTATAAGACATAGCCACAGTTCTCAAAAGTTCTTCAGACTTCAGAGATCACATTGTA
CGGATTGTACTTCTAAGGATACAGCTATACGTGAACAGACACCAGAACAAGTTAATCTAGTAATGAATAT
TCACAGGAGTCTTCATACTGCAAATGACAGAAATTCCAACGTTTGCACTGTTCTCAGCG

Protein Sequence : Show Sequence

>gi|116253124|ref|YP_768962.1| putative outer membrane protein related to bp26 antigen of Brucella [Rhizobium leguminosarum bv. viciae 3841]
MAPIYTKTVLMTALLALSLAAAAPAFAQEAKPREPVISVTGDGESSVAPDMAIVNLAVVKQAKTAREALD
ENNKAMNDVLAALKSGGIAERDLQTSGFSIQPQYNYPQPVDGQQQQPQLIGYQTINSVTVRLRDLAKLGA
VIDQSVTLGINQGGEIQFTNDKPDAAIEAARKAAVADAVKRAKTLSEAAGVKLGRILEINENVPRAMPQP
VYRATMMKEASDAAVPVQGGENNYNVSVTVTFAIEQ

Related Vaccine(s): B. melitensis with deleted bp26 (CGV26)

38. RplL

Gene Name : RplL
Sequence Strain (Species/Organism) : Brucella abortus 2308
VO ID : VO_0010908
NCBI Gene ID : 3788918
NCBI Protein GI : 489054195
Locus Tag : BAB_RS21965
Genbank Accession : AM040264
Protein Accession : WP_002964371
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 1229918
Gene Ending Position : 1230292
Gene Strand (Orientation) : -
Protein Name : 50S ribosomal protein L7/L12
Protein pI : 4.49
Protein Weight : 11356.05
Protein Length : 124
Protein Note : present in two forms; L12 is normal, while L7 is aminoacylated at the N-terminal serine; the only multicopy ribosomal protein; 4:1 ratio of L7/L12 per ribosome; two L12 dimers bind L10; critically important for translation efficiency and fidelity; stimulates GTPase activity of translation factors

DNA Sequence : Show Sequence

>NC_007618.1:1229918-1230292 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
CTTACTTGAGTTCAACCTTGGCGCCAGCAGCTTCGAGCTGTGCCTTGATCTTCTCAGCTTCGTCCTTCGA
GGCGCCTTCCTTGACAGCCTTCGGAGCGCCTTCGACCAGGTCCTTGGCTTCCTTGAGGCCGAGACCGGTG
AGTGCGCGCACTTCCTTGATCACGTTGATCTTGTTAGCGCCGCCGTCAGCGAGAACGACGTCGAATTCGG
TCTTTTCTTCTGCGGCAGCAGCAGGGGCAGCGCCACCGGCAGCAGCAACAGCGACCGGAGCAGCAGCCGA
AACGCCCCACTTCTCTTCGAGAAGCTTGGACAGCTCAGCGGCTTCCAGAACGGTCAGGGCCGAAAGGTCT
TCAACGATCTTTGCGAGATCAGCCA

Protein Sequence : Show Sequence

>WP_002964371.1 MULTISPECIES: 50S ribosomal protein L7/L12 [Brucella]
MADLAKIVEDLSALTVLEAAELSKLLEEKWGVSAAAPVAVAAAGGAAPAAAAEEKTEFDVVLADGGANKI
NVIKEVRALTGLGLKEAKDLVEGAPKAVKEGASKDEAEKIKAQLEAAGAKVELK

Molecule Role : Protective antigen
Molecule Role Annotation : Study was designed to evaluate the immunogenicity and the protective efficacy of a divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein, rplL) and Omp16 protein (outer membrane lipoprotein). This divalent DNA vaccine induced a significant level of protection against challenge with the virulent B. abortus in BALB/c mice (Luo et al., 2006b).
Related Vaccine(s): B. abortus DNA vaccine encoding RplL and Omp16

39. RpsL

Gene Name : RpsL
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
VO ID : VO_0010963
NCBI Gene ID : 1196463
NCBI Protein GI : 161511151
Locus Tag : BMEI0752
Genbank Accession : NZ_GG703780
Protein Accession : NP_539669
Taxonomy ID : 224914
Chromosome No : I
Gene Starting Position : 782951
Gene Ending Position : 783322
Gene Strand (Orientation) : +
Protein Name : 30S ribosomal protein S12
Protein pI : 12.15
Protein Weight : 12482.71
Protein Length : 123
Protein Note : interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone; located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side; mutations in the S12 gene confer streptomycin resistance

DNA Sequence : Show Sequence

>gi|17986284:782951-783322 Brucella melitensis 16M chromosome I, complete sequence
AATGCCTACCGTAAACCAGCTTATCCGCAAGCCGCGCACTGCGCCGGTGAAGCGCAATAAGGTTCCTGCA
CTGCAGGCAAACCCTCAGAAGCGCGGCGTTTGCACCCGCGTTTACACGACGACCCCGAAGAAGCCGAACT
CGGCTCTGCGTAAGGTTGCCAAGGTTCGTCTGACGAACGGCTTTGAAGTCATTGGTTATATCCCTGGTGA
AGGGCATAACCTGCAGGAGCACTCCGTCGTGATGATCCGTGGCGGTCGTGTGAAGGACTTGCCGGGTGTG
CGTTACCACATCATCCGTGGCGTTCTCGATACCCAGGGTGTCAAGAACCGCAAGCAGCGCCGTTCCAAGT
ACGGTGCAAAGCGTCCGAAGTA

Protein Sequence : Show Sequence

>gi|161511151|ref|NP_539669.2| 30S ribosomal protein S12 [Brucella melitensis 16M]
MPTVNQLIRKPRTAPVKRNKVPALQANPQKRGVCTRVYTTTPKKPNSALRKVAKVRLTNGFEVIGYIPGE
GHNLQEHSVVMIRGGRVKDLPGVRYHIIRGVLDTQGVKNRKQRRSKYGAKRPK

Molecule Role : Other
Related Vaccine(s): B. melitensis vaccine strain Rev. 1

40. sadfasfd

Gene Name : sadfasfd

41. SodC from B. abortus strain 2308

Gene Name : SodC from B. abortus strain 2308
Sequence Strain (Species/Organism) : Brucella abortus 2308
VO ID : VO_0010856
NCBI Gene ID : 3827840
NCBI Protein GI : 489062065
Locus Tag : BAB_RS28905
Genbank Accession : AM040265
Protein Accession : WP_002972093
3D structure: PDB ID : 2AQM
Taxonomy ID : 359391
Chromosome No : II
Gene Starting Position : 534068
Gene Ending Position : 534589
Gene Strand (Orientation) : +
Protein Name : superoxide dismutase [Cu-Zn]
Protein pI : 6.74
Protein Weight : 16741.77
Protein Length : 173

DNA Sequence : Show Sequence

>NC_007624.1:534068-534589 Brucella melitensis biovar Abortus 2308 chromosome II, complete sequence, strain 2308
GATGAAGTCCTTATTTATTGCATCGACAATGGTGCTTATGGCTTTTCCGGCTTTCGCAGAAAGCACGACG
GTAAAAATGTATGAGGCGCTGCCGACCGGACCGGGTAAAGAAGTTGGCACCGTGGTCATTTCCGAAGCCC
CGGGCGGGCTGCACTTCAAGGTGAATATGGAAAAGCTGACGCCGGGCTATCATGGCTTTCATGTTCACGA
AAATCCAAGCTGCGCTCCGGGAGAAAAAGACGGCAAGATCGTACCGGCTCTTGCTGCCGGCGGGCATTAT
GATCCGGGTAATACCCATCACCATTTAGGACCTGAAGGTGATGGACATATGGGCGATTTGCCACGCCTGA
GCGCCAATGCTGACGGCAAGGTGAGTGAAACCGTTGTCGCTCCACATCTCAAGAAATTGGCGGAAATCAA
GCAGCGTTCTTTGATGGTCCATGTCGGAGGGGATAATTATTCCGATAAGCCTGAGCCGCTTGGTGGCGGT
GGTGCCCGTTTTGCCTGCGGCGTGATCGAATA

Protein Sequence : Show Sequence

>WP_002972093.1 MULTISPECIES: superoxide dismutase [Cu-Zn] [Brucella]
MKSLFIASTMVLMAFPAFAESTTVKMYEALPTGPGKEVGTVVISEAPGGLHFKVNMEKLTPGYHGFHVHE
NPSCAPGEKDGKIVPALAAGGHYDPGNTHHHLGPEGDGHMGDLPRLSANADGKVSETVVAPHLKKLAEIK
QRSLMVHVGGDNYSDKPEPLGGGGARFACGVIE

Molecule Role : Protective antigen
Molecule Role Annotation : IMMUNOGENICITY: Induces antigen-specific Th1 immune response, as indicated by the specific induction of serum IgG2a, but not IgG1, antibodies and by the secretion of IFN-γ, but not IL-4, by the Cu/Zn SOD-stimulated splenocytes. Has been used for vaccine development (Vemulapalli et al., 2000; He et al., 2002; Onate et al., 2003).

MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replacement exhibited much greater susceptibility to killing by exogenous O(2)(-) than the parental 2308 strain, supporting a role for SodC in protecting this bacterium from O(2)(-) stress. The B abortus sodC mutant was much more sensitive to killing by cultured resident peritoneal macrophages from C57BL6J mice than 2308, and its attenuation in cultured murine macrophages was enhanced when these phagocytes were treated with gamma interferon. The attenuation of the B abortus sodC mutant in both resting and IFN-gamma-activated macrophages was alleviated in the presence of the NADPH oxidase inhibitor apocynin. Consistently, the B abortus sodC mutant also displayed significant attenuation in infected C57BL6J mice compared to the parental strain. These findings suggest that SodC protects B abortus 2308 from the respiratory burst of host macrophages (Gee et al., 2005).
Related Vaccine(s): B. abortus DNA vaccine expressing BCSP31, SOD and L7/L12 , B. abortus DNA vaccine pcDNA-SOD , B. abortus DNA vaccine pcDNA3-SOD encoding Cu-Zn SOD , Recombinant B. abortus RB51SOD

42. SurA

Gene Name : SurA
Sequence Strain (Species/Organism) : Brucella abortus 2308
VO ID : VO_0010971
NCBI Gene ID : 3787419
NCBI Protein GI : 489056605
Locus Tag : BAB_RS19295
Genbank Accession : JMRZ01000012
Protein Accession : WP_002966738
Taxonomy ID : 359391
Chromosome No : I
Gene Starting Position : 688353
Gene Ending Position : 689309
Gene Strand (Orientation) : -
Protein Name : molecular chaperone SurA
Protein pI : 10.47
Protein Weight : 32511.89
Protein Length : 318

DNA Sequence : Show Sequence

>NC_007618.1:688353-689309 Brucella melitensis biovar Abortus 2308 chromosome I, complete sequence, strain 2308
GTCAACGATTGACGATGGTGGCCTTTTCGCGCAGTTCCTGCACGTATTTCTTGCTGAGTTCCTCAGCCTT
CTTTTCCTGCCCCGCAGGGGAATCCGCGCCTTCCATGGAGAAGACAAGCTGTGCAACGCGGTCATCCGAC
ACCTGACGGGTGGAGCATACGGCCAGGAATTCAACACCCTTTTCCGTATCGTGCGGCTTGGTCGTCCGGT
TGACGCCAGCGGCCTTCACATCCTTGGACCATTCGCCGGGCAATTGCGGCTCGATGATACGGCCAAGATC
GCGGACGGTCACATCGAGAATGCCCTTGGCTTGCTGGCGCGTGCTGTCACAATTCTGGAAGCGCGCGCGC
AACGCATTGGCTTCCTGACGGCGTTTTGCCAGAAGAGCGGGCGAACGCTTGGAGGCGGGGACCACGAAAA
TCACCTGCTGGAGATGATATTCAGTTGCAACGGGCTTCTTTCCGCCGTTCTTCAGCATACGCTGCACGGC
TTCCTGCTCACTGACCATGCCGGTCGCGCGGAAGCGGGCGCTGACAAGGCGGCCCCAGCCCATCTGGACC
ATGATATATTTCTTGAAATGTTCCGGCGTGACGCCCGACTGGTTCATAACCTGATTGAGCTGCGCCAGCG
TCATCTTGTTGCGGCTTGCAAACCCGGCATAGGCGTCATCCACTTCCTTATCGGAAATATTGATGCCACG
CGATTTCATCTCGATGCGCTTGAGCATTTCTTCGGTAAGCTCGTTGCGCGCAAGCTGGTTGAGATTGCCG
CTTTTACGCTGAAGCTTGAGGAAGGCCATACGGTGCTTGATGTCGCTATTGGTAATAGCATTGCCGGACA
CGATGACTTTGACCTCGGATTCTCCTGCGGCGAAAGCTGGAGCCGCAACCGTTCCAAGCGCCGTCAAGCA
AACGGCAGCGCCTAGCATGGAGGCGATAAGAGGTCTTGCAAACATCA

Protein Sequence : Show Sequence

>WP_002966738.1 MULTISPECIES: peptidylprolyl isomerase [Brucella]
MMFARPLIASMLGAAVCLTALGTVAAPAFAAGESEVKVIVSGNAITNSDIKHRMAFLKLQRKSGNLNQLA
RNELTEEMLKRIEMKSRGINISDKEVDDAYAGFASRNKMTLAQLNQVMNQSGVTPEHFKKYIMVQMGWGR
LVSARFRATGMVSEQEAVQRMLKNGGKKPVATEYHLQQVIFVVPASKRSPALLAKRRQEANALRARFQNC
DSTRQQAKGILDVTVRDLGRIIEPQLPGEWSKDVKAAGVNRTTKPHDTEKGVEFLAVCSTRQVSDDRVAQ
LVFSMEGADSPAGQEKKAEELSKKYVQELREKATIVNR

Molecule Role : Protective antigen
Molecule Role Annotation : Brucella SurA is a protective antigen (Delpino et al., 2007b).
Related Vaccine(s): Brucella recombinant SurA protein vaccine

43. surA test

Gene Name : surA test

44. Tig

Gene Name : Tig
Sequence Strain (Species/Organism) : Brucella melitensis bv. 1 str. 16M
VO ID : VO_0010969
NCBI Gene ID : 1196780
NCBI Protein GI : 17987352
Locus Tag : BMEI1069
Genbank Accession : AE008917
Protein Accession : NP_539986
Taxonomy ID : 224914
Chromosome No : I
Gene Starting Position : 1112655
Gene Ending Position : 1114112
Gene Strand (Orientation) : -
Protein Name : trigger factor
Protein pI : 4.64
Protein Weight : 50680.09
Protein Length : 485
Protein Note : Tig; RopA; peptidyl-prolyl cis/trans isomerase; promotes folding of newly synthesized proteins; binds ribosomal 50S subunit; forms a homodimer
Protein Annotation : Also called Tf: Trigger Factor.

DNA Sequence : Show Sequence

>NC_003317.1:1112655-1114112 Brucella melitensis bv. 1 str. 16M chromosome I, complete sequence
ATCAAGCCTCTTCGGACTTGCCTTCTTCGGCCTTCTTCTTCGGCGCAGCCTTCTTCTTCGCAGCCGCCTT
CTTGGCAGGCTTTGCTTCCGAAGCTGCATCTTCGTCTTCAGCCGTCAGCTCTTCCTTCGAGACCTTCTTG
TCGGTCACATTGATGTTGGCCAGCAGATGATCGACGACCTTTTCTTCAAAGATCGGCGCGCGCAGATTGG
CGACGGCATCCGGCGTACGGCGCAGGAAGTCGTAGATTTCCTTTTCCTGACCCGGATAGCGGCGAACCTG
ATCGTAAACAGCGCGCTGCAGTTCTTCTTCGGTCACTTCCACGCCTGCCTTCTCGCCGATTTCGGAGAGA
ACGAGGCCAAGACGAACGCGGCGTTCTGCAAGCTTGCGATATTCTTCGCGAGCAGCTTCTTCCGTCGTTT
CCTCGTCTTCAAAGGTGCGGCCAGCCTGCTGCAGGTCGAAGTTGATCTGCTGCCAGATGTTGTTGAACTC
GGCGTCAACCAGCTTCTGCGGGGTTTCAAACTGATAATCACCATCAAGGGCGTCGAGAATCTGACGCTTC
ACTTTCTGGCGGGTGATCTGGCCGTACTGGCTTTCGATCTGTTCGCGCACAACCTGACGCAGACGCTCAA
GCGACTCAATGCCGAGCTTCTTTGCGGTTTCGTCATCGAGAACGAGTTCGTTCGGCTTGGCAACTTCCTT
CACCTTGATGTCGAAGGTTGCTTCCTTGCCAGCCAGATGCGCAGCGCCGTATTCAGCCGGGAACGTTACG
GTGATGACCTTCTCGTCGCCAGCCTTCAAGCCAATGAGCTGTTCTTCAAAGCCCGGAATGAACTGGCCGG
AACCGAGAACGAGCTGTGCGTCATTGTCTGCACCGCCTTCAAACGGCTCGCCGTCGAGCTTGCCCAGATA
GTCGATCGTGACGCGATCTTCGTTTTCGGCCTTGCCCTTCTTGGTTTCAAAGGTGCGGGTCGACGACGCA
ATGCGCTTGACCTGTTCATCGACTTCCTCATCGGAAATGTCGACGACTTCACGGGTCACGGCGATCTTGG
AGAAGTCCTTGACCTCGATTGCCGGCAGCACTTCATAGTTCAGCGAGAAAACGAAATCGGCCTTGCCGTC
GAGAACCTTCTCGGCTTCTTTTTCGTCTTCCGACATGATGACTTCAGGCTGGGTCGCCGACTTTTCGTTG
CGTTCGGCAAGGATGGAACGCGACGAATCGTTGAGGATTTCGTTGACGATCTCGGCCATGAAGGACTTGC
CGTACATCTTGCGCAGGTGAGCCGTCGGCACCTTGCCCGGACGGAAGCCGTTGATGCGGGCGCGGCCGCG
CGCGGTTTCGAGCCGCTCAGCGAGCTTGGCTTCAAGATCCCCGGCCGGAACCACGACTTTGATCTCGCGC
TTCAGCCCTTCATTGAGCGTTTCGGTAACCTGCATGTTCAAACCTTCACTTCTTGTCA

Protein Sequence : Show Sequence

>NP_539986.1 trigger factor [Brucella melitensis bv. 1 str. 16M]
MTRSEGLNMQVTETLNEGLKREIKVVVPAGDLEAKLAERLETARGRARINGFRPGKVPTAHLRKMYGKSF
MAEIVNEILNDSSRSILAERNEKSATQPEVIMSEDEKEAEKVLDGKADFVFSLNYEVLPAIEVKDFSKIA
VTREVVDISDEEVDEQVKRIASSTRTFETKKGKAENEDRVTIDYLGKLDGEPFEGGADNDAQLVLGSGQF
IPGFEEQLIGLKAGDEKVITVTFPAEYGAAHLAGKEATFDIKVKEVAKPNELVLDDETAKKLGIESLERL
RQVVREQIESQYGQITRQKVKRQILDALDGDYQFETPQKLVDAEFNNIWQQINFDLQQAGRTFEDEETTE
EAAREEYRKLAERRVRLGLVLSEIGEKAGVEVTEEELQRAVYDQVRRYPGQEKEIYDFLRRTPDAVANLR
APIFEEKVVDHLLANINVTDKKVSKEELTAEDEDAASEAKPAKKAAAKKKAAPKKKAEEGKSEEA

Molecule Role : Protective antigen
Molecule Role Annotation : protective antigen (Yang et al., 2007)
Related Vaccine(s): B. melitensis bp26 and TF Nasal Vaccine

45. virB2

Gene Name : virB2
Sequence Strain (Species/Organism) : Brucella melitensis biovar Abortus 2308
NCBI Gene ID : 3827981
NCBI Protein GI : 83269021
Locus Tag : BAB2_0067
Genbank Accession : AM040265
Protein Accession : YP_418312
Taxonomy ID : 359391
Chromosome No : II
Gene Starting Position : 65610
Gene Ending Position : 65927
Gene Strand (Orientation) : -
Protein Name : type IV secretion system protein VirB2
Protein pI : 10.63
Protein Weight : 10115.27
Protein Length : 105

DNA Sequence : Show Sequence

>gi|83268957:65610-65927 Brucella melitensis biovar Abortus 2308 chromosome chromosome II, complete sequence
TTTACCTAAGCAGGTAAGAGGCAATTTCGGCGGCAGCGCCAACCACCAGGGCGCCGCCCAGCACCGGCAC
TACATCCATGAAGCGGGCGTGCCGGAATGCCATCTTGTAACCGGACCAGATGATGGCTATGGTAACGATG
GTGATCGATACGCCGCTTAGCAAGTCCAGCACTTTTTGCATGCTTGTATTTACCTTATCGAGGCCACCGT
TGGCGTGCGCCAGGTTAGGCTCGATTGCAGCGATGGAGACAATGAGGGCCAGCAGTAGGTGAGGTAGAAT
CCGCGACAGCGACTTCTTGCTGGGGGAAGCGGTTTTCA

Protein Sequence : Show Sequence

>gi|83269021|ref|YP_418312.1| type IV secretion system protein VirB2 [Brucella melitensis biovar Abortus 2308]
MKTASPSKKSLSRILPHLLLALIVSIAAIEPNLAHANGGLDKVNTSMQKVLDLLSGVSITIVTIAIIWSG
YKMAFRHARFMDVVPVLGGALVVGAAAEIASYLLR

Molecule Role : Virmugen
Molecule Role Annotation : A virB2 mutant is attenuated in Brucella abortus and provides protection in mice (Kahl-McDonagh et al., 2007).
Related Vaccine(s): B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA

46. VjbR

Gene Name : VjbR
Sequence Strain (Species/Organism) : Brucella melitensis 16M
NCBI Gene ID : 1198888
NCBI Protein GI : 17989461
Locus Tag : BMEII1116
Genbank Accession : NC_003318
Protein Accession : NP_542094
Taxonomy ID : 224914
Chromosome No : II
Gene Starting Position : 1150819
Gene Ending Position : 1151526
Gene Strand (Orientation) : -
Protein Name : TRANSCRIPTIONAL ACTIVATOR, LUXR FAMILY
Protein pI : 6.65
Protein Weight : 23978.21
Protein Length : 235

DNA Sequence : Show Sequence

>gi|1198888|gb|N56040.1|N56040 J6249F Human fetal heart, Lambda ZAP Express Homo sapiens cDNA clone J6249 5', mRNA sequence
GTGAACATTTTAGACACCTTTTCTTTGGGTAGGCTCTTGCCCAGGCGCCGGCTCTTCTCCCAAAAAAAAA
AAAAACCTTATCCTTTCCCTAACCTGATAACCTCCAGATCCAGGGTTTCTAACTAAGTGAGTCTTTGAAG
TATTAAGGGACATGAATAGCT

Protein Sequence : Show Sequence

>gi|17989461|ref|NP_542094.1| TRANSCRIPTIONAL ACTIVATOR, LUXR FAMILY [Brucella melitensis 16M]
MALLTRIRDEIGCRYVTHTYRGRVGDCTKVNSADLTVLMTLPATWVARYSSKNYFAIDPVFQEDAPYYRN
DTSAIARDLKEDADICPAVAELLHDAEKHGLGNLFIAVSARNPKGVAGCTVFTFEVEDEDRTQFLARMRP
RLLSLAGIIHGTVCGCKDANSVASLLTPREVDCLRWAANGKTDGEIAEILSIARWTVVTYLQNAKIKLNC
SNRTSAVATALSLGIIDMPEVQHLV

Molecule Role : Virmugen
Molecule Role Annotation : The deletion of vjbR gene in Brucella melitensis strain 16M made a live attenuated vaccine and provided significance protection against mice (Wang et al., 2011).
Related Vaccine(s): Brucella abortus S19 vjbR mutant vaccine , Microencapsulated B. melitensis vjbR mutant vaccine

47. vjbR

Gene Name : vjbR
Sequence Strain (Species/Organism) : Brucella abortus S19
NCBI Gene ID : 6326704
NCBI Protein GI : 189022339
Locus Tag : BAbS19_II01090
Genbank Accession : CP000888
Protein Accession : YP_001932080
Taxonomy ID : 430066
Chromosome No : 2
Gene Starting Position : 117845
Gene Ending Position : 118624
Gene Strand (Orientation) : +
Protein Name : LuxR family regulatory protein; VjbR
Protein pI : 6.76
Protein Weight : 26640
Protein Length : 259

DNA Sequence : Show Sequence

>gi|189022234:117845-118624 Brucella abortus S19 chromosome 2, complete sequence
AATGAGTCTTGATCTCGTTCATTTTCCGAATTACAAAAAAACCTTTTTTGGTTCTTCCTTTCAAAGCGAT
ACTTTGGCGCTTCTAACCCGCATCCGGGATGAAATAGGATGCCGCTACGTAACGCATACCTATCGTGGTC
GCGTAGGCGACTGCACGAAGGTGAATTCAGCCGATCTGACTGTTCTTATGACGCTGCCTGCTACCTGGGT
CGCGCGCTATTCCTCGAAAAACTACTTTGCCATTGACCCGGTTTTTCAGGAAGACGCTCCGTATTACCGC
AATGATACGAGCGCCATTGCCCGCGACCTGAAAGAAGATGCGGATATTTGCCCGGCCGTTGCCGAACTGT
TGCATGATGCTGAAAAGCACGGCCTGGGAAATCTTTTCATCGCCGTATCCGCGCGCAATCCCAAGGGCGT
TGCGGGTTGTACGGTTTTCACTTTCGAGGTGGAGGACGAAGACCGTACGCAATTCCTTGCCAGGATGCGC
CCGCGCCTTCTAAGCCTTGCCGGCATCATTCATGGAACTGTCTGCGGCTGCAAGGATGCAAATTCAGTTG
CAAGCCTTCTCACCCCGCGCGAGGTCGATTGCCTGCGCTGGGCTGCCAATGGCAAGACTGATGGCGAAAT
CGCCGAAATCCTCAGCATCGCCCGCTGGACGGTGGTGACTTATCTACAGAATGCCAAAATCAAGCTGAAC
TGTTCCAATCGAACGTCGGCAGTGGCGACGGCGCTTTCCCTCGGCATTATCGATATGCCCGAGGTACAGC
ATCTCGTCTG

Protein Sequence : Show Sequence

>gi|189022339|ref|YP_001932080.1| LuxR family regulatory protein [Brucella abortus S19]
MSLDLVHFPNYKKTFFGSSFQSDTLALLTRIRDEIGCRYVTHTYRGRVGDCTKVNSADLTVLMTLPATWV
ARYSSKNYFAIDPVFQEDAPYYRNDTSAIARDLKEDADICPAVAELLHDAEKHGLGNLFIAVSARNPKGV
AGCTVFTFEVEDEDRTQFLARMRPRLLSLAGIIHGTVCGCKDANSVASLLTPREVDCLRWAANGKTDGEI
AEILSIARWTVVTYLQNAKIKLNCSNRTSAVATALSLGIIDMPEVQHLV

Molecule Role : Virmugen
Molecule Role Annotation : A vjbR mutant is attenuated in BALB/c mice and induces significant protection against wild type challenge (Arenas-Gamboa et al., 2009).
Related Vaccine(s): Brucella abortus S19 vjbR mutant vaccine

48. znuA

Gene Name : znuA
Sequence Strain (Species/Organism) : Brucella melitensis biovar Abortus 2308
VO ID : VO_0012365
NCBI Gene ID : 3827700
NCBI Protein GI : 83269918
Locus Tag : BAB2_1079
Genbank Accession : AM040265
Protein Accession : YP_419209
Taxonomy ID : 359391
Chromosome No : II
Gene Starting Position : 1063213
Gene Ending Position : 1064217
Gene Strand (Orientation) : -
Protein Name : periplasmic solute binding protein
Protein pI : 6.31
Protein Weight : 33961.81
Protein Length : 334
Protein Note : similar to BRA1122, zinc ABC transporter, periplasmic zinc-bnding protein

DNA Sequence : Show Sequence

>gi|83268957:1063213-1064217 Brucella melitensis biovar Abortus 2308 chromosome chromosome II, complete sequence
TTTATTTCGGCAGGCAGTCTTTCAGCGAATTGGCCAGATTGCGGATGAGTTGCGGATAAAGATCAGGGCC
GTCCTTCAGTTCTGCGCCAAGAGGATCAAGAACACCTGTCCGGGCTTTCGTTCCGTCAACCACCGTCTTC
ACCAGTTTCGGCTCAAATTGCGGCTCTGAGAAAACGCAGGTTGCACCGAGTGACTTTATCTTGTCGTGAA
TTTGCTGGATACGCGCCGCACCCGGCGCTTTTTCCGGGCTGACCGTGATGGAGCCGGCTGCTTTCATGCC
GAAGCGATTCTCGAAATATTGATAGGCATCATGAAAGACGATGAAGGGCTTGTCCTTGACCGGCTTCAGT
TCAGCAGCCACTTCCCTGGTCAAGGCATCGAGTTTTTCTCCATAGGCCTTGGCATTCTTTTCATATTGCG
CGGCGTGTTCCGGGTCGCTCTCGCCAAGCGTTTTGGCGATATCGGCAGCCAGAATCTTGCCATTTTGCGG
GTCAAGCCAGAAATGCAGATCATATTCGCCGTGATGGTGGTGTTCATGGCCTTCTTCTGCGACTTCGGCC
GCATGGTCGTGATCGCCTGAACCATGTGCGTCATGCTCTTCCTCATGGCTCCCCCCATGGCCATGATCGT
GCGCCTCGAACGGCCCACCCTCGCGGAATTTTAGTTTCGTCAACCCTTTCGCATCGCCAAGAGCCACCAC
TTTCGCGCCCTCGCCCAGCGTATCAATGGGCTTGTCGAGAAAGGTTTCCATGGATGGCCCGGCCCAGAAA
ATCACCTTGGCGTGCTCGATAGCCTCGGCATCGGAGGGTTTCAGACTATAAACATGCTCGGACCCAGCCC
CCTGAACGATCAGCTTCGGCTTACCCACGCCCTGCATGACGGCGGAAACAATCGAGTGAAGCGGCTTGAT
CGAAACAACCACGCCCTCACGTTCGCCTGCAAGGGAAGAACCGCAAAAGCCAGCCAGAAAGGCAGAAGCA
AGAAACAAGGAATGCAGATTTTTCA

Protein Sequence : Show Sequence

>gi|83269918|ref|YP_419209.1| periplasmic solute binding protein [Brucella melitensis biovar Abortus 2308]
MKNLHSLFLASAFLAGFCGSSLAGEREGVVVSIKPLHSIVSAVMQGVGKPKLIVQGAGSEHVYSLKPSDA
EAIEHAKVIFWAGPSMETFLDKPIDTLGEGAKVVALGDAKGLTKLKFREGGPFEAHDHGHGGSHEEEHDA
HGSGDHDHAAEVAEEGHEHHHHGEYDLHFWLDPQNGKILAADIAKTLGESDPEHAAQYEKNAKAYGEKLD
ALTREVAAELKPVKDKPFIVFHDAYQYFENRFGMKAAGSITVSPEKAPGAARIQQIHDKIKSLGATCVFS
EPQFEPKLVKTVVDGTKARTGVLDPLGAELKDGPDLYPQLIRNLANSLKDCLPK

Molecule Role : Virmugen
Additional Molecule Role : Virmugen
Additional Molecule Role Annotation : Deletion of gene znuA attenuates Brucella abortus and this live attenuated vaccine was challenged in mice. These mice showed significantly fewer spenic CFU (Yang et al., 2006).
Related Vaccine(s): Live attenuated B. abortus with deletion of znuA

III. Vaccine Related Host Genes

1. ANXI

Gene Name : ANXI
Sequence Strain (Species/Organism) : Ovis aries
NCBI Gene ID : 100302599
Taxonomy ID : 9940
Gene Strand (Orientation) : ?
Protein Name : annexin I
Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis vaccine strain Rev. 1 , B. melitensis WR201 (16MΔpurEK)

2. BAK1

Gene Name : BAK1
Related Vaccine(s): B. melitensis vaccine strain Rev. 1

3. Ccl2

Gene Name : Ccl2
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 20296
NCBI Protein GI : 6755430
Locus Tag : RP23-350G1.3
Genbank Accession : AJ238892
Protein Accession : NP_035463
Taxonomy ID : 10090
Chromosome No : 11
Gene Starting Position : 82035576
Gene Ending Position : 82037451
Gene Strand (Orientation) : +
Protein Name : chemokine (C-C motif) ligand 2
Protein pI : 10.38
Protein Weight : 14837.89
Protein Length : 148
Protein Note : Also known as JE; HC11; MCAF; MCP1; MCP-1; Scya2; Sigje; SMC-CF; AI323594

DNA Sequence : Show Sequence

>gi|372099099:82035576-82037451 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
TGCAGAGAGCCAGACGGGAGGAAGGCCAGCCCAGCACCAGCACCAGCCAACTCTCACTGAAGCCAGCTCT
CTCTTCCTCCACCACCATGCAGGTCCCTGTCATGCTTCTGGGCCTGCTGTTCACAGTTGCCGGCTGGAGC
ATCCACGTGTTGGCTCAGCCAGGTGAGACCCCCCCAGCTCCCTTCCCAGCATATCACCCCATTTTTGAAT
TGTCGTGGATTGTGATAGCATAGTCTCACATGGTCAGGTACTTTTTTTTTTTTCTTTAACCAAGATAAGG
AGCATAAAGAAGGAAGGACAAAGAGCCAACCCAATTACAAGATTGCTTCTGGAAAGCAACTAGAATTTTA
ATTGTTAGATCTAAATTTGGAATCACACCTTCATATAGTTCCTGTTCCAGTTACTTCCCTCAGTATTTGG
GAACCTGGGTGATCAAACAGAGGCTTGGGTTGGTGCCTTTTTCCAGATAGAGGAGAAAGGGGAAGAGATC
CAAGATCCGAGCTGTGTTTCACCCAGCCCTGCTTCCAGAGATAGCAGCTTAGCGGAGGTGGTTGGGATCA
GAGATACTCATGATTTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCAGCCTACAGTAATGTA
CTCAGGTAATCTTCTCAGGTCATAGTAATTTGACTTCTAACTCCCCCAAATGACAGTCCCCAGAGTCACA
TAGTTTTAATGGCATCCCTCTACCCAAGACTGTGAGCCTACTTTAAGCTGCAAATAACTGAGTCTGTTGT
CAAAGATCACATCCCAGATCTGATGTATTGGCATTTATATCCCATCCTGCTGAAACTGCCTTCTCCCCGT
GGTCCTTCTCTTCTCTAAGGTCAGAAGCATCTTTCCTGTCCTAATGTGCTTCTCTTTTACTCTCCAGATG
CAGTTAACGCCCCACTCACCTGCTGCTACTCATTCACCAGCAAGATGATCCCAATGAGTAGGCTGGAGAG
CTACAAGAGGATCACCAGCAGCAGGTGTCCCAAAGAAGCTGTAGTGTGAGTTACATACCCCGGCCCTCCC
TGGTCCAAAGGTTTTTCCTTAAGAACAAGGGATGGTCCTCATATACTTATAGTCAGTCACACACTCAGAT
CCAATGGGGAAACCAAGGCCAAGAAGGCAAAGGCAGTTCTCAACAGCATTGTCTCTATGGCTGCTGTTCA
GGCCCTTTCTACTCCACAAGCTTATCTTAGAAAACCTGCAGGAGAAGCAGGTCACTTTGAGTCCCCTTTT
TCTACCTGCCCTCCCCCGCTGAGCTCTACACAGCCCCTCCATGTATACCAGACTGAACTTCATCTAACAG
TGTCTTTTCTCTTCCCACAGTTTTGTCACCAAGCTCAAGAGAGAGGTCTGTGCTGACCCCAAGAAGGAAT
GGGTCCAGACATACATTAAAAACCTGGATCGGAACCAAATGAGATCAGAACCTACAACTTTATTTAAAAC
TGCATCTGCCCTAAGGTCTTCAGCACCTTTGAATGTGAAGTTGACCCGTAAATCTGAAGCTAATGCATCC
ACTACCTTTTCCACAACCACCTCAAGCACTTCTGTAGGAGTGACCAGTGTGACAGTGAACTAGTGTGACT
CGGACTGTGATGCCTTAATTAATATTAAACTTATTTAACTTATTGATGTTATGGTATTCCCTTTCATGAA
TACTAAAATTTCTTAAATGCAAGGTGTGGATCCATTTTTCCCTCTCTGTGAATCCAGATTCAACACTTTC
AATGTATGAGAGATGAATTTTGTAAAGATGAATGGGTAAACTTTGTGTTTGAGATTCCAAGGTATTGTTT
AAAATATTATTATGGATATTCCTTATTATTAAAAGAAATATATTATTTTTGTACAC

Protein Sequence : Show Sequence

>gi|6755430|ref|NP_035463.1| C-C motif chemokine 2 precursor [Mus musculus]
MQVPVMLLGLLFTVAGWSIHVLAQPDAVNAPLTCCYSFTSKMIPMSRLESYKRITSSRCPKEAVVFVTKL
KREVCADPKKEWVQTYIKNLDRNQMRSEPTTLFKTASALRSSAPLNVKLTRKSEANASTTFSTTTSSTSV
GVTSVTVN

Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK)

4. Ccl3

Gene Name : Ccl3
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 20302
NCBI Protein GI : 6755432
Locus Tag : RP23-320E6.7
Genbank Accession : AL596122
Protein Accession : NP_035467
Taxonomy ID : 10090
Chromosome No : 11
Gene Starting Position : 83647842
Gene Ending Position : 83649377
Gene Strand (Orientation) : -
Protein Name : chemokine (C-C motif) ligand 3
Protein pI : 6.3
Protein Weight : 9749.32
Protein Length : 92
Protein Note : Also known as Mip1a; Scya3; G0S19-1; AI323804; MIP1-(a); LD78alpha; MIP-1alpha; MIP1-alpha

DNA Sequence : Show Sequence

>gi|372099099:83647842-83649377 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
GTCACTTGTTAAAGGGCATATTTATTACTTCTCTGGTATAAACAAAGCATCTATTGTACATTTGTCAGTT
CATGACTTTGTCATCATGTCTACCTAGAATAGCTGTCACCAAACAGTGTGACCAACTGGGAGGGAGATGG
GGGTTGAGGAACGTGTCCTGAAGTCTTTCAGAATAAATAGTCACAAATACAAGTATGACAATAAAATAAA
TTACAAAATTAAATAGTATTAAACCAATAGGATTAAATTAAATAAAATTTCAAGTGAAGAGTCCCTCGAT
GTGGCTACTTGGCAGCAAACAGCTTATAGGAGATGGAGCTATGCAGGTGGCAGGAATGTTCCGGGGCTCA
AGCCCCTGCTCTACACGGGACCCATGGAGGTTTGGGGGGTTCCTCGCTGCCTCCAAGACTCTCAGGCATT
CAGTTCCAGGTCAGTGATGTATTCTTGGACCCAGGTCTCTTTGGAGTCAGCGCAGATCTGCCGGTTTCTC
TTAGTCAGGAAACTACACAGAGAGAGGTAAGGGTCAAAAAACTTAAATATCCAATGGGAGAGTCTGACTT
CCTCTGTGGTTTCTCCATCGCTCCCGTCCTCTCACTGGCACCCTTTAGATGATCCTGTGCTTCCCTTTTT
GTGACTGCACCCCCGCCCCCACCCCACGACTGAAAAACCCTCTCTTACACTGTTCCTCACCCCACTTTAT
CAGGAAAAGCACGAGAACAGAACTTACATGACACCTGGCTGGGAGCAAAGGCTGCTGGTTTCAAAATAGT
CAACGATGAATTGGCGTGGAATCTTCCGGCTGTAGGAGAAGCAGCAGGCAGTCGGGGTGTCAGCTCCATC
TGTAGGGGAAGAAAGTCATCATTGAACAGGGTAGGACACCTAAAACAACTTAAGAGGCGAGGAAGGTGCT
TGGGGTGGGAGTTGGAAGGCTAAGGATCTGAAGGCATTTGGGCATTTGGGACCAGAAATGTCATTGTTTC
TGTCTCTGTTCTATCTATATTTTCACTGTGGGCTTTCTCTTTCTCTATGTGTTGCCCTGTGTCTTTCCCA
CAGCTTTCTCTAATACCAGAAGTCAGCAAAGAAGACACCAGAGCATCACCATAAGACATCCCAGAGGCAG
AGCTCCTTAAGAATCCCAGGGCTGGCTAGTAAGTACATGACAACACTATCCTTACTGTGATTTCAAGTTC
TGGGTACCTATAAAAGGTTAGACCCTTCCACACCATAGAGAGGAAAATAAAAATCTCAAAGAGAAAGACC
AGCTTCTTTTCTCTTGTAGACTCTGAAACCACAGAAAAGACTGCTATGGTCTGCCTTAGACCAGAGACTG
GGGACACCTCCTGTAGCAGTGTAGACTCACATGGCGCTGAGAAGACTTGGTTGCAGAGTGTCATGGTACA
GAGAAGAACAGCAAGGGCAGTGGTGGAGACCTTCATGATGTTGAGCAGGTGACAGAGGGTGAGCTTGTCA
GCAGAACAGAAAAGGGACTGGTACTCGCTGCTGCTTGTATCCTTCTGGTGTCTGAAGCCATATGCC

Protein Sequence : Show Sequence

>gi|6755432|ref|NP_035467.1| C-C motif chemokine 3 precursor [Mus musculus]
MKVSTTALAVLLCTMTLCNQVFSAPYGADTPTACCFSYSRKIPRQFIVDYFETSSLCSQPGVIFLTKRNR
QICADSKETWVQEYITDLELNA

Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK)

5. Cxcl10

Gene Name : Cxcl10
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 15945
NCBI Protein GI : 10946576
Genbank Accession : AC109603
Protein Accession : NP_067249
Taxonomy ID : 10090
Chromosome No : 5
Gene Starting Position : 92346637
Gene Ending Position : 92348888
Gene Strand (Orientation) : -
Protein Name : chemokine (C-X-C motif) ligand 10
Protein pI : 10.57
Protein Weight : 10391.5
Protein Length : 98
Protein Note : Also known as C7; IP10; CRG-2; INP10; IP-10; Ifi10; mob-1; Scyb10; gIP-10

DNA Sequence : Show Sequence

>gi|372099105:92346637-92348888 Mus musculus strain C57BL/6J chromosome 5, GRCm38 C57BL/6J
ATTTCATGTCAGTTATTATTACTTTATTACATTTTGGGTCTCTTACTACTTTCAATACAGTACATTGTCT
TTTGAATGTTACATAATACAAAAGGTATTGGACGGTTTTAAAAATAAACTTTAACTACCCATTGATACAT
ACTTGATGACACAAGTTCTTCCATATACAATGCAAAGCATACAAAAAATACATTAGGAATTCTACTTTGT
ACAGTCGTTCATTAAATAGTATTTACACATACATTTTCAGGTTCCTCTGAGTATCTTGATAACCCCTTGG
GAAGATGGTGGTTAAGTTCGTCCTTACAAACTTAAATTTGTAGTCTTACATCTGAAATAAAAGAGCTCAG
GTAAACTTAGAACTGACGAGCCTGAGCTAGGGAGGACAAGGAGGGTGTGGGGAGCAGCCTGGGCATGGCA
CATGGTGAAGGGCGTCGCACCTCCACATAGCTTACAGTACAGAGCTAGGACAGCCATCCCAGCCACTTGA
GCGAGGACTCAGACCAGCCCTTAAAGAATTCTTGCTTCGGCAGTTACTTTTGTCTCAGGACCATGGCTTG
ACCATCATCCTGCAGGAGGAGTAGCAGCTGATGTGACCACGGCTGGTCACCTTTCAGAAGACCAAGGGCA
ATTAGGACTAGCCATCCACTGGGTAAAGGGGAGTGATGGAGAGAGGCTCTCTGCTGTCCATCCATCGCAG
CACCGGGGTGTGTGCGTGGCTTCACTCCAGTTAAGGAGCCCTTTTAGACCTGTAGGAAGAGGAAACTGTA
TTGAGCGGAATAGACTCTGCTTTCACTTTGGGAACCCAAAGACCCTGGGGCAAAAGGCCTGGTGCATTTT
CCTCTGCTACACAATCTCCATGGGTCACGGGTGGGTGGGGGTTGAGGGGACAGAATGGGTTTGTGTGTTT
TTTGTTTTTTTTTTTTTTAAGTGAGGAAGTGGGGGGGGGGTGGGCATTTGGCAGCTTTACCCGTGACAGG
TATAATAACTGCTCCACTTCTAGACACTAGGAATGTATGACCTAAGAAGGCACCTCAGTGTCTGTGTAAA
TGGAGAGACAAAGGCACATGCCGGTGCCATGAGTTTAGGGCAGATGCCCCACAGCAAAGCCCAGGGCAGG
CGCTGCTCCCCAGACCACCATTTCCTGAAAAAGCAACATCAAACCTACCTTTTTTGGCTAAACGCTTTCA
TTAAATTCTTGATGGTCTTAGATTCCGGATTCAGACATCTCTGCTCATCATTCTTTTTCATCGTGGCACT
ATAGAAATAAGAGTGAGATACTCAGATTAACGTCAGGCCAACAGAGCTGATGGCCCTGCAGGTCCATGTC
AGAGTTCAGGCACTGTGCCTTAGTTAGAGTCACAGACCCGTCCCTATCTTTCCTGGTTTCCCTCACTTAT
TTACTGTGTGGTTACGGGAGGGACGTTTATCGGCAGGTGGGCTTGTACTCACATGATCTCAACACGTGGG
CAGGATAGGCTCGCAGGGATGATTTCAAGCTTCCCTATGGCCCTCATTCTCACTGGCCCGTCATCGATAT
GGATGCAGTTGCAGCGGACCGTCCTTGCGAGAGGGATCCCTGCAGGAAGAGAGGGGGAGAGCCAGGAAGG
TCAGCACACGGTTTCATTTTAGGCACTTAAAATGGATGAGGTAGTGTTTAGCAGACCCTGTCTGATCTGT
GGAGAGACGCATCCCATCGTATCATAGGGCTGAGTGTTTGAATATCTTGGTCATGGTAAAGAGAGATCTG
CAACTTGTCAGTTACGAAATCCTGCATTTATGCACTGCTCACAGTATTGGTTAGGCTCAGGCAAGGAGGC
ATCCGTGCCTTACCCCATCCCACTCTTTCGCCCTTTCTCCTGACTCTCTCTTCCCTCCTTCTTCCTCCTC
CCTCCTCCTTTTCTCCCTTTCTTCCCTTCTTCGTTCCTTTGCTTTTATTCTATTTTTCTCTGACTTCAAC
CAGCCTATGATAAACTCTGCAAGCTGAAGGGATTTCTTCCTGCTTCCCTCTTCTTTATAGGTACACACAT
TAAAGCTTAAATACATGCTGTGTTTAGAACTGAGCTTAATCGTCTGACTTCTGACTTCGTTAATTAAATG
GCCTTGGTGTCCCTTACCTTGAGTCCCACTCAGACCCAGCAGGATGAGGCAGAAAATGACGGCAGCACTT
GGGTTCATGGTGCTGATGGGGAGGCTTCCGGAAGGTTGGCTCGGGATGTCTCTCAGCGGTGGATGAAGCG
CTTCTCGAGTGC

Protein Sequence : Show Sequence

>gi|10946576|ref|NP_067249.1| C-X-C motif chemokine 10 precursor [Mus musculus]
MNPSAAVIFCLILLGLSGTQGIPLARTVRCNCIHIDDGPVRMRAIGKLEIIPASLSCPRVEIIATMKKND
EQRCLNPESKTIKNLMKAFSQKRSKRAP

Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK)

6. Cxcl9

Gene Name : Cxcl9
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 17329
NCBI Protein GI : 110626107
Locus Tag : PSTAB_3782
Genbank Accession : AC109603
Protein Accession : NP_032625
Taxonomy ID : 10090
Chromosome No : 5
Gene Starting Position : 92321330
Gene Ending Position : 92328078
Gene Strand (Orientation) : -
Protein Name : chemokine (C-X-C motif) ligand 9
Protein pI : 11.28
Protein Weight : 14046.52
Protein Length : 126
Protein Note : Also known as CMK; Mig; MuMIG; Scyb9; crg-10; BB139920

DNA Sequence : Show Sequence

>gi|372099105:92321330-92328078 Mus musculus strain C57BL/6J chromosome 5, GRCm38 C57BL/6J
AGACATTGAAAAACATGTTTATTTTGGAATTTAGTGCACTTTTACTGATATCACTACGCTTTCACGAAAT
AGCTTCAGAGCACATATGCTAATTTGCTTTGAATTAAAAATTAGAGTACACATATGAAGTCATACTGTAG
GCATATGCATCCAACATAACTATTTAGTAAAAATTACACAGGCTTTGGCTAGTCGTTATGCATACTACCC
AGCTGTCAGATGCAAGGGTAGCTAACTAGTTAGGAAACAATTTTAGACTTTTTTTTTTTTTTTCCAAAGT
AAATTACCGAAGGGAGGTGGACAACGTTTTGACTGTGCAATGTTGTTTGGATGGGAGTCCCACCAGCAGC
ACAAAAACCACCTGCATGCAGCGCCAGGAATGGCAGTATTTGAGAAAAAGCATGCTCAAGACGGAACTTC
TGCCCAGAGACATTCTTTTCTATCTAATTCATCAGACCTCCTCTCTAGAGCAGTTTCCAGCTCCCACACA
GGCTAACTTGGCCCTGTCCACACTTCCACTCGCAGAATTTACTGCTTCCTGTAGCTCTTAATTCCTTTAA
AAATATCTCTGTAAAGATTTTTATTTGCCGTCTGAGATTATGGGTGTATGTCATGGGGGCCTGTGTACAC
CTGTGCAATGCTTGCAGAGGCCAGAAGAGAGAAATGGGTTCCCTGGAGCTGGAGTCACAGGTGGCCACAA
GGCTCACGCACACGTGGGGGTGGGTGCTGGGAATGGAACTCTGGCTCCCTCTCCAGCCCTGATCTTTCCA
TTTCACCACTCCTAGCCTGATGTGGCAATCCATACAATCATACACTGGGATTTCTGCAATGAGGGAGGGA
AGGTGGCAAGGAAATTCATATTCACCTAAGATAAACTTGCTAAAGGATTTGGCAGCTCTTTTGTTGACTC
CTAGGGAGCTTGTCCTGATCAAGAATGATATTAGAGGAATTTTGTTTTGAGTGAGGAAAGATCTAGTATT
TGCCAATCAGTCAAACCTGTCTTCCATGTAAGCTTATGTTTCTAGATGGCCTGTGTAATTTTTCCTGAGC
AGTCCCAAATATCCGCAAATGTCTTGAACATGTGATTCCTGTTTGTTAAAGACACGAGCCTCCTGTCACA
AGGTAAGGCTCTTTTTCACCCTGTCTGGCTCTGTGCGCTGAAGATGTCTGAAGATAATAAGAAAGCTAGA
TAATTTAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGGAGGGAGG
GAGAAAGGAAGGAAGGCAGGCAATCAGGTGTAGTAGCACACACCTTTAACCCCAGCATTCAGGAGGCAGT
AGAATACAGATATGTATGAATTTGAGACCAGCCTTGTCTACTTTGAGAGTTTTAGGACAGCCAGATATAA
AACTTTCTTTAAAAAAAAAAAAAAAAAGTGGTAAGCAAGCAAGGAGGCCAAAGGTTAGTTAGGCAATTTG
GAGCAGCCGGGGATTGGCCAATGCCTGGTGTGTAACAGCCTTTCTACCTCTCACACATACAATTAGGAAA
TTATTCAAAACCAAGTTTTTGTAGGCACTGTGGAAGATTTAGGGGAATAGTCTGTGGTCCCTACTCTTAA
AAACCCGTCTCGTTGGAAAAAGTAAAACAAACAAACAAACAAATCCAATTAGATAGCAGCGAAGTGTTTA
CTTGTGAAACAGGAATAAATTTAAGAGAATTTGAGTAGCCAGAAAATGTTCTTTAAATTGGTTAAGTTTT
TGCACTGTTAGTGAAGGACCTGGTCCCTGCAACACCAAGTGTTCTGCCACTAAGCTACAGCCACAACCTT
CTAGGAGAGTTTTATTGAAGAGGCAAACTTAGAATAAGCTCTGAAGATGGGATCAAGTTAATAATGAAAT
CCCATGGTCTCGAAAGCTACGTGGGAGGTTCTGAAGGCCAACTCTGGTGGTCTCCACTGTAGAACCCCAA
AACCATTAGCACCATCTCTGAGACACAATGTGTGCAGGGGCTCTAGGCTGACCCAAATGCAGCTGCCGAG
GGCCTCTCCAGCTTGGTGAGGTCTATCTAGCTCACCAGCAAACAGACAGGCCTGGGATTTGGTGACGTGA
GCCTCAGAAGTCTTCGGAGGCTGCCAAATGTGTGGCTCTGGAAGCCAGACAGCTGTTGTGCATTGGATAG
CTATGAAGGAAAGGGACACTTGCCCAGATCTGATGTTATCACGACTAGGCTCAAGGGCGTGATGAAATTT
TGTTGGCTGTGTAGAACACAGAGTTTTTGCCTCTAGCAATTGTTACTATTGGAGTTTTGCAATTAACTTC
CTAAAGTTAGTTATAATTTCAAATTAACACTTTATGTTTTGTAGTTGAGTTAATGTATTAAAAGCCTATG
TATTAAAGGCTGCTCTGCCAGGGAAGGCTTTTCAGTACAATCTAAAACCCATTAAGATTCAGGGTGCTTG
TTGGTAAAGTAATGGTCTCTTATGTAGTCTTCCTTGAACGACGACGACTTTGGGGTGTTTTGGGTTTTCT
GTTTTTCATGTTCTTTTGATGTTTTTTCCCCCTCTTTTGCTTTTTCTTTTGGCTGATCTGCAAGAAATGA
GAAAAAGGCAATGCTTTCCAATGTTGTAGTTTCTCCCCTTCGAGATGGTCCAACTCCTGAGTGTGATCTC
TCCTTATCCTCAGAGCCAGCTCACGTCGCTGCTCTCTCAGAGGCGCTGGCCTCATTATCTGCTGCCCCTA
CATTAAAGAAGCTACAGTTCCCTCTTTGCTTGTTTGTCTGTTTTCTGGCATCTTGCTGTCTTTCATCTTC
TCCCTTCATCTCCCACCTGGGCCAAACACAGCCCTTTGGGGCTGGCTGGTAGCGTTATCACTCACTTTGC
ATATTAGCCAGTGGTTCTCAACTTGTATGTCGAAACCCATTCGGGGGCACATAGCAGATATCCTGTGTCT
CAAGTATTTACATTATGATTGTTAACAGTAGCAAACATTACAGTTATGAAGTAGCAGTAAGATAACTTTA
TGGTTGGGGGTCACCTCAATATGAGGGACTCATGCATTAGGGTCTCAGCATTAGGAAGGTTGAGAACCAC
TGAAACTGGACAAGGCTAGGCGAGTGAGTAGCCTGAAGCTTAAGGGCTAGGGTCTAGGGCAGACCCAGCA
GTTAGGTGTGGGGACCCAAGCTCCCCACCACATACCCCATGGCTCTTCTCAAACCCAGCTCCTTAGCTAT
CTCACAGCTCTTTTCCCTTTTTCCTTGGCTCCTTTCTCATCTCAATCCCTTTGTTCTCTGCATTTAAATT
CCAGTTACATTACTTCAGACTCACTGAACAGACTTTACTCAAAACCACCAACGCCCACACTGTACTTAAT
TAACTGCCTGGTAAATGTCTTATCCTCAAAGATCCAGATCAGAGATCACTTGATAGGAGAAGTCTACCTT
AATACTTTCTATATTGTCTCTTGGTCAAGTCAATTACCCTTTCCATCATAATTCTCAAAGTTCTCATGTA
CACACTATTTATTCTAAATGTCTCTCACCACGTCTGTTGATTTTTATACATTGTTAATGACTATCTGCTA
TATGGGGGAGGGGTGATAGCTTATTAATTTTGAATCCTTAGTGTCTTACTAGTTGATGCTATTCAAAAGG
ATGGAAAATGGGTCCTTAATGGGTGTGCCCAGGATCTGCTGACTTTGTGAGCTGACCTCTGAAAGAAAGC
CATTTGGGTTCCTCCCCCACCAACCTTCTTTTCCCATTCTTTCATCAGCTTCTTCACATTTGCCGAGTCC
GGATCTAGGCAGGTTTGATCTCCGTTCTTCAGTGTAGCACTGTGCCAAAGAAACACCAGTGAGCTTTCTC
CCCCCAGTAACAACTTCATAATTCTTAGTAGAAACAGTGGAGGAAAACGTGCATTTTATTGAGTTTTCCA
GTGAAACCACTTAAAATGTGGCAAAACGTCTTCCTAAGATTAACAGGTATATTTTTAAAAACTGTAGCAG
ATTTTTCAGGAGAAACCTCAATTTCTAAAAATTAATTTCTCTGTATAGCTTGAGAATAATAATGGCTATT
CTATATAGAATTCCTTATTTTAGTTGTCAAAGGTCAAATATATTACATACATGTATGTATATATATATTT
ATATCCTTTATATATGTATGTGTATATATTTATATCCTTTATATCGTATACATACATACACACATATAAA
TATATTATATAATATTATATATCCTTTAATTTCATAGTTCTGATTTCTAAGAGGCTTGGAATGGTGGTTT
ATTCCTGGAATCCCAGCATTCACGTGGACTGAAGTCAGCCTTGGCTACCTAGCAAGACTCTGTCTCAAAA
CAAAACAAACACGAAATTCTAGTCTCTAGAAAAGAATTACTAGGAAAGAATTAAACACAATCCTACAACA
GTAATAGTCTGACAACAGTGAATTTTTTTTAAACATAACCGTTGTTTCTAGCAATGGGCCATGTGCTATA
CAAATTATGGCTTATCAATATGATGTAAAACAGCTTAGCCATCAAAAGTCATTATTAGGCCAGGGAGTTG
ATGTGACTGCTAAGCATACTTGCCTCATAAGCCCAGAGAGCTGAGTCAACCCCAGAACCCCAAATTAGGA
CAGAAGAGAAAACCGACTCCACCAAGTTGTTCTGATTGCTGTATGCATGCTGTGGGATGTGTTCTTGAAC
ATACAAAGTATGGGTTAAAATTTATTTTATTTTTAACTTCTTTGTGTCTCTGCATGTGTATGTGTACTAG
TGTGCAGCTGACCACAGAATCCAGAAGAAGGGATAGGATCTCTGGGGTGGAGTTACAGATGGTTGTGAGT
TGTACACTGTGGGTAATAGAAACCAAACTCGGGTCCTCTTAACCTCTCAGCCATCTCTCTGCAACCCCTC
AAAAAAATTTTAAATGCCGCTTTTAGGATTCAGGGTTAGGGTTAAGTAGAGAGAGAGTACATGCATAGCC
TGTGCAAAATCCTAGGTTCAACCCTAGCACCCCCAGACAACTGACAAGTATGGCATTTTTAGAGAAAATT
AATTGTCATGAGAAACTGTCGTTGTTATTCTGTTAAGGAAAAAACAAATTACAAATGGCAACTTCTCCTC
CCCTGTAGGGAAGATGTCCAGGTTCCTACACTCTCAGATGGTACCTACGTACCTATATGCCTTACTTAAG
ATAAAGTCTAATGTGTAAACTAAACAGACTAAGGTATTAACCGCACATTTTATTATTTAAAGATATGTCA
TCTTCCATTTTCAGTTTCCAGAAGAAATTTCTTATTTTGAAGAGGAAGAAAGAAAAGGAGTAGACAGATT
TATGGGGGGGCCTCCTGCCTACATGAACAAGTAAGCAAGCTGAGGGTGAGAATCCCACTAAGTCCAGTGT
AGGATGCATGCGTTGGGAGCATTTACTTACATGATTTCAGTTTTGTTGCAATTGGGGCTTGGGGCAAACT
GTTTGAGGTCTTTGAGGGATTTGTAGTGGATCGTGCCTCGGCTGGTGCTGATGCAGGAGCATCGTGCATT
CCTTATCACTAGGGTTCCTAGGCGGAAGATAATGCACATTACTTAGAATGACATCCTTTCGAATGAGGCT
TGTCTCAGTCACTATTGCTGCGACTGAGTGTCTGTGACTGCTTTTCAAGGTAGGTGGTATTTCCATTCTG
TATACCAGGAAGCCAAGGTTAAGGGCAAAGTCATTTAGCAAAAGGGAGCAGGGGAAGAACTTCATTTTAG
GTCATTTAGAGTTCTTAACAACATCACTTCACAACCTTGGAAGAAGAGAAAACCTCCATCATACTTAAAT
CCCTACTGTTAGACACACATATATGCAACCTGTCAGTACTACGGGGACCGGTTTCTTAAGCAGTTCCTCA
ATCTACTTCTTGCTACTGGGGTCATGGAGTTGATGTAGGTGTGGACAGAAAGCTCTACTTACAACAATTG
ATTACCATTTCAATCCTATTCCCTCTCATCCTCACTGCTCTGAAAAGTCTCTTTAAACCTATGTCTCCAT
CCCTTATTGCTTACCCAGGTCAGTGTCTATTTACACAGGTTTTGCCAACACACAGTAACTATGGCACACC
TACTTTACACACGTGGAAAACGCTCTCTAGGAAGGTTTTTTTTTTTTGTCCGAAGTAAGCAAAGTCATGA
ATAAGGAGGTCAAAGGCAATCTCTCTGACTTCTGAATTCTCAGTTGGTTAACCACAGACATTCTTATCAG
TGCACAGCATCGGTTGAGGAAAGTGATGCAGGAGACAACTTAGAAAAGGATCTCTTATGTCACTCTCTGT
TGCCAGGGCTGCGGATGAAATATTTCACAGGATAAATTCGAAGTAAAGCACCCAGAATCCCCTTTACATC
TGAGAAATGTTTTTTCATTATTAAAACATTTAAATATGCTTTGAACCCTCATTGGGAACTCACAATACCT
ACGCCAAGAAGGCATATTTAACTTGGCAGGTATAGATTACGACCTTTGGATAACTGCTCACAGCATCTAA
CTGCTTTGATGACCAAACAGTATTACTTTTTATTGCATGCAAGACATTCAGCTTTATCTGCTGGCCTGAG
AAGGCTTTTACGGTGATTCAGTCCTCAGAACTTACTAACGTAAAACTCCTCACCTCGAACTCCACACTGC
TCCAGGAAGATGATGCCCAAGAGGAAAAGAACAGCGGACTTCATGGCAGAGCTGAGTTCTATTGAGTCAC
TGTGTTGGAGTGAAGTCCGAGAATGTCTT

Protein Sequence : Show Sequence

>gi|110626107|ref|NP_032625.2| C-X-C motif chemokine 9 precursor [Mus musculus]
MKSAVLFLLGIIFLEQCGVRGTLVIRNARCSCISTSRGTIHYKSLKDLKQFAPSPNCNKTEIIATLKNGD
QTCLDPDSANVKKLMKEWEKKISQKKKQKRGKKHQKNMKNRKPKTPQSRRRSRKTT

Molecule Role : Vaximmutor
Additional Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK)

7. Ifng (Interferon gamma)

Gene Name : Ifng (Interferon gamma)
Sequence Strain (Species/Organism) : Mouse
NCBI Gene ID : 15978
NCBI Protein GI : 33468859
Genbank Accession : NM_008337
Protein Accession : NP_032363.1
Other Database IDs : MGI:107656; UniProt: P01580
Taxonomy ID : 10090
Gene Strand (Orientation) : ?

DNA Sequence : Show Sequence

>gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
AGTATACCTTTGCAACC

Protein Sequence : Show Sequence

>gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
LLPESSLRKRKRSRC

Molecule Role Annotation : IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.
Additional Molecule Role : Vaximmutor
Additional Molecule Role Annotation : The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes (Wang et al., 2009).
Related Vaccine(s): B. abortus DNA vaccine pcDNA-SOD , B. abortus subunit vaccine using L7/L12 , B. abortus vaccine strain RB51 , B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 , B. melitensis WR201 (16MΔpurEK) , Brucella abortus pgk mutant vaccine , Brucella abortus pgm mutant vaccine , Brucella recombinant SurA protein vaccine , Microencapsulated B. melitensis vjbR mutant vaccine , Recombinant B. abortus RB51SOD

8. IgG

Gene Name : IgG
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16059
Genbank Accession : AF010213
Taxonomy ID : 10090
Chromosome No : 12
Gene Starting Position : 881411
Gene Ending Position : 914690
Gene Strand (Orientation) : +
Protein Name : immunoglobulin heavy chain (V7183 family)
Protein Note : Also known as IgG; IgH; VI24H; VH7183; B9-scFv; IgVH1(VSG)

DNA Sequence : Show Sequence

>gi|94393741:881411-914690 Mus musculus strain 129/SvJ chromosome 12 unlocalized genomic contig, MGSCv37 alternate locus group 129/SvJ
CATGGACTTTGGGCTCAGCTGTGTTTTCCTTGTCCTCATTTTAAGAGGTAATTTGTAGAAATAAGATCCT
GCCAGTATTGTGTACAGGAGAAATAGAAAAATTTTTCTTTCCTCTATTTTGTTTTGTTTTGTTAGTGACA
GTTTACAAATAAGCATTCTCTGTTGTGAGGTGCCCAGTGTGAGGTGAAGATGGTGGAGTCTGTGGGAGGC
TTAGTGCAGCCTGTAGGGTCATTGAAACCCTCCTGTGCAGCCTCTGGATTCATTCTCACTGACTACTGAA
TGACCTGGATCCTTCAGGCTTCAAAGAAAAGGATGGAGAGGGTGACAATAAAATTTTTCCCACTCACACC
CACTTGCTGGCCCTGGCGTTCCCCTGTAATGAGGCACATAAAGTTTGCAAAACCAAGGGGCCTCTCTTCT
CAATGATGGCTGACTAGGACATCTTCTGATACATATGCAGCTAGAGACATGAGCTCCCGGGATACTGGTT
ACTTCATATTGTTGTTCCCCCACAACAGTTGCAGACCCTTTTATTTCTGTGGGTACTTTCACTAGCTCCT
CCATTGGGGGCCCTGTGTTCCATCCAATAGCTGACTGTGAGCATCCACTTCTGTAGTTGCTAGGCCCCGG
CATAGCCTCACAAGAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTTGCTGGTGTATGCAATGGTGTC
AGAGTTTGGAGTCTGATTATGGGATGGATCCCCAGGTATGGCAAACTCTAGATGGTCCATCCTTTCCCAA
CAATAATTTTTAATGGTGGAGATAGCACCTACTATCCAGACACAATGAAGGGCCAATTCACTATCTCTAG
AGATGATGCCAAAAACACACTTTACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTATACA
TATATTCCTAAGCTTGAGTAAGTGGACTTAAACTGATTCCATCACAACTTGCATGAGATGGATATTCCCC
AGTGTTAAGACCTGTCACCATCACTGTCAATCAGAAGACAAAGTTTATGCACAACAAAACAAAAAAACCA
AAAGCAGAGGCCTCCAATTACAAGTAATAGACCCAGACCCACAGTCTCTGAAAACTGACTGTACAGTTGG
ATCCAGTCTTTTACTTCTTTTCCCTGGATTTTATATTACTGAGGAAATGAGGAAAGCTCTACAATATCTG
TTCTCCATAGTGCTCAACACCTCCAAGCACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTTCTT
GTCTTGTAGACTACTTCAACCTATTTTGTACTCCAGTTAATGAAACTCAAGTCTAGCAGCCTGTCACTGT
TTATTCTAAAGTATTATGAACAGGTGACCTCCCATCCTTCCCCAACGCAATAATCATATTTAGGAATTTG
AGGTTTTATGAGATATGATCTCAGGGTAGAGAGAGAAAGCAAACTACATAGAAATATAGACTGACATAAA
TCAAGACTTGCATAAGCTAGTCCCCAAGTTCCATGTCCCTAAGTGGCAAGGACTATCTTCTGAGCCTAAT
GAGATGAGATCCAAATCAAACCTCCTGGGTCTTTTTAGATAAACATGTGAGATCAATAGACTAAATGCTT
TGGCTGGGCTTCCTTGCAATCCAATTCCCAAACAAAAATGGATCTGGCTCCACAGACACCACAAGAATAG
TCTTAAATAGTTCTTTAAGTAGAATGTCTGATCACTACGAGCCCAATTCCATCCTAAATACTCTTCTGGA
TTATACATAAATAAAAATTGAACATAGGGCATGGGGCACTGATCTCCCTGTGCTACATGAATGGGGGCTC
ATTTACTAAATGTTCCCATTTTTCTTTCTAGCGCTGCACAGTGCAAATCCTACAACTTCCTGTTTATCTA
CAATGTGAACTCCAAACAGTACAAGAAAAAACGTTCCTTATGTTCCTCTCCAGGTTCTCCAACAAGCACA
GAGCAACCTTCTGTCACCAGGACGGAAAACTGGAAACCTTGCTCACTGCTTCCTTTTATTCCCTCGGGAA
CCTCCCCCAATGCAAAGCAGCCCTCAGGCAGAGGATAAAAGCTCACACAAAGACGAGAAGCCCCATCCTC
TTCTCATAGAGCATCCATCAGAGCATGGCTGTCCTGGGGCTGCTTCTCTGCCTGGTGACTTTCCCAAGCT
GTAAGTGTTTCAGGGTTTCAGAAGAGGGACTAAGACATGTCAGCTAGAAGATGTGTGACTAATGGTGATG
TTGCTTGTCCCCAGGTGTCCTGTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCA
CAGAGCCTGTCCATCACATGCACCGTCTCAGGGTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCC
AGCCTCCAGGAAAGGGTCTGGAGTGGCTGGTAGTGATATGGAGTGATGGAAGCACAACCTATAATTCAGC
TCTCAAATCCAGACTGAGCATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTC
CAAACTGATGACACAGCCATGTACTACTGTGCCAGAAACACAGTGTGGGAAGTCCAATGTGAGCCTGCAC
AAATACTTCTCTGCAGGGATGATCACAACCAGCAGGGGGCGCTGATGACCCAAAGGGACTTCCCAGGATC
TCTTCTGGAATCTAGGGAGTTCTGGCCTGTGTCTATCAGCATGTGTTTCAATGTTAGAGTTGTGAGTTTT
CCTTCCAGCAACAGAGATATTTTAGAGCCCACTTTTCATGGTCATTCTACTAAATTTGTTCACATAGTGG
AAAGATTTGTTAAATGATTCTATAGTCTAATAGGGTCAAACAAAAACAAATAATTGAGTTCATATCTACC
AAAAAAAAAAAAATTCCCTCAAAGTGGACAACTGTGTAGGTGAGGAAAACCAGGGGGATTTGGGAATAGA
TTATTTCTCTCCCGACTGTGGTGTTAGTCACCTTTCAGCCATTTACTGTATTTAATTCATGTTTAAAGTT
AATTGTATTCATCTTCCCTAACATGAAGTTTTCAAACACATGTCCACAATTTAATGATGACACAGTTATC
ATTGTGAATGATAACTCATAAGATCTCTCTCCATATATGAAACACACGATATTCTGTTATTAGCTATAGC
CAACAAAGTTACATATCATTATTATTACTGAAATAATTCTTCCCATCTAACTGAATAGTTTTCTCACTCG
ACACTGCCTATGCTGCGATCAGCCTGCTCTAATTTTACCTTTGCTCAGAGCACTGCTTTCTGTTTCATTT
GATAAGATGGTGCCTGGTTGTCACTGAAAATGTGTCCTCCAGTTTCACAGTGATTAATGTGATTTTCAGT
ACATTGAGAACAGAGCCACAGCAAAAATGAGATGGAATGTCATCATTTTTACGCCAGGTGCTGCAGAAAT
AGCTAGGTGGTTAAGAGAGAATATTGAACTTTGAGGGGTTCAGATTAAATTCCTGATACCCACAATGTGC
ACCTCATAACCACATGTACATATAGAAAACTCAGTATAAATGTGGCCTCCGTGAGCACCACACTACTCCC
ACAAACACATATACACATAATTAAAAGTAAAGATTTTAGAAAAATGGCTAATCTAATGATAGGAAGTAGT
CAAAAAGAGAGTTCTTTTGTCATGTACATATGTGTAGCAGACTTAAATGTTAAACATTCAAGAATACATT
CCTCGATCCACATTAAAATTTTGCAAAGAGTAGCACAGACGGTGGCAATTGCTAAACTTATATCTAGAAA
CACAATTATGTGTGGTGATATTTAATTACACATTTATACCAGGACATATGACAATATGGAAACCAAACAT
GTTGTATCCACATGCTCTAAGGAAAACTAAATGGAGTGTGATAAAACCAAAGAAAATGTGAATATGAAAT
ATTTTTCCAACTCTGCATCTTAAAACGGTTTCTTTCATGTGTCATATCTGCTATGAGGACTTTCTTCTGC
CCATGTCCAACTCCAGAGCATGCCACAGCAGGAAGACCTACAGGTATTACTTCTCTGCACCCAGGAAAAC
CACCTCTGTCCTGACCCTGCAGCTCTCAGAAGAGCCCAGACCTTCATTCTCAGGCCCTCATCCAGTAATC
AGCACTGAATACAGAGCACTCACCATGGACTTTGGGCTCAGCTTGGTTTTCCTTGTCCTTATTTTAAAAG
GTAATTCATAGAGATAAGATTCTATCTGTTTTGTGTACATGAGAAACAGAAAAATTGTATTGTTTCTCTA
TTTTGTTTTGTTTTGTTAGTGACAGTTTCTGACTCAAGATTCTCTGTTTGAAGGTACCCAGTGTGAGGTG
AAGCTGGTGAAGTCTAAGGGGAGGCATAGTGCAGCCTAGAAGGTCCATGATACTCTACTGTGCAGCCTCG
GATTCACTGTAAGTGACGACTGGTTTGTCCGTGTTTGCCAGGCTCCAAAGAAGGGGCTGCAGTGGGGGAT
GGGAATAATTTTTCATGGTTGTGGTAGCCCCTCTTATGCAGACACCTTGAAGAAGTGGGTTGGACGTAAC
ATATTCAGAATCAATATTTAAAGATTCTAATCCTTGAAGATATCACTTTTGACCAAGTATATATGAACCA
TGTTACTGAGGTTTATGGAGGTTTGAGTATGTTAGGTCCATGGATAGGGAAAATATTAGGGGATTTTAGG
AGTAACTGAGGCTTGTTGTAGGAAGGACATCACTGTAGGGGTAGGCTCCGTGTTCCTATCTTCAAGCTCT
ACCCAGTGCAGAATAGAGCCCTCTTCTGCCGGCAAGTGGAAAGAGTTTCTCTTCCTGGCTGCCTTCAATC
CAAGTTGTAGAATATCAAATCTCCTAACACTATGACTGCGAGCATGCTGACATGCGTCCCACCATAAAAA
TAGACTGAACCTCTGAAGCTTTAAGCCAGCCTCTAGTAACTGTATTCTTTAATAAGACTGAACTTGGCTA
TGGTGTCTTTTCACAGTAAAATGGAAACATAGACAAGGTTCTAACTCTCTGTACTAGAGGACCATCTCTA
TGTCCTTGGTGTTGTATGTAAATTATTGAACAAATACTATAGACAAGTTGTATGGCCAAAAGTCCATCCC
CTTCAACAATCTACTATCTGGAACCATATAGATTAGATTCCTTTCCTGCACTCATTTCCCTTACTTGCTG
AGACATTTTGAAGACATGCTCAGAATCCCTGAACTTCCTGCTGAAAAAAAAATACCCCTCCAATTTGAAG
ACAGTTCTCTTCCAAAATTCATCATAAATACTGATCCACATGTCCAGGCATATCATGTAGTTTTAAAAAA
CAAACCAATCAATGCTAAAGTGGGTAAGTGCCTACATCATTGGTTTATGTCTGTTCATAACCTGGTATAT
AGCTAGAGACCAGGACTGCATGTTTCTCCTAGGCCACACCTCTCCCACAAATGCTGGCTCTGCCTCTCCA
GAATTCCAAGATCATGGATCTCTGGGTCCCCAAGGAACAATAAGTGTGCACTCTTGCCAGCCTGTACACT
ACTGCACTAGCTTCTCCCCCTGGAGCTTGGTCATTGCTCAATCTTCCCTTTCCAAAGCCTGGCCAAATTC
CTCCTACCTTTTGTTCTTTCAGTCAGGCCACCTAAGTCATCTTGAATGAAAAACAACACAAAATCTGAAC
TTAAAATCAACAAATAATACAAGTGCTGCGCACAAAATCAATCATTCTAAACTCATCAACTATTTTATGA
TGGAAATCTTCCAACATACAAGCTACCACCAGGTCTAAGAATTACTCATCTACATGTTGCTTCCTCTCAC
TCACAGCCTAACCATAAAAGGGCTGTTTCTTCCTCCCATGTCCCCTCTTTTGCCTTCAGAAGCAGAAGCT
CCACCTCCTCCTCTTTGCCCAGCAATTGGCTTCTTGTCGTCTTTATTATCATATTAATTACTTAGGGGAA
AATCCCGTGTAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGG
AAGGCTCACCAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAG
CCATAGGGGCTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACG
CCTTTCATCTGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAA
TATAAGGACATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTG
AGTAACTGCTAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGA
CTCTAAGTCATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTG
ACTAATACAGAAGTTGGTACCAGGAGTGGTTCTAGAGTAACAGAAGTACAAGGATGAATCTTTTAAAATA
CTGGAATTGGCTTGTTGATCCACCAGCACTTTCAACTATTGAAACCTCTCCAGATTCTCTCCCTCCTGGG
AGCTCAGAGAATTTTGAAGACCCATGGTTGAAACTATATTCCGAACTTAAAGAAGCAAATGCCCTTGATT
TTCTTAATGAATTAGGTGATTCAGTGCACAAAGCTTTCTACAAGATGGGGAAAAAATTGGAAAATGATTT
TACTGGCTGGCTGCTCTTAGTATCTGTGGAAAAAATGATGAATGAAAGGAAGGAGTTGTGTGATAAAATC
GAAAGGCTCCAGACACAAGTAAACGATCTAAAAGTTGCTAAGTGTGTCCTTGAGGAGAATCTTCTCTCTT
GTAGCAATAGAGCTCAAGTTGCAGAAAATCAAACAGAAACTCTCATTGTAAGGTTGGCTGAACTACAGCG
AAAATTCAAGTCTCAGCCTCAGAGTGTGTCAACAGTTAAAGTAAGGGCTCTAATTGGCAAAGAATGGGAT
CCTACAACATGGGACGGGGATGTGTGGGAAGACCATGTTGAAGCTGAGAATTTTGAATCTTCAGATTCTC
AAGGGTTTGCCCCACCTGAGGAAGTAGTACCCTCAGCCCCACCCCTTGAAATAATGCCTTCCCCACATGA
GGAAATTAATTTTGCAGAGTCTGATAAACCAGCAATGATTTTCACTACTGATGTTTCTCAAGGCCCACCA
ATAGTTTCTTCTAGACCTGTAACCAGACTCAAAGCAAAACAGGCTCCTAGAGGGGAGGTAGAAAGTGTAG
TCCATGAGGAAATTCGCTACACTACTAAGGAGCTTAATGAGTTTGCTAATTCATTCAAGCAGAAACCTGG
TGAATATGTGTGGGAATGGATTTTAAGGGTGTGGGATAAGGGTGGAAGGAACATAAGACTAGAGCAGGCT
GAGTTTATTGACATGGGTCCTCTGAGTAGAGATTCTAGGTTTAATACGGAAGCTCGCATAATTAAAAAAG
GTGTCAAAAGTTTGTTTGAATGGTTGGCTGAGGTGTTTATCAAAAGATGGCCTACTGGAAATGACTTGGA
GATGCCTGATATTCCGTGGCTTAGTGTTGATGAAGGGATTTTAAGACTTAGGGAAATTGCAATGCTAGAG
TGGATATATTGTGTAAAGCATAATTGTCCACAATGGGAAGGTCCAGAAGATATGCCTTTCACTAGCTCTA
TAAGACGCAAATTGGTGAGAGGGGCACCAGCACATTTGAAGGGTTTTGTTCTTTCCCTTTTCCTTGTACC
AGATCTTAGCATTGGAGATGCTTCTGCTCAATTAGATGAATTAAATTCACTGGGTTTAGTTGGATTCCGA
GGTAACAAGGGCCAGGTGGCAGCATTGAATCGCCGGAGACAAGGTGATTCTAGTTATTATAATGGACAGC
GTAGACAAAAGAATGTTTATAATAACATACCCAGCAATGGTCAGCACAGGAGAGGTGAAATTTATAATGG
CATGACTCGGTTGGACCTTTGGTACTGGCTAACCAATCATGGTGTTTCCAGGAATGAAATACATAGGAAG
CCTACTGCATATTTGTTTGATCTGTATAAGCAGAAAAATTCTCAAACAAATGAAAGAAAGGCTACATTAG
ATCATGGTAAACAGCAATCTCGGCCAGTGAATCAATTTCCAGACTTGAGACAGTTTGCAGATCCAGAACC
CCTTGAATGAAGGGGTGGCCAGGTTCCGCTGAGGAAGGATCTTGATAAGACACCCAAAGGTTTTGCTGTT
ACCCTTTCTCCAGTTCTTCCCCAGAGGGACCTAAGGCCTTTTACAAGGGTAACTGTACACTGGGGAAAAG
GAAATAATCAGACTTTTCAGGGTCTGCTGGATACTGGTTCTGAGTTGACACTGATTCCAGGGGATCCCAA
GAAACATTGTGGCCCTCCAGTTAAAGTAGAGGCTTATGGAGGGCAGGTGATTAATGGAGTTTTGACTGAT
GTCCGACTCACAATAGGTCCAGTAGGTCCCCAGACACATCCTGTGGTGATTTCCCCAGTTCCAGAATGTA
TAATTGGGATAGATATACTCAGAAATTGGCAGAATTCTCATATTGGTTCCCTGAACTGTAGAGTGAGGGC
TATTATGGTTGGAAAGGCCAAATGGAAACCTTTAGAGTTGCCTCTGCCAAAGAAAATAGTGAATCAAAAA
CAGTATCGTATTCCTGGAGGCATTGCAGAAATTACTGCCACTATCAAGGACTTGAAAGATGCAGGGGTGG
TGGTTCCCACCACATCTCCGTTTAACTCTCCTATCTGGCCAGTGCAGAAAACAGATGGATCATGGAGAAT
GACAGTTGATTATCGAAAACTAAATCAGGTAGTAACTCCAATTGCAGCTGCTGTACCAGATGTAGTTTCA
TTACTTGAGCAAATTAACACATCTCCTGGCACCTGGTATGCGGCTATTGATCTGGCAAATGCCTTCTTCT
CAGTACCTGTCCATAAGGACCACCAGAAGCAATTTGCTTTCAGTTGGCAAGGCCAACAGTATACTTTCAC
AGTTTTGCCTCAAGGATATATTAACTCTCCTGCCCTGTGTCATAATTTAGTTAGAAGGGATCTTGATCGT
TTGGATCTTCCACAAAATATCACATTGGTGCACTATATTGATGACATTATGCTGATTGGACCAAGTGAGC
AGGAAGTAGCAACCACTTTGGACTCATTGGTAACACATATGCGTATCAGAGGATGGGAAATAAATCCAAC
CAAAATTCAAGGACCATCTACCTCAGTGAAATTCTTAGGAGTCCAGTGGTGTGGAGCATGCAGAGATATT
CCTTCTAAGGTGAAAGATAAGTTATTGCACCTGGCCCCTCCTACAACCAAGAAAGAAGCACAACGTTTAG
TGGGTCTATTTGGATTCTGGAGACAACACATCCCTCACTTGGGTGTGTTACTTAGGCCTATTTACCAAGT
GACTCGGAAAGCTGCTAGCTTTGTGTGGGGCCTGGAACAGGAGAAGGCCCTTCAACAGGTCCAGGCTGCT
GTGCAGGCTGCACTACCACTTGGACCATATGACCCAGCAGACCCGATGGTACTTGAGGTGTCTGTGGCTG
ATAGAGATGCTGTTTGGAGCCTCTGGCAGGCCCCTGTAGGTGAATCACAGAAAAGACCTTTGGGATTTTG
GAGCAAAGCTCTACCATCATCTGCAGACAACTATTCTCCCTTTGAAAAACAGCTCTTGGCCTGCTATTGG
GCCTTAGTGGAAACTGAACGTTTGACAATAGGACACCAAGTTACTATGCGACCTGAACTACCCATCATGA
GCTGGGTACTATCAGACCCTGCAAGTCATAAAGTGGGACGCGCACAGCAGCAGTCTGTTATCAAATGGAA
GTGGTATATACGTGATCGGGCCAGAGCAGGTCCTGAAGGCACAAGCAAGTTACATGAAGAAGTTGCTCAA
ATGCCTATGGTTTCTACTCCTGTTACACTGCCATCTGCTGCCAAACATGTGCCTATAGCCTCATGGGGTG
TTCCCTATGATCGACTGACCGAAGAGGAAAAGACTAGAGCCTGGTTTACTGATGGCTCTGCACGTTATGC
AGGCACCACCCAGAAGTGGACAGACAGCTGCAGCATTACAACCCCTTTCTGGGACAACCCTGAAAGACAC
AGGTGAAGGGAAATCTTCACAGTGGGCAGAACTTCGGGCAGTACACATGGTATTACAGTTTGTTTGCAAG
AAGAAATGGCCAGATGTACGATTATTCACTGACTCATGGGCTGTAGCCAATGGATTGGCTGGATGGTCAG
GGACTTGGAAAGATCACAATTGGAAAATTGGTGAGAAAGACATCTGGGGAAGAAGTATGTGGATAGATCT
CTCCAAATGGGCAAAGGATGTGAAGATATTTGTGTCCCATGTAAATGCTCACCAAAAGGTGACTTCAGCT
GAGGAGGAGTTCAATAATCAAGTGGATAAGATGACCCGTTCTGTGGACAGTCAGCCTCTCTCCCCAGCCA
TCCCTGTCATTGCTCAATGGGCACATGAACAAAGTGGCCATGGTGGTCGAGATGGAGGTTATGCTTGGGC
TCAGCAACACGGGCTTCCACTCACCAAGGCTGACCTGGCTACAGCTGCTGCTGATTGCCAGATCTGCCAA
CAGCAGAAACCAACACTGAGTCCCAGATATGGCACCATTCCTCGAGGTGACCAGCCAGCAACCTGGTGGC
AGGTTGACTACATTGGACCACTTCCTTCGTGGAAAGGACAGCGTTTTGTTCTTACTGGAGTAGATACTTA
TTCTGGTTATGGATTTGCCTTTCCTGTACGTAATGCCTCTGCTAAAACCACCATTAACGGACTGACAGAA
TGCCTTATCTATCGTCATGGTATTCCACACAGTATTGCTTCTGACCAAGGAACTCATTTCACAGCCAGAG
AAGTACGACAGTGGGCCCACGATCATGGAATTCACTGGTCTTACCACATTCCCCATCATCCTGAAGCAGC
TGGTCTGATAGAAAGATGGAATGGCCTTCTGAAGACGCAGTTACAGCGCCAATTAGGTGGTAACAGCTTG
GAAGGCTGGGGTAGAGTTCTTCAGAAGGCAGTATATGCTTTGAATCAGCGCTCGATATATAGTACAGTTT
CACCCATAGCCAGGATTCATGGGTCCAGGAATCAAGGGGTGGAAAAAGGAATAGTTCCACTTACTATCAC
TCCTAGTGACCCTCTAGGAAAATTTTTGCTTCCTGTCCCCATAACTCTAGGTTCTGCTGGCTTAGAAGTT
TTGGCTCCAGAGAGGGGAGTGCTCCTACCAGGAGCTACAACAAACATTCCATTGAACTGGAAGCTCAGAC
TTCCCCCTGGTCATTTTGGGCTTCTAATGCCCTTAAACCAACAGGCTAAAAAAGGAGTAACAGTGTTAGG
AGGGGTGATAGATCCAGATTACCATGGGGAAATTGGATTACCTCTTCACAATGGTGGTAAGCAAGATTAT
GTCTGGAGTGTAGGAGATCCCTTAGGGCGTCTCTTAGTACTACCATGTCCTGTGATTAAAGTCAATGGGA
AACTACAACAGCCTAATCCAAGCAGGATGACAAAGGACACAGACCCATCAGGAATGAAGGTATGGGTCAA
TCCTCCAGGAAAAGAGCCAAGACCTGCTGAGGTGCTGACTGAAGGAGAAGGAAATATAGAATGGGTAGTA
GAGGAAGGTAGTTATAAATACCAATTAAGGCCACGTAACCAGTTGCAGAAACGAGGATTATAAAGTAATA
TGAATGCCCATTGTAAATTTACTAATGCGTTTGCGATTGTACGAGGGATAGTTATATCATGTTAGGCGTA
TTTACAAACTTGTTATTGTTTTATGTGAACATGAGATATTATTTGTGTCAAGTTGACAAGGGGTGGATTG
TAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGGAAGGCTCAC
CAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAGCCATAGTGG
CTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACGCCTTTCATC
TGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAATATAAGGAC
ATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTGAGTAACTAC
TAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGACTCTAAGTC
ATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTGACTAATACA
TCCCTACATACAGGAAACTTGATGTATAAGTAAAGAAAATAGTAAATCTAAAAATTTCCTTATCAAATAC
ATGCAAGAAATCCAAAATACCATGAAAAGACCTGATCTAAAAATAGTAGGAACTGAAGGTGAAGTGTCCC
AGCTCTGAAAACTAGAAAATGTTTTCAATATTTTTCCTAACAGTGAAGACATGGATCTAATGAGGCCACC
TCTTATAGCCATGCAAGACTGACAGTGGAGGGATAAGGACACCAATCCACCCACAAAACTTTTGACCCTA
AATCAGTTTTATCTAAAAGCAATGCAGGGGCACAAATGGAGCAGAGACTGGAGGAATGGTCAAACAATAA
CCTGTCATATCTGAGACCCACCTAATTGGCATACACCAGTCACTGACATTATTAATAATGTTCCATTATG
CTTACAGGCATTTCTCTAGCATTACTATTCTTGGAGAGACTTCACACAGCATCTTATTGAAACAGATGCA
GACACCCAGAACCAAACATTGGATGGAGATTGGGATCCTTAAAGAAGAGTTGGGAGGATAATTGAGAGAC
CTCAAAGGAATAGCAACCCCATAGAAAGACACGAACAGGGTCAGTAAACCTGGACCCATGGGGTATCTCA
GAGACTGATCACCAACCAAAAATCACAGAGGGCCTGGATTGATTCCCCTGGCACACATGTAGCAGAGGTC
TGCCTTGTCCTTCAGTAGGTGAAGATGAGCCTAAGGCTTCAGAGACTTGATATATCAGCATACAGCAACA
CCCAAGTGTGTCCCACTATCTCAGAGGTGAAGGGGTGGAGATGGGCAGAAGGGTCCTGATAGGGGACAAC
TGCAAAGAGGCAATATTTGGGACAGAAAGAAAGGAAGAGAGAGGAAGATAAAGAGAGAGATGAAGGAAGG
AAACAAACAAACCAAGATGAAGAGAGAGAAAAGGGGGAAAATAGCCTTGAATGGTTCAGGGATTCAAAGG
GACATACCTAAGCATGGTAAAACAATGCACATAATGGCAGCAAGTAGCTAACACTGAATTAAATAGAAAG
ACACATAAAGCAGTTCTACTAAAGTAAGAGACAGAGTTGCCCAATCTCACCCTATTTATTCAATAATAAT
GTACTTGAAGTTCTAGCTAGGGCTGTAAGACAACTCAAGGAGATCGGAGGATACAAATTAGAAAGAAAAA
TTCAAAGAATTGTAATTGGTAGATGATAGGATAATATACATAAATGACCTCAAAATTCTTCCAGAGAACT
CTGAAAGCTGATAAATACCTTCAGCAAAGTGGCTAGAAACAAAATTACTTCATAGAATTCAGGAGCTATC
CTTTATAGAAAAGTTAAAGTGGCTGAGAAAGAAATTAGGAAAATCACATTCTTTGCAATAACCAAAAATA
ATATGAATTAGCTTGGTGTGACTCTAATCTTGCAAGTGAAAGATGTGTGTGACAAGAGCTTCAGGACCCT
GAAGAAAGAAATCAAAGAACTCAAAGATGCAAAGTACTCTAATGCTCATGGATAGGCAGAATTAACATAA
TGAAAATGCCAAATTTAACAATTCAATCTACAGATTCAGTGGAATTCCCATTAAATATCCAACCCAATTT
ATTACATTCTTGAAAAAGCAAATCTCAACTTCATATAGAAAAACAAGAAATTGAGGGTAGCTAACAAAAT
CCTGAACAATGAAAACACTTCAGGAGAATTCACCATCCCCTACCTCAAGCTGTATTTTAGAGCAATAGTT
ATTAAAACTGCATGGTATTTGTATAGAAACAGATATGATGATCAATGTAATTGAATTGAATACACTGACA
TAAAACCACACTGTTATGGACACTTGATTTTTGACAAAGAACCCAATAATCATAATAAAAATCATAATAA
GAATGCATCCCCCAACAAATGGTCCTGATCTAAATGCAAATAGATTCATATCTATCATCCTGCACGAAAT
TCAAATCAAAGTGAATTGCAGACTTCGACCTAATACTGGATTAACTAAATCTAAATGAACAAAAAGTAGA
GAATAGTTTTGAACTCATTGATGCAGGATTCAATTTCCTGAACAGAACCACAATGGCTCAGGCTCTAGGA
TCATAAATTGGTAGATAGGATCTCATGAAACTGAAAAACTTCTGTAAGGCAAAGGCAATAAAACAAAATG
GCAACCTACAGATTGGAAAAAAAATAATCTTCAGTATCCCTAAATCCCATTGAAGGCCAATATGCAAAGT
ATATAAAGAACTCAAGATGTTATCCTCCACAAAACCAAATAAATCAATTAAAAATGAACTACAGAGCTAA
CAAGAGAATTCTCAACAGAGGAATCACCAATGACTGAGAATCACTTAAAGAAACATTCAATATTTGTAGT
CACCAGAGAATTGCAAATCAAAACTACCCTGAGATTCTACTTTATACCAATCATAATGGTCAAGATAAAA
ATTCAAATGACAGCGCATGTTGGTGAGGATGTGTATACTTTTGCATTGCTGGTGAGGAAAACAATCTGGC
AGCTCCTCAGAAAATTGTAAATAATTCTACCTGAAGATCCAGCCATACCACTCCTGTGCATATACATAAA
ATGTGCTCCACCATACCACTAGGAGATATGTGCCACTATGCCCATAGCAGCCTTATTTGTTAATAGCCAA
AAGATGGATACAACCCTGATGTGCCTCAAACAAAGATTGTATATAGAAAATATGGGTTCCCTTACACAAT
GGTATTCTACTCAGCAATTAAAACGTGAGAACATCATAAAGTTTTCAGGCAAACTGATCAAATGAAAAAG
TATAATCTTGAGTGAGGTAACAGAACCAAAATGACCTGCATGGGATGTACTCACTGGTAAGTGAATATTA
GACTAAAAGTATAGAATATCAATGATGAAAGCCACAGACCATAAAGAGTTTAATAAGATGGAAAGCTCAA
GTACGGATTCTTCAATCCAATATAGAAAGAGGGACAAAATAATCAGGGGAGGCAGAGGGAGAGAGAGACA
TTTGGTGGAAATGGGAGAAGAAGGGAGAAAGGCAGAAAGGATCAGGCGTTGGGGAACACTGGAAAGCAGC
CCAGGGGTCCTGGTAAATGGATTAAATATTCAGCTGAATGGAGGTGGGAGGCAGGGGGAAGCTCTGCAAA
GTCCAAGAGACCTGGGATGTGAGAGGCTCCCCAGATGATAATCTTAGCCTTCATGCCTAACAGTTGTAGA
TAAACCCTGAAGAGATCACTTCCAATAGATGCAGAGGGCCCTAAGTGGTTGGATGGAGTCCCCCAACTTA
CCTCAAAATTGTCAATACTCATAGAAATTAGGACAATGAAAATCAAAACACCCTGAGATTGTATCTTATG
TCTGTCACAATGGTTAAGACCAAAACCTCAAGTGATGGCTTGTGCTGGCAAAGATTCAGAATAGTAAAAG
TCTCCCCATGGCTTGTGGGAATGCAAACTCTTACAACCTCTTTGGAAGTATATTTGATTGTTACCTGGTA
TAAAATGGCAAAAAAAAAAAATGGTTGAAGGGGGACTAAAAAAGGAAGAAAGGGGAGAACTATGGGATGC
GAAACAAGAAAGTTTGTTGCAAAAGAAATATGTTTCCACTGCAAACCCTGAGTCTCAGACAGAAGGGGAC
CTGGAATTCTTCAGATACAAAGAATCTCTAAACCCTGAGGACATTCTATCACAAATAAGTAAAATTCAGA
AAATTCTGAGTGCTCCCATCACGGAGATGAATCTGCTATGAACAGCTCATAGGTGTGACCCTCTACAAAA
GCCATATTATTGAAAAGCCACATTGTGCCCAGACTTTGGAAAGACTGAGCTCATATCCTGAAATACAGTT
ATGTGTGGTTCTATTTAATTACACATTTACACTAAGAAAACATGGCAGTATGGGAATGAAGCTTGTTCTG
TACACATTAACAGAGGGAAACTAAACAAAGTATGGTGAATCCCTAACCAAAAGTAAAAAAAAAAAAAGAA
AGAAAAGAAAATAAAAGTGAAACTACAATATGTTTCAAATGCTGTAACTGAAATCTGGTTTTTTGATGCT
TATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACTCCAGAGCATGGTATAGCAGAAAGACATGCA
AATAAGCCTTCTCTCTGCCCATGAAAAACACCTCGGCCCTGACCCTGCAGCTCTGACAGAGGAGGCCAGT
CCTGGATTCGATTCCCAGTTCCTCACATTCAGTGATCAGCACTGAACACGGACCCCTCACCATGAACTTG
GGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTAATTTATTGAGAAGAGATGACATCTGTTGTA
TGCTCATGAGACAGAAAAATTGTTTGTTTTGTTAGTGACAGTTTTCCAACCAGTATTCTCTGTTTGCAGG
TGTCCAGTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAACTC
TCCTGTGCAACCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCCAGACTCCAGAGAAGA
GGCTGGAGTGGGTCGCATACATTAGTAATGGTGGTGGTAGCACCTATTATCCAGACACTGTAAAGGGCCG
ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGAC
ACAGCCATGTATTACTGTGCAAGACACACAATGAGGAAATGTTACTGTGAGCTCAAACTAAAACCTCCTG
CAGAGCACCCAGGACCAGCAGGGGGCGCAGAGAGCACATGGAGTTCTGATTCACAGAAGAGTTACAGCCT
GTACAATTAGACCCAATCTTCAACAAACCGTCAAAATATTCGATCCAAAATTGTTCCTGTCTAAAAGTAA
TTCAAGGACAAAATGGACCAGAGACTGAAGAAATGGCTGACCTGTGACCCTCCCAACTTTGGATCTATCT
CATAGGCAGGTACCAAACCTTGACATTTGTCACTGACACTGTATTGTGCTTGCAGACAGGAGCATAGCAT
GGCTGACCTCTAAGAGGCTCTGCAAGCACCTGAATGAGACAGATGTAAATAGAGTGTACAACTGGATTAA
GTTTGAAGACTGCAATGGAAGAGTTAGAGGAAGGAATGAAAAATCTGAAGGGGATCACAACCCCAGAAGA
AGACCAACAGTGCCAATTAAACTGGATGCCTGGGAACTCCCAGAGACTAAGCCACAAACCAAGAATCATG
CAGGCTGGTCTGAGAATCCTGGCACCCAAGTCTCAAGGAACTGCCTTTTCTTGGCTCAGATGGGAGAAGA
TGAGCCTAAAGCTTTAGACTTGACGCCCCAGGGATGGGCAATACAAAGTTGAGTTTCTTGGGAAAGTGAA
GAGGATGGTGGGAGGAGGAATAAATCTGGGAAGTGGGACTGGTTGGGGACAACATATTGGTCCTAAATTT
ATGAAATAATTATCTAATTGATAAAAAGAGTCCTTGGGGTAATGGAGGGCTAGACTCCTCTGTGCCTAGT
TTGTAACTCTACAGGGATCCTCTTTAAAAGAATAGGGTGCACATAGAGTATATGTGTGTGACACTAATAC
AGGGGTAAGTGTTTCTGTAAGAACTTTATGAATAAACTTTATTAAAACATCAAAAAGTATAGGTTGTAGC
AACCCTTGACCTGTACGAATGTTTATAAAACTTTCTATTTTCCTTAATTATATCTGTTTTGCATTTGTTT
ATTTATTTATTTACTTACTTACTTATTTATGATTTCACTGTGTCTTTCTGTAGTCCTGTATGTGTTTATT
TGTCTCTTTATTGCTCTGTTTCTGTTTCTTTCTCTCTGTCTAGTATTGTATCTCTCTGTGTCTCTATGTC
GCCGATTGTGTCTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCATATTGAAA
TGAGATCTCTTCTTCTATCAGTGTACATAATGACTTTGAAATAAAGTCCATCACTGGGCTTGGATATCAC
TATCTTGTTAGAATGGTTGCCCAAAGTGTTCCAACCATCACACTGTTTCTACATATAATAGATGGGTTTA
TTGATTTACTACCAAAACTACCCCATCTTAAGTTATGGATATTAAACACAGATCCTCATGGTGTGTTAAG
AACTTGAAGCACAGAGCTATATGTACAGCCCACTAAAAATGACTTAAATATAAGATAAACTCTGGCTTGA
ACAAAACACAGAGCATCACACGAGGCAGAAGTGAATCTCTATGAGGACCAGGATCACATCCCAAAGAACC
AAAGAACACTTGAGACTGTGGAACCCTAGAGTCAGGGCTGACACTCAGTAAGATTTACTTCATAGAGCAT
GATGTGGGATTCAAGAAGAAATCAGGCAGGGCCTGTGACCCATGAACCAGATGACTTCCAGTCTCTCCAT
CATCCTCACACAAACCATAGGCAACAGCTCAGCACTGACTCACCTGTGATGCTGGTGACAAAATGTGTGC
AAAGCCTCAGAACTGAGACGTGAGGCCAATGTTGCTACCGACACTCAGTGAGCTTCAATTTGCTGCAAAC
TGCTCCAAAACAACTCAAAGGGTAACTTCTTCTTTTTCTATTTGTACTTGTGATGCCTTGGTAGATATAG
TTCCCCAATAATTTAATAGGACAAATCATTTTTCCTTTTAACACATTAATCCCCTTTCCTTCCCCCAAGA
TTCTAAAATTTTTCTTTAACACTGATGTCTGAGAGATATGGCATAATAGATGTTTGTCTTATTCTGAGTT
GTTCCTTATCAAAAGAAATCAGCTGTGGCACTTTGAACCTAAATATAACAATATTTCACAAAGGCATTCT
GGGAATATATAGATGGTATTGCTACAAAAGAATAGGAGGATCTATGGCCATACCACCCTTAATGAACCAG
ATACTATCTAAAAGATTAGGACAGCTGGGCATGTTGGCACAGGCCTTTAATCCCAGCACTAAGGAGGCAG
AGGCAGGCAGATTTCTGATTCGAGGCCAGACTGGACTACAAAGTGAGTTCCAAGACAACCAGGGCTATAC
AGAGAAACCCTGTCTCGAAAAAACAAAACAAAACAAAACAAGAGTAGGAGGGTATTAGATGCGAGGTGAT
GATGGCCATTCAATCAAACCAGAATGTGACCTGAGAAAAGGTCTAAGTTTGTCAGCTTGTCCTGGAGATG
TGTTGCCTCTGATAAATGCAGAGCTGGAACTGCAATACATTGGATTCCTGTGAGTTACGGAGAAATAAAA
GGAATAGCCTCTGTTTCCTTTGGTTCATCAAGTTGGCAGTGAGCTAGAAGATGATACTGGGAACCATCAC
ATGTACTTCTACAGAGTTATTCTACATTCTACAAGTCAGTCTTGCTTGCTTTCGTTTCTGTGAGGAGCTA
AATACAGAATGTTTTCAATGTCTCATAATGTTCTGTGCACACCCATGGGTGCCTAGCCAAGGATAGAAAC
TTGTATCTGATAAGGAAAGAGGATGCTGCAGTGGCCACACTCTGAGATCACCTCCTGCCAAATTATACTA
GAGTGTTTTACATAGTCTTGAAAACACTAGGTCAAATATGTTGTCATCCAGATATGAAAACTCTGTGCAA
CAATTCAGAAATACAGTGGTCAGGACAACTGGTATGTAACACTTTAGTTCCAGCCCACATTAATCTCACA
TCTTTTCTGTGGTTTCAATAAAGAGCACACATGTTTGGAACACCATCTCCACTTTGTATGCTTATCCTTA
TGCATCAAACTTTTCCTGTAATTTCCTACCCCGCACAGGTTCCTGTCTTGATCTCTTTTTCTAATGAACA
GCAATACAGAAGTGTTGGCCAAATGAACACTTTCACCCCAAGTTGCTTTGCCATTGTGTTTCATCACAGC
ATTAGTAACTCCCAGTAAGGCTACTGGTTACCCTGCATCTTCTATGTAGATCTTTTGATGAAGTTCCAGG
CTTGGGGTCTTTATCTGACTGTTATCCTGGTTAATTCATGTCCACCAATAGAATATTGTTCTCATTTTCA
ATATCATATGAAGTTACCTGTTTATAGGATCTTCCTAAAGCAGAAAACTATATAAAATGTCTGCTTACTT
TAAGAAAAGTATGTGTCCTTGGAGGTAAATGGAGGAAAGGGTGGAGGATGTTGAGTAATGGAAGACTGGC
TAATACAGGAAGGTCACAGAATTGAATGATTTTAAAAATTTTAACTCCTCATCAATGAGGTACTTCAAGT
TGAGGCAGGAGTCCTTGATGCACAGGTGACCCAAAGGCCCCAGCCTCTGTTTCTTGGTCTGCTCCAGTCT
CCCGGCTCAGCACAGTTCACTGAGTGACAATCTTTAAGATAGTCTTTCAGGATACAGTTATCACAGTTTT
CAAACTCTCTTCATTGAAACAATATAATGAGTCAGAGTCCAGTGTGCCATTAATAGGCCCTATGCAATAG
GATTTTACTTCATCTGTGGAAAGAAACCACCATGGCCTCATCAAGGCCTCATTTGATGATTAGTGTAGAA
AGCGTCCCCAGAGCTTTGCTGGGATGAAAACCCTGGCAAGATGTTTAGGGCACTCTCCATCTGACAGGAC
AATTCTATCAAGGGTTGCTTCCATATAGAGAGAAATCTCCACATCTGCAGTATTTCCCGATTTATCAACA
GTTCTTTACCCCGTGTCATATGCATAAAATCTTTTCTCTGTAGAATTTTCAGTACTAAAAACTAACAAGG
ATGTTGGTCCTGATATCAGACATAATAAATAAATAAACATCAAATTATACCCTAAACATGTGGAGATGGT
TTTCTGTTATGAATTTATTGGCTCTCTAAAAAGTGTTAATTAAGCCAGGCGTGATGGCACATGCCTTTAA
TCCCAGCACTTGTGAGGCAGAGGCAGGCGAATTTCTGAGTTTGAGGCCAAACTGATCTACAGAGTGATTT
CCAGGACAGCCAGGGTTACACAAAAAAACCCTGTCTCCAAAAAGTAACAAAAAGAAAGTGTTAATTAACA
TCTACACTTTAAGATAATTTGGTGGCAAAGGTTAATAGTCTGAAATACTAGATATGAAAGTATGACACCT
AAATTGCATGCAGAGAATAAAGCTGAATTCCAATGAGATTCATGCCTTGTGAATCCATTCCAATCTGATC
TCAATCTTCAAACATGTTTGTGCATAATTTACATCTTAATCAGTTGCTGGAAATTAAAAGGACATAAGCT
AAACTTAAAACTCTTTCTATTTAATGTGTCAGAATAGAATATGTGCACTGAAGTTTTCATGTGCATAGGA
TATCATTGTTACAATGATGGTTCAAATACGCACCAGTAGCACAGGTGATGCTTGACATGAAAAAAACTGT
GACCAGAGCCCAGACGTTGATGTTGGCTGAAAGAGCCTAGTGTCTCACATTTGATCAAGCAAAGTGTTAT
TCAGAGAAGCAGTGCCAGATTTGGGATCCTTCTTAATGGATCAAGAACATGAGGAAGATTTGGAAGCCAG
ATTGATGAGATTACTAGAATCCTGGATCTGAACACACAACACACAATAGTAAGTTGAACTTTTCCACGCA
ATGCTAAAGATAAAGCATCCAGTATCATGTTATACAGGACCAAGGTGAGGATCAGTCTGTGGGTGAAGTA
CAATGAACTGGAAATTGTTTGGATTTTAAATGTTGGTTTTTAAATTATATATAAAATATATATATATATA
TATATATATACATATATATATATATATATATATATATATATATATCGGAACCAACATTTAAAATTTGGAT
TTTAAATGTTGGTTTTTAAATTATATATAAATTATATATATATATATATATATATATATATATATATATA
TATATATATATATATCGGAACCAACATTTAAATTCCTAATTCTTAAGGACTTCACTTTTGACCAAAAATA
TTTGAAATGGGTTATTTAGGTCTGTGGTGGTTTGAATATGCATAGCCTATAGGAAGTGGAAGTATGGCCA
TTTTGTAGTATGTGTAGCCTTGATGGAGGAAGTACATCACTATATGGTGTTGTGAGAGTTGAGATCCTAT
GTTCAAGTTCTGCCAAAAACAGAAGAGAGTCCCCTCCTGGATATTTGAAACAGATGCAGAGGCCCAAAGC
CAAACATTGGGTATATCTCAGGGTTTCTTATGGAAAAGTTGGCTGAAGGATTGAAGGCCTTAAAGGGGAT
AGGAACTTCACAGGAAAACCAACAGATTCATCTAACCTAGACTCTAGGGGTCTTTCAAAGGTTGAGTCAC
CATACAAAAAGGACACAATGGCTAGACCTAGGTCCCTGATACATATGTAGCAAATGTGCAGCTTAGACTC
CATGTGGATTCCCCAACGACTAGAGCAGGTATTGTCCCTGAAGTTATTGCTTGTCTGTAGAATACATTTC
CCAACATAATTGTCTTGTCTGGCCTCAGTAGGAGAGTATGTTCCAATCCTGGAGAGACTTGATATGCCAG
GATTGAGAGATTAAGGGTCTCCCACCATCTCAAAGTTCATGGGTATGACAGGGGAGGGGCAGTGCAGGTT
TTCCCCATCTCTGATTTCCAGCATTTGCACCCCCAATATTGAGGGGGAGGTCTAGCAATTGGAGGGGGGA
CAAACAGTATGAGAAAGCTAACTTTAGTGGTGTTGTCACAGTGTGGGGTATTGTGGGTGGGAGTGGAGAT
GAATCCTCCTCCTCCTCAGGAGGCTGTAGCAGGTGCTTGCCCTCTTTTGGGACAGTAGAGCTGTGGTCAG
TACTGGCCTGTTCCTGACAAATTTATTCTGTGCTGTGACCATTTATTCAAGGGAGGAAGATTTAAGACTT
GCTATGATAACCTGACGAATCTGGACAAACAAGAGACAGGAGGTAACACCTGAGTTACTCTTTTGCTTGC
TAGTACAGAAGAGCACTATAATCCACAAATTGGGGTCCCACATATTCTTGAGTGGGATCCAAGGTGCCAT
AATTTCAGCCACATTCCAAAGTCCCTCAAGGTCTGACAGTTTAGTCTTTAGGCTTCTCCTAACCAAATCA
TATTTGGAGTTCTTTAACATAAAAGGGTAGTTTCCCCATATCACTGCCAGCAAAACAGGTTGAATTTGGA
CAGACAAGCAAAACTATCACAAACAAGACAGACTATGTGTGCGATCCAAATGTCTTGTGATTAGAGGGGA
AGTTCTGCAGCTTATTAGGCTGTGTCCTTATGCCCACAAATGTCTTCAGATAGGAAAGGGCCATTGGGTG
CCAATCCTTAGTTCTTCTGTTTCCTGGGCTGTCAGTTTTTATGTGGAGAAGACATGAACCAAATGCAAAG
TCATGTATCCTACAAGAACTGACATACACAGACAAACAAGGAATAACAATGAGCTCTCTCATTCACCTAA
GGGGGTCTTATAACATAGAACAGAAAGGGGCCAACTTAGCAAGAATTGACCAAAAGGTGGTCACCTAGAC
CACACCACAATGCAGGAAGGATATCAATGAAGGAAGAACAAAGGAAAGGCCAAATCAAGTTTGTTGGCAC
ATGACATAAAACAGTGCTCAAAAAACAATAGATGCGAGCAAAATGAAGCATTGGAATCATATCGGGGTAC
ATAGGGGTCACTCTTACCCCTGTTCAAGTGCCAGATGTTGTTTTAGCCTTAGGCTCCCTGAGTTTGTCTT
TAGGGGAAATGGGTAAGAATACACAAAAATAATGTCACAGAATCTTAGAGGCAGATGAGAAGTCAAAGCA
GACTCATTTATTGCTATAGAAAAGAATGCCTTTATACCTTCTGTCCATAACACCTCTGCCCATATATGCT
CATCTCTGTGAGGCAATGGACTACCTGCAGACAGGCTGGTATCCAGTCAAGCTGAGGTCTGAACCACAAT
GGTCGTAACTCACCTAAAGGACGTGGTAGGCATGACGCGATAGGCGTTCCCTCATGCTCCTGGAACTCCG
GCCCCTGCCTAAGGTACCACCTCCCACAGCCCCCACAAGAGAAGCATGGTCAGTAGTCATGTAAGCAATG
GCCCAAGCTTCTGACCTTCAGCCTAAACTCCTCCCCAGTTACCTAGCAACAGTGAAGACCATAAAATGGG
ATGTTAGGCCCCCACCTCACTCTCTTACTCCTTTGTTCCTTTACCTCTCACTTCTCTCAATTCTCTCTCC
TCTTCCCTTTCTTTGTCTTCTTCTTTCCTTGTCTCTCTGTCTTTCTCTTTCTCTCTAGCCTTCTCTGCCT
CTCTCTCTCTCTCTGTCTCTCTGTCTCTCTCTTCTCTCTTTCCCTTGAATTTCTTTTTTTCTTTTTTCTT
TTTTTGATGAGCACAGTATAAATAGTTTATTGCATTGTTTCTGAATGTGGCTGTATTCTCTATTGTTCTC
TTTCTTATTTTTTTTCTTTTTTTGGTTGTTTTTGTTTTTATAGTCTCGCACAGAATTCTACATCTACCAA
ATCCCCATTGTGTACTTTAGTTTTGTCTTGTATTCAAAGGTTCTTTCAGAAAGAATCTTAAAGATGAAAT
TTGCCTTCCAACTTTTCAAAAATACATATAAAGATAGATGTTACATAGTTCACGGAATAGACACATATAC
GGAGATGCAGCAATATCTCCTTTGTGCCTCTTGTATATTCATGTTATTTCCTCAACTAAAAATACATAGC
CACAAAGACATACAATGAGCACTCCACTTAGGAAAATATGGCCATATTTTTTTACATTTTTATGATTTTA
TGATTAGGTATATTCTTCATTTACATTTCCAATGCTACCCCAAAAGTCCCCCAACCCTTCCCTCACTCCC
CTTCCCCACTCCCACTTGTTGGCCCTGGAGTTCCCCTGTACTGAGGCATATAAAGTTTGCAAGACCAATG
GGCCTCTCTTTCCACTGATGGCCCACAAGGTCATCTTCTGATACATATGCAGCTAGATACATATACATAC
ACGAGCTCCAGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTATAGGGTTGCAGATCCCTTCAGCTC
CTTGGGTACTTTCTCTAGCTCCTCCATTGAGGGCCCTGTGATCCATCCAATAGCTGACTGTGAGCATCCA
CTTCTGTGTTTGCTAGGCCCCATTATAGCCTTGCAAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTT
GCTAGTGTGTGCAATGGTGTCAGCATTTGGGGGCTGATTATGGCATGGATCCCCGGATATGGCAGTCTCT
AGATGGTCCATCCTTTCATCTCAGCTCCAATCTTTGTCTCTGTAACTCTTTCCATGGGTGTTTTGTTCCC
AATTCTAAGAAGGAGCAAAGTGTCCACACATTTGTATTCATTACTCTTGAGTTTCATGTGTTTCCCTTGC
ATTTCTATAATAAACCATAAGGAGTCTCTGCTCTACCAAGACCCGCTGCACACTCTGGTCAGTGTTGGGA
ACTTTTCCCCTATTCCCTCTCTCCTATAACTCCGGGGCTACAGGGTGTCTCCTTTGGGTCCCGGTTGGGA
GCTGTCTCTTCTCAACCCCCTGACTCATGGGTCAGAGGCCTAAATCTCCACCCAAGGCTGTGTGAAAAGC
ACCGGGTGGTCTCCCCATATCTCCCTGTCCAGAGCACAGGAACTCTGGCCGGACATGGCATATTTTTCCT
CCCCAACTTCTTCCCCGGCCTCCTCAGGGCTGTCCCTTCATTTTGTTCCCCACACATCTCCACATGGCTG
CCACCATCCAATTGGCTGCTGAGGTCACACACTCTGTCTTTGTTCTTCTCTGAGTCTCATGCAGGTTTTG
TGTTAGTAAATGCAAAAGTGCCTGCTGTGCATGCATGAACCATTACAGGCTGCTAGGCAGAACATGCTGA
CTTGCTCCTGGATTATAAATCCATCACTGTGATAGCAGGACATATCCAGAAGACATTATTTAACAACACT
CCTCTTCGTGCTCAACCTCTCATGGTCTTTCTACCTCCTCTTTCTTAGTGTTCTCTGAGCCTACATGAAA
TGTGAACAAACCTGAAAAAAATCTCTGTGTCAAATACATAGTGTGGATTGGGAAGGAAAAACCCTGCACT
TGTGTGTGGGCAGGGAAATGCTGGTGCTTTAACAGGACAAGTGCGGTGTGGCTAGAGAAAGTGATGAGAA
GAAGGGAAGCATGAGAACTGGGTGGGTGGATCCCATGTCTACTGAAAATGCTATGTTGATGTCAAGATAT
TGTGTCTTGTTACAAAAATTCATTGAGTACCTAGGTTATTCTCAGTATATAAAAGGGGAGGAATGAAACT
AGAATTAAACACACACACACACACACACACACACACACACAAACACACACACACGAGTAGAGAAAAGAAA
TAGTCATGAGTTGCCTAGTGAATGAAGAGCGGAAAATGGTGCAGTTAATAGGGATCATAGAAAGAACTGG
GGGATGCACACGAATGGGTTTCCTGTAATTATGTCTTCATAGTAATCTCTGCTCAATAATCAGACAGTGA
CAATGTATGCCTCATTTACAAGCCCTGATGGCCTCTCAGAGGAAAGCATCTCTCTGAAATGAATAAAGTT
CAGAAATGTCCTAAGTGTCCCTGTCACAGGAAAGCAGTGTTGGTAACGTTTCCAGGAAGCTCAGTCTTTG
TCAAATATCCACAACAAGAAGAAGCCATGTCTAGACAGACAACAGACTGGGAAAGACTGAGCTCATGTAT
GGAAACACAACTATGTGTCATGCTTTTATTTTCACATTATACTGAGGGGATATGACATTATAGAAACACA
GTTTGTTCTTTGCATATGCTGAGAGAGGAACTAGATGAAGTGTGCTAATTCTTAGCAATAAAAAGATATA
CAAAGTGGTACTTTACTGTTTCAATTTTTGTAACTGGCATCATTGTCTTTGATATTTTATATCTTCCTTG
AGCACTGCCTTCTCTCAAGTGTCCAACTTCAGAGTATGCTATAGCAGGAAGACTACCAAATAAGATTAAT
TTTTTTGTACCCATGAAAAAATTATGTGCCCTGACCCCTGTTCTCTGAAAGAGGAGCCAAGTTCTGGATT
CCCAGATCCTCATATTCATTGATCAGCAGTGAACACAGATCATTCACCATGGACATGGGGCTCATCTGGA
TTCTCCTTATTGTTTTTAAAAAAGGATTTCATTGGGAAAAGCTGCCTCATATTTCTATGACCAGGAGAGG
AAGATACAGCTAGAGACACAAGCCCCACCATGTAAAATCTGTATGGTACTCTCGTTTTCATTTTACAACA
TTTTGCTTTTGCATTGCAAAGGAGCAATAAGGGTTCAGCAATCAGCACTGTAACTGTACTTTTAAAATTT
CCACCTCTACCCTCTGTGTCCTCTATCTAGTGATAGAAAGTGAAATAAGCACATAAAGCATGGGACAAGA
AGAACACACAGAGGAGCAGAGACTGGCTACAAGTGGCAGCCAGCATGGAGCTGGACAGAATTTAAAAAGA
TAAAGAGAAATGTCATGGCATGAAGCAGTGACTTTTTCTGTTCACAATGCCTGCAAAAACTTTATGGAGC
CTACTACTGCTGAGATATGCAGGTTTGGTTCCAGAGAGGATTTTCTGTTTTATTTAATTTGCTTTTAAAT
TTTTCTTCTTTGTATAGTCTGTATTTTTAAAAAGGGGTTGAATGAATACCTAAGCAGTTGGAAAATTTGT
GAGTAGAAACCGAGGGCCTGAGAAACAAATAAATCAAAATTTTGAAATGGCAAAAGAAAGGGTTCATTCT
ATTTTCTCTTTTCAGAAAAGGTTGCAAAGTTGGATGTGCAAATGGAGATGTTATGGGTGGACTTGGAACA
TCTTGGGAAGGAAGGAACCCAGGAAAAGAAAGAATGAAATGGCTCAGCCTCAATGACTGAGCAAGAGAGT
TAGAGTCACCCACAGGAGAAAAGAAGAAAATAAACAGCACTGGGGTGAATTTGGGTCAGAGAAAACCTTA
AAATGCCAGAGGACAATGTGATGAAAGAGACCATTTGAAAGAAAGGGTTAACCTCATTCCATCAGTCATG
CCAGAGTTAGAGAATGGGCAGTCTGGAGTTACAAGATCACGATTAGCCTTCCCAGTATGTATACAGCATA
TTCCTGATAATGAGATGAAGCAAAGTTTGACAAGGTAAGATTGTATCCTATAGTAATATATAGATCAAAG
GCATGTTGCAGTAAATCTCCAACAGAAATAAGCCCGGGCAATGAAAACACAACTCAATTAATATGAATAC
GTGCTGTGCACCTAGACTGGGCAGATCTACCACTCCACTACCATATGAGAGATCCCTTATAACTTGTGGT
TTCTCCAGGCCAGCTGCTTCTGCTCTACTTTCCTTCCTCCTCCTCCTATGTCATCCTCTCCCTCACTCTT
TCTCTCCCAAAACTTTCAGCTGCACCTTCCCCTCTTCATCCCCCAATCAGTGGCTCTAGCCTTTATTTAT
AAATTAAGGTAGGAAGAAGGTTTATAGGAAATTACCTGAGTGTTGACGTGTTGATAACCCCACACAAGAG
AACAAAATTAATATCAAATATGATTAGCTCCAGGGTTATATGCAACAAAGGCATGATAAAGTGGTCATGA
TTTCATATGAGATGTACTGGACTCATGTGAAAAAACGTTTAAATACATGGGCTTACTCAAAATATAGACT
CATACCCCCAAGATGGGAAGAGACTGGTAACATTTGTACTGGAGGCTGGTCTGCTGTGGCAGCCATTAAC
ACAGTGGAGGGAAGAGCCTCAAAGAGTGAAATAGAGGAAGGGGAACAAATACAGTAAACCACCAGTTACT
ACTTAAAGGGCAGTGTTCTGATGTCCTAGGGAGGGCACTCCAAAATACCAATGGCCTTATCCTTAAATTT
ATTGTTTAATGAGCCTACACTGATCTCAGTGGCCCACTACTAAGGAGAAATGACAGGCACTTGAACAGCT
GATATGAGAACAGCTGGAGGCACAGTATACAGAAGAGTTTACAAGCCTATGGAACTCCCCTGTATTTTTT
TATGATGAGGAAATCTGAAAAATGTAAAATGTTGAAAGATTTAAGAGCAGTTATTAGAGTAGATCAACCA
ATGAGTCTCTTGCAGCCTGGAATTCTTTTATCTTGTTTGTAACAACAATCAGGCTCCATAAATTATAAAC
TATAAAAATTTACTTTATAAATTATAAATATATATATATGTGTGTCTGTAGATAGATAGATAGATAAATA
GATAGATAGATAGATAGATAGATAGATAGATATATGGATTTGATGGTTGCAGCAAATTCTAATTGGTTCC
AACAACCCTACTCACATAATACATTCATACAGGTTTGATAGATGGAGCTAAGTTTTAAATAAATTATTTT
TCTCCCATGGCTTATATATACACCACCAAAATTCTCAAAAATTAAAATGTGATTGTGTTGTATTTTTCTT
TTACTGAATGACTATAAAAAGTTACAACATTCTCCATAAATTTACATGAAAAAATATTATGTAGTGCAGG
TAAAGAAAACAAATTGACCCAAGAATGGTGTATATTCATTACTAAGCAACTTTTTAGATTCACAAAGTGT
GGGTAAACAAGGTAATTTTTTCAATCAGTTTTTTTTAACTGGCAGGCAGCAATTCAGAGTTACAATGAGA
AGATTAATAATTTTATTGTGTATTTTAAAATAAATCTTACAAAAATATTAATAGAATCACAAATTTATAC
CTTTGTATAAAAACAATCAGTCATTTCTACTTTAAGAAACAGAACTCACATCTACTCATCAATCATTTTA
TTAAGTCATATTACAAAGCTGAGTGCTAACATGGGTATAAGAAAACCATAACCTTATTCACCAGCCCAGC
GTCAAAAAGAAAAAAACCAGTCATATCAGCTGCTGCTTCAAGAGTTCTTGTTCCTTGACATTAACAAAAT
CCCTAGCTTAACTATTAAATTTTTTTTCAAAACTTCTAATTGATCCCTTAGATAAATGTTTGTGCTAACC
ATCGGGACACATCCCATGAGTTCTGAAGCAGTGTGTTGTTCTTCATGCATGGCCCTTTTGTAGAGCTGTG
AGTGTAGGGGAAGAGGGGGGAGAGAGAGCCCGTGTCCAGCCAGAGATCCTGTGCTCTGGGCAGGCAGACA
CGGGAGGACAACGGAACACTTTTCACTCGGCCTTTGGTGGGCATCTGGCTGTGTGAAGTTACTGACCCCA
CATGGTGGGGGATGGACAAGGGGCAGCCCCTGGTACCAGGAGCCCCAGGGCTACACTCTCGGCCCCAGAT
ATACAAGAAGAGGGCAGAGGGAGAGAGGCTCCCACACAGGCGAGAGTCCTTAGTCTGGTCTGTGGCTGGA
GCAGGGGAATTCCTTCTGATTGGAGATTAGGCACAGCTGATTAGGGGAAAGCCTACCCCATCATCCAAGC
ACAATGGACTTTGAGGAACAGAGCCAGTCTAAGCTTTTATAGCTTTATGGTAGAAAGGCAGGGAGAAAGG
AGAGAATGTGGAGAGAGACAGAGAGAGACTGGCCATGGCCAAGAGGAGGGAAGGGGGAAGAGAGAGAAAC
AGGAAAAGCTAGAAAGTAAGATAAGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGCAAAGTG
GGGCCAAGCAGCCCCTTTTCTAGTGAGCTTGTCATCTCACAGTTGCTAGGTAACTGGGGAGGAGTTTAGT
CTGAAGGTCAGAAGCTTGGGACCTTGTGTATGTGACTACTAACCACAGCTTCTCCTGTCGGGACTGTGGG
AGCAGTAACTTTGACAGGAGACAGGGATCCAGGAGACATGAGGGAACACCTTCTGTCCCACATAGGTGGA
ATCGGTTGTACCAGGGTTCAGAACTCAACTCCACTGGAGACCAGCCTATGTGTGCATAGCCCATTGCCCT
ACAGCCTTTGACATTCTACAGAGTTCTGAGACTGGTAGAGATACAAAATAGCTAGGATTACACAGAGAAA
CACTGGCTTGACAATAAAACTTCCAAAACAAATATAAATGAATAAATACACAAATTGGAGCAAGTGAACT
TGCACTAAATCCATCAAAACTTGCACAGGATGGCTGTCTCCATAATGTTCAGATCTACTTCTATTAATGT
CATTAAGAAGACAAAGATTATGCACAAAAAGAAACAAAACAAGAAACCCAAAAGGTAAAGGCTCCAATTG
TAAGTAATAGACCCACAGTCTCTGAGGCCTGACTGTGCAGGTCCTCACCTTTGGTAATCAGCACTGAATG
CAGACCACTCCTCATGGACTTTGGGCTCAGGTTTGTTTTCCTTGTCCTTATTTTAAAAGGTAATTCATAG
AAATGAGATCCTGCCAGTATTGTGTACATGAGAAATAGAAAAATTGGTTTTCTTTGCTCTATTTTGTTTT
GTTTGGTTAATGACAGTTTCCAAATCAGCATTCTTTGCTTTGAGGTGCCCAGTGTGAGGTGAAGCTGGTA
GGGTCAGGGCAGCCTGGAGGGTCCCTGAAACACTCCTGTGCAGCCTCTGTAGTCACTGTGAGTGACTACT
GAATGACCTGGGTCCTTCAGGCTCTAAAGAAGGGGCTGGAGAGGGTGGAAATAATTTTTAATGGTGGAGG
TAGCACCTATTATCCAGACACCATGAAGGGCTGATTCACCATCTACAGAGATGATGCCAGAAACACACTT
TACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGAGTGTGTATTCATATATATATATATAGTGTGTATGTATATTCATAT
ATATATGTATATTCATAAGGTTGAGTAAATGGACTTAAACTGATTCCATCACAACTTCCATGGGATGGAT
ATTTCCCAGTGTTAAGACCTGTCAACATCACTGTCATTCAGGAGACAATGATTATGCACAACAAAACAAG
AAACCCAAAAGCAGAGGACTCCAATTACAATAGACCCAGACCCACAGTCTCTGAAGATTGACTGTACAGT
TCAACCCAGCCCTGTACTTCTCTTCCCTAGAATTTACATTACTGAGTAACTGAGGAAAGCTCTACAATAT
CTGTTCTCTATAGTGGTCAACACCTCCAAACACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTT
CTTGCCATAATGTAGACTACTTCAGCCTATTTTGTACTCCAGTTAACGAAACTCAAGACTAGCTGCATGT
TAGTCCTTATTCTGAAATATTATGAACAGGTGACCTCCCATCATTCACCAATGCAATAATCATATTTAGG
AATATGAGGTTTTATGAGATATAAGCACAAGGGAGAGAAAGTAAGAAAACTACATAGATATATAGACTGA
CATAAATCAAGACTTGCATGAGCTAGTGCCCAAGTACCATGTCCCTAAGTGGCAAGGAGTATCTTTTGAG
CCTAGTGAGATGAGGTACAAATCGGACTCTTACATCTTTTTAGATAAACATGTGAGATCAATGGACTAAA
GGCGTGAGCTGGGCTTCCTTGCAATCCATTTTCCATACAAGATAACAATAGATCTGGCTCCACAGACACG
ATGAGAATAGTCTTAATTAGTTCTTTAAGTAGAATGACTGATCACTAAGAGCCCAATTCCATACTAAATA
CTCTTCTGGATTATGCACAGATAAAAATTGCACATAGGGCATGGGGCACTGATCTCCCTGCACTACATGA
ATGGGGGCTCATTTACTAAATGTTCCCATGTTTCTTCCTAGTGCTGCACAGAGCAAATCCTACAACTTCC
TGCTTGTCTACAATGTAAACTCCAGACAGTACCAGAAAATCATTCCTTATGTTCCTCTCCAGGTGCTTCA
ACAAGCACAGTGCAAATTTCTGTCACCCTG

Molecule Role : Vaximmutor
Additional Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK)

9. Ighg1

Gene Name : Ighg1
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16017
Genbank Accession : AC160982
Molecule Role : Vaximmutor
Related Vaccine(s): B. abortus DNA vaccine encoding RplL and Omp16 , B. abortus subunit vaccine using L7/L12 , Brucella abortus S19 vjbR mutant vaccine

10. Ighv1-9

Gene Name : Ighv1-9
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 668478
Genbank Accession : AC073561
Taxonomy ID : 10090
Chromosome No : 12
Gene Starting Position : 114583568
Gene Ending Position : 114583861
Protein Name : immunoglobulin heavy variable V1-9
Protein Note : Also known as Igg2a; Gm16697

DNA Sequence : Show Sequence

>gi|372099098:114583568-114583861 Mus musculus strain C57BL/6J chromosome 12, GRCm38 C57BL/6J
GTCTTGCACAGTAATAGATGGCAGAGTCCTCAGTTGTCAGGCTGCTGAGTTGCATGTAGGCTGTGTTGGA
GGATGTATCTGCAGTGAATGTGGCCTTGCCCTTGAACTTCTCATTGTAGTTAGTACTACCACTTCCAGGT
AAAATCTCTCCAATCCACTCAAGGCCATGTCCAGGCCTCTGCTTTACCCACTCTATCCAGTAGCCAGTGA
ATGTGTAGCCAGTAGCCTTGCAGGAAAGCTTCACTGAGGCCCCAGGCTTCATCAGCTCAGCTCCAGACTG
CTGCAGCTGAACCT

Molecule Role : Vaximmutor
Related Vaccine(s): B. abortus DNA vaccine encoding RplL and Omp16 , B. abortus subunit vaccine using L7/L12 , Brucella abortus S19 vjbR mutant vaccine

11. Il10 (interleukin 10)

Gene Name : Il10 (interleukin 10)
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16153
NCBI Protein GI : 6754318
Locus Tag : AL513351.1
Genbank Accession : NM_010548
Protein Accession : NM_010548
Other Database IDs : MGI:96537; Ensembl:ENSMUSG00000016529;
Taxonomy ID : 10090
Gene Strand (Orientation) : ?

DNA Sequence : Show Sequence

>gi|6754317|ref|NM_010548.1| Mus musculus interleukin 10 (Il10), mRNA
GGGGGGGGGGATTTAGAGACTTGCTCTTGCACTACCAAAGCCACAAAGCAGCCTTGCAGAAAAGAGAGCT
CCATCATGCCTGGCTCAGCACTGCTATGCTGCCTGCTCTTACTGACTGGCATGAGGATCAGCAGGGGCCA
GTACAGCCGGGAAGACAATAACTGCACCCACTTCCCAGTCGGCCAGAGCCACATGCTCCTAGAGCTGCGG
ACTGCCTTCAGCCAGGTGAAGACTTTCTTTCAAACAAAGGACCAGCTGGACAACATACTGCTAACCGACT
CCTTAATGCAGGACTTTAAGGGTTACTTGGGTTGCCAAGCCTTATCGGAAATGATCCAGTTTTACCTGGT
AGAAGTGATGCCCCAGGCAGAGAAGCATGGCCCAGAAATCAAGGAGCATTTGAATTCCCTGGGTGAGAAG
CTGAAGACCCTCAGGATGCGGCTGAGGCGCTGTCATCGATTTCTCCCCTGTGAAAATAAGAGCAAGGCAG
TGGAGCAGGTGAAGAGTGATTTTAATAAGCTCCAAGACCAAGGTGTCTACAAGGCCATGAATGAATTTGA
CATCTTCATCAACTGCATAGAAGCATACATGATGATCAAAATGAAAAGCTAAAACACCTGCAGTGTGTAT
TGAGTCTGCTGGACTCCAGGACCTAGACAGAGCTCTCTAAATCTGATCCAGGGATCTTAGCTAACGGAAA
CAACTCCTTGGAAAACCTCGTTTGTACCTCTCTCCGAAATATTTATTACCTCTGATACCTCAGTTCCCAT
TCTATTTATTCACTGAGCTTCTCTGTGAACTATTTAGAAAGAAGCCCAATATTATAATTTTACAGTATTT
ATTATTTTTAACCTGTGTTTAAGCTGTTTCCATTGGGGACACTTTATAGTATTTAAAGGGAGATTATATT
ATATGATGGGAGGGGTTCTTCCTTGGGAAGCAATTGAAGCTTCTATTCTAAGGCTGGCCACACTTGAGAG
CTGCAGGGCCCTTTGCTATGGTGTCCTTTCAATTGCTCTCATCCCTGAGTTCAGAGCTCCTAAGAGAGTT
GTGAAGAAACTCATGGGTCTTGGGAAGAGAAACCAGGGAGATCCTTTGATGATCATTCCTGCAGCAGCTC
AGAGGGTTCCCCTACTGTCATCCCCCAGCCGCTTCATCCCTGAAAACTGTGGCCAGTTTGTTATTTATAA
CCACCTAAAATTAGTTCTAATAGAACTCATTTTTAACTAGAAGTAATGCAATTCCTCTGGGAATGGTGTA
TTGTTTGTCTGCCTTTGTAGCAGCATCTAATTTTGAATAAATGGATCTTATTCG

Protein Sequence : Show Sequence

>gi|6754318|ref|NP_034678.1| interleukin 10 [Mus musculus]
MPGSALLCCLLLLTGMRISRGQYSREDNNCTHFPVGQSHMLLELRTAFSQVKTFFQTKDQLDNILLTDSL
MQDFKGYLGCQALSEMIQFYLVEVMPQAEKHGPEIKEHLNSLGEKLKTLRMRLRRCHRFLPCENKSKAVE
QVKSDFNKLQDQGVYKAMNEFDIFINCIEAYMMIKMKS

Molecule Role Annotation : IL-10 plays an important role in Th2 type immune response.
Related Vaccine(s): B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 , B. melitensis WR201 (16MΔpurEK)

12. Il12b

Gene Name : Il12b
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16160
NCBI Protein GI : 6680397
Locus Tag : RP23-388G23.1
Genbank Accession : AL607030
Protein Accession : NP_032378
Taxonomy ID : 10090
Chromosome No : 11
Gene Starting Position : 44400062
Gene Ending Position : 44414016
Gene Strand (Orientation) : +
Protein Name : interleukin 12b
Protein pI : 6.5
Protein Weight : 35952.67
Protein Length : 335
Protein Note : Also known as p40; Il-12b; Il12p40; Il-12p40

DNA Sequence : Show Sequence

>gi|372099099:44400062-44414016 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
CAGAAGGAACAGTGGGTGTCCAGGCACATCAGACCAGGCAGCTCGCAGCAAAGCAAGGTAAGTTCTCTCC
TCTTCCCTGTCGCTAACTCCCTGCATCTAGAGGCTGTCCAGATTCAGACTCCAGGGGACAGGCTACCCCT
GAACCAGGCAGCGTGGGAGTGGGGTAAGTGGATTCTGGGAGCATCTCGGATGGCTTTCCCCGCTGGTGGA
AACCAGGGGCTTTGACGACAGGGGCTTCAAATAGTCATTTAAAAAGTCAGCTAATTACAGATGTGATGGC
GCACACCTGTAATCTCCAAATCTGGGAGGCAGGAAACAGAATGCACAGGAGTTTAAGGCCAGATTCAGCT
GTGTAATGAGTTTGAGAGAGTCTCAAAAAATTGAGCTACTAATAATATGTGCCAAGCATTGTGGACAGAT
GTGTATTTGATAGAAAGGTTTGCTTTGTCTATATAGACACATATACTATGTGCATTTTCTTAAGTATTAA
TGCATATGTGTTAAGGAGTGTTGTTAAAATTCTGTTCTTGCCTTAAGAGTGAAACTTAAAAAAAAAAAAA
GCCTTTCATGTACCCCTTCAAGCCTAAGCTCATCACTGAATGTCCTACCTGTGATGGCCTTTAGAATCAG
CTATGATAATCAAAGTGGAGAGCTGGGTTTGGGGGTTCCTTTGGATTTTAACTAACTTTGCCACCTCTTC
AAAACTGGAAAGCCCAAGGCATGTTCCAAACTATTTCCTAAAGGGTTCTAAAATCTGTGAGAAAGGGAAG
GCTAATCTTCATGGGTTGGCTTCCTCTGCTTGCCCAGGTGAAATCATGAGCACCAGATGGGGCAGGGTGA
TGGGGCAGGGTGACATCTTGCTTTCACCCAGGGATCACTGAGCCTCAGCTGGGGGCTCCGTTTGTTCAAG
CAAGGCATTTCAAGATGAAGTTAGGTCACCCCCAAGAATTCATTTTGCTGAGATCTGAAATACTGTGATT
ATTGCACCAACAATCCATGGACTCTCTCTAGGCTAGATTCTGGATATAAGACTAGACAGATATGACCTCT
GTCACACACCTCGGTATGGGAAAGGGGGGACAGACATTAAAGACGTAATCAAATGATTGTCATTTCAGCG
ATGCTGAAGGGGAAGAGTAGCTATTTGGGGTCCTGTTTTCATTTGGGGCTCAAGCTGGCACTTTCTGTGG
ATCATTTCATGAACTCCTAACCTGACAGAGTTATTTTTAATCTAGGAGTACAGGCTTGACAAAGTCAACA
CAACTTGTCAAGGTCACATAACTAACAAGTGGCAGACTGAGGTCTGTTTGGCTGTAGAACCAAGGCCCTT
TGCCCGTGCCCTCCTTGCCATCCCTGACAGCCACGCCATCTGTACTGTGCATTGTTGTTTCTGGGCATTT
TTATTTTTACATATCATTTCTCTTTTAAATTAAAGAATAACAGAATGAAACTTGCAAAAGGGATGTCCAC
TCAGGCACCCGCTGGCAGCAATGTTTGGAAGCATTTGCATGCTCTAGGGAGCTAGAGTATCCAGCCCAGG
GTTCCTGTGCTCTTTGCACAAGACTTTCAGGACTTAAGAAAACTAATGAAAACAAACAAACAAACAAACA
AACAAAAAAGAATTGTTAAAACATAGCATATGGAAGAATTGTGGAGTGAGAGGGAAACAAAGCCCAGCAT
CTGCCAATCAGCCTGAAAGCCAAAGCCTGGCTACATACTGCACACTTTTTTGCTTGTGCAGATTTGATTA
AGAGGCGACCTGCCATCATCTCCACCCTCTGCTGGTCTTCTATGATCTAAGATGTAGGTGATGCCGAAAT
GAAGATTGTTCCTTGGACCATTGCCAGGGCTCCCTTCAGCCTGAAATATGGTTCACGTGTGATGCTCAAG
TGCATCTGAGGCTGACAGAGGAAATGCTTGGCATGTAGCCAAAGGGGAAATCCCTGTGTTGAGAGCATAT
GAAGAGATCACCAGGAGATGCCAGGAATCTCTGCCTTTTTTCCCTGCCCAGAGTCCTACCATCTGGGTTT
CACAGCCGTGTATAATTGCATCACCTTCTCTGGGCATTTCTCTCTACAGCCTGGCAGATTTTTATTTTTC
AACCCAGTGTGCACAAAACAGAAAGAATTTCAATTTTTTTCCTTAGCTTTTTACTAGTGCAAGGTATTAT
ACAATGTCATCTCACTGCATGCCCAATAGCTCTTGAAGATCACATAAGCCTTATGTCTTTTTATATGAAG
GCAGTCGGGCTCAGAGGAACTAAACCAACACCAAACAGCTACTGAGTAGTAGGGCCAGAATCCAAGTCCA
TGTCTGCTTGACTCCAAGCCTATGAATGTAGCAACCAGCACCATTTCAGCTTGTACTTGTCTTGACTATA
TGATAATTTGGACCTAGACATGTCCTGACTCCTAGTCCTGTCTCTGTCATGAAAAAGAAATCATAGCAGG
GCCCTCAAGAGGTTAGCAGTACTTCTGTTCTCTCAAAGGTCGTGATTTCTGACCAAGGCCTGTTTATTTT
TAAGGCATTTGCCTATAACATTTAAGCCTTAATTCATATGGGTTAGACTGTGGTCTCTCAAATCTTGTTC
CTGACGGGCGGTGGCACCCTCCAGGATAGATGAAAAGTATTTCTGAAGGGAATTAGTAATCTACACTGAT
TATCTCAACCACATTTATGAGTGAGGTATAATCTTTACAGTCTAAAGGTTTGTGTTGCCCTGGTGTTAAT
CTAGACTGGGTTACAATACAGGATGGTTACTGACTTATCTATTTCATGATAGGTTAATCAATATGGTACA
GTCTTCTGCCAAAGAACACCTTGAATTTTAGGAGTTCTGGACTCTCAAACCTAGCTAGCACATTTGCCCT
CACAATGTGTTCAATGGATCATAACATCAGCTTTCAGCACCTCCAAGACATGTTAAGTCAGACACTCTGT
TCTGGGCTGAGACCCAACAGTCTCCGTGAACCCAGGTTATACACACACCCAAGCTTAAGAAATGCTGCAT
TTTGTTGTGAGGGAGAGAATTATTTTAGAATTTGGAGTAATCTCTGCCTAGGTTTAAAAAAACCTAATCC
ACTACAGGTCCTTGTCAGAACTTGAAAGTTTACCCTGTGTCACCTTTCCCACACCTAAGCTGGTCCTCTA
GCCTGGGGCATCCCAGTGCCTACTGCACAGCAGGGTGATTCGGATGCCCAGTGACACTGTTCTCGTCCAT
ACTGGCAGCATGGCAGTACTTTCCCATTCTGTTCAAAGCTCTTTGGGTATTATGTTAATATTACAATCAT
AACTAAGGAAATATCTGATGACTGTGGACCTGGGAAGCCACGGTCATCTCTAAGTTTATGTTTCTGAACC
TTAAAAAAAAATAAATAAGATGGGTGTGGTGGCTCTCGCCTTTAATCCCAGCACTCAGGAAGCAGAGGCA
GGTGGATCCCTGTGAGTTTGGGGTCAGCCTTATCTACATAGAGTTCCAGGACAACGAAGGCTGAAAGTCT
GTCTTAAGAAGAGGGAGGGAGGAGATGATTGTGGATATCAGGAAGACAGTTCAGCAGGTCACATTACTTC
TGCACAAGCCTGGTGACCTGGGTTTGAACCCTGAACCCAGAGTGAAAGGAGACAGTCAACTCCCAAAAGT
TGTCCTCTGACCTCCACACATGCACACATACAATAGTCATACATCAATATATTTTTAAAAAACAAAATGG
TATCAGGTAGCTGGGCCCTATGATTATTTAAGCTCCAGGTAGCCTCTAGTTCTTTATTTGGAGATGTTTT
TACCCAAATCTAGAAGAGACCTCCTATAATCCTGGTCCAACAGTGTGAAAAGAAAGGGGAAAGTGAGTAT
TTGGAAGGCAGATAAGCTGTTGATCGGGTTAATTGGATAACAGTTGACATTCTCTCTCCCATTTCCCCGC
CTTTTCCTTCTCCTCTGCTCCCCTTCTTCCTCCCTCCTGCCCCTCCTCCACACAGATGTGTCCTCAGAAG
CTAACCATCTCCTGGTTTGCCATCGTTTTGCTGGTGTCTCCACTCATGGCCATGTGGGAGCTGGAGAAAG
ACGGTAAGCAGCCTTTTCCCTGTTTTCTTTGGAGCGCCAGCACCTAAACTTGATCTCCAGGCAGCCTGCT
GGGAAGGGATAGTGAAGTCTGAAGTAGGCAACCGTGCATGGGATTGTCTCAGGAAAAATCCTCAGGGAAG
ATGGAGGGTTAGCGTCTCTTCCTCCACCTATCTCTCTCCCTTGTTTGGTTTTCATGTTGGATGACAGGAA
AGGAGTTTCAGGTGAACTATGGTGGTGTGTGGGATATGATCTTGGCCTTAGATACCAGAAAATGACTCTT
CTAAACAATTGAAATTCCCTAATAGAGAATTTGTAACGTAGCAAGATTGTCTTCTACCCTCTCTTGTCTT
GCATATTACAACGTGCTCTCAGTGGGCACCATGATGGTTGTCCTCTGGCTATTTTGGGATTGGCATTCAC
ACTGACTTGGTTTCAGGTCATGGCTCTGCCAGGTATTGATACTGAACCTTTGAGGCTGGGTAGTCTTGTG
ACCTCAGTTTTCTTTCCTTTTTTTTTCCCCCAGACAGGGTTTCTCTATATAGCCTTGACTTGTCCTGAAA
CTCACTCTGTAGACCAGGCTGGCCTTAAACTCAGAAATCTGCCTGCCTCTGCCTCCCGAGTGCTGAGATT
AAAGGAATGCACCACCACTGCCTGGCTGACCTCAGTTTTCTTAATTGGGTGTTCAGTATAGCACAGCCCA
CATGGACTATTGAATATGTTAATAAATACAGAAAATAACATATGGTAGAGTGAGCAAGCACTATTATTTA
AAACAAAAAGTCTCTGAACTTTTCATTATCCCAATGGCAATAAGATTATTAGTAGACAAATAATGAAGGC
ATAGAAGGGGGTGCTCTCTGTCCTCTGTCCTTGTGCCATGTCACAGTTAGCAAATGTCCATCAACTCAGT
CCTCAGATGGTCGTCACAGGATCTCAAATGTTTCATGGAATACAAGGTAATCAAGTCAGGAATTTCTGCT
TTTATAGCTACACTTTAGTAATAATTAATATTTATTTAACACTCAATTTCGCAACAACCATGTAAAGTAG
GAGCTATCTGTATTCCATTTTACAGATAGTAAAAACTGAGGTTCAAGAGGCTAAGTAAGTTTCCCACAAG
GTCCAGAATAGAACTTGATCCCAGTTTAGTCTCACTTCAGAGCCTGTGTGCTTAAATGCTAGATTTTACA
AGTAAGGCGTGAAGCAACTATTTCCTGTGGCCATAAAGAGGAAATGGGTGTAAATTATAAATGAAAAGAT
TTCCCAGCTGCTGATTAGAAATAATCTTCTGAGAATCCAGGAAAAAAAAAAAAGGTGAGCCTTTTTTTCA
TTCTGAAGAATTACAAGAGTTTGAACGATATTCGCAGGTAAAGGTGCTTGCCACCAAGTCCGATGACCTA
GACTTCATCACTGCGATCAGCATGATGGAAGGAGAGGATCGAGTTCTCTAAATTGCCCTCTGCTCTCAAG
ACATGAGCTGTGACACCTGTGCACACACACACACACACACACACACATGAAAGAATTAAATGCAACTTTA
AAAAGAGTAATCTCCAGCCTGGCCACCCACGCCAACAGAATTTTGGATGCTTTCCTAAGTAAAGCCTTTG
CCACAGCCAGATGGACAACTTAGGCCCTGGCAGAGTTAACCCCTTAGTTACTTCTGACCTGATAAACCAC
AGAAATTTCAGAAAAGCAACAGGAGAAACACAGAGAGAGCTTGTGTTGGAGTCACAATGGTGGCCCGAAG
CCCAGCAGATATCTAAGCTCTGATTCCAACGTGTCCAAGAAGTTCTTTCCCTGCCCTGGGGCTAAGGTCT
TCTAGGGTTTCTGAGTTCAGGTTCTAAAAGGAAAATAATAGACAGCCTGTTTCATGGCCTAGGGGACAAA
GGGAAACTGGGAGCCAAAGGGTCCTGTGCACTGGAATCAGCTCAGGCTAACGATTTCTGAAGAGCTTGGC
CTCAAGTGATTTGTACCTCTTATCTTTGCTCCCCATTCAGCAGTGACAAATCCCACTGATGTAAAAGTAA
GAGCTTAGCATTTCACAAGGCTTTAAGCTCCAATGCCAATCACAAAGCCACCATTCACAGGGCACTTAAG
GAAACTGTCTTAAGCTTGCATACAAATTAGTTTAGATGTTACCTTCTAAAGAAAGCACTAATATTTTGCT
TTCTTTTTTCTTTTTTTAAAAGAATGACATCAGACTAGGGCATGGCAGTTCATGCCTGCAATCCCTGAAC
TTGATAGATCAAGACAAGAAGAAAGCCCAATTTTGTGGCCAGCCGGGGCTATAAAGTAAAATTCTAAGTA
GCTGGCTGTCTCTTCCCACCCCCGAGGCCATGGCTCTCTGAAAGCCCTTTGCTGGCTCTGCTCCATAGCC
GTGCTATTCCAAAACCCAGGCTCTTCACCACTATGCCTTCCATATTCAATCAGGCATCAGATGACTGGGG
CCATCCTGATCTGACTCAGCAACCAAGAACAAACCTCACTGATGGGTTTTCAGGTGATGCTGATGATGGA
GGTTGAAAGACGACCCTGCTTTACGGGTCACTGCATTAAGCTAGTCTTTCGATTAATAATTGATATGTAG
GTAACCTTTGAAGCTTTGTCACATGAGGCTTTGGTGTGACCCACTCCAGAATACCTTATGGAGATATTCT
GGAGGCTCCTTCAGAAACTAGCATCAGATATCCATTGCACAACACAGGAGACAAAAGATCCGAAAGACAC
CATTTGTTACCCTTCACACTTGATGGGACCTCACTTAGCCCTTGGCCATCAGCAAAAACAGTTCCTTCAA
AAACTGAGACAATCATCTACTGCTTTGTAAGAGTGTAAAATAGCTTTTAAAAACAAGTAGTTAATGGCAA
TCTCCGTCCACAAATTTCATGCAGAAGAGACTTAAAAAAAAAAAAACCTAAATCTTTCTGGATAATTTTA
AGAGTTTTTCAGTGCATTTGCCTGGCTCTTTGGCCTGTGCATGACAGTGATGATGATGATGGTGGTGGTG
GTGGTGATGATGATGATTTTAAAAAGCTAGCACAGGGTTATCCTGCCGTAACCTTAGCTGTGCTAAGGTG
CATGCTTTTTTACCATCTATCCTCACAGCTAATCCTATTAGCATAGACAATATTGTTCTTACCATTTTGT
GAGGACTCTGGGGCTACTGGTGGTTCAGGACCTTGCTCAAAATCTCCTTTGCAATTAGAGAAGATAGGAT
TTCTGCATCTTTCTTTCTCCACACCTATGCTTTAAGCCACTATGTTATTCTGCTCAATACTCTGCCCTGT
GTATTCCCTGTGAATTACAACTGGAAGCTTACTCCCCCTCATCTCCATTCCCAACACACACACACACACA
CACACACACACACACACACACACACACACTAGTGGCTTCTGACAAGGAATCTTGTGCTGTTTGCATCTTT
TCTTGTTTCAAGGTCTTCCCTTCCTAATCAGAGACCGATTATTACTGGCCACCTGCCAGTTAAATGACTC
GGTGGCAGCTATAGAACTGTTTCTCTGTTCTGTCCCCATGCCCTGAGATCTCTCAGCAAGCACTTGCCAA
ACTCCTGTGAGCTATGACGTTCCAAGGGCCATGGGTGTGTCAAGACACTGAGTGAAACCCAGTTCCCGGG
GTTTGTGAGGCTCCTGGTCCAGGTCCTCACTGCTGGTGCTCTCCAGTTTATGTTGTAGAGGTGGACTGGA
CTCCCGATGCCCCTGGAGAAACAGTGAACCTCACCTGTGACACGCCTGAAGAAGATGACATCACCTGGAC
CTCAGACCAGAGACATGGAGTCATAGGCTCTGGAAAGACCCTGACCATCACTGTCAAAGAGTTTCTAGAT
GCTGGCCAGTACACCTGCCACAAAGGAGGCGAGACTCTGAGCCACTCACATCTGCTGCTCCACAAGAAGG
AAAATGGAATTTGGTCCACTGAAATTTTAAAAAGTAATTCCATCCCCCTTGACAGTATCTTTTCTTCTAC
CCCTCCTTAAAAAGTAATAATTGCAAGTGTGTGTGTGTGTGTGTGTGTGTGCGCGTGCGCGTGCGCGTGC
ACTGAGGCTCAGAAATGTTTCTCATTTCCTTTGAAACAGGAACTCTCATTGGCCCATAGCTTACCAATAA
GCTTTCTTGGTTAGCCAATAACATCCAGAGACCTTGTCTCAAAAAAAAAAAAAAAAAAATCTCACCCTTG
TACCATGTAATGGCCAGTGATCCATCCACAGTAAAAAAGAAATAAATAAATAAAATAAAAATAAAAAATA
ACAAAAACAAATTTCTTTATTAAAAGAAAACTCCTAAATATTTAATTTTTCTTTTCTTTTCAAATGCAGA
TTTCAAAAACAAGACTTTCCTGAAGTGTGAAGCACCAAATTACTCCGGACGGTTCACGTGCTCATGGCTG
GTGCAAAGAAACATGGACTTGAAGTTCAACATCAAGAGCAGTAGCAGGTAAGGGAGCTGCCATGATTTCT
CAAGGTTTTGTGTGATCTACTTCATAACAAAAAGAAGTACAAACTGCCCATGGATTATCAGTGACTGGTA
ATGGAACAGCAAAGTCAATTCTGTATTTTTTTTTTCAACTTCCCTCTGCTCGCCTAAGGAAATAGCATGG
AGCTTTAAGCCAGCCCTCTGAGACTAGTTGGCTGGGTAGTTTGAATTCACTCATCCGAATTGCCTGGCCG
TGCTTCATTAAGGCTCACAGCACCATGGGGAGGAATTAAAAAGAAGCCACAGCTACAAATAACTGGCCAG
AGCTCGACCTTGTGTCAAAAGCAGAATTGAGTGCTCCAGGGCCTTGCTGTTGGAAGCCCTGGAACAGATT
CCAGAACCCTCTGAGGCCTTTCGAGATTTTCCTAGAGCCTTTTCAACTTCTTCCCCCCCCCACCCCCACC
CCCCAACCGTTATTCTGAAGTTCAGTTTCCCCAATGCACTTGGGCTTTTCCTAAAAACATCATCTCCCAG
GGCTGCAGAGCGGGTGTGTCAGACTGCTCTACAGCTGACTTTAGTCAGCAACTAAATCCCTGAGCCACAT
GGAGGGCAGGGAGTGAGCGCCCTGGCTCTCCCACTATTTAAATGAATAAACGGGGGACAGGGGGTGTGGG
GGGGACGACTCCCTTTTCCATCTTTATCATGAATTTGCTATGACTTAACTTAGCTAAGGAAAATAATGGT
TCAGGGTGACATCAGAGTCCTTGTTGCTTCTATGAGAATTTTCTGATCTGGTAAAGGTGGCCCCAAAGGA
GACCAGTGTACAATGCAGATGCTTACATATAGAAACATGCCAGACCTCTATGTGCTTTAAAAAATTAGAC
AAGCACGATACATTTTCCTGCTAGAGAAATCTTGCACGTGTTCCTGAAGAAACTAGTACATGGATAAGGG
TCAGTGGAACATTTTGCATAATTAGCAAAAGCATGCTCAAATGGAACATCAATGTGCATCTATTGAAATA
AATAACTCAACTTTCGTGTTCTGTTTAGAGAACTCCCCCACAATACTTTCAGAGAGGAAAAAGACGTTAC
AAACTCATGCATATATATTTTTCATTTGTCTTTAAAGTTGTGCTACTCTTTGGATAAACTACATATGTAC
ATATATGTCTGTGTGCATGTCTATCTTAAATATTCATTTGGAAAAACTCTAGAAGTAACAAACTGTGAAC
AATGTCTATATGTGGGACTCAGATTTGAGTAAAAAGGAGAATTGTGGCGACACGCATGTTTTCTTTATAA
TCATCTTTGTTGTTATAATTCTTTATAATTCAGCAGTTTCTCTTGCATTACGATATTTTCAGGTTCATTT
AGGCAGAGATGCAACTTTCAGTCTCTTACAGCTAAGCTTCCACTCTGCAAAGGGCAAGGGGGTTTTTGTT
TGGTTTTGGTTTTGGTTGTTTTATTCCACTGGAGAAATCCAACCAGCTGGACAGACTGGCCTCGGACTGT
AGACACCAGGCACTCTATCTCTGATCTATAATACAGAACTCATTCTGTCTTTGCCATCAGTTCCCCTGAC
TCTCGGGCAGTGACATGTGGAATGGCGTCTCTGTCTGCAGAGAAGGTCACACTGGACCAAAGGGACTATG
AGAAGTATTCAGTGTCCTGCCAGGAGGATGTCACCTGCCCAACTGCCGAGGAGACCCTGCCCATTGAACT
GGCGTTGGAAGCACGGCAGCAGAATAAATATGAGAACTACAGCACCAGCTTCTTCATCAGGGACATCAGT
GAGTTTTGCCTGGGAGCAGGTGCTAGGGAAGCAAAGACGATGTCTGCCACGTGTCCATGATACCCTGGGG
CATAGGATTGGCCTGCATTCTTTTCCATTCTCCTAAAAAGCATGATACAGACACTACCCTCTTCATCTTA
CAGATGAGGAAATTAAAGGGTTAAGCTAACCTTTTTCCAGATCTCAAATCTCACAGACAGCAGACCAGAC
CCAGACCTGCCCCAATGGTGGCACCTAATGGATTATGGGTTAACTACATGCTTAGTGTAAAGCAGAAACC
AAGCACAGGGAGGGTTCCCTGATTGCTGAGCCCAGATACGAGACTCTATTAAGCAGAATGACTCAACCAG
TAGGGACTTCCGGTCTGTGCAGTGCAGAAAGGGTTCTAAAATGTAGGATATGGCCAATAATGGTGACTTC
CTCGAGTGGAAAGATCACTCTCAGCAGATCCCTCACAGGTGCTGCCCTGATGCTCAGAGAAGTGAAAGAG
CTATTCCAGAGACTAGAAGGTGGAGGGCTCTGTCAGCCAAGCTCAGGAGCCTAAGTCCTAGCTCCAAAGC
CTGGCCAGGATAATAAAGGATGCTTGTCTTCTTCTGCAGTCAAACCAGACCCGCCCAAGAACTTGCAGAT
GAAGCCTTTGAAGAACTCACAGGTGGAGGTCAGCTGGGAGTACCCTGACTCCTGGAGCACTCCCCATTCC
TACTTCTCCCTCAAGTTCTTTGTTCGAATCCAGCGCAAGAAAGAAAAGATGAAGGAGACAGAGGAGGGGT
GTAACCAGGTAGGATTTATGCAGCCCATGTTGGGGCCATTGGAAAGATCCTGACAACCAGGTGCTTGCCT
CAGGACCAGAACTGTGTTAAGGGCTCTCCATGTGAATCACACACAACCTATACAAAGTCCCAAAGGCAGC
CAGTATTGCTGTCACCTCTCCACAGAGGCCAGGAAAGCTCAGAGAGGCTATGTTTTGCCCACGTTCTTCC
AGCTAGAGCAGTGGCAGAACCAGTACCCAGCAATGGTTTGATGGAGAAAGAGATGGTTAGCTCAACCACT
TCAATTCCTCCAGTATAGTCGATTGTCAATCCTCAACCAAAGTTGTTCATGATATAGAAACCTGGGATCC
AGGAGCCTATAATGATTGTTTAAACTGAGTAAATATAGTAAATGCTAAAACATTGATGCTGGGACCCACC
AAATAAGGATAATCTCTACTTCCTTAATATGAGCAATCATTTCACCTTACAAGATGTCCACCTTTACTGG
GCTAATATGGTGACTTTCTACCTTTCGGGTCCTTAGCACAGTGATCTCTTGCTAGGTTTGAGGAACACTT
TTATGAGCATTTAAGTCACAGAGCAAAGGATTCTTCCAACCTAGCATTGAGAATGTGATAGCAATTCAGC
TCAGAGATTCAACCACTTCCTAAAAGCAGGAGCAAAAAATGGGATTATTTTGAAACAGATTTTAACTGCT
ACCTAAGTTTCATCCCTGTGTGTATGTATTTAATATACCAATCTTAAATAGGTAATGTCTAGTGCTTTCT
ACTTGCTAAAAGCTTTCTACGCATTTTTACATAAATGTTGTATTTAGCTGCTGCAATTCTTAGAGGCAGG
CATCCTGGGACCTACTCATGAATAAGGAGAGACACAGAGAACCAGAGATATTTTCCTGAAGCACCACAGC
TGTTTAGTAGCATTGCCAGGATTTGAAGTCACTTTTGTAAGCTGACAGGCATGGTAATTCTTGATGTCAA
GACAGCTAAAGAAAGCTGGTCTCAGTCCCAACATCAGCTTCATATGGGAGTGGTTACCCATGGGACCTTG
GGGTAATGCTGCTACTTCAAGAGGCAGAAGGGGGAGCAAGCCATTTCTGTTGGAGTTTACTAAATAGAAA
AGTGAGAGTGGGGTGGTGGATGAATCATGCTGGAATATGAAGACCTGAATTTTAACCCCCAGAACCTCTG
TAAAACTGAGTAGTAATGCCTGAACCTGGGCTCTGGAAAGAGGTGGGACACATACACACACACACACACA
CACACACACACACACACACACACACACACACACCTCTGATTATAGCTTCTACCAGCAGGTGGTGCAAGGG
GAGCGCCCATGCCAGCCTGCCTTATATTGCCTAAAGCCCTTACTTAAATTTTCCTCTCCTTTGCAGAAAG
GTGCGTTCCTCGTAGAGAAGACATCTACCGAAGTCCAATGCAAAGGCGGGAATGTCTGCGTGCAAGCTCA
GGATCGCTATTACAATTCCTCATGCAGCAAGTGGGCATGTGTTCCCTGCAGGTGTGTGAGCAGGACCGTG
AAGCCCAACCACACCTGCACATTTAGTGGTCCTGGTGGAGGACAACAGGAGGCTTGTGAGGGAGGTGGGG
GTGGAATTCCTGGCATAGGGATTCCAGTCAGAAACACATTTGTTCATCAGCAGATGTTAACTTGATGTGT
ATGTTAGGTCAGGCACTATGCTAGGCCAAGGATATTACAATAAAGAAAACAAGCATGGGTCCTACCCTTG
TACAGGGAAAGGCAAGAAGGACCAGAGGAGGAGGAAATCAGGAGTCAGAGTATGGAGAACTTGGAAGTAG
ACAGAAGTTGGAACCATATCTTAGGGGTTCTGGGGAACCACTGAAGTCTTTTTAATAAGGAAATATCCCA
ATCAAAGCCCTTTTAAGAAAAATCTCTCAAGAGAGTCCCTGGCAAGCATGAGACCAGCTGAAGTCCAAGC
CCTGTAAGGAAGGGTTGGGCTGTCTCGCACAGAAATCCTCAAGACCCAGTGTCTGGGGATAATAATGTGT
GGTGTGAAATAGGAGGGTATTGAGGCTATACCTCTGACCAATATGGACTTACCTACCCACATTCCTTTAC
AGGGTCCGATCCTAGGATGCAACGTTGGAAAGGAAAGAAAAGTGGAAGACATTAAGGAAGAAAAATTTAA
ACTCAGGATGGAAGAGTCCCCCAAAAGCTGTCTTCTGCTTGGTTGGCTTTTTCCAGTTTTCCTAAGTTCA
TCATGACACCTTTGCTGATTTCTACATGTAAATGTTAAATGCCCGCAGAGCCAGGGAGCTAATGTATGCA
TAGATATTCTAGCATTCCACTTGGCCTTATGCTGTTGAAATATTTAAGTAATTTATGTATTTATTAATTT
ATTTCTGCATTTCACATTTGTATACCAAGATGTATTGAATATTTCATGTGCTCGTGGCCTGATCCACTGG
GACCAGGCCCTATTATGCAAATTGTGAGCTTGTTATCTTCTTCAACAGCTCTTCAATCAGGGCTGCGTAG
GTACATTAGCTTTTGTGACAACCAATAAGAACATAATATTCTGACACAAGCAGTGTTACATATTTGTGAC
CAGTAAAGACATAGGTGGTATTTGGAGACATGAAGAAGCTGTAAAGTTGACTCTGAAGAGTTTAGCACTA
GTTTCAACACCAAGAAAGACTTTTTAGAAGTGATATTGATAAGAAACCAGGGCCTTCTTTAGAAGGGTAC
CTAAATTTAAAAGAATTTTGAAAGGCTGGGTATCGGTGGTATATGCTTTTAATTCCAGCACTCAGGAGAC
CAAGGCAGGCAGATCTCTGTGAGTTTGAGGACAGCCTGGTGTACAGAGGGAGTTCCAGCACAGCCAGTGC
CACACAGAAATTCTGTCTCAAAAAC

Protein Sequence : Show Sequence

>gi|6680397|ref|NP_032378.1| interleukin-12 subunit beta precursor [Mus musculus]
MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIG
SGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCS
WLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELAL
EARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEK
MKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRS

Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK) , Microencapsulated B. melitensis vjbR mutant vaccine

13. Il18

Gene Name : Il18
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16173
NCBI Protein GI : 6680413
Genbank Accession : AC025500
Protein Accession : NP_032386
Taxonomy ID : 10090
Chromosome No : 9
Gene Starting Position : 50565367
Gene Ending Position : 50581836
Gene Strand (Orientation) : +
Protein Name : interleukin 18
Protein pI : 4.4
Protein Weight : 21142.27
Protein Length : 192
Protein Note : Also known as Igif; Il-18

DNA Sequence : Show Sequence

>gi|372099101:50565367-50581836 Mus musculus strain C57BL/6J chromosome 9, GRCm38 C57BL/6J
AGGCACAGCTGGACCTGGTGGGGGTTCTCTGTGGTTCCATGCTTTCTGGACTCCTGCCTGCTGGCTGGAG
CTGCTGACAGGCCTGACATCTTCTGCAACCTCCAGCATCAGGACAAAGAAAGCCGCCTCAAACCTTCCAA
ATCACTTCCTCTTGGCCCAGGTAAGATGTGTCTCTCTTTATTCGGGCACACTGGCGTGACGGTGATCACA
GAAGGGACAGAAGCAGACAGCAGGTTGGTTTTCTCTAGCTTTATTTGATGTGGGAGAGTGTCACCTCAGG
ACAGAAATTCTTTTTTCTCTCTTGAAAACTATTAAGGACCCTGAAGAGCTTTTGTTTCCCTTGGCTATCT
CCCATACTATTGCCATGCACTGTGTTAGAAAGTAAAGCTGAGAAATTTTTTAAAGTTACCTAGTGGGATT
TTTGTAAATATGTTACATATATTCTTAAATAACATTTTAAAAGACAGCCATCTATCCTTTTGTATATTTG
CAAATCCCAATGGAAGGAAGCAGAGTTCTTCTCGCTTTGTCTTCAGACTGTTGCAATGGTACACAGAATT
CGCCTCTAATACTATCTTATCCACTTGTAAGAGCAGGAGAGCTACAAAGCAAATGGCATCCAGGATGACT
AGAAACAGCTTGAGCTACTCTGTGAGCCACTAAGATCCTCTGCTTTGGAATGCTGAATCAAACTTTTCTT
TCAAGGAAGCCTCAAATCCAAACTAGTTCTCTCAAAGCAAACAAGACCTTGTGCGAAGCTGGCAGTCAGT
GAGTGCCACGTGATAAGACTTGAGCTGCTCTGTGCTTGGATAACATGATAAGATTCCCCAGCAAGACTTT
ATTTCGCAGGGGAAGGGCTGAAGAAATAAATGATCTTCTATTTTGAAGTAATATAACAAAACCAATTAAG
ACACCTTAATCTCTTTACTTTCTGCCTGTTTTCAGCTGGCCAAATCCTATGCCACGATCCTTCAGAATAT
CTTCCTCTCTGCCTGCAGTGCCTTCCCATTGCTGTTAACATCTCAGTCTGAGTCTCCCATAAAATCCTCC
ATCTTCTCCTGCTCACTTCAGGATAGAATGCTCCACCTGCCACCCCACCCCAACCATAGCTCTGTTTCCC
TCCCACACAAGGAGGAGGGAATATGGAACACCCAGTCTTCTTTCACACACACGAATTCCAAGCCTGTGAG
CTGCACTTGACCTTTTTTTTTAATTAAGCCTATATTTAACAGTTGATTAAATATACCTGTCATTAACTAT
TTAATTTCCTGTTGTGTTCTACCCCTATCCCTTCTACATTCCACATACATACATTTGTAAGATGGAGCAA
TTGTCAAGGGTTAACTGACATGCCAAACTGAAATATCACCTGGCTAGTGAGATGGCTCAGCAGGAGCCAG
CAGGTGATATTTCAGTCAATGCCTGCTTTCCTGAGATTCACACATGGATCCCTTATAAAGATGGAAGATG
TCCCTGACTTCCACACACATGCTATCATAGACTCATATACACACATTAAATACACGTGTTTTGGTTTGGT
TTAGTTTGGTTGGTTGGGTTGTTTGTTTGGTTTGAGACAGGGCCTCACTATGTATATAGCTTTGGCTGTC
ATAGACCTATGTAAGCAAGGGTGGCCTCTTACAGAGATCTGCCTGTTTCACCATGCTTGAATTAAAGATG
TGTGCTGCTACAGCTGGCTACAGTAAGGGTGTTTTTCTTAAAAAAGAACCAAAATGTTGAGTGTTGGTCT
TGCTGAAGCCAGGATGACTTCCCACGTGTTTGTGGAGATTTAATCACACCGATTCCACAGAACTGGAGTT
CCACAGACAGGACAAATGGATCAGAGTCGCCTTTCAAGTTCAAGGCATTTTATTTTTAATACAATATTAC
TTTTTTTAAACTCATAGCGATTTTAAAATACTGGCTGAATAATATTCTGTAACTGTGTGTTGCCTTCCAG
TAGTCCTCAACCTTCTTAAAGCTGGGAGGGACCCTTTAATACATCGCCTCACATTGTGGTGATCCCCAAC
CATAAAATCATGTTCATTGTTACTTCATAACTGTAGTTTTCTACTGTTATGAATTGTAATGTAAATATCC
AGGTTTGCCAGTGATCTTAGGTGACCCCTTTGAAAGGGTGGTTCAACGCTCAAATGGGTCGAGACCCACA
GGTTGAGAACTACTGTAAGAGGAAGTGGCTACTAGGACATTGGCCCCATATAAATGGCTCTTTCCTGGCA
ACTTTAACTTTAGCCTAGAATTGCAGAATGCTGGGGCTGGAAAAAACTTACGTTTTTTCACGTCCAGCTT
CCTTGTTTTTTTAAATGAGGAAACTAAGACCCCCCAAAATTAAGTAACTTGCCCTAGGCAAAATTGGAAC
TCATGTGACCTAGTTTTCATCATGATATTCTGTCATCTCTCTGTGAGCTAGTTTTCAAAGGCTTATACTA
CAACTTTTTTATTTCGAAGACCTAATTTTTTCTATATACTCCTGGGAGGCTCTTTGTGAGAACGCTAGGT
GAAGGCTGGAGAGATGAAAAGGTTGGAAAAGGACTCAAGGGCCTGCATTCAATCTCTAAAACACAAGCTT
ACAAAGCAAGCAAGCCAAGCTGTGCAGAGAGTTCGCACTCCCAATCCCAAGATGACAGAAACGGGTGGAT
CCTTGGAGCTTGCTGGCCATCCAGTCAAGCCAGCAGGCAAGTTCCAGAACACTGAGAGGTCCTGTCTCAA
GAACTGGGCTGTGGCCAGCAAGATGGCTCAGAGGATGAGTGTTTGCCAAGTCTGGCCCCAGAACTGACTT
CTGCAAGTTGTCCTCTGACATTATACACACACACACACACAATATTTTTTCTTTACTTTTTAAAAGGATA
ATAGTACTTAATGAATAATACACATAATTGTCCTCTGACATATGAGTGTGGGCACACTCACAGACACACA
TGCACGTACATGTGCACGAATGAACATTTACACACACATACATGTGCAAGAGATTACTAGATAAAATGTT
CAAGGCATTCTTACCCACTGGGAACTGTATTTCATAGATTAGAATTGAGAAAGCAAAGAAACATGCATGA
GAACGAATCAGAGGACAAAACGGGAAGAGGAGTAAGGAAGATTAGACTTGACACCCTGATACACTTCGAG
CTAACAGGAGTGAAACACAGCGAGTGAAATATTCACAGTAAATACATAGAACAAAATTAACTAGGAAACC
ACAAGAGTATTAGATCCATTTCTCTTCTTTCTTTTTTCTTTTCTTTTCTTTTTTTCTCTTTTTTCCTTAG
GTTTATTTATTTATTTTATGTTTGCGAATGCACTGTTGCTCTCTTCAAACACACCAGAAGAGAGCATCAG
ATGTCATTACAGATGTTTGTGAGCCACCATGTGGTTGCTAGGATCTGAACTCAGGACATCTAGAAGAGCA
GTCAGTGCTCCTAACCGCTGAGCCGTCTATCCAGCAAGGAGAATATTTGAGAAAGTCATATATTTTGATT
AATGTGTTTTTAGGCTTCCCTTCTTTTCTTTCTTTCATTGGGTTATAGAGGACAATTTTAAGGTTTGTCC
CCCAAATAGAATGTATTGGCTATGACCCAGGTGAGTTTTTAAAATTCTAATGTAACCTGTTTTTCTCCTC
CCCAAAGAAATCAAGGTTGTATAAACGAGATCTACTACCTGGGTCTCCTTCCCTGGTTCTTATTAAAGGA
ACTACACTGCAAGGTCCTCTAAACTAAATTAGGCAAAATCTAAATAGTGTAATAGGAAAATAATGATTTA
AACTTTGTAAGTAAAATGAAATAATAGGAATATTTTCAAATTAAACATTTGGCCTAGAGTGGCATGATTT
CAGAGCTGCTAGGCCAAGGGGATTGCACTATTGCCGGGTGGAAGACAATGCCCTGGTGGAATCATCTGCC
CCCGTCTCTATGGAGTAAGTTAAACCATTGCTTACATATCTCAGAAGCTCTTCCACCCAGCCCTAACTCT
AACAAGTTACCTAAGCTGACCTTGAACTCACTCTGAATTACCCAAGTGGGCATCCTGTCTCATCTGCCCT
TGTAACTGGTGTTACAGGCCTGTGCCATCACTCTGGATTACAATGCTATTATTAAAGCATTATTTTATCA
CGGTGTGTGCATATGCATGAAACAGGTGTGTGGAAGTCAGAGCACCACTTTTGTGGAGTCACTTCCTTCC
ACCTTTATGTGGGGTCTGGGAATTGAATTCAGGTCTCCAAATATGGATGGCAAATCCCCAGAACCTTCTC
CCCAGCTACATAACACTACTGACGTCATACTTGCTTTATTTCCTTTTTGCCTTTTTGAGACAGGGTCTCA
TAAAACCCATACTGGACTACAACTCACTGTGTAGCTAGGAATAACCTTGAACCTCCTGCCTCCACCCTGA
TCCCCTGGCCTTTACCTACCCAAAGTGATTACTGGTGTACAGGAACACACCCCAGTTTAAATATTTTCTT
ATCTGATAACAATGTTACCAAGGTATTAAGGAGCCTTGTTACTATTTGTGATATGAACAATCTCTAGGTG
TACAAGCGAGAGGCAAGAATACAGTGTTAAGGCGACCAAAGTGCCACCATGATAAGACGTGAGGAGAATG
AACTTCTCAAAGCATGGTTAATAGTGCTGAGAAGTGGGTGGGAAGAAGGCATGCATTCACCTTCATGGCT
GTCAACATGAGCACCCCGAGAATGGTGCCCTTGTTACATCATTACATCTACTACCTAAGAACAAAATAAT
CCTGGAAGCACGTGGGCTCTTTAGAAACACAGTCCTTTCTGAGAACTGTGACCACACTTAGTGAAACCTC
AAGTCTTGGTCCCCCAGCCTCCCTGCTCCCTAGCCCTCCTCCCCGGTCACTAGCCCTCTAAGCCCTCCCC
TGCCCTTGACGAGGCTGTCCTCTGCTCATGCTGCACTGGGTGACATCACTGTGAAACCTCCAACAGCAGC
ACAAACCAGATCCTCCAGCCTCTGCCATGCTTTGTCTTGCCCACGGCATCTGAGTCACTGGACGATAGGA
GCTAAGTTTTGTTCAGCTTCTAAACCCACAACTGACTCATATTAGAGAGTGGTTAAATGATAAACAAGTT
CAAGTATTGTGGGAAAGAGTTTTTTGTTTCTTTCTCTGTTGATATTCCAATTTTTTAATTTTTTTTTTTT
CCCCTTCCCTTTCTCCCTCTTGCTCCAGCCCTGCTCACTCCTGTCCCCGCTCACTCCTGTCCCGCTCACT
CCGGCCCATAGGGTTTTTTTGTTTGTTTGTTTGATTGATTGATTGATTGATTGATTGATTGATTGTTTCT
CTTTTCAGATAGATGGTTGTGAGCCACCTTGTGGTTGCTGGGATTTGAATTCATGACCTCCAGAAGAGCA
GTGAGTGCTCTTAACCACTGAGCTATCTCACCAGCCCTGTTATTCCAATTTTTAAAGGGCTACACAGAGC
CATGTACAAGCCAGCCAAGCTCCCAAACACTGAGCCACATCTCTAACCTCTGGTTTTTGTGACAGGGTCC
CACTATGTAGCCCAGGGAGGCTCCCCTCTAATTTGTGACCCTATAGCTTTGGCTTCTCAATGTTGAGACT
GCAGATGTGTATCACCAGGCCCATCTAGGAGTAGTTAATTAATAAATTATTTTATATGTACAGATATTTT
GACTGCATGTATGCCTACTGCCTGTTGAGTCCATGAGAGGGCGCCAGGTCTCCTGGGACTGGAGTTAAAG
ATGGTTGTGAGCTACCATGTGGGTGCTGAGAATGGACCTGGGCCCTCTTGAAGAGCAGCCCGTGCTCTTA
ACCATTGAGCCATCTCTCCACACATAGGAGTGTTTTTCTAGGGTAACTGAATCCTTCTCTAAGGTCATTC
ACCTAATAACTAAACACTCACTACAGTAAATATTAGTCATTTTAAAATCCAATTTTTGTCCCTGGTGTTT
ACTGTATTCCAGACAAATCACTTTTGAAAATGTGTAATATATATAATATATATATGTATATATATTATAT
ATATATATATATAGAGAGAGAGAGAGAGAGAAGACAACATGAGCCATTATCTCACTTGTGATGAATCACT
AGAGTCCTGCCCTTCTACTCCTTCTTCTAAAGTCTTCCTTCTACTCTCATATTTTTTTAAACCTAGATTT
TGCATCTGAGAAAAATATATTTGTCATTCAGAGTCTGGCTGACTTCACTTAAGACGGTGACTTCCAGTTT
CAGCCATTTTTCCATCTCTAATGTAATTCTTCCTTTTTACAGCTGAATAATACTCTGTTGTGTAAATATA
CTACATCTTTATCTACTCACCTGCTGATGGGCACCAAGGCTGATTCTATAAGTTAGTTGGCCCTTGTGAA
AAGTGGCATGAGTAATGCAGATAGGCAGGTATCCCTACTATGTATGACTTGATCCCTACTGTGTGTGGCT
TGGATTTCTTTAGGTATATACCCAGGAGTGATATACCAGGTTAATATGATAGTTCTAATATGAGATACCT
CCATTTTGATTTCCATAGAGGTTAAACTAAGTTACATTTCTACCAGGAATGTACAAGGGTTCCTTTTTCT
CTATATCCTCACTAAATTTCTCTTTTGTCTTGTTTTTTTGTTTTCTTGATGATTAGTATTCTGATGGGGG
TGAAATGGAAACTCAATGTAACTTTTATAAAATTTATTTTTTATTATTTCAAATCATGTGTGTGTACATG
CCTTTGTGCAGGAGTATGTGCACGTGAGTGTAAGTTCCTATGGAGGCCAGAGACATCAGGTCACCTGGAG
CTAGAGTTACAGGCAATTGTGAACTAATGTGAGTGCAGGGAACTAAACTCAGATCCTCTGCGAGACCAGT
ACGTGCTCTTTACAACTGAGCCAGCTCTCCAGCACCTCAATGTATTTTACATTTGTATTTCTCTGGTGGC
TAAAGGTGTGAACTTTTTTTCGAATATTTATTAGCCACTTATGCTTCTTTTGAAAACTGCACATCAGTTC
ATTTACCCATTTATTGACTAGAACATAAAATATACTTAATAACTATTCACATTTGAATATAAGTAACTGA
ATCTAGACTAAACTGTTTACGTCAACCAAATAACAAATACTTTAGGTTAGCTTAATTAAAATTGAGTTTT
CAACTGAAATTTAATTTCCTTCTTCTATTGAACTACTTGGCCTCAAATTGTGCTAAAAAATTTTTAAGAG
AACATATTTATAAATATCCTCTAAATAATATTGTTTTGGTCAATTTTCTATAGCTATAAAGAATACCTAA
AGCCAGACAACACACACAAAATTTATTTGTCTTGCAGTACAAGAGCTGAAAAGTCTAAGAGTAGTAGCCA
CATCTGGTAAGAGCTGAAAAGTCTAACATTAATACATTAATAGCCCATCTGGTAAAGGCCTCTTACTGCT
TCAACTCCTGGTGGAAGGTGAAAGACAATCAGGCACCCAGAAAAGAAACACAGACACATGAGCTTGCTGC
AAGAGCTCTCCTGGGACTGGAGAGACAGCTCAACAGTTAAAAGTGAGTACTGCTCTTACAGAGGACCTGA
GGTCAGTTCCCAGCACCCATGTCAGTAACTAGAGCTCTTGGGGGAGAGAGAGAGAGAGAAAGAGAGAGAG
AGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
AGAGAGAGAGAGAATATGAGAGAAAGAGAATGAGAGAGAGGGAGAGAGAATATAAATTTTAGGTGGTCTC
TAATGTGAAAAGGCACTGGTCCATCCCTTCCTGTGGGCTCACTCTAATTATCCAAACATCTAACGGAGGC
CACTCCTCCAGCACTGACACATAGAGACCAAGTGTCAACACCAGTTTTACTATCTACAAACCATAAAAAC
AATTAGGAGTTTTGACTCAGTCACCACCCTGGGTGCTCCATCCATTAAGTGGCTTCACTGCAGGAGACAC
CAGTTAATTCTCTGGAACACAGCTGAGTGTAGGGGAAGTTTGACATTTTCCCCTGAAGGTACCATGTTTG
AGTCTGCTGAAATAAGACCTGCAATCAACGGATTACCAGGAGCAAAGGCTACAGAAGGTTAGCAACACAC
ACAGGCACCTGAGCTCCAGAAGCCAGGGAGGAAAAGAAGTAAGGCTTGCAGGTGGCGTTAAAGGGGGTGA
ATTGCTTTAAGGAAAGAGTGGACCCAGAGTCAGATATGGATGTGGTGCTACACAAGGCTGTGCTGAGACA
GAGGTATTGGGATTCCAAGACCACCGTAGGGTGTATAACAAGACCTGCCTCAAGAGAGAAAAGGCAGTAA
ACAAGACTGCAGGTAACTTTGTCCTTCTTTGGTGGACCCCGAGTTCAGAGGCCAGGGAAGCAGAGAAGTT
TTTTCCGTACATCTTTAGGTGAGAAAGGGATCAAGAGAACCTGACCATGGGGAGTGCACAGGGAGACCTG
AGTCTGCTGCTGTCATCCAACCTGTTATTGTCACATTAAATGCAGGAAACTCGTTACATTAGAATAGCTA
TTAACAGCTGCGGAGGCTGATGTTGTACAGGGACTTATGTAGCAAACTCATTACATAGCTTTGCACTCCT
GGTCCCGAAGGTACTGAGTTAAAATCCCAGCAAACACATGGTGGCTCACAACCATCTGTACAGCTGCAGT
GTACTCATATACATAAAATAAAAAAATTAATCTTTTTTTTTTAAAAAGAAAAGAAACAAGATCTATCAGG
GTAATTTCGATGTAATAAAGGAATTAAACAGTATTTCAGGACTCCGGTAGCAACTGTAGCCTGATGATAA
AGGAACATTTCTACTAGTGGCAGGGTTGTGGGTACCACTGTAAACACTGTGGTTTATTTCCCATATAACA
CGAGGAGGGGTGCTACATTTCAGCTTAGAAATAGATGAGAACAAACATGTGTGTTTTTCCCCCAAAGTCA
CGGATTTCTCTTACACGGAGCTCCAAGACAGTGCCATGACAGAACTCTGAAAGGCTACACACATGTAAGT
GCAGAGTAGGTTGAAGGGAAAGCAAAAAGCAAATACAAGAGTTTGAATTTTTTCAAACCTATTATTTGTT
TTTGCAGAAACGACATTTTTATGTATTACTCATACACAAACATAGACAACCCAGATTTCAGATCAAAAGC
TGTTTGCTGCCTAGGGAGGGAACCCACCACATGCCAGAGCCTTTGGGCTTTCTCCCACCCTGCCCCAAAC
GCCAGGTTGAAGTATCACTTTTTATTGCCTCCTCTCCTTTACCAGCGAAGTCCCAAACCTTCAGCATCTC
CTCTACAGGAGACCACTGAGTTTTAAGTTCAGACAGAACTGGTTCCCATTTAAGGGTGTATTTCTAGCAT
CCTCAGGGAACACGAAACTAATAACTCAATAGTGAGCTGTACAGTCACCCTTTAAAATATTGTTTAATGA
GACGGCACTCCTCTGATTCCAAATAGCTAATGATTTGTGAAAGAATATAAACACGAGTGTTATAGACTGA
TAATTAAGCTTATCTGACATCCGCCATAGTCATCAGCATACTGGATGATAAATGACATTCAAATGTGCAG
GTTTAGAAGGTAGTATTAAGGAGCTGGAGAGATGGCTCAGCAGTAGCACTAGCAGCACTCATAGCACTGA
CTACTCTTCCAGAGGTCTGGATTTCAGTATCAGCACCCACATGGTGGCTGGATCCAACGCCATCTCTGGA
CTCCATCAGAAGTGCATGTGATGCACAGACATACATGTAAGCAAAGTACCAAATACATAAAACAAAATAA
AATTCCCTTTAAAAAAAAAGAAGAAGAGAAGAGTTTCGTTCATTTTATGTGTACAAAGAACAGTCTTTGC
CTCTTCATAGGTGACTCTTTGCTTTCACTAGGAACAATGGCTGCCATGTCAGAAGACTCTTGCGTCAACT
TCAAGGAAATGATGTTTATTGACAACACGCTTTACTTTATACGTAAGTCTAAATCAGTAGGACAAATGCA
GGGCTCAGATACAGGTATTCAACAAGAAAAGAAATCATACAGTGAACTTAGGCCCCTGTTTGTCATCAAA
TTCTACTGCAATGTCTACTCCCCTCTCTAAAAATAACCATAAGATTCCTGAGGTCCCAGTGCCTTGTCCC
ACCTCAGGGATGGCACTCTGGCAGTAGCTCACCAAGATGGTGCCTGGGGCCCATCATGAAGATCCCATGA
AAATGTGCCATTGAGAAAACCCTGCTTCCCAAAAGAAATGCTCATCATGATATTCTAGACCTTGAGTTCT
GTGAACACCATTCATGTGAATATATTTGACCAGAGAGAGAGGAAGGAAGGAAGGGAGGGAGGGAGGGAGG
GAGGGAGGGAGGGAGGGAGGGAGGGAGGGAGGGAGGGAGGAAGGAAGGGAGAGGAAGGAAGGAAGGAAGG
AAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGAGCAAGGAAGGGAGGGAGGGAGGGAGGGAGGGAGG
GAGGGAGGGAGGGAGGGAGGGAGGGAGGGAGGGAGATTCTTCTCATTAAGCTTCCATGGGGGATTTGACT
TCACTGAAAGTTCGGCTTTCCTCAGAAGCTTCCTGAAAAAGTCCTTAGATGTTTTTCCATTTAAACAATA
AATTTAAAAGAAGAGTTTGCTGCTTTATAAAAAATACTTTTGCTATGTATTGAGATTTTAAAATCCTGGA
ATTAAATCTTTTAATTATTTTTTATTGTATGTATATGAGTGTTTCTTCTGTATGTATGTCTGTGCACCAC
ATGCATGTGGTACCCATGGAGGTCAGAAGAGGACACTGGATCCATAGAACTGGATATGAGCTAACATGTG
GGTGCTGGGAATCAAAGTACTAGTCCTCTGGAAGAGTAGACGGTGCTCTTAACTACTGAGCCATCTCTCC
AGCCCTGGATTTTGGTTTTATACCTAACATAGCTAAGCACACATGAACCCTAATAGGCTTGGTTTTATGG
GCTTGAATGCTTATCAAATCTGATATTCCTACTGGAGGCCAAAAGAGCCCATCCACAAACACAGAAGTTA
AGGAGTGAGGAGTGGGGACCAGGCACCACACCTTCAATCTCAGCACTTCAGGAGGCAGAGGCAGGTGGAC
TCTCTAAGTCTGGGGCCAGTCTAGTCTACAGAGTGAGTTCCAGGTCAGCCAGAGCTATATAGTATCTCCC
TGTCTACAGAGAGAGTTGGGGGAGGGGAGTGGAAGGAAGAATAGAGTTGCAAAAGGGTGGGAGAGAGGGG
ACATTTGAGCTGAACTGTATAATTTAACATATCGTGTTTCTCTTTTCCTCCCTTTAGCTGAAGAAAATGG
TAAAGTATAAATTTATTTTTCTTTCTTTGCAAATTAGAAGGCACTTGAGACATATCTGCTGTCAGCTGGG
AGAAACTGTCCATAGGGTTGTTTCCTAGGTAGATAATCATTACAGTTATATTAAATTCATGTGGTGAGAG
CATAATAAAACTATAATTCCTCCACTGATGGACTTATAAGTTGTTTCCATCTTACGACTTTTGTTTACAG
CACCCTTGTGGGATTCTTGGAGATTTCAGCTGTTCGGTTTGGTTTGATACTCATTCAGTAGGCTGGCCCA
GAATTCACTATATTACCTGAACTGGCCTCAACTTTTCGATCCTCCTGCCTTAGCATCCTGAGTACCAGGA
TCACAAGTGTGCAGCATTCTTAGACAACAGTGTTAGCACAATGGGTCTGAACTACCTGTTCAGGATAAAA
TCTAGGAAGCAGAAATGCCAGGTTGACAACAGAGAAGGAAGAGCTGGCAAATCAAAGCTTGAAGCCGCTA
CACGAAGTACAAGTGGGCTCTCCCTTAGACGCTCGGACACTTTTCCAGTATTTTTCTTTAGTAAGGGAAA
AGAACTGGTCTAGTGTGGTGGCATGCACCTTTTAGCCCACTTAGGAGGCAGAGGCAGGCAGATCTCTGAG
TTTGAAGCCGGCTTGGTCTACAGAGCAAGGTCCAGGACAGCCAAGACTACACAGAGAAACCCTGTCTCAA
AAAAGAAAAGAGACAGGGGGTGGGGGTCAGGGGAGGGAAGGAGAAGAAGACAGGGCCAGGAGACGAATGG
GAGGGCTTTGTAAGGTCTGAGAACGTGGACAGCGTGAGTCAAAATGTAAGGAAACAAAAGGGCAGGAGGC
TGGTCAGACAGTAAGACAGTGGAACCTCTGGCCGGAGAGTAGCTCCAAGCACAAACAGGAAACAGAGTGT
CTTAGAAGCGGATGAATGCAGCAGTCAGCTTGATCATTGCTGCACCTAGAGGTATGTACTGACTCTAGAG
AACAGTAGTACTCGGTCTATTTGTTATCTGGAAAAAAAAAAACCTAACTATTAATGATTCAATGTATATT
ATAGGAGACCTGGAATCAGACAACTTTGGCCGACTTCACTGTACAACCGCAGTAATACGGAATATAAATG
ACCAAGTTCTCTTCGTTGACAAAAGACAGCCTGTGTTCGAGGATATGACTGATATTGATCAAAGTGGTAC
TTTTCCCCTATTTATTTAAAAACACAGAGATGAGAAGACCACCCATTATTCTCCCTCCATTTTACTGCCT
ACACTCTCAAATATTGCATCTTTGACCCCATCCTTAAATGGAAAGTCACAGTAGTAAATATAATTTCACT
TTAGAGCGTGCCCATACTTTTAGTTGGAGGGAGGAGTTGGGTCCAATAAAGACGCTGGCAGAGGACAAGT
CACTCTGAGTCTACATGTGTACCACTAGTTCCCTTATTTTAATTGTATCCTCTGAGGAAGAGCCTCACCA
AGTTAGATGCTTCATCCCCACTGGTTATAGCTAAACATACTGCTGACACCATCAAAACTCAATATTAAAA
GCAAAACAGGGGCTGGCGAGATGGCTCAGTGGTTAAGAGCGCCGACTGCTCTTCTGAAGGTCCCGAGTTC
AAATCCCAGCAACCACATGGTGGCTCACAACCATCCATAACGAAATCTGATGCCCTCTTCTGGAGTGTCT
GAAGACAGCTACAGTGTACTTACATATAATAAATAAATCTTTAAAAAAAAAAATAAATAAAAGCAAAACA
GAAGCCTTTCAAATGAACCTGCCTTCCACCAGAACACAAGAGCACCTCAGAGGATGGCATGATTAATGGG
CGCCTCAAGTTATAAGTTCAAAATCACACAGTTTAGGACCTAGTTGAATGAATATTTTCAAAAAAGAAAA
TACTATCCTAAGATTCTTACCGCAGCAAATAGGTTTTTAATATTCCGTTGAACATTCAACAGTTAAACAT
AGTCTTTAGATTCAGAATAATGCTCTGTTTGAGAGTTGGTTTTGTTTTTGTTTTGGGACAGGATCTCACT
ATGTATCCCTAGCAGACTTAGAACTCTATCGGCCAGACAGACATAAAATTCTACCTACCCCTGCCTCCCA
AGTCATGGAAATAAAGACATGCAGATACCTTTATTTCCACACCCAGCAGGGTTCATGGAATCTTTAACAC
ACTCAAAAATTATCAGAGTGTCCTTAATACATTCAGAATATCTTTTTTATGTATATTGACGTTTTGCCAG
CATGTATGTCTGTGTGAAATTACAGACAGTTGTGAGCGACATGTGGGTGCTCAAAACTGAACCCAGTGCT
CTTAACCACTGAGCCATCTTCCCAGACCCCACTCAGAATATCTTTAGCACACTCATGTTGCCCACTCATG
TTTTATAACACCTTGTAAGTGTGTTTTAAGGGGTGTCTGGTCAACGGGGCATTATGTCTGTCAACTGTCT
GACCAAAACTGAGTGCAGAGTAGTGATCGGCCTATTAAGGTGGATCTAGCCTTTGGCTACGTTTCTGCAG
GTGCTGATTTAGGAGAAAACTATTGTAACTAGTGGCATCACTTATGAATATTTGTTTCAGCCAGTGAACC
CCAGACCAGACTGATAATATACATGTACAAAGACAGTGAAGTAAGAGGACTGGCTGTGACCCTCTCTGTG
AAGGATAGTAAAATGTCTACCCTCTCCTGTAAGAACAAGATCATTTCCTTTGAGGTAAGATTCAGCTTCA
TTTGGGTTTTAGTCATATTAATGGACAAAATGATCATATCCAGTGATTTTTCAGACCAACCCTTGATCTA
GAGCTGGAAGACCAGAGACATCCACTGAAATTGATGGTAGTAGGGAATTATCAAGCCCTTTGGTCTAGTG
TGATGATACTTGCTTGTCTAATTTTGTCTCTGAGTCTATCAGAGAGGAAATGACCACTGAGTGTTTTCTT
TTCAGAAAGGGTTTCTTGTATTCTAGACTGACCTTATACTCAGTGTATAGCTGAGGGTGACCTTGAACTT
TTAACCCTTCCATCTCTACTCCCATGTGCTAGGATTACGGGTGTCTGTCACTGTACCCTGTCTCATGCTC
TGGGTCTTTCACTAATACAAATCTTAGCCACTGTGGCCACAGACAGGGTTCGGATAAGACCCAGTTGCAG
CTCCTGCTGTATCACTAGGGCTTTGTAGCTAAGAATTAGTTCTCAGCTAGACTTTGAGCTTACGTTTGGT
CCTAGATCAGCTCCTGCAGCTTACAGTCTCTCCCTAAGTTGTGGCTTAGCAGGCACAGTTTCAGAAGCAG
CTGCTAGTGAGAGAGTACTTAGCATGACCGTCAACCCCGAGGCCATACTTGTTCATAAAGGACAATGGCC
AAAAACTATGACTCTCAGTTCTATAACTAGTTCAGTTAAAACCCTCCTCAGAGTCTTCTATGCATCTTAG
GGGGTTAGGGTGCCTTTTCAATTCTAGAGATTTCTCTATCAATCCATAGGATCATGATGATCTTTGGTAC
CATGGAGTCAAAATGCACTCCAAAATATTAGTTCTATGATTAACATGGAAGAACCTCGGGCAGTGCCCAT
ATCTTCTAATACACCCTGAAAAGGTAGACAAGATGTAAGAATAGGAAAAGCCAGGCACTCCTAGCAGCTA
CAGGCCCAGTGTGAGGGACTACAGCTTCCAGACACCTAATCCTGATAGACTCTGGTGTCTGAATAAAAGA
GAGAGGAATCAGCATGTGGTCTCTCTGGGCAGGACCCACCAAAGAGATTATACTCTGGACAAAAAGGAGA
GACAACTGTGCACTGTCACGCTTGGCAGAAAGGCAGAATCAGGGGCCACAGACTGAGCCAGTACAGGCAG
GCTATTGAGAAACCCAAGACTCAGTCATAGCACAGCTCCTGGGTTTAATCACGCTGCAGCTTAGCTCCAG
GATCCACAGAAAGAAGCAGCTGACCTTCTTCACACCTCCTGCATCTCACTGTGAGCTGCGGAACTCAAGG
AGGAGGGCAGTGTTTGTAGCTACAGACAACCGAGGAAGACAAGAACAGGAATTAGCCCAAAGTGATAGCT
AGCTTTGCTAGAACTTTACTCCATCATTAGCAGACAGACTCCACTTCGTGGAAGAGAACGGAAGGAAGCT
CTCTAGGCATAAGGGAATTCTGAGGTGGAAAAGGTCAGAATGGATGGGGAAAAAAAGAAGTTAAGAGTTA
AAGGGCTGGAAAGATGGCTCAGTGGTTAAAACCACTGACTGCTCTTCCGGAGGTCCTGAGTTCAATTCCC
AGCAACCACATGGTGGCTCACAACCATCTGTAAAGGGATCTGATGCCCTCTTCTGTTGTGTCTGAAGACA
GTGACAGTGTACTCACATACATAAAATAAATAAAGCTTAAAAAAAAGAAGAAGAATTAAAGAAAGGTGGT
CAGTACTCATATTATTCTATATTCAGAGGTTTTTTTTCTTAACTTTTGAAAAAATTAAAACTGCTTTAGG
TCTGTTTAGCAATAGACTTCTAAATAAACTGTGCATATTCAATTTGTTAATATCCTCTTTTAAAAAATAT
TTCACTTCGTGTGTGTGTGTGTGTGTGTGTGTATGTATGTATGTATGTATGTTTCTTCAGAGGTCAGAAG
GAAGAATTGGATCTCCTGGTACTGGAGTTCAGGCATTTGCGAGCTGCCAAATTCCAGACTTCTGAGAGCA
GGGCAGCAAGCACTCTTAACCCCGAGCCTTTCATCGCTCCTGCCCCGTTTGTTTATATCCTTAAAAATTA
TGTGTTTTGTGTTTTCTCCATAGGAAATGGATCCACCTGAAAATATTGATGATATACAAAGTGATCTCAT
ATTCTTTCAGAAACGTGTTCCAGGACACAACAAGATGGAGTTTGAATCTTCACTGTATGAAGGACACTTT
CTTGCTTGCCAAAAGGAAGATGATGCTTTCAAACTCATTCTGAAAAAAAAGGATGAAAATGGGGATAAAT
CTGTAATGTTCACTCTCACTAACTTACATCAAAGTTAGGTGGGGAGGGTTTGTGTTCCAGAAAGATGATT
AGCACACATGCGCCTTGTGATGACCTCGCCTGTATTTCCATAACAGAATACCCGAGGCTGCATGATTTAT
AGAGTAAACACGTTTATTTG

Protein Sequence : Show Sequence

>gi|6680413|ref|NP_032386.1| interleukin-18 precursor [Mus musculus]
MAAMSEDSCVNFKEMMFIDNTLYFIPEENGDLESDNFGRLHCTTAVIRNINDQVLFVDKRQPVFEDMTDI
DQSASEPQTRLIIYMYKDSEVRGLAVTLSVKDSKMSTLSCKNKIISFEEMDPPENIDDIQSDLIFFQKRV
PGHNKMEFESSLYEGHFLACQKEDDAFKLILKKKDENGDKSVMFTLTNLHQS

Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis WR201 (16MΔpurEK)

14. Il2

Gene Name : Il2
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16183
NCBI Protein GI : 7110653
Locus Tag : DN-144H19.3
Genbank Accession : AF195954
Protein Accession : NP_032392
Taxonomy ID : 10090
Chromosome No : 3
Gene Starting Position : 37120712
Gene Ending Position : 37125953
Gene Strand (Orientation) : -
Protein Name : interleukin 2
Protein pI : 4.63
Protein Weight : 18506.61
Protein Length : 169
Protein Note : Also known as Il-2

DNA Sequence : Show Sequence

>gi|372099107:37120712-37125953 Mus musculus strain C57BL/6J chromosome 3, GRCm38 C57BL/6J
ATTTTTTTTTAGAGGAGAGCTTTATTTCTTGAAAACACTGATTAACATAGAGTTCACAGGAATAACTGAG
AAGTTATTTTAGCGCTTACTTTGTGCTGTCCTAAAAATGACAGACATCTGAGCTTATTTATATTTGAATC
ATCTAAATACTTTTATTAATGAGTCTACCTACACATGATATTTAACAATTCAATATAATAAATAATTTCA
GATAAATAGTTTAAAACATTTTTGAGCCCTTGGGGCTTACAAAAAGAATCTTTAAAGATCCATATTTATC
ATCTGAAGACTAGTAGTTACAAAAGATAGTAAACAATACATCCAAAAATAAATTAAAGTTAAATATTTAA
ATAAATAGAGAGCCTTATGTGTTGTAAGCAGGAGGTACATAGTTATTGAGGGCTTGTTGAGATGATGCTT
TGACAGAAGGCTATCCATCTCCTCAGAAAGTCCACCACAGTTGCTGACTCATCATCGAATTGGCACTCAA
ATGTGTTGTCAGAGCCCTAAAAAAGAATATAAAATTGTAGGCTAAGGTAGCTTACTTTGCATATAATTAT
TCTTCACGGAAGCTTTTAGGCATTTATTTTAACACTGGTTAAATATATTGAACATTCACATTTCTGAAAT
GATCACAATTATTGGGTTATGTTTTATTATGATATCAAATGGTAAAGCATAAAAAATAAAGCTCTCCAGA
GTTGATTACCAACGAGCATTTGATGGGAACACTGAACACTTCTGTAGAATTCAGTTGCTTGACCACTTTT
TCTCTGGTAAGTGTACACAGCTATGCATCAATTTAGGCTTCAGGAATGGAGAAATGATACTTGTTATATG
TTCTTTGCTAAATCTTAAGAGTCTATTATTCAATTCTTTCCCCCCCAAGTCAGAATGGGAACAACCCAGA
GTAGGTTAGGACAAGCATCTATTGGGGGAAATTTGGAGAATTTTGTTATAGATATACCTACCCTGATACC
AGTGTAGATGAATCACAAAGTTTGTACATGTATAAATATTATAAATTTGTTCTGTGGATTAGCTTTTTGA
AAGCTAACCCTCTTTGCTAAAGGAGATATTTTAATTCTGTTTTTAGGTGACAAGCTGAGAAGGAAATATT
TTGACAAATTTATGGGATGGCTTTTCCAAATCTGACTAATTCCTTGTAAGTCAAATGAGGCAGATTATTC
CTTTTAAATAAATACTCCTTTTCAAATAAGCTGCTGTGGTCTTATATACCCTCTTTACATAGCTACTTCA
ATATTCTAATGTCTTGAATTTTTCATTTTTAAAAATATGTGGCCCTTGAAACATTTTTCTAGTTCTCATG
TAGCTCTAAAGTTTGTACCATTCATTAGGGGTGAACTTTCTGATGTTGGCCATAGATTTTAGAGCATCCA
TCTTTGCATACGTAAGTACTCGATTTTAGAGCATCCATCTTAGCATACGTAAGTACTCACACCTTTCAAC
GTCTAGATGATGTGTATTTCAGCCTGCTTTAAAAACCTCAAATGGAAGCTGGGCAGTGGTGGTGCAGGCC
TTTAATCCCAGCACTTGGGAGGCAGAGGCAGGCGGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAGAGT
GAGTTCCAGGACAGCCAGGGCTACACAGAGAAATCCTGTCTCAAAAAAACAAACAAACAAACAAACAAGA
AACAAACAAACAAAAAAAACAAAAACAAACAAAACAAAACCTCAAATGGAAACAGTGCACTGAAATGTGA
CTTTGGTTTGGAAAGGACTAGCCCACACCCTCTTGGAGGCTTGCTGCTACTGTCTCACCAGAGTCCATGA
TTCTTGTGCATTTAAAAACAAAGCTCTGCAGTGGGCTCTCCCCGTCCTGCTCTGTCCATTTTAATGGCTG
CCATTTTTGGAGAGAAATGTCTGTTTTTCTACCAATACCAGCACAACTTCTCTGGAAAAACTTTTCAGAT
AATTTTTTCTGATCTGATGAATGTAACACCAGCAAGAGTTGCTTGTTTCTTGTGGAATTCTACTCCGTGC
TTTCTCTCACATCCAGTTCTATGCTGGTGTGGAGGGAGCAGAGTGTTCATGTTCCCAGTTTCCTTGCAGG
TGATGGTAGGTGGAAATTCTAGCATCATCCTACAGTGGAAGGATTCACTTGCACAGTGACTTTAAACTTT
GGCTGACTAAATGCACAGAACCCATCAAAGACCAGAAATGGCAAGCCACTTAAAAATGCATTTCTTCTCT
ATTTTATTTCCAGATTAGCAAATAAAGCAACACCTTACCTTTAGTTTTACAACAGTTACTCTGATATTGC
TGATGAAATTCTCAGCATCTTCCAATTGAAAGCTTTTGCTTTGAGTCAAATCCAGAACATGCCGCAGAGG
TCCAAGTTCATCTTCTAGGCACTGAAGATCTTTCAATTCTGTGGCCTAGAGGAGTAATAAGCTTAACCAT
CAGCTCAGCTCACCACATACTGAAGAGCCAGAAAGTTAGTCTGCAGTCTCTCTAATCAAGAGAAGGCAGC
ACATAGCTTTTACCACTCCCTGTCCTCTGTAAAGGGGGACTGAGGTAATCGATGCCATAAATCTAGAAGA
GCAAGAGCTCACAACCATAAGGGTCACCTTGACTGTTAGGCCACTCTAGTGAGCTCTTCTGGCTTCATTA
GACTTTGTAAAAAGTCTGTGTTTCTCTACCAATGCATAGCACAAGTTCAGACTATTGTTCCAATCTACAA
AGAAATCTGCAAGGTTCACATTCTAATATCTAATCGCAGAGTTGAGAATCACAGAAGGGTAAGGGACAGG
AATCCTTGGATGCCAACTGTCATAGGCCTAAATCTTACAGATTAGGTTATCATGGCCCTGACTGAGGGGT
GTCAAGATAGCCAGGAAGACACATGTAATATTTTTTAAATTTATACTTCTCTGCAATTACTAAAGATGAG
TTTTTTAAAAACCCATATGTCAAGCTAGGAAGATGGCTTTTAAGGTAAAGGTACCTGCCACCAAACTTGA
TGATTTGAGTTCAATTGCAGTGACCCACCCACATTGTGGAAAGAATGGCCCAACTTTCATATTTCGTCTT
CTGACCTCCACAGTTACACTGTGATACACATGCACCTCCACACATACATACATACATACATACATACATA
CATACATACATACATACATACATACATAAAATGTAAAATCTATTTGTCCCAATGAAAAAAGTCATAACAT
TTTGGCAGAACACTTGGGAGAATTTTTCTGATCCATGTATGAAATAATGTTTAAATACATCATGCATACT
TACATACATATACAGGGAAAAAGGATATTGTCTAGCTCTATAGTACACTATGATTTCCATAAAGTCAGCT
GCTTTAAGTCTACAGTGAACTGTGTTATCTCCATTTTACCAAGTCTCACAATCAGTGTCTTTCCCACAAC
CACATGAACGGGGAGCAAGGGTGGCCCGGTCGGTCGGTCGCTCCTTTCATTAACCACAGCCTTTGAATTA
CATGCTTCTATTGTTTTTAAAATCTTACATACCGAATGCAGGTTAAATGAAAACATCAGCAGAATTTACC
ACATTACTCTTGTTTTCAATAATTATTTTAAAACTTAGATTTCTAGGAATTTCACCACTCTCTAAATTAA
CATGATCTCTGTTGTTTCTCTAACAATCCTTAGAGGAAGAGGTTTGACAAGATAACACGTAGTTCCTGAT
TGGTCTGCTATTGACCTTCCAACTTGTTATGGTGTGTCTTGGGTATTCAGTGTGGAGCTCCTTCCCTCAC
AGAACTCTCCAGTTTGTTACTGTGGGAGCTGAACATTATGTGACTGTAATTAAGCTGGAAGAGCAACTGG
GGCCTTTCTTTTTCATCTCCTGTAGAACAGCTAGAGGCAAAGTTCCCCTGACTCAATAGGAATGGGTCAA
CAGCTGCCTCTTTGTCCCCTTAGATCCCATTTTGCTCTAGGCTTGGATTTACTTGGGACAAGCTCTTTCT
AGGACCAAAGTTATCCATTCTCTTTTGACTTTCGGGACTAGAGCAAATTTCTACCCTTGCTGGAGTTCTA
AGAGCTTGTGTAAGCTGTTTTGTATCACACAACATTCTGCCTCCAAAGGAGACCAAAAAACCTTTCAATA
TTGAGAGATAGTATCATGTAGTAATATTACAGCTCTCTAGTTCCACTAGTTAAAAGAGACTGTATAAATC
CAAAATTGTTTTATACATCTCGGACTTCTTCTCTAGCACTAATAGTGTGTTTATGTGCTGTTGGCCAGAC
ACTGTTCTGAAACCTGACAAGTGATAAGCATAGCAATGATCATTTATGTAAGTGGGTGAATGAGCATAGA
CAACTTCCTGAGGCCATGAGAGCTAGGCCCTAGCAGGGCTGGACTCCACTGCAGATCATTGGCCCTAGAA
TCTTAACATTGGTTATGCTGCTCCTCAAAAATGCAGTCATAGGAATCATTCTTAAAACAGTAAAGTGTGT
GTAAAATGAGACCCTCTCAAGTCAATTTTTACATTTAAGAAGCTGAAATAATGCACCTCTCTCAAATATC
TGTAGGACAAGCATAAAACAGAAATCAACAGTCTTTAAATTATCCCAGCATCAAAATGCAATCATCTTGC
ATTTTCTTCTCATTCCCTTTCCCAACACATAAATACACAGGAAAAATGTAAAGAAAACCATTTAAAAGAA
GTACCATTGTCAAGATTTTTTTACAGAGAGATATCAGAGAAACTTATTTTCTTCAGATGAGGTACTATTC
ATCTGGTCACATGTTATTTACACGTTATACACATGTATGTTACTTTGAATTCATTAGAGCACCAGTTAAA
CACAGAAACTCACTCACCTGCTTGGGCAAGTAAAATTTGAAGGTGAGCATCCTGGGGAGTTTCAGGTTCC
TGTAATTCTGAGAAAGCGTAACACATTATTATTAAAGGTTATTAAACACAGCCTTTGGCAAGAAAGCTAA
AGGTATTGCCTATAGATGGGATGGCTGTGCACTTACCTCCATCCTGCTCAGGAGCTCCTGTAGGTCCATC
AACAGCTGCTCCAGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGTGCTTCCGCTGTAGAGC
TTGAAGTGGAGCTTGAAGTGGGTGCGCTGTTGACAAGGAGCACAAGTGTCAATGTGACACAGGATGCGAG
CTGCATGCTGTACATGCCTGCAGGACTTGAGGTCACTGTGAGGAGTGATTAGCAAGGGTGAT

Protein Sequence : Show Sequence

>gi|7110653|ref|NP_032392.1| interleukin-2 precursor [Mus musculus]
MYSMQLASCVTLTLVLLVNSAPTSSSTSSSTAEAQQQQQQQQQQQQHLEQLLMDLQELLSRMENYRNLKL
PRMLTFKFYLPKQATELKDLQCLEDELGPLRHVLDLTQSKSFQLEDAENFISNIRVTVVKLKGSDNTFEC
QFDDESATVVDFLRRWIAFCQSIISTSPQ

Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 , B. melitensis WR201 (16MΔpurEK) , Brucella recombinant SurA protein vaccine

15. Il4 (interleukin 4)

Gene Name : Il4 (interleukin 4)
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16189
NCBI Protein GI : 10946584
Locus Tag : RP23-188H3.4
Genbank Accession : NM_021283.1
Protein Accession : NM_021283.1
Taxonomy ID : 10090
Gene Strand (Orientation) : ?
Protein Name : IL-4, Interleukin 4

DNA Sequence : Show Sequence

>gi|10946583|ref|NM_021283.1| Mus musculus interleukin 4 (Il4), mRNA
GGATCCCCGGGCAGAGCTGGGGGGGGATTTGTTAGCATCTCTTGATAAACTTAATTGTCTCTCGTCACTG
ACGGCACAGAGCTATTGATGGGTCTCAACCCCCAGCTAGTTGTCATCCTGCTCTTCTTTCTCGAATGTAC
CAGGAGCCATATCCACGGATGCGACAAAAATCACTTGAGAGAGATCATCGGCATTTTGAACGAGGTCACA
GGAGAAGGGACGCCATGCACGGAGATGGATGTGCCAAACGTCCTCACAGCAACGAAGAACACCACAGAGA
GTGAGCTCGTCTGTAGGGCTTCCAAGGTGCTTCGCATATTTTATTTAAAACATGGGAAAACTCCATGCTT
GAAGAAGAACTCTAGTGTTCTCATGGAGCTGCAGAGACTCTTTCGGGCTTTTCGATGCCTGGATTCATCG
ATAAGCTGCACCATGAATGAGTCCAAGTCCACATCACTGAAAGACTTCCTGGAAAGCCTAAAGAGCATCA
TGCAAATGGATTACTCGTAGTACTGAGCCACCATGCTTTAACTTATGAATTTTTAATGGTTTTATTTTAA
TATTTATATATTTATAATTCATAAAATAAAATATTTGTATAATGT

Protein Sequence : Show Sequence

>gi|10946584|ref|NP_067258.1| interleukin 4 [Mus musculus]
MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCTEMDVPNVLTATKNTTESELVCR
ASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRAFRCLDSSISCTMNESKSTSLKDFLESLKSIMQMDYS

Molecule Role : Vaximmutor
Molecule Role Annotation : IL-4 plays an important role in Th2 immune response.
Related Vaccine(s): B. abortus DNA vaccine pcDNA-SOD , Brucella recombinant SurA protein vaccine

16. Il5

Gene Name : Il5
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16191
NCBI Protein GI : 6754336
Locus Tag : RP23-239O19.2
Genbank Accession : AC084392
Protein Accession : NP_034688
Taxonomy ID : 10090
Chromosome No : 11
Gene Starting Position : 53720793
Gene Ending Position : 53725102
Gene Strand (Orientation) : +
Protein Name : interleukin 5
Protein pI : 8.9
Protein Weight : 14616.09
Protein Length : 133
Protein Note : Also known as Il-5

DNA Sequence : Show Sequence

>gi|372099099:53720793-53725102 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
GCGCTCTTCCTTTGCTGAAGGCCAGCGCTGAAGACTTCAGAGTCATGAGAAGGATGCTTCTGCACTTGAG
TGTTCTGACTCTCAGCTGTGTCTGGGCCACTGCCATGGAGATTCCCATGAGCACAGTGGTGAAAGAGACC
TTGACACAGCTGTCCGCTCACCGAGCTCTGTTGACAAGCAATGAGGTAAAGTATAACTTATTCCTTCAGC
TTTGTTTTTAAGATCAGGACCTTGCTATACCGCTCTGACTGGCCTCAAACTTGCTATGTAGGGTAGGCTG
TCCTAACCCCTACCAGATCTCCTTACCTATGTCTCCCAAATACTAGGATTACAGACACATTACCTTGCCT
GACGCTATGGTTCTTCAGAATGCATAAATAGCTGCATTTGGCCTTTAATCCCAGAACTTGGGAGGCAGGG
TCAGGTGGATCTCTGTGAGTTCAAGGCCAGACTTGTCTACGTGGCCAGTTACAGGACAGCCAGAGCTAAA
GCAAGACCCTGATTCAAAATAATTTTTTTTCAAAACAAAAAAAAAAAACCCAAACCATTTGTGGCAATTC
ATTTCTAAACATAAAGATCTGCTTTAAATAGTGCAATTATGGCTTGTTCCCTTGCCTTCTTGCTCCCGTT
CTGTCCTCTTGTCCCACTCTCTCCCCATTCCACCCCCACCATGTGCTCATGGCCCGCATCTCTACTTCTC
TACTCTCTTTCTCTCCCTCTCCCCTCCTTCTTCCTTTCCCTCTCTCTCTCCCTCTTCTTCTCCTCCTCTC
TTTCTCTCTCTCTCCCTCTCTCTCTCTCTTTCTCTCTCTCTCTGCTTTTTTCTATCTCTACTACCCTCTC
AACTCCCCTCTCCATGCCCTGAATAAGCTCTATTCTATACTAAAAAAAAAAAGTGCAATTATGAATGTGT
TAGTGTTAATGCACAGGTGATAACCCTATCACCAGCAAGCATTGCATTAAAAAAGGCAACGGACTCTCTT
TAGGATGACCCTATGATGTTCTTTCCTTTGCAGACGATGAGGCTTCCTGTCCCTACTCATAAAAATGTAA
GTTATTCTTTACTGCCGTGCTTGCATGAGTAAGTCAGCTTCGCATACTAAGCTATAAGTCATCTGCATCT
AGCTTTCTGGTGTTGTGTGTGTCTGGGATGGGGACCTCTCTAGGTCTCAAGCTCCTGGGTTCAAGTGATT
CTCTTGCCTTGATAGAGCAGCTGGGACACAGGCCTGTGCCACCACACCCAGCAGAGCTTTTGATTTCAGT
TAAACTGTTTGACTTTCTTGGAAAAGAAAATTTATGTAGGTAGATATGAAAGTTTGTGCTTATAAATAAA
AAGAATATGAGAGTGGCAAATTATGTAATCCCAGTACTTGGGAGCCAAAGGCAGGGGTAGTCTGAGTCTA
GGGCCAGCTTAGATACATTGCCCTGTATGTATCAAAAGTAAATCCTATAAATAAATAAACAAAAACATTA
GAGGGCTGGAGATATAAGCTCTGTTGATAGATGGCCTAATATGCTGGGTTGACTCTTAGCACCCCATAAA
CTAAACATGGAAGTACCTGGCTGTAATCTCATGATGGTGAAATGGAGGCGGGAAGATCATAGGTTCAAGG
TCATCCTCAGCTACATTTTTGAGCTAGAGGCCAGCCTGGGCTATGAGACACGCAAAAACCACCAGCCAAT
TAATATTAGGAATGGCTTTGAGCTAGATCTGTTATGTAAGTGGCCAGCTGGAGCTGTCAGTCATACATCT
CACAGCCTCACAAGATTCTTTGCATGGCGAGAGGTCCTGCTGGGCTCCCTTTGGCTCTGTCCATGGCTCT
CTTCATCCTAGTGCCTCTCTTTGTTTTCCTTGTCTTATTTCTTACTGCTGAGGATCAAGCCCAGGGCCTT
CAGTGTGTGAAGTGAGCACTCTACCACTGAATTCCAGAGCCCGCCCACTCTAATGCCTTTCTGAAAGTAT
TAAGAGTTTAGGGTTATATATTCCTTTTGTTTATTTTATGTGTATGAGCATTTTGCCTGCATATATATAT
ATATATATATATATATATGTGTGTGTGTGTGTGTGTGTGTGTGTATATATATATGTATGTATGTATGTAT
GTATGTATGTATGTATATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTCCACGTATGTGTCTATGTG
TCTGGTGTTCCTGAAGGCTAAAAGAAGGGCATCAGATCACCTGGGGCTGGATATGCAGATGGTTGTGAGC
CAACCATCTGGATGCTGGGAACTGCATCAAGTGTTCTTAACCACTGAGCCATCTCTCCCGCTCAGAGGGT
TATATTCTTAGGTAATGATAGAAAGACATAAAAATATCATGAATGCCTTTATTAATAATTTCTAAACAGT
TTAATGAATATGACTATGTAGTGATATTGTATACATTTCAATATTATCTTATTCTAGCGTAAAGTACATT
ATTTAACTTTTTCTAAATAGAAGAAAATTCATCAGCCTAAATTTCAAAAGAAAATATTAATATGGGTGTG
GTACCACTCACCTTTAATCCAGATGGTTGTGAGCCACCACAAGGGTGCTGGTAACTGAACCCAGGTCCTC
TGGAAGAGGACCCAGTGATCTTAACCACTGAGCCATCTCCCCAGCCCCAATCCTAACTTTGGGTTCATTT
TTTTGAAATGATCTCATGTAGCACTAGCTGGCCTCAAACTCTATGTATCAGAGGCTGGCCTTCAACTCCT
GATCCTCTTACCTCAACTTCCTGAATGCTGGCATTACAGATAAGCACCATCACATCTTGTATTGTCTGGG
GTTTTTTATTGATGCATTTAAATTGCATGTATTTATTGCATATGGCATGATATTTCAAAATATGTGTACG
TTGTGGGCAGTCTGATCTATTTGCTTCTTGATAATCTTCTTTCAGCACCAGCTATGCATTGGAGAAATCT
TTCAGGGGCTAGACATACTGAAGAATCAAACTGTCCGTGGGGGTACTGTGGAAATGCTATTCCAAAACCT
GTCATTAATAAAGAAATACATTGACCGCCAAAAAGTAAGTTCCCCAGGGACCCTGTGAATCCGGCTGCAG
CTGGTTCTCCAGGAGCCAACCTGACAGTCTGTTCTTTTCACAGGAGAAGTGTGGCGAGGAGAGACGGAGG
ACGAGGCAGTTCCTGGATTACCTGCAAGAGTTCCTTGGTGTGATGAGTACAGAGTGGGCAATGGAAGGCT
GAGGCTGAGCTGCTCCATGGTGACAGGACTTCACAATTTAAGTTAAATTGTCAACAGATGCAAAAACCCC
ACAAAACTGTGCAAATGCAAGGGATACCATATGCTGTTTCCATTTATATTTATGTCCTGTAGTCAGTTAA
ACCTATCTATGTCCATATATGCAAAGTGTTTAACCTTTTTGTATACGCATAAAAGAAATTCCTGTAGCGC
AGGCTGGCCTCAAACTGGTAATGTAGCCAAGGATAACCTTGAATTTCTGATCCTCCTGCCTCCTCTTCCT
GAAGGCTGAGGTTACAGACATGCACCATTGCCACTAGTTCATGAAGTGCTGGAGATGGAACCCAAGGCTT
TGTGCATGTTACCAACTGAGTTATACTCCCTCCCCCTCATCCTCTTCGTTGCATCAGGGTCTCAAGTATT
CCAGGCTGACTTTGAACTCAGTGTGTAGCCAAGGGTGACCCTGAACTCTTGGTCCAGATGGACGCAGGAG
GATCACATACCCAACCTTAGCATCCTTTCTCCTAGCCCCTTTAGATAGATGATACTTAATGACTCTCTTG
CTGAGGGATGCCACACCGGGGCTTCCTGCTCCTATCTAACTTCAATTTAATACCCACTAGTCAATCTCTC
CTCAACTCCCTGCTACTCTCCCCAAACTCTAGTAAGCCCACTTCTATTTCTTGGGGAGAGAGAAGGTTGA
CTTTTCTTATGTCCTATGTATGAATCAGACTGTGCCATGACTGTGCCTCTGTGCCTGGAGCAGCTGGATT
TTGGAAAAGAAAAGGGACATCTCCTTGCAGTGTGAATGAGAGCCAGCCACATGCTGGGCCTTACTTCTCC
GTGTAACTGAACTTAAGAAGCAAAGTAAATACCACAACCTTACTACCCCATGCCAACAGAAAGCATAAAA
TGGTTGGGATGTTATTCAGGTATCAGGGTCACTGGAGAAGCCTCCCCCAGTTTACTCCAGGAAAAACAGA
TGTATGCTTTTATTTAATTCTGTAAGATGTTCATATTATTTATGATGGATTCAGTAAGTTAATATTTATT
ACAACGTATATAATATTCTAATAAAGCAGAAGGGACAACT

Protein Sequence : Show Sequence

>gi|6754336|ref|NP_034688.1| interleukin-5 precursor [Mus musculus]
MRRMLLHLSVLTLSCVWATAMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGL
DILKNQTVRGGTVEMLFQNLSLIKKYIDRQKEKCGEERRRTRQFLDYLQEFLGVMSTEWAMEG

Related Vaccine(s): B. abortus subunit vaccine using L7/L12 , Brucella recombinant SurA protein vaccine

17. SIGLEC10

Gene Name : SIGLEC 10
Sequence Strain (Species/Organism) : Homo sapiens
NCBI Gene ID : 89790
NCBI Protein GI : 283837876
Locus Tag : UNQ477/PRO940
Genbank Accession : ABBA01068274
Protein Accession : NP_001164627
Taxonomy ID : 9606
Chromosome No : 19
Gene Starting Position : 51410020
Gene Ending Position : 51417802
Gene Strand (Orientation) : -
Protein Name : transcript variant 7
Protein pI : 8.82
Protein Weight : 66342.77
Protein Length : 639
Protein Note : Also known as SLG2; PRO940; SIGLEC-10

DNA Sequence : Show Sequence

>gi|568815579:51410020-51417802 Homo sapiens chromosome 19, GRCh38 Primary Assembly
GTAAGGTGAAAGCAAGTTTATTAAGAAAGTAAAGGAACAAAAGAATGGCTACTCCATAGACAAGAGCAGC
GCCTAGAGCTGCTGGTTGCCCACTTTTATGGTTATTTCTTGCTTATTTGCTAAACAAGGGGTGGATTATT
CATTCCTCCCCCTTTTGGGACATATCGGGTAACTTCCTGATGTTGCCATGGCATTTGTAAACTGTCATGG
TGCTGTCAGGAGTGTAGCAGTGAGGACGACCAGAGGTCACTCTCGTGGCCAACTTGGTTTTGGTGGGATT
TGGTTGGCTTCTTTACTGCAATCTGTTTTATCAGCAAAGTCTTTATGACCTGTATCTTGTACGGACCTCC
TGTCTCATCCTGTGACTTAGAATGCCTCCACTGTCTGAGAATGCAGCCCAGTAGGTCTCAGCCTCATTTT
ATTCAGCTCCTATTCCAGATGGAGTTGCTCTGGTTTAAATGTCTGACAGCTGGGACTACAGGCACACACC
ACCAAGCCCAGCTATGTTTTGTATTTTTTGTAGAGATGGGGTTTCACCATGTTGCCCAGGCTGGTCTCGA
ACTCCTGGGCTCAAGCAATCCACCCACCTTAGCCTCCCAAAGTGCTGGGATTACAGACACCCAACCCATT
TGGAGGATTTTTTTTTTGAGATGGAGTCTCGCTTTGTTGCCCAGGCTGGCGTGCAATGGTGTGATCTTGG
CTCACTGCAACCTCCGTCTCCCAGGTTCAAGTGATTCTCCTGCCTCAGCTTCCCAAGTAGGTAGGATTAC
AGGCGCCTGCCACCATGCCCAGCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTCACCAAGTTGGCCAG
GCTGGTCTCGAACTCCCGACCTCAGGCGATCTGCCCACCTCAACCTCCCAAAGTGCTGGGATTACAGGCG
TGAGCCACTGTGCCCTGGCCAGATGTTTTTTTAAAAGAGAGAGAAAGAGAGAGAGAGAGAGAAAGAGAGA
GAGAGAGGGAGAGAAGGAAACTTTGCACTCTGTTATCTTCAACCTCTTACTCTACCTTCCTCCCTAGCCG
AAGTCCCAGTCCTAAAGCCTAAGAGACCCTCATTGGAACTTGACTTCTGCATAATCCGCCTGGGTGCCCT
TGGGCATCCGGGCCTCAGGCCTGGGTCTGACGCCTGGGAAGTTGAGCGTGGCATAATGGAGCTCCTCTTG
GCTCTCCTGGGATTCTGGGGCTTGAGTGGATGATTTGGGTTCTGGGAAACTGGGCAACTGATACTGCTTT
TTCTGGTTCTTCTTTGATTCTGGGGAGGGAGCACCTGGTGGAAGAGGGGTCCGAGGACTGTTTGGTGTGG
CTTTCTGATTCCGCTTCTGAGCCTGAGGGAAGAACCACCATCCTTCATTCATTCATTCAGCAAATATTTG
AGCACTTACCACGCGTCGGGCACTGATTTACAGCACAGAGTGAAACTAAGTCCCTGCCCTTGCCTTGCTG
AGCTTGCATTCCATCTTGGAAGGAGGAACAGACAATAATTAGCAAAAGTACAATGACTGGTAAGTGACAA
ATGCCATCAAGAAATTTGAGCACCTTTAGAAGGCAGCGAAAGGGAGGGTGGGATGACTGTTTAATAGGTC
ATCCAGGGAATTTCAAGACCGGCCTGGCCAACATAGCGAAACCCTGTCTCTACCACAAATACAAAAATTA
GCCGGGCGTGGTGACACATGCCTGTGGTCCCAGCTACTCAGGAGGCTGAGGCAGGAAAATCACTTGAACC
TGAGAGGTGGAGGTTGTAGTGCGCTGAGACTGCGCCACTGCACTCCAGCCCGGACAACAGAGACAAAATC
TGTTTCAAAAAAATAATTGATAGCCGGGTACGGTGGTTCACACCTGTAATCCCAGCACTTTGGGAGGCTG
AGGCGGGTGGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGATCAACATGGTGAAACCCCGTCTCTAC
TAAAAATACAAAAATTAGGGGGGCATGGTGGTGGATGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCA
GATGAATCGCTTGAACCAGGAGGTGGAGGTTGCAGTGAGCCGAGACCTTGCCACTGCACTCCAGCCTAGA
CAACAACAGTGAAATCCCATCTCAAAAAATAAAATAAAATAAAAATAAATAAAATAAAGAATAGCATGCA
TGCACGGAGAGAAAGACTGGAGGGGGTGAGAACGGAAGCAGAGAAGGCATGCAGAAGGGGCCAGTGGTGC
CCGGGGTGGGGTGGGGGGTGTTGATGCATGGCTTGTAGTAGTGAGGGAAGAGTAGGGAGAACTGGCTTGG
TTGTATTTTGAAGGGAATTTGCTGATGGATTGGTTGTGGGGTGACAGAGAAGAGAGGAGTGAAATATGAT
TCTAAAGCTTTAGACTTGGCTGGGAAAATGTGGTGTTATTTGCTAAGATGGGGATAGAGATGGAGCATAA
ATGGTGGAATTAGTCTTTTTTTTTTTTTAGATGAAGTTTCGCTCTTGTTGCCCAGGCTGGAGTGCAGTGG
CATGATCTCACTGCAACCTCCACCTCCTGGGTTCAAGTAATTCTCCTGCCTCAGCCTCCCGAGTAGCTGT
GATTACAGGCACCCATCACCATGCCCAGGTAATTTTTTGTATGTTTAGTAGAGATGGGGTTTCACCATGT
TGAACACGCTGCTCTTAAAATTTTGACCTCAGGCGATCCACCCACCTCGGCCTCCCAAAGTGCTGGGATT
ACAGGTGTGAGCCAGCAGGCGTGGCCTTTTTTTTTTTGAGACAGGGTCTCACTCTGTCACCCAGGCTGGA
GTGCATGGTGTCATCATGGCTCACTGTAGCCTCCAACTCCCAGGCTCAAGAGATCCTCCCACCTCAGCCT
CCCAAGTAGCTGGGACAATGGGCATGCACCACCACACCCGGCTAATTTTTTATTTTTTTTGTAGAGAAGA
GGTCTCACTATGTTGCTCAGGCTGGGGAATTATCTTAAGTTGGTTTTGGACAGGCTAAGTTTGAAGTGCT
GATTAGACACCCACATGGAGATGTTGCATAGACAGTCTTCAGGGAAGGAGCCACGAGATACAATTTTGCA
GTCATCAGCATAAGATGTTATCTCTTAATAATTTCCAGAATTTACAGAGTATTACCCAGGGGCCAGGTGA
TATTCTGAATATTTTATTATGCAAGTACAATATATTTAACACCCAGCATCATCCTAGGAGGTGGCCGCTA
GTATTGTCTCCATGTTACAGCTAAAGAAATTGAGGCACAGAGAAGTTAAGACACTTGTTTCATGACACAG
TGATGACAGCAGGATTTGAACCCATGCAGGCTGATTTCAGACCCCCTGTGCTGAATCCCTAGGATGCCCA
GCCTCCCGATGATACACATAATTGTTAAGCAGTTAAGTGTAGTCATGTCAATGGTGGCAGTAATAATGGA
ACAATGGCTACAGATTGAGAAAGTGCATGTATTCTAATCCTCAAACCAACTCTCAAAGGAGACAGAGGAA
GAAATGAAGGCTCAGAGGGGGTGAGTGACGTGGCTGAGGTCTCATAGCTAGTAAGTGCCAGGCAGGATTT
GAATTCAGAACTATCGGTGCTTTTCCCACCTTGATGTCGCTAAGACAAGGGGTGCAAAAGTCAGAAAGTG
GGATGTCAGCTTTAGAGAAGAGAAAAAGTGGAAGCATGGCCCAGACACTCACCAGGGGGCCAGCCGTCGG
GACCACATTGATGTAATCCAGGATCGTGCTGTGCCGGGAGAACCTGGGCCTCGGGGTTTCTGTCTGAGTC
CGTCTCTTCGGTAGAATCTTCATGCTGAGGAAATGAACCCACCTGTTTGTGCCCTGCTGCACCTCCCTGT
GACAGACTGCCACGTTTACTACCTGAGACCGTCACTATGACAGTTACTACTGTTACCACTTGAGACCGTC
ATTATGAGACTGAAAGAAGGAGGACAAACGTAGAAATGAAAACTTAAGACAAAAGAAATTATTTTAAAGG
AAGGGGTCAGGGGAAGAAGAAGAGGGTTCCCTGCTACTAGTGAGCCAGGGCAGCTGTCTGAGCCTCTACA
GCCCTTTGTATTTATTGGGTAGAAAGAGCAGAGAGCAGGAGGTAACAATTGGTCAGCTGTTTAATTGATC
ACAGGTTCATATTATTACTAACAAGCTTCAGCTGTGCCTAATTACAAGAAACACTTCGCTTGGGGCGTGA
CTGCCCTCAGCATTCCCTCTGGGAAGCAGACGCAGTTTGTCAGTTGGACAACATTCTGCATTTATGAGAA
CAGTTTGCTGTTTACTCATGTAACCTCCAGAGGTATACTGCGTTGATCACGACCTTCACTCTTTCGGCCT
GCAACACCTCCCCTCTTCCTGGGTCCAGGCCCCAGACCCCGCCACGCCTCCTCTTAACCTACATGATCAG
GGCCAGGCAGAGGAAAAGAAGAGCCGTGATGCCGATTCCCAGAAACGCTCCGTTGGAGAATGCCGTTGAG
ATGAGTCCCTTCTTATCTGCACACGGAGAGGGCAAGGTGAGCATTTCCCATCCACGCAGGGCTCACGAAG
CCCGCTCATCACTCGGCATTAAGGCTTCCGGTTCCCATGGCGGACATTGTATCTGCAACCCCTCTGTTTA
CTTTTAGGAAACCCTGCCACACCCCGGCCCAGGTGTTAGGACTTCCCATTGTGTTTTCCTGTCTACATAC
AGATGCCACGGGTCTGCTGTGTCCCTCCAAGCTCCTGCTCCAACCACAGGACCCTACTCTTTGCCCCAGT
CAGCTTCTCCTCCAAGAACCTTGGCATCCAGGCGGCCCCCTAACCTGGCAGCTGCAGGATGGATCCACTC
TGGGCCCCATGGACGTTCCAGGCCTCACAGCGGAGCCTGAGGCCGGAGCTGAGCCCTCCATGGAGGCTCA
GGGAGCTGTTGGCCCAGGGCCCGGCTGAGCTGGGGGTGACCTCGAAGGAGTCCTGGCTGCTGTTCCCCTC
CAGCAGCTCCTCCCCAAGCCACCAGCGCAGAGAGGGGGCCGGGCTGGCCTGGGAGGAGCAGCTGCAGTGC
AGACCCTCAGCCTCCCAGGAGCAGGAGGGGCCCAGCAGCTTCGGGGAGTCTGAGGGGAGGGAGGACAGGA
CTCAGCAGGGTCCCCTTCCTGGGACCCAGGTGTCCCCTTTCCCCCACTCACAGTGCACGGAGAGGCTGAG
AGAGACGTGCTGGGAGCCCAGTGGGTGCCGAGCGTGGCAGGTGAACTCTCCTTCGTGCTCCACTTGAACC
CGAGGCAGCTCCAGGACCCCGGGGTCTGAGGGCTGGGAGGGGCTCAGAACCTGTCCCCTCTGGGTCCAGC
TCAGCCTGGCTGGGGGGCTGCTGTGTGTGACACAGACCAGGCACAGGCTTTGGCCCTCCAGTACTGGGAG
AGACGTGCCGTTCCCAAGGTTTTCCAGGACTAGGGAAGGAAGAGGCAGAATCGATGAGCAGCTCAGGGCT
CAGGGACCCTCCTGCGTGGGGACCCTCCAGACTCCTGGGCCCCCAATTCGGCACTGAGAGGCCTTGGCTC
CTCTGTCCCCTTTCCTACCTGTCCTGTTTGCTTGGGAAACCATCACTCTCAGGTTCTCTGGAGGATCTGA
AATGGAGACAGGGGACCGGCTCTAGACGGACCAGGGGCTTCCCTCTGGGTAAAGGGAACCATCCTGGACA
CTGAGGTGGGGGAAGTGGGTGGGATAGAAGGGCAGGGCAGAATCACCCACTGAGTCCCAGACACAAACTG
CATGAGGGTCTACACAGGTAAGAAGGTCGGTCTCCGAGGCCTGGGGCTCCAGGCCCCCTCAGCTCTGGGA
CCCTGAGCCCAGCCCCTGTATCCCTCTGCCCTCCCAATGGACTCCAGGCCCCTGCTGGGCACACTCACAC
TGCACAGAGAGGTCCAGGGCTCGCTGCTGGGAGCCAAGCCTGTTCTCCGCTCGGCAGGTGTAGCGCCCTG
AATCCCCAGCCTTCACCCCGGGCAGCTCCAGCCCCAGGGGTCTAGGGCCCCAGGGATGGGACGAGGAGAG
GACTCTGTTCTGCAGGACCCAGCTCAGTGTGGCAGGGGGCTGGCTGTCAGCAGCACAGAGGAGCCGCAGG
AACTGGCCTTTTTGGGCTTCCAGGTATGGGACATTTCCCTGGGGCTGGGGCTCCAGGGCTGGAGTGGGAG
GAAAAAAAAAAAAGAGAGAAAGGGAGGGAGAAAGAGAGAAGGGGTACAGGGAGGAGCACATCCCCTCATC
CCCTGAAGCCTTTTCATCTAAAGACAACTGGCCCAGCCCCAGCCCGACGGCCCTCAGTACCTGGCGTGTT
GTCACGTGAAATGCTGATAACAAGGTCTCTGGGGGCATCTGCAACAAGATTGTGAGCTGGCTTCAGGGAG
GGACAATTTATTCCTCACACCTGGAAAAAACTCCCTCAGGGAAAAGAAAGTGGGACTATCCCGGGAAGAC
AAGTGACAACCAGCGCCAGGGCTCACGTGTGTGGACCAGACGCCATTCCCATCCCCCTCCCAGGGCTGCG
GCGGCATCCTGGGACCCCACAGCTTCCTCTCCCTGGATGCTCCTGAGCTGGGAGCCGCTCACTGTCCCAC
TGGGCTCCTCCACCTCCCCACCCACCGGGGCTGTCTGCACACCCCACCCTCCCAGGCCACACTCACAGGC
CACACGGAGTCGGACGGTCCTCTGTGCGCTCACACCCTTTCTGGAGAAGTCCACATGGCAGGTGAGGTCG
GTGTTGTGGTCCTGGGGTCTGGGCGTGAAGCTGAGCACTGAGAAGTGGGAGGTCGTTGGTTTGGTTCCTT
GGGAGGAGAGGGCAGCCCCCGTCCAGGAGAAAGAAGGGGGTGGACATTCCTCAAAGGCCCAGTTAAACAC
ACAGATGACCGTCACCGGCTGCCCGGGCTCCAGGGTCTCGGGGATGTAGACATCAGGCTTCTGAGTCAGG
GCTGGGACAGAGACCGTGGTGGGAGATTCTTGTGCTGCAGGGGTCCCTGAGAGCCCTCTCTGCTCAGCCC
ATAGGCTGTCCCCAGGGTCCCTCCCCAGTGTGAGAGGCAGGGGTTCCCACCCCATTCCATACCTGTTACT
TTTAGAAAGAACCCATCGTTCATGAAATTATATCTCACATAGCTTCCTCTCTCCACCCGAAAGAAGTACT
GTGACTCATCCTGCATCTGCGCGTCTCTGATCACCAAGGAGCAGTTCCCCTTGGCGGGATCCCCAGTGAG
CTGGAATCGGCCCCGGGTGCTCATTTCCACCTCTCGACTCTGGTGGTTTGTGGCCACAGGAGCACCCTTG
GTTGTCTCAGTCACTGCTTTGAACCAGTAGCCATAAGCTGGGGTAGACCCTGTCCAGTCCTGTCGGGGGT
AGGAGAAAGAGCAGGGCACAGAGATGCACAGGCCCTCCGGCACCATCACTGACTCCTGCACTCGTATCCA
GAATCTCCCATCCATAGCCTGGGACCCTGTGGGGAGACAGAGGCTCAACCTGCAACCCCAGCCCTAGCTC
CGCCCCAGGTCCTTTCCGGCCCTTGGCCCACTCACCGCCCAGCAGCGAGGACAGCAGCAGTGGCAGTAGC
ATCTCCGCATAGGAGGCGCAGGGCCTGCCTGAGACAGGCCTGTTCTCTGGTCGTGCTGTGAGTGGCTCAG
GGCTCTTGGCAGAAGGGGAAGCCGAAGGCGGAAGCTGAGCCCTGGGGCCTGATGCATGAAATGAGCTTCA
GACGCTGAGCTCACAGAACTCCTTTGCCTTCCCCCACACTCTCCGGCCCACCTTGCCCAGTTGTCCTCTG
GGTCTCCTGGGGG

Protein Sequence : Show Sequence

>gi|283837876|ref|NP_001164627.1| sialic acid-binding Ig-like lectin 10 isoform 2 precursor [Homo sapiens]
MLLPLLLSSLLGGSQAMDGRFWIRVQESVMVPEGLCISVPCSFSYPRQDWTGSTPAYGYWFKAVTETTKG
APVATNHQSREVEMSTRGRFQLTGDPAKGNCSLVIRDAQMQDESQYFFRVERGSYVRYNFMNDGFFLKVT
VLSFTPRPQDHNTDLTCHVDFSRKGVSAQRTVRLRVAYAPRDLVISISRDNTPALEPQPQGNVPYLEAQK
GQFLRLLCAADSQPPATLSWVLQNRVLSSSHPWGPRPLGLELPGVKAGDSGRYTCRAENRLGSQQRALDL
SVQYPPENLRVMVSQANRTVLENLGNGTSLPVLEGQSLCLVCVTHSSPPARLSWTQRGQVLSPSQPSDPG
VLELPRVQVEHEGEFTCHARHPLGSQHVSLSLSVHYSPKLLGPSCSWEAEGLHCSCSSQASPAPSLRWWL
GEELLEGNSSQDSFEVTPSSAGPWANSSLSLHGGLSSGLRLRCEAWNVHGAQSGSILQLPDKKGLISTAF
SNGAFLGIGITALLFLCLALIIMKILPKRRTQTETPRPRFSRHSTILDYINVVPTAGPLAQKRNQKATPN
SPRTPLPPGAPSPESKKNQKKQYQLPSFPEPKSSTQAPESQESQEELHYATLNFPGVRPRPEARMPKGTQ
ADYAEVKFQ

Molecule Role : Vaximmutor
Related Vaccine(s): B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA

18. TLR10

Gene Name : TLR10
Sequence Strain (Species/Organism) : Ovis aries
NCBI Gene ID : 554255
NCBI Protein GI : 209693400
Protein Accession : NP_001129397
Taxonomy ID : 9940
Gene Strand (Orientation) : ?
Protein Name : toll-like receptor 10
Protein pI : 6.7
Protein Weight : 85284.46
Protein Length : 776

Protein Sequence : Show Sequence

>gi|209693400|ref|NP_001129397.1| toll-like receptor 10 [Ovis aries]
MSLRKVPEDLTPITTTLDLSYNLLSQLQHSDFRSLSKLKVLILCHNRIQELDIKTFEFNKELRYLDVSNN
RLKRVAWFSLAGLRHLDLSFNDFDTVPICVETGYVSHLETLGLSGAKIQKSDFQKIAHLHLNTVFLGLRT
LSHYEEGSLPILNTTKLHIVLPVNTNFWVLLHDGIKTSKILEVTNIDLQKSQFTSYGSQQNPILENAKTS
ILLLNKVDLSWDDLFLIFQLVWHTSVEYFQIQHVTFGGKVYLDHNSFDYSNTVMRTIKLEHVHFRIFNIP
QESVYLLFTKMDVENLTISDAQMPHMLFPMYPTRFQYLNFANNILTDDVFKKSIQLPHLKTLILKDNKLE
TLSLVSYFASNTSLRHLDLSENLLQHENDENCLWPETLVTMNLSFNKFADSVFRCLPRNIQILDLNSNKI
QTVPKEITHLTSLRELNLAFNFLTDLPGCSHFRRLLVLNVEMNLILSSSLDFFQSCQEVKTLNAGRNPFR
CTCELRDFIQLGKYSEGMMVGWSDSYICEYPSNLKGTQLKDVHLPEISCNTGLLIVTIVVIMLVLGVAVA
FCCLHFDLPWYLRMLCQWTQTWLRVRKTTQEQLKRSVQFHVFISYSEHDSAWVKYELIPSLEKEDGSVLI
CLHEGNSDPGQSMTEDTINCIEKSYKSIFVLSPSFVQTEWCHYEPYFAHRNLFHESLDYIILILLEPIPL
YCIPTRYPKLKALMEKKAYLEWPQDRRKCGLFWANLRAALHVNLLDTTGTCELQTFAELNEVFRGSAVSL
IRTDCL

Molecule Role : Vaximmutor
Related Vaccine(s): B. melitensis vaccine strain Rev. 1

IV. Vaccine Information

1. B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA

a. Type:

Aerosal Vaccine

b. Antigen

The vaccines tested in this study include B. abortus unmarked mutants BAΔasp24, BAΔvirB2, and BAΔmanBA, and B. melitensis unmarked mutants BMΔasp24, BMΔvirB2, and BMΔmanBA (Kahl-McDonagh et al., 2007).

c. Gene Engineering of asp24

Type: Gene mutation
Description: This asp24 mutant is from Brucella abortus (Kahl-McDonagh et al., 2007).
Detailed Gene Information: Click here.

d. Gene Engineering of virB2

Type: Gene mutation
Description: This virB2 mutant is from Brucella melitensis (Kahl-McDonagh et al., 2007).
Detailed Gene Information: Click here.

e. Gene Engineering of manA

Type: Gene mutation
Description: This manBA mutant is from Brucella melitensis (Kahl-McDonagh et al., 2007).
Detailed Gene Information: Click here.

f. Gene Engineering of manB

Type: Gene mutation
Description: This manBA mutant is from Brucella melitensis (Kahl-McDonagh et al., 2007).
Detailed Gene Information: Click here.

g. Preparation

Each vaccine consisted of 5 × 10^7 CFU/ml in a chamber nebulizer, which is thousands of organisms per dose. The bacteria were introduced in Farrell's medium: TSA supplemented with 5 mg/liter nalidixic acid, 25,000 IU/liter bacitracin, 100 mg/liter cycloheximide, 5000 IU/liter polymyxin B sulfate, 20 mg/liter vancomycin, 100,000 IU/liter nystatin 10% (vol/vol) horse serum, and 2% (wt./vol.) dextrose (Kahl-McDonagh et al., 2007).

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Groups of four or five female 6- to 8-week-old BALB/c mice were vaccinated via i.p. injection of 1 × 10^6 CFU/ml of unmarked deletion mutant or PBS for naïve controls (Kahl-McDonagh et al., 2007).
Persistence: Mice receiving a dose of 5 × 10^7 CFU/ml had lung colonization with B. abortus strain 2308 that gradually increased over the first 4 weeks postchallenge, then gradually decreased over the following 4 weeks to 90% of the maximum value. Despite this slight decrease, colonization by the organism in the other tissues was consistent with a chronic infection. Colonization of the liver, although barely detectable at 1 week postchallenge, steadily increased over the first 4 weeks postchallenge and then declined negligibly between weeks 4 and 8. The spleens of infected mice displayed a colonization pattern similar to that of the livers, although the total number of CFU recovered was consistently higher. Spleen colonization increased between weeks 4 and 8, consistent with a persistent infection (Kahl-McDonagh et al., 2007).
Side Effects: Mice receiving a dose of 5 × 10^7 CFU/ml had lung colonization with 2308 that gradually increased over the first 4 weeks postchallenge, then gradually decreased over the following 4 weeks to 90% of the maximum value. Despite this slight decrease, colonization by the organism in the other tissues was consistent with a chronic infection. Colonization of the liver, although barely detectable at 1 week postchallenge, steadily increased over the first 4 weeks postchallenge and then declined negligibly between weeks 4 and 8. The spleens of infected mice displayed a colonization pattern similar to that of the livers, although the total number of CFU recovered was consistently higher. Spleen colonization increased between weeks 4 and 8, consistent with a persistent infection (Kahl-McDonagh et al., 2007).
Challenge Protocol: BALB/c mice were challenged with an aerosol chamber dose of 5 × 10^9 CFU/ml of the homologous wild-type strain at 20 weeks postvaccination. Four weeks after the virulent challenge (corresponding to 24 weeks postvaccination), the mice were euthanized and the recovery of the challenge orgainsm was measured (Kahl-McDonagh et al., 2007).
Efficacy: The bacterial burden in the spleen following aerosol challenge was reduced 2.02 U by vaccination with BAΔasp24 and by 0.86 U by vaccination with BAΔvirB2 relative to the burden in naïve mice. The rough BAΔmanBA mutant was unable to elicit significant protective immunity relative to the immunity of naïve mice. At 24 weeks postvaccination, less protection was observed in the lungs of mice vaccinated with BAΔasp24 and BAΔvirB2, although the protection was significantly greater than that observed for naïve controls. The rough mutant, BAΔmanBA, protected mouse lungs to a lesser degree, which was not significant(Kahl-McDonagh et al., 2007) .

2. B. abortus DNA vaccine encoding RplL and Omp16

a. Vaccine Ontology ID:

VO_0011380

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

B. abortus ribosomal protein rplL and outer membrane lipoprotein 16

e. Gene Engineering of RplL

Type: DNA vaccine construction
Description: Full-length open reading frames of the L7/L12 gene and Omp16 gene were amplified with PCR from the genome of attenuated B. abortus strain RB51. The gene amplified with L7/L12 primers (FL and RL-1) and the gene amplified with Omp16 primers (FO and RO) were inserted into pcDNA3.1(+) vector (Invitrogen) at the EcoRV/XhoI and BamHI/XhoI sites to construct recombinant plasmids L7/L12-pcDNA3.1 and Omp16-pcDNA3.1, respectively. To construct the recombinant fusion plasmid L7/L12-Omp16-pcDNA3.1, the L7/L16 gene fragment was amplified with the L7/L16 PCR primers (FL and RL-2) first, which removed only the TAA stop codon from the L7/L16 gene. This PCR product and the amplified Omp16 gene above were digested with EcoRV/BamHI and BamHI/XhoI, respectively, and ligated with T4 ligase; the ligated product was then inserted into the pcDNA3.1(+) vector between the EcoRV and XhoI sites (Luo et al., 2006b).
Detailed Gene Information: Click here.

f. Gene Engineering of Omp16

Type: DNA vaccine construction
Description: Full-length open reading frames of the L7/L12 gene and Omp16 gene were amplified with PCR from the genome of attenuated B. abortus strain RB51. The PCR primers were designed as shown in Table 1. The gene amplified with L7/L12 primers (FL and RL-1) and the gene amplified with Omp16 primers (FO and RO) were inserted into pcDNA3.1(+) vector (Invitrogen) at the EcoRV/XhoI and BamHI/XhoI sites to construct recombinant plasmids L7/L12-pcDNA3.1 and Omp16-pcDNA3.1, respectively. To construct the recombinant fusion plasmid L7/L12-Omp16-pcDNA3.1, the L7/L16 gene fragment was amplified with the L7/L16 PCR primers (FL and RL-2) first, which removed only the TAA stop codon from the L7/L16 gene. This PCR product and the amplified Omp16 gene above were digested with EcoRV/BamHI and BamHI/XhoI, respectively, and ligated with T4 ligase; the ligated product was then inserted into the pcDNA3.1(+) vector between the EcoRV and XhoI sites (Luo et al., 2006b).
Detailed Gene Information: Click here.

g. Vector:

Expression vector pcDNA3.1

h. Immunization Route

Intramuscular injection (i.m.)

i. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: The mice were anesthetized with methoxyflurane (Metofan; Mallinckrodt) and inoculated intramuscularly with 100 μg of pcDNA3.1-L7/L12-Omp16, pcDNA3.1-L7/L12, or pcDNA3.1-Omp16 in 100 μl of PBS (50 μl of the solution was injected into each tibialis anterior muscle). The control mice were infected with PBS or the expression vector alone (pcDNA3.1). Each mouse in another group was injected with 10 μg of rL7/L12-Omp16 in 100 μl PBS according to the same schedule. Each mouse was injected on weeks 0, 2, and 4. The mice used as positive controls were inoculated intraperitoneally on day 0 with 2× 10^8 CFU of B. abortus strain RB51 in 0.2 ml of PBS (Luo et al., 2006b).
Challenge Protocol: Two weeks after the final vaccination, five mice from each group were challenged intraperitoneally with relatively higher dose of strain 544 (5 × 10^5 CFU). Four weeks postchallenge, the mice were killed by cervical dislocation, and their spleens were removed aseptically and weighed (Luo et al., 2006b).
Efficacy: This divalent DNA vaccine induced a significant level of protection against challenge with the virulent B. abortus in BALB/c mice (Luo et al., 2006b).
Host Gene Response of Ighg1
- Gene Response: Sera collected 2 weeks after the last immunization were assayed for the presence of L7/L12- and/or Omp16-specific antibodies by ELISA. The pcDNA 3.1-L7/L12-OMP16 vaccine elicited significantly higher levels of IgG1 antibodies than did the negative control vaccine, pcDNA 3.1 (Luo et al., 2006b).
- Detailed Gene Information: Click here.
Host Gene Response of Ighv1-9
- Gene Response: Sera collected 2 weeks after the last immunization were assayed for the presence of L7/L12- and/or Omp16-specific antibodies by ELISA. The pcDNA 3.1-L7/L12-OMP16 vaccine elicited significantly higher levels of IgG2a antibodies than did the negative control vaccine, pcDNA 3.1 (Luo et al., 2006b).
- Detailed Gene Information: Click here.

3. B. abortus DNA vaccine expressing BCSP31, SOD and L7/L12

a. Vaccine Ontology ID:

VO_0000321

b. Type:

DNA vaccine

c. Antigen

B. abortus BCSP31, SOD, and L7/L12 (Yu et al., 2007).

d. Gene Engineering of SodC from B. abortus strain 2308

Type: DNA vaccine construction
Description: The DNA vaccine comprising genes encoding the antigens BCSP31, superoxide dismutase (SOD), and L7/L12 was constructed and evaluated for its immunogenicity and protective efficacy (Yu et al., 2007).
Detailed Gene Information: Click here.

e. Gene Engineering of B. abortus strain 19 L7/L12

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of BCSP31

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Vector:

pJW4303 (Yu et al., 2007)

h. Preparation

The coding regions for the antigens BCSP31, SOD, and L7/L12 were amplified from B. abortus strain 2308 chromosomal DNA. GenBank accession numbers for the sequences reported in this study are M20404 for BCSP31, L19101 for L7/L12, and AE017334 for SOD. All antigen-coding regions were fused individually to the tissue plasminogen activator signal sequences, and the DNA constructs were purified using the Qiagen Mega plasmid DNA kit (Qiagen, Valencia, CA) and verified by commercial DNA sequencing. The DNA vaccine was diluted in saline solution to a final concentration of 1–2 mg/mL before use (Yu et al., 2007).

i. Virulence

None

j. Description

Vaccine combines three known antigens, BCSP31, SOD, and L7/L12, in a single DNA vaccine.

k. Mouse Response

Vaccination Protocol: Plasmids carrying BCSP31, SOD, and L7/L12 genes were administered by intramuscular injection of 150 ug DNA (50 ug of each plasmid) in 150 uL saline solution into each of the quadriceps. For the vector control group, 150 mg pJW4303 empty vector DNA in 150 mL saline was used for injection. As an additional negative control, mice were injected with 150 mL saline. Immunization of mice was repeated thrice at 3-week intervals. The positive control group of mice was vaccinated intraperitoneally with 5x10^6 colony-forming units (CFU) of B. abortus
Immune Response: Mice vaccinated with the combined DNA produced a rapid and specific IgG response 3 weeks after the initial vaccination, and peak titers were detected 3 weeks after the last immunization. The S19-vaccinated mice also induced antibody production, but the rise was not as pronounced. Combined DNA–vaccinated mice had significantly higher BCSP31-, SOD-, L7/L12-, and Brucella-specific total IgG production than S19-vaccinated mice. Combined DNA–vaccinated mice produced significantly higher levels of IFN-g and TNF-a ( p < 0.01) compared with the two negative control groups. A significant T cell response was observed after incubating spleen cells from combined DNA–vaccinated mice with the specific antigens rBCSP31, rSOD, rL7/L12, and heat-killed B. abortus (Yu et al., 2007).
Challenge Protocol: Mice were challenged intravenously with 5x10^6 CFU (Yu et al., 2007).
Efficacy: The levels of infection were evaluated by measuring CFU in the spleen. The combined DNA–vaccinated mice displayed a significantly higher level of protection than mice vaccinated with vector DNA or saline (3.58 log units higher; p < 0.001; n=10). In addition, our vaccine provided significantly higher protection than S19 (log units=2.87 for S19; p=0.034); that is, after infection, the number of CFU in the spleen of the combined DNA vaccine group was reduced to less than 20% of that in the S19 group. Indicating that the combined DNA vaccine affords a significant degree of protection against Brucella infection (Yu et al., 2007).

4. B. abortus DNA vaccine pcDNA-SOD

a. Vaccine Ontology ID:

VO_0000018

b. Type:

DNA vaccine

c. Antigen

B. abortus Cu/Zn Superoxide dismutase (Munoz-Montesino et al., 2004).

d. Gene Engineering of SodC from B. abortus strain 2308

Type: DNA vaccine preparation
Description: B. abortus sodC was subcloned into the expression vector pcDNA3 (Munoz-Montesino et al., 2004).
Detailed Gene Information: Click here.

e. Vector:

pcDNA3 (Munoz-Montesino et al., 2004)

f. Preparation

Recombinant plasmid pBAII-3, containing the gene for B. abortus Cu-Zn SOD (sodC), and its own promoter, was initially obtained from a pUC9 genomic library of B. abortus strain 2308. A 1.1-kb fragment containing the sodC gene and its promoter sequences was excised and ligated into the expression vector pcDNA3 downstream of the cytomegalovirus promoter. The resulting plasmid was designated pcDNA-SOD. A colony of E. coli containing pcDNASOD was cultured and used for large-scale plasmid DNA isolation. The DNA was resuspended in PBS at a final concentration of 1 mg/ml. The pcDNA-SOD plasmid construct was verified by restriction digestion and by sequencing of the complete insert (Munoz-Montesino et al., 2004).

g. Description

Cu-Zn superoxide dismutase (SOD) is one of the protective immunogens of Brucella abortus. Intramuscular injection with a plasmid DNA carrying the SOD gene (pcDNA-SOD) was able to induce a protective immune response in mice (Munoz-Montesino et al., 2004).

h. Mouse Response

Host Strain: BALB/c mice
Vaccination Protocol: Mice premedicated with atropine (16 µg/mouse) were anesthetized with ketamine (2 µg/mouse), their abdominal regions shaved. One 3-mm-long incision was made through the skin. The mice were injected in the spleen with 10 µg of plasmid DNA in 30 µl of PBS. Mice were injected i.m. in the right tibialis anterior muscle with 10 µg of plasmid DNA per mouse. The mice were vaccinated once with pcDNA-SOD construct or with pcDNA3 as a negative control. For protection assays, an additional group was inoculated with PBS as a negative control (Munoz-Montesino et al., 2004).
Immune Response: Animals vaccinated with pcDNA-SOD did not develop SOD-specific antibodies, at least until week 4 after immunization (the end of the experiment), and in vitro stimulation of their splenocytes with either recombinant Cu-Zn SOD or crude Brucella protein induced the secretion of gamma interferon (IFN-γ), but not interleukin-4, and elicited the induction of cytotoxic-T-lymphocyte activity. Upon analyzing the SOD-specific T-cell responses, the pcDNA-SOD vaccination was found to be stimulating both CD4+- and CD8+-T-cell populations. However, only the CD4+ population was able to produce IFN-γ and only the CD8+ population was able to induce cytotoxic activity (Munoz-Montesino et al., 2004).
Challenge Protocol: Four weeks after vaccination, six mice from each group were challenged by intraperitoneal injection of 10^4 CFU of B. abortus 2308. Two weeks later, the infected mice were sacrificed, their spleens homogenized, and dilutions of the extract were plated to determine the number of Brucella CFU per spleen (Munoz-Montesino et al., 2004).
Efficacy: Immunization (i.s.) with pcDNA-SOD induced a significant degree of protection (1.52-log-unit increase in protection) compared to the control group (P < 0.008). The mice that were immunized (i.m.) with pcDNA-SOD showed minimal protection, (P < 0.2). No significant difference was seen between the CFU numbers in control groups injected with pcDNA3 and PBS. Vaccination with pcDNA-SOD vaccination (i.s.) therefore provided a significant degree of protection against Brucella infection (Munoz-Montesino et al., 2004).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: pcDNA-SOD induced Cu-Zn SOD specific IFN-γ production from CD4+ but not CD8+ T cells from in pcDNA-SOD immunized mice (Munoz-Montesino et al., 2004).
- Detailed Gene Information: Click here.
Host Gene Response of Il4 (interleukin 4)
- Gene Response: pcDNA-SOD did not induce interleukin-4 production in immunized mice (Munoz-Montesino et al., 2004).
- Detailed Gene Information: Click here.

5. B. abortus DNA vaccine pcDNA3-SOD encoding Cu-Zn SOD

a. Vaccine Ontology ID:

VO_0004393

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of SodC from B. abortus strain 2308

Type: DNA vaccine construction
Description: Vector pcDNA3 expressed Cu-Zn SOD (Onate et al., 2003).
Detailed Gene Information: Click here.

f. Vector:

pcDNA3 (Onate et al., 2003)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Vaccination was able to induce a broad range of immune responses including antibody production, CD8+ cytotoxic T cells (CTLs), and CD4+ T helper cell activation (Onate et al., 2003).
Efficacy: Immunization with pcDNA-SOD resulted in a significantly higher degree of protection (2.16 log increase in protection) compared to the unimmunized control groups (P < 0.0005). The level of protection was similar to the one induced by B. abortus vaccine strain RB51. Thus, pcDNA-SOD vaccine afforded a significant degree of protection against Brucella infection (Onate et al., 2003).

6. B. abortus DNA vaccine pcDNA3.1-p39-L7/L12 encoding p39-L7/L12 fusion protein

a. Vaccine Ontology ID:

VO_0004392

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Antigen

p39-L7/L12 fusion protein from RB51 (Luo et al., 2006a)

f. Gene Engineering of B. abortus strain 19 L7/L12

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of P39 from Brucella abortus

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Vector:

pcDNA3.1 (Luo et al., 2006a)

i. Immunization Route

Intramuscular injection (i.m.)

j. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Inoculation of plasmid DNA containing the L7/L12-P39 gene leads to both TH1 type antibody and CMI responses (Luo et al., 2006a).
Efficacy: Among the three DNA vaccines (including pcDNA3.1(+)-L7/L12 and pcDNA3.1(+)-P39), the pcDNA3.1 (+)-L7/L12-P39 DNA vaccine could provide the highest protective level against Brucella infection, as it confers protection against A544 challenge (Luo et al., 2006a).

7. B. abortus DNA vaccine pVF278

a. Vaccine Ontology ID:

VO_0004546

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of BAB1_0278

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

pVF (Sislema-Egas et al., 2012)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0003057
Immune Response: Mice injected with pVF278 had a dominant immunoglobulin G2a (IgG2a) response and elicited a T-cell-proliferative response (Sislema-Egas et al., 2012).
Efficacy: Data from two independent protection experiments demonstrated that immunization with pVF278 DNA vaccine resulted in a significantly degree of protection (1.28 log increase in protection) with P < 0.05 after determination of CFU in the spleen (Sislema-Egas et al., 2012).

8. B. abortus P39 deletion vaccine

a. Vaccine Ontology ID:

VO_0000826

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Preparation

A B. abortus vaccine that is recombinant B. abortus strain 19vaccine with the p39 gene deletion (Tibor et al., 1998).

e. Immunization Route

Intramuscular injection (i.m.)

9. B. abortus pcDNA-BLS

a. Vaccine Ontology ID:

VO_0000421

b. Type:

DNA vaccine

c. Antigen

Brucella abortus lumazine synthase (BLS) (Velikovsky et al., 2002). It was was cloned and identified in 1995 (Hemmen et al., 1995).

d. Gene Engineering of ORF

Type: DNA vaccine preparation
Description: The Brucella abortus lumazine synthase (BLS) gene was cloned into the pcDNA3 plasmid. This gene is driven by the cytomegalovirus promoter. The plasmid was amplified in E. coli JM109 (Promega, Madison, Wis.) and isolated with Mega Prep plasmid isolation columns (Qiagen, Dorking, United Kingdom) (Velikovsky et al., 2002).
Detailed Gene Information: Click here.

e. Vector:

pcDNA3 (Velikovsky et al., 2002)

f. Preparation

The Brucella abortus lumazine synthase (BLS) gene was cloned into the pcDNA3 plasmid. It is driven by the cytomegalovirus promoter (Velikovsky et al., 2002).

g. Virulence

No.

h. Description

This is about pcDNA-BLS, a B. abortus DNA vaccine encoding lumazine synthase (Velikovsky et al., 2002).

i. Mouse Response

Vaccine Immune Response Type: VO_0000286
Efficacy: Two independent protection experiments demonstrated that mice given pcDNA-BLS had a significantly higher degree of protection (1.65 log increase in protection) than did controls receiving PBS (P < 0.01) (Velikovsky et al., 2002).

10. B. abortus strain 19

a. Vaccine Ontology ID:

VO_0000022

b. Type:

Attenuated live vaccine

c. Status:

Licensed

d. Location Licensed:

USA; European countries

e. Host Species for Licensed Use:

Cattle

f. Antigen

Whole Brucella organism

g. Preparation

Strain 19, first described in 1930, is a laboratory-derived strain attenuated by an unknown process. It was originally isolated from bovine milk as a virulent strain in 1923, but became attenuated after storage at room temperature for over a year. Strain 19 is able to induce protective immunity in cattle (Schurig et al., 2002).

h. Virulence

Although effective, strain 19 vaccine has a tropism for the placenta and causes abortion when given to pregnant cows , is infectious for humans , and causes serologic responses in calves that are the same as those in cattle infected with natural field strains (Cheville, 2000).

i. Description

Strain 19 induces reasonable protection against B. abortus, but at the expense of persistent serological responses (Schurig et al., 2002).

j. Cattle Response

Vaccination Protocol: Mature female cattle were immunized with strain 19 ( 2x10^8 and 6x10^8 CFU respectively) and 6-12 month old calves with strain 19 ( 4x10^10 and 12x10^10 CFU ) . Mature females and calves were inoculated with sterile vaccine diluent and formed a non-vaccinated, in-contact control group (Geong et al., 2000).
Challenge Protocol: Cattle were allowed to graze for 24 months under conditions where infection was possible (Geong et al., 2000).
Efficacy: Of the 599 animals bled initially, 83.5, 72.6, 73.8 and 64.1%, respectively, were represented at 3, 6, 9 and 24 months post infection, respectively. No significant differences between the two villages in the percentage of animals presented at each sampling were found. During the trials, no difference was observed in the presenting of animals identified as seropositive and those identified as seronegative (Geong et al., 2000).

k. Mouse Response

Vaccination Protocol: Mice (10/treatment group) were injected i.p. with 0.2 ml of a 0.15 M NaCl saline solution (controls) or with 0.2 ml of saline containing approximately 1x10^5 cfu of strain 2308 or 1x10^7 cfu of strain 19 or RB51. Blood samples and spleens were taken from age-matched noninfected control mice and from infected mice at 2, 4, 6, 10, or 20 weeks respectively after infection (Stevens et al., 1994b).
Challenge Protocol: No challenge performed.

11. B. abortus strain 45/20

a. Vaccine Ontology ID:

VO_0000723

b. Type:

attenuated live vaccine

c. Antigen

Whole Brucella organism

d. Preparation

The 45/20 strain was isolated from guinea pigs in 1938 (Moriyon et al., 2004).

e. Virulence

The original strain of 45/20 was known to revert to smooth pathogenic forms when injected into cattle. Due to this instability, the vaccine is not currently marketed (Moriyon et al., 2004).

f. Description

B. abortus strain 45/20 is a rough form of the bacterium that can confer immunity (Moriyon et al., 2004).

g. Sheep Response

Vaccination Protocol: 15 lambs were vaccinated with 45/20 bacterin, and a control group remained unvaccinated. Revaccinations were performed 18 weeks later. At regular intervals after vaccination and revaccination, blood samples were taken and animals were examined for genital lesions (Blasco et al., 1993).
Side Effects: One ram died from enterotoxemia during the course of the experiment (Blasco et al., 1993).
Challenge Protocol: Challenge inoculations were performed 31 weeks after the second vaccination with a virulent strain of B. ovis obtained from a naturally infected ram. Each ram received a total volume of 60 uL ( 1 x 10^9 CFU), as shown by viable cell counts made on the day of inoculation), both conjunctivally (30 uL) and preputially (30 uL) (Blasco et al., 1993).
Efficacy: Two weeks after challenge, ten of the 15 control rams excreted B. ovis. All animals were slaughtered 15 weeks after the challenge inoculation and subjected to bacteriological and histological examinations. A ram was classified as protected if no B. ovis was isolated from any of the 13 organs sampled at necropsy. Significant levels of protection in comparison with the control group were obtained by vaccination with 45/20 bacterin (PC 0.05) (Blasco et al., 1993).

12. B. abortus subunit vaccine using L7/L12

a. Vaccine Ontology ID:

VO_0000323

b. Type:

Subunit vaccine

c. Antigen

B. abortus ribosomal protein L7/L12 (Oliveira et al., 1996).

d. Gene Engineering of B. abortus strain 19 L7/L12

Type: Recombinant protein preparation
Description: Recombinant Brucella abortus L7/Ll2 ribosomal protein was fused to maltose binding protein (MBP). The detail is described (Oliveira et al., 1996).
Detailed Gene Information: Click here.

e. Preparation

The recombinant Brucella abortus L7/L12 ribosomal protein was fused to maltose binding protein (MBP). The animals vaccinated with MBP-L7/L12 received 25 mg of the specific B. abortus L7/L12 ribosomal protein. Different protein concentrations per dose containing the same MBP amounts were used to vaccinate each group to ensure that both mouse groups received the same amount of MBP (Oliveira et al., 1996).

f. Virulence

None

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Five groups of 15 BALB/c mice were immunized intraperitoeally with 0.2 ml of the following treatments: either phosphate-buffered saline (PBS); Immuneplus adjuvant system; adjuvant containing 75 micrograms of maltose binding protein (MBP); 4 adjuvant containing 100 micrograms of MBP-L7/L12 fusion protein; or B. abortus strain 19 (Oliveira et al., 1996).
Immune Response: There was a specific antibody response from animals immunized with recombinant MBP-L7/L12 fusion protein. Serum samples from mice immunized with MBP-L7/L12 contained anti-MBP and anti-L7/L12 antibodies. No anti-MBP-L7/L12 antibodies were detected in the sera of naive mice used as a negative control (Oliveira et al., 1996).
Challenge Protocol: Mice were challenged one week after their final immunization (day 28) with an i.v. injection of 1 x 10^6 c.f.u. B. abortus in 100 microliters of sterile phosphate buffer saline (Oliveira et al., 1996).
Efficacy: Three immunizations with 100 micrograms of the recombinant L7/L12 ribosomal protein fused to MBP protected mice against B. abortus infection, while vaccination with 75 micrograms of MBP alone resulted in no protection. The recombinant L7/L12 protein engendered substantial protective immunity to BALB/c mice against challenge when compared to the protection levels conferred to mice vaccinated with B. abortus S19. The greatest levels of protection observed in immunized mice were at 2 and 4 weeks post-challenge (Oliveira et al., 1996). The irrelevant Escherichia coli protein (MBP) does not protect mice against brucellosis (Oliveira et al., 1996).

h. Mouse Response

Host Strain: BALB/C
Vaccination Protocol: Three intra-muscular vaccinations of DNA vaccine encoding L7/L12 protein at 3 week intervals.(Abtahi et al., 2008)
Immune Response: Activation of Th1 cell response. (Abtahi et al., 2008)
Efficacy: Lower bacterial cfu from vaccinated mice in comparison with control groups show the efficiency of L7/L12 DNA vaccination in mice model. (Abtahi et al., 2008)
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: Splenic lymphocytes from L7/L12pCDNA3-vaccinated mice produced high levels of IFNy (3100 pg mL(-1)) 3 weeks post-vaccination. (Abtahi et al., 2008)
- Detailed Gene Information: Click here.
Host Gene Response of Ighg1
- Gene Response: IgG1 titers induced post-immunization with L7/L12pCDNA3 vaccine. (Abtahi et al., 2008)
- Detailed Gene Information: Click here.
Host Gene Response of Ighv1-9
- Gene Response: L7/L12pCDNA3 immunizations elicited high IgG2a isotype response in mice immunized (Abtahi et al., 2008)
- Detailed Gene Information: Click here.
Host Gene Response of Il5
- Gene Response: Splenic lymphocytes from L7/L12pCDNA3-vaccinated mice produced low levels of IL-5 (300 pg mL(-1)) 3 weeks post-vaccination. (Abtahi et al., 2008)
- Detailed Gene Information: Click here.

13. B. abortus vaccine strain RB51

a. Tradename:

RB51

b. Manufacturer:

Colorado Serum Company CZ Veterinaria

c. Vaccine Ontology ID:

VO_0000021

d. Type:

Live attenuated B. abortus strain

e. Status:

Licensed

f. Location Licensed:

USA, Mexico, South American, India, Spain, Middle East, Iran

g. Host Species for Licensed Use:

Cattle

h. Antigen

The antigen for this live attenuated vaccine is the whole cells of strain RB51. This strain has rough characteristics and is devoid of O-chain. The RB51 was derived from the virulent smooth B. abortus 2308 by several passages in media supplemented with sub-inhibitory concentrations of rifampicin (Schurig et al., 1991).

i. Virulence

RB51 is a rough attenuated strain (Schurig et al., 1991).

j . Approved Age for Licensed Use

Calves (4–12 months of age) are vaccinated with RB51 at the full dose of 1.0–3.4 × 10^10 colony forming units. In Brucella-infected herds the vaccine can be safely used in cows at a reduced dose of 1.0 × 10^9 CFU (Poester et al., 2006).

k. Description

RB51 has been the official cattle Brucella vaccine in the USA since 1996 and now in many other countries (Schurig et al., 2002). RB51 is a rifampin-resistant rough attenuated mutant of Brucella abortus derived by repeated passage of strain 2308 on Trypticase soy supplemented with 1.5% agar and varying concentrations rifampin or penicillin. Rabbits, goats and cattle hyperimmunized with sonicates of RB51 develop antibodies to B. abortus cellular antigens but do not develop specific antibodies for the Brucella O-chain (Schurig et al., 1991).

l. Mouse Response

Host Strain: BALB/c mice
Vaccination Protocol: ~4 x 10^8 CFU
Persistence: Inoculation (ip) of RB51 into mice results in a splenic colonization which is cleared within four weeks post infection. RB51 does not revert to smooth colony morphology upon passage in vivo (mice) or in vitro (Schurig et al., 1991).
Side Effects: No obvious symptoms were observed in immunized mice.
Efficacy: The CFU in spleen decreases 1-2 logs.
Description: Vaccination of mice with RB51 induces specific cytotoxic T lymphocytes (CTLs) against strain RB51 and strain 2308-infected J774.A1 macrophages but not against Listeria monocytogenes-infected J774.A1 cells. Antigen-specific cytotoxic activity is exerted by T lymphocytes but not by NK cells. CD3+ CD4+ T cells secrete the highest level of IFN-γ and induce low but significant level of lysis of Brucella-infected macrophages. In contrast, CD3+ CD8+ T cells secrete low levels of IFN-γ but high levels of specific lysis of Brucella-infected macrophages. No nonspecific lysis was observed. Hence CD3+ CD4+ and CD3+ CD8+ T cells play synergistic roles in anti-Brucella activity (He et al., 2001).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: IFN-gamma is up-regulated in RB51-immunized mice (He et al., 2001).
- Detailed Gene Information: Click here.

m. Cattle Response

Host Strain: Crossbreed
Vaccination Protocol: At Day 0 of the experiment, heifers in the vaccinated group were divided in two sub-groups: 12 heifers were vaccinated at Day 0 of the experiment and the remaining 8 heifers were vaccinated at the 60th day of gestation, with a 2 mL dose. The heifers of the control group received 2 mL of sterile saline solution (Poester et al., 2006).
Immune Response: Sera from all animals of RB51 vaccinated and control groups did not show anti-Brucella antibodies on Days −30, 0, 15, and monthly thereafter until the day of challenge (Poester et al., 2006).
Challenge Protocol: All animals were challenged with the virulent B. abortus strain 2308. Each heifer received a 3.0 × 10^7 CFU challenge per heifer (Poester et al., 2006).
Efficacy: Vaccination with RB51 vaccine did not result in the production of any antibodies against the O-side chain of lipopolysaccharide. The results indicate that vaccination with RB51 prevented 59.4% of abortions, 58.6% of cow infections, and 61.0% of fetal infections. The relative risk revealed that non-vaccinated animals have 2.462 times higher risk of aborting than RB51-vaccinated animals (Poester et al., 2006).

n. Cattle Response

Vaccination Protocol: Mass vaccination of the cattle population of 3 Azore islands (Terceira, S. Miguel and S. Jorge) targeted breeding herds with the RB51 vaccine supplied by CZ Veterinaria S.A (Pontevedra, Spain). It was administered to heifers or adult female cattle s.c. at 10–34 × 10^9/dose (2 ml). In herds still infected with an intra-herd incidence of more than 10% after 6 months, all adults were re-vaccinated, as were adjacent herds (Martins et al., 2009).
Persistence: During the study period, supramammary (N = 303) and retro-pharyngeal (N = 342) lymph nodes and spleen (N = 298) samples from 343 sero-positive animals slaughtered due to brucellosis suspicion were submitted for culture. Brucella was isolated from 176 animals (51%). Similar isolation rates (39%) were observed for supramammary and retro-pharyngeal lymph nodes, but a lower rate was seen for spleen (7%) (Martins et al., 2009).
Immune Response: During the study period, supramammary (N = 303) and retro-pharyngeal (N = 342) lymph nodes and spleen (N = 298) samples from 343 sero-positive animals slaughtered due to brucellosis suspicion were submitted for culture. Brucella was isolated from 176 animals (51%). Similar isolation rates (39%) were observed for supramammary and retro-pharyngeal lymph nodes, but a lower rate was seen for spleen (7%) (Martins et al., 2009).
Side Effects: No side-effects, such as abortion were reported (passive reporting). The only outstanding observation that could be related to vaccination was a weak newborn calf from which RB51 was isolated. The annual number of human cases was also low (≤4) and none of them was due to RB51, but to field strain B. abortus biovar 1. It was impossible to relate the disease occurrence in humans with the prevalence in animals (Martins et al., 2009).
Challenge Protocol: n/a (Martins et al., 2009)
Efficacy: The overall trend is a regular decrease of the three parameters from the beginning of the vaccination programme up to the end of the study period. Average herd incidence, herd prevalence and animal prevalence decreased 69.26%, 39.26% and 75.41% respectively, from 2002 to 2007 for the whole area. Mean within-herd prevalence followed the same pattern, declining on a gradual pace until 2007 (Martins et al., 2009).
Description: RB51 vaccine supplied by CZ Veterinaria S.A (Pontevedra, Spain) (Martins et al., 2009).

o. Cattle Response

Vaccination Protocol: To establish the efficacy of RB51 in cattle, female calves were inoculated SC at 3, 5, 7, and 10 months, respectively with RB51 (n = 26), S19 (n = 22), or saline (n = 15) (Cheville, 2000).
Persistence: B. abortus strain RB51 was cultured from biopsies of superficial cervical lymph nodes in heifers vaccinated with RB51 and S19 at 10 weeks, but not at 12 weeks (Cheville, 2000).
Side Effects: In cattle, RB51 is less virulent than B. abortus cattle vaccine Strain 19.
Challenge Protocol: Calves were bred at 16 to 17 months of age and challenged during the first pregnancy with virulent B. abortus (Cheville, 2000).
Efficacy: After vaccination, heifers administered RB51 developed no serum antibodies that reacted in the agglutinate test , but yielded a positive dot -blot assay using RB51 antigen . B. abortus strain RB51 was cultured from biopsies of superficial cervical lymph nodes from cows challenged with RB51and S19 vaccines at 10 weeks , but not at 12 weeks. Three month old vaccinated heifers were protected from infection and abortion; strain 19-vaccinated heifers were not infected nor aborted. Control heifers were infected. Vaccination at five and seven months of age gave equivalent, but less than complete protection. Heifers given strain 19 (n = 16) were protected 95%; those given RB51 were 87% protected; controls (administered saline) (n = 15) exhibited a high incidence of infection and abortion. No significant differences in the efficacy of either vaccine was found in animals at any given age. However, when compared to controls marked differences in the efficacy of each vaccine were noted. No gross or microscopic evidence of brucellosis was found in the tissues and organs of cows not infected at birth (Cheville, 2000).

All heifers vaccinated with RB51 at three months were protected against infection and abortion. Vaccination at five and seven months of age yielded equivalent protection. Heifers given strain 19 were 95% protected. In calves, the results obtained suggest that RB51 protects at dosage levels comparable to those of strain 19.(Cheville, 2000).
Description: Strain RB51 is protective in cattle at doses comparable to those of strain 19 (Cheville, 2000). Brucella abortus strain RB51 is the vaccine of choice against brucellosis of cattle in the United States .

p. Water buffalo Response

Vaccination Protocol: Thirty Brucella-free female buffaloes were divided in three groups. Group A consisted of 10 non-pregnant water buffaloes 4–5 years old that were vaccinated once with RB51 (10.2 × 10^10 CFU/ml) during lactation. Group B consisted of 10 adult water buffaloes 28–36 months old at the first lactation that were previously vaccinated twice (4 weeks apart) as calves (6–9 months old) with 10.2 × 10^10 CFU/ml RB51, but were not revaccinated with RB51 as adults. Group C consisted of 5 adults 4–5 years old during the fourth month of lactation and 5 adult water buffaloes 28–36 months old at the first lactation that were not vaccinated (controls) (Longo et al., 2009).
Side Effects: No side effects attributable to vaccine administration were noted in any treatment group. All the experimental water buffaloes appeared clinically normal throughout the study (Longo et al., 2009).
Efficacy: RB51 was identified from milk samples collected during the first week post-vaccination (days 1 and 4) in 3/10 of the vaccinated animals of group A but was never isolated in groups B and C. Moreover, RB51 DNA was detected during the first week until the fourth week post-vaccination in the milk samples from group A but was not detected in milk samples of the animals of B and C (Longo et al., 2009).

q. Squirrel Response

Host Strain: Richardson's ground squirrel
Vaccination Protocol: Each Richardson’s ground squirrel received 250 µl of inoculum directly into the mouth via tuberculin syringe. All squirrels were observed twice daily for clinical signs for 21 days and once daily thereafter. RB51, strain 19 (S19), and virulent B. abortus strain 9941 (S9941) were administered orally to squirrels to further characterize B. abortus infection in this species. Six groups of nongravid ground squirrels were orally inoculated with 6 x 10^8 CFU RB51, 2.5 x 10^4 CFU S19, 2.5 x 10^7 CFU S19, 1.3 x 10^6 CFU S9941, 2.1 x 10^8 CFU S9941, or vaccine diluent (control) (Nol et al., 2009).
Persistence: One of 5 animals in the lower-dose S19 group and 2 of 3 animals in the higher-dose S19 group showed persistence of bacteria in various tissues at 14 weeks post-inoculation (WPI). At 18 WPI, 1/5 animals in the RB51 group and 1/5 animals in the high-dose S9941 group were
culture positive. There was a general lack of persistence of the three strains of B. abortus in Richardson’s ground squirrels at 18 wk PI (Nol et al., 2009).
Immune Response: On examination, all livers displayed hepatocellular vacuolization with a pronounced centrilobular pattern consistent with lipidosis and occasional multifocal areas of pleocellular infiltrates consisting of small and large mononuclear cells, suggesting mild hepatitis. One animal in the RB51 group also had focal necrotizing hepatitis. Other lesions observed in these animals included multifocal interstitial pyogranulomatous nephritis and nephrosis, focal necrotizing pancreatitis, and sparse mononuclear cellular infiltrates in the oviduct and uterus (Nol et al., 2009).
Side Effects: There was no evidence of pathology caused by B. abortus strains in nonpregnant squirrels based on clinical signs, gross lesions, and microscopic lesions (Nol et al., 2009).
Challenge Protocol: Richardson’s ground squirrels experience minimal clinical signs and pathology at challenge levels ranging from 2.5 x 10^4 CFU to 6 x 10^8 CFU (Nol et al., 2009).
Efficacy: It is unknown if and when the three animals that were culture positive at 14 wk and the two positive animals at 18 wk may have cleared the infection if given more time. No evidence of shedding of RB51 or S19 beyond 2 days PI, and only 2/25 animals cultured at 18 wk showed evidence of persistent infection. Even if infected, squirrels are unlikely to be severely affected by B. abortus or serve as sources of Brucella in the field (Nol et al., 2009).
Description: In summary, RB51, S19, and S9941 do not produce disease in nonpregnant Richardson’s ground squirrels when given orally at challenge doses ranging from 2.5 x 104 cfu to 6 x 108 cfu. This species is unlikely to act as a reservoir or source of infection for either vaccine or wild type strains of B. abortus. The Richardson’s ground squirrel would be a poor model for oral Brucella infection as well. These data provide useful information for researchers and those charged with the management of brucellosis in wildlife in the GYA (Nol et al., 2009).

r. Deer Response

Host Strain: Red deer (Cervus elaphus)
Vaccination Protocol: A novel approach of immunization was examined using alginate composite microspheres containing a non-immunogenic, eggshell-precursor protein of Fasciola hepatica (Vitelline protein B, VpB) to deliver live RB51. 54 1–2-yr-old female red deer (Cervus elaphus elaphus), used as a model for elk, were vaccinated orally (PO) or subcutaneously (SC) with 1.5 x 10^10 viable organisms per animal. Specifically, animals were randomly distributed into six different treatments (n=9/group). Three groups were inoculated SC with a total dose of 1.5 x 10^10 CFU of either nonencapsulated RB51, encapsulated RB51 with alginate, or encapsulated RB51 with alginate and VpB. Two groups were vaccinated PO; one group received 1.5 x 10^10 CFU of encapsulated RB51 with alginate, and the second group received with encapsulated RB51 with alginate and VpB. The control group received a SC injection of 1 ml of empty capsules (no bacteria entrapped). A single vaccination dose was given to all animals (Arenas-Gamboa et al., 2009).
Persistence: At 12 wk postvaccination, animals that received the encapsulated vaccine with VpB in the formulation (regardless of the immunization route) were the only individuals that had a statistically significant proliferative response compared with the controls (P<0.0005 PO vaccinates, P<0.005 SC group; Fig. 2). Interestingly, the cpm counts in animals that received encapsulated RB51 with VpB PO were also higher than in deer that received the same formulation via SC (P<0.3). None of the animals that received nonencapsulated vaccine had a significant cellular response compared with naïve nonvaccinated animals. Immunization with RB51 elicited an anti-Brucella IgG response that was clearly detectable by 6 wk postvaccination. During the initial 17 wk, anti-Brucella IgG levels were higher in animals that received SC vaccine compared with the groups that were immunized PO. Between 17 to 28 wk, anti-Brucella IgG levels in animals that were PO-vaccinated had an increase in anti-Brucella IgG compared with deer SC-vaccinated (Arenas-Gamboa et al., 2009).
Immune Response: Humoral responses post-vaccination (immunoglobulin G [IgG] levels), assessed at different time points, indicated that capsules containing live RB51 elicited an anti-Brucella specific IgG response. Furthermore, the encapsulated vaccine elicited a cell-mediated (CMI) response that the non-encapsulated vaccinates failed to produce (Arenas-Gamboa et al., 2009).
Challenge Protocol: At 7 mo postvaccination, three to four red deer from each vaccination group (except RB51/alginate SC; n=2) were challenged with a dose of 1x10^9 B. abortus strain 19 organisms by conjunctival exposure. Dose exposure was confirmed by serial dilutions and plating onto TSA plates. At 2 wk post-challenge, animals were euthanized, and spleens were harvested, weighed and homogenized. At 3–5 days postincubation, bacteria were enumerated (Arenas-Gamboa et al., 2009).
Efficacy: Only animals that received encapsulated RB51 vaccine (either route) exhibited significant reduction in bacterial counts in their spleens. These data suggest that alginate-VpB microspheres provide a method to enhance the RB51 vaccine performance in elk. At 2 wk postchallenge, only animals that received encapsulated SRB51 with VpB had a significant decrease in bacterial load in the spleen. Red deer that received the vaccine PO were the only group that was statistically significant compared with the nonencapsulated, injected RB51. Animals that were PO-immunized with the VpB capsules had a 1.27 log reduction in spleen counts compared with animals vaccinated with nonencapsulated RB51 and a 1.68 log reduction compared with naïve, nonvaccinated, but S19 exposed, animals. S19 spleen counts in deer that received the VpB capsules via SC were also diminished by 1.21 log compared with the nonencapsulated RB51 and by 1.62 log compared with non-RB51 vaccinated controls (Arenas-Gamboa et al., 2009).

s. Buffalo Response

Host Strain: Bison (Bison bison)

t. Mouse Response

Host Strain: CD1
Vaccination Protocol: Four groups of 10 female CD1 mice per group (5-6 weeks old) were vaccinated intraperitoneally (IP) with 3-5 x 10^8 CFU in 100 µl of RB51, RB51leuB, RB51leuB/pNS4, or RB51leuB/pNS4/GFP. Another group of 10 mice were vaccinated with saline to serve as a negative control. Three mice from each group were bled at 5 weeks post-vaccination to harvest serum. The sera were screened for GFP-specific antibodies by immunoblot (Rajasekaran et al., 2008).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	RB51	10	in volume		female	5.5 week	no	Vaccinated intraperitoneally (IP) with 3-5 x 10^8 CFU in 100 µl of RB51. Three mice were bled at 5 weeks post-vaccination to harvest serum, which was screened for GFP-specific antibodies by immunoblot (Rajasekaran et al., 2008).
2	RB51leuB	10	in volume		female	5.5 week	no	Vaccinated intraperitoneally (IP) with 3-5 x 108 CFU in 100 µl of RB51leuB. Three mice were bled at 5 weeks post-vaccination to harvest serum, which was screened for GFP-specific antibodies by immunoblot (Rajasekaran et al., 2008).
3	RB51leuB/pNS4	10	in volume		female	5.5 week	no	Vaccinated intraperitoneally (IP) with 3-5 x 10^8 CFU in 100 µl of RB51leuB/pNS4. Three mice were bled at 5 weeks post-vaccination to harvest serum, which was screened for GFP-specific antibodies by immunoblot (Rajasekaran et al., 2008).
4	RB51leuB/pNS4/GFP	10	in volume		female	5.5 week	no	Vaccinated intraperitoneally (IP) with 3-5 x 10^8 CFU in 100 µl of RB51leuB/pNS4/GFP. Three mice were bled at 5 weeks post-vaccination to harvest serum, which was screened for GFP-specific antibodies by immunoblot (Rajasekaran et al., 2008).
5	Saline	10	in volume		female	5.5 week	yes	Injected intraperitoneally (IP) with 100 µl of saline to act as negative controls. Three mice were bled at 5 weeks post-vaccination to harvest serum, which was screened for GFP-specific antibodies by immunoblot (Rajasekaran et al., 2008).

Persistence: Mice vaccinated with the leuB mutant and the complemented RB51leuB strains were able to clear the virulent challenge strain B. abortus 2308 (S2308) at significant rates compared with clearance in the mice vaccinated with saline. No significant difference was observed in the rates of clearance of the challenge strain in the mice vaccinated with auxotrophic vaccine strains and the standard strain RB51 and also between the RB51leuB strains. In a separate experiment, the leuB auxotroph and the complemented leuB auxotroph were found to be cleared from CD1 mouse spleens by 4 to 5 weeks, at the same rate as the parent vaccine strain RB51 (Rajasekaran et al., 2008).
Challenge Protocol: At 6 weeks post-vaccination, all groups of mice were challenged IP with 4 x 10^4 CFU of B. abortus strain 2308 (S2308). At 2 weeks post-challenge, mice were euthanized by CO2 asphyxiation, and their spleens were recovered, homogenized, serially diluted, and plated on trypticase soy agar (TSA) plates to estimate CFU (Rajasekaran et al., 2008).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	40000 CFU in volume 0.1 ml	Intraperitoneal injection (i.p.)	day	6 week

Efficacy: The leuB/GFP construction was shown to complement a leucine auxotroph of RB51, which protected CD1 mice from virulent B. abortus 2308 (S2308) and elicited GFP antibodies. The leuB auxotroph and the complemented auxotroph of strain RB51 were able to protect the CD1 mice against an S2308 challenge. There was no significant difference in the protection levels (as measured by splenic clearance) afforded by the leuB auxotroph when the protection levels in the mice vaccinated with the complemented leuB auxotroph and with the complemented leuB auxotroph expressing GFP were compared to the protection level in the mice vaccinated with strain RB51. There was, however, a significant difference in protection afforded between the mice vaccinated with any of the RB51 strains and the saline control. Only sera from the group inoculated with RB51leuB/pNS4/GFP possessed GFP-specific antibodies (Rajasekaran et al., 2008).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	90000 CFU	Each of the RB51 groups (RB51, RB51leuB, RB51leuB/pNS4, and RB51leuB/pNS4GFP) increased clearance by ~ 1 log (10^4 CFU vs. 10^5 CFU for saline control group, so reduction of ~90,000 CFU). However, there was no significant difference (NSD) between groups (Rajasekaran et al., 2008).

u. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: To characterize the optimal aerosol dosage of Brucella abortus strain 2308 (S2308) and B. melitensis (S16M), 10^3–10^10 CFU were nebulized to BALB/c mice. A range of dosages was evaluated to determine optimal dosages for aerosolization. Protection in vaccinated and non-vaccinated mice were compared after experimental B. abortus challenge via IP and aerosol routes. For aerosol delivery, the nebulization apparatus consists of a compressed air tank and a jet nebulizer connected via a rubber hose to a port in a metal cage cover. A flow rate of 2 l/min produces a 5 ml particle size. Compressed air was used to jet nebulize 2 ml of challenge inoculum directly into a plexiglass cage containing 5 mice. Nebulization continued until all inoculum, plus 2 ml saline was delivered over ~15 min.
Experiment 1: S2308 or S16M were spectrophotometrically adjusted to concentrations between 10^3 and 10^10 CFU and delivered by aerosol to female 10-week-old BALB/c mice. At 2 weeks after nebulization, mice were euthanized with CO2. Spleen, liver, and lung from each mouse were removed and weighed. Tissues were macerated and serially diluted, with standard plate counts used to determine bacterial concentrations.
Experiment 2: Mice were injected IP with 0.2 ml of saline +/- ~1 x 10^7 CFU of SRB51. At 12 weeks after vaccination, mice were challenged with S2308 IP (0.2 ml saline + 5 x 10^4 CFU) or via nebulization (~10^9 CFU). Two weeks after challenge, mice were euthanized with CO2. Spleens, livers and lungs were weighed and processed for isolation and quantification of Brucella as described in Experiment 1.
(Olsen et al., 2007)

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	Nebulized S2308 CFU	10	in volume		female	10 week	no	Brucella abortus strain 2308 (S2308) was spectrophotometrically adjusted to concentrations between 10^3 and 10^10 CFU and delivered by aerosol to female 10-week-old BALB/c mice. At 2 weeks after nebulization, mice were euthanized with CO2. Spleen, liver, and lung from each mouse were removed and weighed. Tissues were macerated and serially diluted, with standard plate counts used to determine bacterial concentrations (Olsen et al., 2007).
2	Nebulized S16M CFU	10	in volume		female	10 week	no	Brucella melitensis strain 16M (S16M) were spectrophotometrically adjusted to concentrations between 10^3 and 10^10 CFU and delivered by aerosol to female 10-week-old BALB/c mice. At 2 weeks after nebulization, mice were euthanized with CO2. Spleen, liver, and lung from each mouse were removed and weighed. Tissues were macerated and serially diluted, with standard plate counts used to determine bacterial concentrations (Olsen et al., 2007).
3	IP saline vaccine	15	in volume		female	10 week	yes	Control mice were injected IP with 0.2 ml of saline. At 12 weeks after vaccination, mice were challenged with S2308 IP (0.2 ml saline + 5 x 10^4 CFU) or via nebulization (~10^9 CFU). Two weeks after challenge, mice were euthanized with CO2. Spleens, livers and lungs were weighed and processed for isolation and quantification of Brucella as described in Experiment 1 (Olsen et al., 2007).
4	IP SRB51 vaccine	15	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice were injected IP with 0.2 ml of saline containing 10^7 CFU of SRB51. At 12 weeks after vaccination, mice were challenged with S2308 delivered either IP or via nebulization. Two weeks after challenge, mice were euthanized with CO2/O2. Spleens, livers and lungs were weighed and processed for isolation and quantification of Brucella (Olsen et al., 2007).

Persistence: Total CFU per tissue increased beginning at 10^6–10^7 CFU dosages, with 10^9 CFU appearing to be an optimal dosage for S16M or S2308 aerosol delivery.
(Olsen et al., 2007)
Immune Response: (Olsen et al., 2007)
Side Effects: (Olsen et al., 2007)
Challenge Protocol: At 12 weeks after vaccination with 10^7 CFU of SRB51 or saline (control), mice were challenged IP with 6.4 x 10^4 CFU or via aerosol (1.76 x 10^9 CFU) with S2308.
(Olsen et al., 2007)

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	64000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	12 week
2	S2308	1760000000 CFU in volume 4 ml	nebeulization (aerosol)	day	12 week

Efficacy: Mice vaccinated with SRB51 had reduced splenic, liver and lung colonization after IP challenge with S2308 as compared with control mice after IP S2308 challenge. Control and SRB51-vaccinated mice did not differ in splenic, liver, or lung colonization after aerosol S2308 challenge.
(Olsen et al., 2007)

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	2 CFU	Mice vaccinated with SRB51 had reduced splenic (decreased by ~2 CFU/g x tissue weight), liver (decreased by ~3 CFU/g x tissue weight), and lung (decreased by ~5 CFU/g x tissue weight) colonization after IP challenge with S2308 as compared with control mice after IP S2308 challenge. Control and SRB51-vaccinated mice did not differ in splenic, liver, or lung colonization after aerosol S2308 challenge (Olsen et al., 2007).
2	assay of CFU reduction in liver	3 CFU	Mice vaccinated with SRB51 had reduced splenic (decreased by ~2 CFU/g x tissue weight), liver (decreased by ~3 CFU/g x tissue weight), and lung (decreased by ~5 CFU/g x tissue weight) colonization after IP challenge with S2308 as compared with control mice after IP S2308 challenge. Control and SRB51-vaccinated mice did not differ in splenic, liver, or lung colonization after aerosol S2308 challenge (Olsen et al., 2007).
3	assay of CFU redcution in lung	5 CFU	Mice vaccinated with SRB51 had reduced splenic (decreased by ~2 CFU/g x tissue weight), liver (decreased by ~3 CFU/g x tissue weight), and lung (decreased by ~5 CFU/g x tissue weight) colonization after IP challenge with S2308 as compared with control mice after IP S2308 challenge. Control and SRB51-vaccinated mice did not differ in splenic, liver, or lung colonization after aerosol S2308 challenge (Olsen et al., 2007).

Description: (Olsen et al., 2007)

v. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Investigators evaluated the effect of oral inoculation (PO) of Brucella abortus RB51 in BALB/c female mice against a challenge infection with B. abortus (S)2308. For IP immunization with live bacteria, mice were given 2 x 10^8 CFU of B. abortus RB51 in 0.2 ml of sterile saline or 2 x 10^4 CFU of strain S2308. For PO immunization, a gastric lavage needle was used. Ten minutes prior to oral inoculation, mice were administered 0.2 ml of 10% sodium bicarbonate (NaHCO3) to neutralize gastric acidity or 0.2 ml of sterile saline. Mice were inoculated PO with 2 x 10^10 CFU of RB51 or S2308. On days 10 and 18 after PO RB51 or S2308, preceded or not by gastric acidity neutralization, mice were killed and their spleens removed. Spleens were homogenized in 1 ml of sterile saline. Aliquots of the resulting suspensions were plated to assess spleen colonization.
In separate experiments, mice were inoculated PO with RB51. Oral inoculation was preceded by gastric acidity neutralization. To evaluate the excretion of bacteria after oral exposure, fecal samples were collected daily for 3 days after inoculation. At 7, 15, 30, and 42 days after infection, mice were bled and killed and spleens were aseptically removed, weighed, homogenized in PBS, and plated to determine the outcome of infection (Pasquali et al., 2003).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	IP RB51	5	in volume		female	13 week	no	For IP immunization with live bacteria, mice were given 2 x 10^8 CFU of Brucella abortus RB51 in 0.2 ml of sterile saline (Pasquali et al., 2003).
2	IP S2308	5	in volume		female	13 week	no	For IP immunization with live bacteria, mice were given 2 x 10^4 CFU of B. abortus 2308 (Pasquali et al., 2003).
3	IP saline	5	in volume		female	13 week	yes	For negative control of IP immunization, mice were given 0.2 ml of sterile saline (Pasquali et al., 2003).
4	PO RB51 + NaHCO3	5	in volume		female	13 week	no	For oral (PO) immunization, a gastric lavage needle was used. Ten minutes prior to oral inoculation, mice were administered 0.2 ml of 10% sodium bicarbonate (NaHCO3) to neutralize gastric acidity. Mice were orally inoculated with 2 x 10^10 CFU of RB51. On days 10 and 18 after PO RB51 or S2308, preceded or not by gastric acidity neutralization, mice were killed and their spleens removed. Spleens were homogenized in 1 ml of sterile saline. Aliquots of the resulting suspensions were plated to assess spleen colonization (Pasquali et al., 2003).
5	PO RB51 + saline	5	in volume		female	13 week	no	For oral (PO) immunization, a gastric lavage needle was used. Ten minutes prior to oral inoculation, mice were administered 0.2 ml of sterile saline. Mice were orally inoculated with 2 x 10^10 CFU of RB51. On days 10 and 18 after PO RB51 or S2308, preceded or not by gastric acidity neutralization, mice were killed and their spleens removed. Spleens were homogenized in 1 ml of sterile saline. Aliquots of the resulting suspensions were plated to assess spleen colonization (Pasquali et al., 2003).
6	PO S2308 + NaHCO3	5	in volume		female	13 week	no	For oral (PO) immunization, a gastric lavage needle was used. Ten minutes prior to oral inoculation, mice were administered 0.2 ml of 10% sodium bicarbonate (NaHCO3) to neutralize gastric acidity. Mice were orally inoculated with 2 x 10^10 CFU of S2308. On days 10 and 18 after PO RB51 or S2308, preceded or not by gastric acidity neutralization, mice were killed and their spleens removed. Spleens were homogenized in 1 ml of sterile saline. Aliquots of the resulting suspensions were plated to assess spleen colonization (Pasquali et al., 2003).
7	PO S2308 + saline	5	in volume		female	13 week	no	For oral (PO) immunization, a gastric lavage needle was used. Ten minutes prior to oral inoculation, mice were administered 0.2 ml of sterile saline. Mice were orally inoculated with 2 x 10^10 CFU of S2308. On days 10 and 18 after PO RB51 or S2308, preceded or not by gastric acidity neutralization, mice were killed and their spleens removed. Spleens were homogenized in 1 ml of sterile saline. Aliquots of the resulting suspensions were plated to assess spleen colonization (Pasquali et al., 2003).
8	PO saline	5	in volume		female	13 week	yes	For oral (PO) control, a gastric lavage needle was used to inoculate mice with 0.2 ml of sterile saline. On days 10 and 18 after inoculation, mice were killed and their spleens removed. Spleens were homogenized in 1 ml of sterile saline. Aliquots of the resulting suspensions were plated to assess spleen colonization (Pasquali et al., 2003).

Persistence: Gastric acid neutralization prior to the oral inoculation contributed to a more homogeneous and consistent infection with both RB51 and S2308. Clearance and immune response following oral infection with RB51 was successively assessed. PO inoculation gave a mild infection, which was cleared 42 days later and induced a delayed humoral and cell-mediated immune (CMI) response (Pasquali et al., 2003).
Immune Response: (Pasquali et al., 2003)
Side Effects: (Pasquali et al., 2003)
Challenge Protocol: Finally, they immunized mice PO with RB51 and challenged them with S2308 PO or intraperitoneally (IP) 42 days after vaccination. Mice were PO vaccinated with RB51 preceded by gastric acidity neutralization or were IP inoculated with RB51 as mentioned above. Additional mice served as unvaccinated controls. PO and IP vaccinated mice and controls were challenged PO (2 x 10^10 CFU) or IP (2 x 10^4 CFU) with S2308 42 days after vaccination. PO challenge was preceded by gastric acid neutralization. Mice were bled and killed at 18 days after challenge. Spleens were weighed and homogenized to determine CFU as a means for assessing the protective response induced by vaccination. Sera were used to evaluate antibody titer against both S2308 and RB51 (Pasquali et al., 2003).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	2000000000 CFU in volume ml	oral gavage (actual dose = 2 x 10^10)	day	42 day
2	S2308	20000 CFU in volume ml	Intraperitoneal injection (i.p.)	day	42 day

Efficacy: PO RB51 was able to protect mice infected with S2308 PO but not to mice infected IP. Results indicate that oral inoculation of mice with RB51 is able to give protective immunity against oral infection with virulent strains and that this protection seems to rely on an immune response at the mucosal level (Pasquali et al., 2003).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	2.5 CFU	Mice were bled and killed at 18 days after challenge. Spleens were weighed and homogenized to determine CFU as a means for assessing the protective response induced by vaccination. PO RB51 was able to protect mice infected with S2308 PO (decreased CFU by 2.5 log) and to mice infected IP (1.5 log decrease). IP RB51 protection was not significant, though CFU was decreased by ~1 log following vaccination via PO and IP. Results indicate that oral inoculation of mice with RB51 is able to give protective immunity against oral infection with virulent strains and that this protection seems to rely on an immune response at the mucosal level (Pasquali et al., 2003).
2	assay of CFU reduction in spleen	1.5 CFU	Mice were bled and killed at 18 days after challenge. Spleens were weighed and homogenized to determine CFU as a means for assessing the protective response induced by vaccination. PO RB51 was able to protect mice infected with S2308 PO (decreased CFU by 2.5 log) and to mice infected IP (1.5 log decrease). IP RB51 protection was not significant, though CFU was decreased by ~1 log following vaccination via PO and IP. Results indicate that oral inoculation of mice with RB51 is able to give protective immunity against oral infection with virulent strains and that this protection seems to rely on an immune response at the mucosal level (Pasquali et al., 2003).
3	assay of CFU reduction in spleen	1 CFU	Mice were bled and killed at 18 days after challenge. Spleens were weighed and homogenized to determine CFU as a means for assessing the protective response induced by vaccination. PO RB51 was able to protect mice infected with S2308 PO (decreased CFU by 2.5 log) and to mice infected IP (1.5 log decrease). IP RB51 protection was not significant, though CFU was decreased by ~1 log following vaccination via PO and IP. Results indicate that oral inoculation of mice with RB51 is able to give protective immunity against oral infection with virulent strains and that this protection seems to rely on an immune response at the mucosal level (Pasquali et al., 2003).
4	assay of CFU reduction in spleen	1 CFU	Mice were bled and killed at 18 days after challenge. Spleens were weighed and homogenized to determine CFU as a means for assessing the protective response induced by vaccination. PO RB51 was able to protect mice infected with S2308 PO (decreased CFU by 2.5 log) and to mice infected IP (1.5 log decrease). IP RB51 protection was not significant, though CFU was decreased by ~1 log following vaccination via PO and IP. Results indicate that oral inoculation of mice with RB51 is able to give protective immunity against oral infection with virulent strains and that this protection seems to rely on an immune response at the mucosal level (Pasquali et al., 2003).

Description: (Pasquali et al., 2003)

w. Mouse Response

Host Strain: C57BL/6 (IRF-1-/-)
Vaccination Protocol: S2308 (the virulent wild-type Brucella abortus strain), S19 and RB51 (live attenuated vaccine strains), cyd and cbp (insertional mutants), and bap (deletion mutant) were used in this experiments. Interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice. IRF1-/- mice were injected IP with diverse strains and CFU of B. abortus in 200 ul of PBS (Ko et al., 2002).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	IP S19 (5 x 10^1)	5	in volume		female	7.5 week	no	6- to 9-week-old interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice. Mice were injected IP with Brucella abortus strain S19 in 200 ul of PBS. After 6 weeks of infection, surviving mice were challenged with 5 x 10^5 CFU of B. abortus S2308 in 200 ul of PBS (Ko et al., 2002).
2	IP S19 (5 x 10^3)	5	in volume		female	7.5 week	no	6- to 9-week-old interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice. Mice were injected IP with Brucella abortus strain S19 (5000 CFU) in 200 ul of PBS. After 6 weeks of infection, surviving mice were challenged with 5 x 10^5 CFU of B. abortus S2308 in 200 ul of PBS (Ko et al., 2002).
3	IP RB51 (5 x 10^5)	5	in volume		female	7.5 week	no	6- to 9-week-old interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice. Mice were injected IP with Brucella abortus strain RB51 (5 x 10^5) in 200 ul of PBS. After 6 weeks of infection, surviving mice were challenged with 5 x 10^5 CFU of B. abortus S2308 in 200 ul of PBS (Ko et al., 2002).
4	IP RB51 (5 x 10^7 CFU)	5	in volume		female	7.5 week	no	6- to 9-week-old interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice. Mice were injected IP with Brucella abortus strain RB51 (5 x 10^7 CFU) in 200 ul of PBS. After 6 weeks of infection, surviving mice were challenged with 5 x 10^5 CFU of B. abortus S2308 in 200 ul of PBS (Ko et al., 2002).
5	IP cyd mutant (5 x 10^5 CFU)	5	in volume		female	7.5 week	no	6- to 9-week-old interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice. Mice were injected IP with Brucella abortus cyd mutant (5 x 10^5 CFU) in 200 ul of PBS. After 6 weeks of infection, surviving mice were challenged with 5 x 10^5 CFU of B. abortus S2308 in 200 ul of PBS (Ko et al., 2002).
6	IP cyd mutant (5 x 10^7 CFU)	5	in volume		female	7.5 week	no	6- to 9-week-old interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice. Mice were injected IP with Brucella abortus cyd mutant (5 x 10^7 CFU) in 200 ul of PBS. After 6 weeks of infection, surviving mice were challenged with 5 x 10^5 CFU of B. abortus S2308 in 200 ul of PBS (Ko et al., 2002).
7	IP saline	5	in volume		female	7.5 week	yes	6- to 9-week-old interferon regulatory factor 1-deficient (IRF1-/-) mice were originally produced by using C57BL/6 (H-2b) mice. Mice were injected IP with 200 ul of PBS. After 6 weeks of infection, surviving mice were challenged with 5 x 10^5 CFU of B. abortus S2308 in 200 ul of PBS (Ko et al., 2002).

Persistence: To count residual CFU in the spleens or livers of mice, 5 mice from each group were examined at each sampling period. Brucella colonies were counted after a 3-day incubation. Serum glutamic oxalacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) were also quantitatively measured (Ko et al., 2002).
Immune Response: (Ko et al., 2002)
Challenge Protocol: After 6 weeks, surviving IRF1-/- mice were challenged with 5 x 10^5 CFU of S2308 in 200 ul of PBS (Ko et al., 2002).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	500000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	6 week

Efficacy: Interferon regulatory factor 1-deficient (IRF1-/-) mice infected with virulent Brucella abortus (S)2308 at 5 x 10^5 CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF1-/- mice were unable to resolve infection and died. In contrast, IRF1-/- mice survived when infected at 5 x 10^5 CFU with several attenuated Brucella strains (S19, RB51, cbp, and cyd). Brucella-infected mice were also killed 12 days post-infection for histologic analysis (Ko et al., 2002).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	% survival of S19 at 50 CFU	80 CFU	Interferon regulatory factor 1-deficient (IRF1-/-) mice infected with virulent Brucella abortus (S)2308 at 5 x 10^5 CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF1-/- mice were unable to resolve infection and died. In contrast, IRF1-/- mice survived when infected at 5 x 10^5 CFU with attenuated Brucella strains S19 50 CFU (80% survival) and 5000 CFU (87.5%), RB51 at 500000 (62.5-87.5%) and 50000000 CFU (100%), and cyd mutant at 500000 (40-80%) and 50000000 CFU (90%). Brucella-infected mice were also killed 12 days post-infection for histologic analysis (Ko et al., 2002).
2	% survival of S19 at 5000 CFU	87.5 CFU	Interferon regulatory factor 1-deficient (IRF1-/-) mice infected with virulent Brucella abortus (S)2308 at 5 x 10^5 CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF1-/- mice were unable to resolve infection and died. In contrast, IRF1-/- mice survived when infected at 5 x 10^5 CFU with attenuated Brucella strains S19 50 CFU (80% survival) and 5000 CFU (87.5%), RB51 at 500000 (62.5-87.5%) and 50000000 CFU (100%), and cyd mutant at 500000 (40-80%) and 50000000 CFU (90%). Brucella-infected mice were also killed 12 days post-infection for histologic analysis (Ko et al., 2002).
3	% survival of RB51 at 500000 CFU	62.5-87.5 CFU	Interferon regulatory factor 1-deficient (IRF1-/-) mice infected with virulent Brucella abortus (S)2308 at 5 x 10^5 CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF1-/- mice were unable to resolve infection and died. In contrast, IRF1-/- mice survived when infected at 5 x 10^5 CFU with attenuated Brucella strains S19 50 CFU (80% survival) and 5000 CFU (87.5%), RB51 at 500000 (62.5-87.5%) and 50000000 CFU (100%), and cyd mutant at 500000 (40-80%) and 50000000 CFU (90%). Brucella-infected mice were also killed 12 days post-infection for histologic analysis (Ko et al., 2002).
4	% survival of RB51 at 50000000 CFU	100 CFU	Interferon regulatory factor 1-deficient (IRF1-/-) mice infected with virulent Brucella abortus (S)2308 at 5 x 10^5 CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF1-/- mice were unable to resolve infection and died. In contrast, IRF1-/- mice survived when infected at 5 x 10^5 CFU with attenuated Brucella strains S19 50 CFU (80% survival) and 5000 CFU (87.5%), RB51 at 500000 (62.5-87.5%) and 50000000 CFU (100%), and cyd mutant at 500000 (40-80%) and 50000000 CFU (90%). Brucella-infected mice were also killed 12 days post-infection for histologic analysis (Ko et al., 2002).
5	% survival of cyd at 50000000 CFU	40-80 CFU	Interferon regulatory factor 1-deficient (IRF1-/-) mice infected with virulent Brucella abortus (S)2308 at 5 x 10^5 CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF1-/- mice were unable to resolve infection and died. In contrast, IRF1-/- mice survived when infected at 5 x 10^5 CFU with attenuated Brucella strains S19 50 CFU (80% survival) and 5000 CFU (87.5%), RB51 at 500000 (62.5-87.5%) and 50000000 CFU (100%), and cyd mutant at 500000 (40-80%) and 50000000 CFU (90%). Brucella-infected mice were also killed 12 days post-infection for histologic analysis (Ko et al., 2002).
6	% survival of cyd at 50000000 CFU	90 CFU	Interferon regulatory factor 1-deficient (IRF1-/-) mice infected with virulent Brucella abortus (S)2308 at 5 x 10^5 CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF1-/- mice were unable to resolve infection and died. In contrast, IRF1-/- mice survived when infected at 5 x 10^5 CFU with attenuated Brucella strains S19 50 CFU (80% survival) and 5000 CFU (87.5%), RB51 at 500000 (62.5-87.5%) and 50000000 CFU (100%), and cyd mutant at 500000 (40-80%) and 50000000 CFU (90%). Brucella-infected mice were also killed 12 days post-infection for histologic analysis (Ko et al., 2002).

Description: (Ko et al., 2002)

x. Mouse Response

Host Strain: BALB/c, DBA/2
Vaccination Protocol: Young (2–3 month old) or old (16–18 month old) adult female mice (DBA/2 or BALB/c) were infected with either an attenuated Brucella abortus strain that over-expressed superoxide dismutase (RB51-SOD) or with a fully virulent wild-type strain (S2308). They were inoculated intra-peritoneally (IP) with 3.4 x 10^7 CFU or 6 x 10^8 CFU RB51-SOD, or with 2 x 10^4 or 4 x 10^9 CFU S2308. Uninfected control mice were injected with saline alone. Spleens harvested after sacrifice were cultured quantitatively for Brucella. Splenocytes (80–120 x 10^6) from mice were harvested and cultured in the presence of heat-killed B. abortus, purified SOD, or the mitogen concanavalin A (conA). Supernatants were assayed for the presence of cytokines by protein array and ELISA, semi-quantitatively measured by densitometry and the intensity of a given dot-blot compared to the mean of the positive control dots. Blood was obtained via retro-orbital bleeds. Total IgG, IgG1 and IgG2a titers vs. two Brucella proteins, bacterioferritin (BFR) and Cu++/Zn++ SOD, were assessed by ELISA (High et al., 2007).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	Young RB51-SOD (3.4 x 10^7 CFU)	5	in volume		female	2 month	no	Young adult female mice were infected with attenuated Brucella abortus that over-expresses superoxide dismutase (RB51-SOD). They were inoculated intra-peritoneally (IP) with 3.4 x 10^7 CFU. Spleens harvested after sacrifice were cultured quantitatively for brucellae (High et al., 2007).
2	Old RB51-SOD (3.4 x 10^7 CFU)	5	in volume		female	18 month	no	Old (18 month old) adult female mice (DBA/2 or BALB/c) were infected with attenuated Brucella abortus that over-expressed superoxide dismutase (RB51-SOD). They were inoculated intra-peritoneally (IP) with 3.4 x 10^7 CFU (High et al., 2007).
3	Young RB51-SOD (6 x 10^8 CFU)	5	in volume		female	2 month	no	Young (2 month old) adult female mice (DBA/2 or BALB/c) were infected with an attenuated Brucella abortus strain that over-expressed superoxide dismutase (RB51-SOD). They were inoculated intra-peritoneally (IP) with 6 x 10^8 CFU (High et al., 2007).
4	Old RB51-SOD (6 x 10^8 CFU)	5	in volume		female	18 month	no	Old (18 month old) adult female mice (DBA/2 or BALB/c) were infected with an attenuated Brucella abortus strain that over-expressed superoxide dismutase (RB51-SOD). They were inoculated intra-peritoneally (IP) with 6 x 10^8 CFU RB51-SOD (High et al., 2007).
5	Young S2308 (4 x 10^4 CFU)	5	in volume		female	2 month	no	Young (2 month old) adult female mice (DBA/2 or BALB/c) were infected with a fully virulent wild-type Brucella abortus strain (S2308). They were inoculated intra-peritoneally (IP) with 4 x 10^4 CFU S2308 (High et al., 2007).
6	Old S2308 (4 x 10^4 CFU)	5	in volume		female	18 month	no	Old (18 month old) adult female mice (DBA/2 or BALB/c) were infected with a fully virulent wild-type Brucella abortus strain (S2308). They were inoculated intra-peritoneally (IP) with 4 x 10^4 CFU S2308 (High et al., 2007).
7	Young S2308 (2 x 10^4 CFU)	9	in volume		female	2 month	no	Young (2 month old) adult female mice (DBA/2 or BALB/c) were infected with a fully virulent wild-type Brucella abortus strain (S2308). They were inoculated intra-peritoneally (IP) with 2 x 10^4 CFU S2308 (High et al., 2007).
8	Old S2308 (2 x 10^4 CFU)	9	in volume		female	17 month	no	Old (16–18 month old) adult female mice (DBA/2 or BALB/c) were infected with a fully virulent wild-type Brucella abortus strain (S2308). They were inoculated intra-peritoneally (IP) with 2 x 10^4 CFU S2308 (High et al., 2007).
9	Young S2308 (2 x 10^6 CFU)	9	in volume		female	2 month	no	Young (2 month old) adult female mice (DBA/2 or BALB/c) were infected with a fully virulent wild-type Brucella abortus strain (S2308). They were inoculated intra-peritoneally (IP) with 2 x 10^6 (High et al., 2007).
10	Old S2308 (2 x 10^6 CFU)	9	in volume		female	17 month	no	Old (16–18 month old) adult female mice (DBA/2 or BALB/c) were infected with a fully virulent wild-type Brucella abortus strain (S2308). They were inoculated intra-peritoneally (IP) with 2 x 10^6 CFU S2308 (High et al., 2007).
11	Young saline	5	in volume		female	2 month	yes	Young (2–3 month old) adult female control mice (DBA/2 or BALB/c) were inoculated intra-peritoneally (IP) with saline alone (High et al., 2007).
12	Old saline	5	in volume		female	18 month	yes	Old (16–18 month old) adult female control mice (DBA/2 or BALB/c) were inoculated intra-peritoneally (IP) with saline alone (High et al., 2007).

Persistence: All young and old mice survived infection with RB51-SOD (up to 6 x 1^08 CFU) or S2308 (up to 8 x 10^8 CFU). Old mice had a lower organism burden in the spleen than young mice 5 or more weeks after infection (High et al., 2007).
Immune Response: Antibody and cytokine responses were Th1-focused in young mice, but Th-mixed in old mice, including evidence of the Th17 subtype immune response (High et al., 2007).
Challenge Protocol: For protection studies, mice were either immunized with 4 x 10^8 CFU RB51-SOD or saline as a control and allowed to recover for 5 weeks. Mice were then infected with 2 x 10^4 CFU S2308 and sacrificed 2 weeks later for determination of CFU/spleen as above (High et al., 2007).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	20000 CFU in volume ml	Intraperitoneal injection (i.p.)	day	5 week

Efficacy: Immunization with the RB51-SOD strain provided protection vs. strain 2308 challenge in young and aged BALB/c, but only young DBA/2 mice (High et al., 2007).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	1.5 CFU	Mean ± SEM cfu/spleen in old and young adult DBA/2 or BALB/c mice two weeks after infection with S2308 in mice that were either naıve or immunized with RB51-SOD five weeks prior to infection with strain 2308. Immunization with the RB51-SOD strain provided protection vs. strain 2308 challenge in young (~1.5 log decrease) and aged BALB/c (~2 log), but only young (~1 log) not in aged (<1 log) DBA/2 mice .Antibody and cytokine responses were Th1-focused in young mice, but Th-mixed in old mice, including evidence of the Th17 subtype immune response (High et al., 2007).
2	assay of CFU reduction in spleen	2 CFU	Mean ± SEM cfu/spleen in old and young adult DBA/2 or BALB/c mice two weeks after infection with S2308 in mice that were either naıve or immunized with RB51-SOD five weeks prior to infection with strain 2308. Immunization with the RB51-SOD strain provided protection vs. strain 2308 challenge in aged BALB/c (~2 log), but only young (~1 log) not in aged (<1 log) DBA/2 mice .Antibody and cytokine responses were Th1-focused in young mice, but Th-mixed in old mice, including evidence of the Th17 subtype immune response (High et al., 2007).
3	assay of CFU reduction in spleen	1 CFU	Mean ± SEM cfu/spleen in old and young adult DBA/2 or BALB/c mice two weeks after infection with S2308 in mice that were either naıve or immunized with RB51-SOD five weeks prior to infection with strain 2308. Immunization with the RB51-SOD strain provided protection vs. strain 2308 challenge only in young (~1 log) not in aged (<1 log) DBA/2 mice (High et al., 2007).
4	assay of CFU reduction in spleen	0.3 CFU	Mean ± SEM cfu/spleen in old and young adult DBA/2 or BALB/c mice two weeks after infection with S2308 in mice that were either naıve or immunized with RB51-SOD five weeks prior to infection with strain 2308. Immunization with the RB51-SOD strain did not provide protection vs. strain 2308 challenge in aged (<1 log) DBA/2 mice .Antibody and cytokine responses were Th1-focused in young mice, but Th-mixed in old mice, including evidence of the Th17 subtype immune response (High et al., 2007).

y. Mouse Response

Host Strain: BALB/c

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	RB51	5	in volume		female	10 week	no	Female BALB/c mice (10 weeks old) mice were divided into three groups; the first group was injected intraperitonealy (IP) with 5 x 10^8 CFU of the live rough Brucella abortus RB51 vaccine (Hamdy et al., 2002).
2	Rev1	5	in volume		female	10 week	no	Female BALB/c mice (10 weeks old) mice were divided into three groups; the second group was inoculated intraperitonealy (IP) with 5 x 10^8 CFU with smooth B. melitensis Rev. 1 vaccine (Hamdy et al., 2002).
3	PBS	5	in volume		female	10 week	yes	Female BALB/c mice (10 weeks old) mice were divided into three groups; the third group was inoculated intraperitonealy (IP) with 0.2 ml of sterile PBS and kept as a control (Hamdy et al., 2002).

Challenge Protocol: Mice were challenged with a B. melitensis field strain. The humoral immune responses induced in mice after vaccination and challenge were detected by the standard tube agglutination test (SAT), mercaptoethanol test (MET), Rose Bengal plate test (RBPT), and buffered acidified plate antigen test (BAPAT). The detection of immune responses induced by the RB51 vaccine was measured by RB51 killed antigen. Mice were bled under anesthesia from the retroorbital sinus or from heart puncture. Sera were stored at -70C unless used on the same day. Five animals from each of the first and the second groups were sacrificed by CO2 asphyxiation at weekly intervals. Detection of Brucella vaccinal strains in internal organs (spleen, liver and lung) was done at weekly intervals. Two weeks after elimination of the vaccinal strains from the internal organs and disappearance of any serological reactions, the remaining animals and control were challenged with 5 x 10^5 cfu of B. melitensis i.p. in 0.2 ml PBS. Five of the challenged animals from each group were sacrificed every week until the end of the experiment. Sacrificed animals were subjected to serological and bacteriological investigations. Bacteriological examinations and viable counts of the Brucella organisms per spleen following challenge were carried out. Identification of the rough form of the RB51 vaccinal strain was achieved by auto-agglutination reaction with acriflavine solution (1/1000) and the ability to stain with crystal violet (Hamdy et al., 2002).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	B. melitensis field strain bv. 3	500000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	2 week

Efficacy: Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice vaccinated with RB51 gave negative results in the conventional serological tests prior to challenge, standard tube agglutination test (SAT), Rose Bengal plate test (RBPT), buffered acidified plate antigen test (BAPAT), and mercaptoethanol test (MET). Sero-conversion took place to a whole-cell bacterial buffered RB51 antigen after vaccination and persisted for 7 weeks post-vaccination. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Protection units were showed that Rev. 1 vaccine was superior to RB51 vaccine in protection of mice against B. melitensis (Hamdy et al., 2002).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	1.14 CFU	Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Log units of protection (decrease in splenic CFU) were measured at 2 (1.14 log decrease), 3 (1.5 log), 4 (~2 log), 5 (<1 log), 10 (<1 log), and 12 weeks (~1 log) (Hamdy et al., 2002).
2	assay of CFU reduction in spleen	1.5 CFU	Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Log units of protection (decrease in splenic CFU) were measured at 3 (1.5 log), 4 (~2 log), 5 (<1 log), 10 (<1 log), and 12 weeks (~1 log) (Hamdy et al., 2002).
3	assay of CFU reduction in spleen	2 CFU	Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Log units of protection (decrease in splenic CFU) were measured at 4 (~2 log), 5 (<1 log), 10 (<1 log), and 12 weeks (~1 log) (Hamdy et al., 2002).
4	assay of CFU reduction in spleen	0.7 CFU	Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Log units of protection (decrease in splenic CFU) were measured at 5 (<1 log), 10 (<1 log), and 12 weeks (~1 log) (Hamdy et al., 2002).
5	assay of CFU reduction in spleen	0.5 CFU	Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Log units of protection (decrease in splenic CFU) were measured at 10 (<1 log) and 12 weeks (~1 log) (Hamdy et al., 2002).
6	assay of CFU reduction in spleen	1 CFU	Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Log units of protection (decrease in splenic CFU) were measured at 12 weeks (~1 log) (Hamdy et al., 2002).

z. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: This study determined if murine interleukin-12 (IL-12) would influence immunity in mice vaccinated with live or killed Brucella abortus strain RB51 (SRB51). Mice received live or irradiated SRB51 bacteria alone, or with IL-12 (0.5 or 1.0 jig, 2x or 3X), whereas other mice received saline or IL-12 alone. Specifically, female 10-week-old BALB/c AnNHsD mice (n = 12/group) were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 3 x 10^8 CFU of live SRB51 alone, or combined with 0.5 or 1.0 ug of murine recombinant IL-12, administered thrice (days 0, 5, and 21). Additional mice were vaccinated IP with 0.2 mL of saline containing 3 x 10^8 CFU of irradiated SRB51 alone, or combined with 0.5 or 1.0 ug of IL-12 administered twice (days 0 and 5) or thrice. Other mice were injected IP with 0.2 mL of saline alone or with saline containing 0.5 or 1.0 ug of IL-12 administered twice or thrice (Lee et al., 2001).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	live SRB51	12	in volume		female	10 week	no	Mice received live or irradiated Brucella abortus strain RB51 (SRB51) bacteria alone, or with murine interleukin-12 (IL-12) (0.5 or 1.0 ug, 2x or 3x), whereas other mice received saline or IL-12 alone. Specifically, female 10-week-old BALB/c AnNHsD mice (n = 12/group) were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 3 x 10^8 CFU of live SRB51 alone (Lee et al., 2001).
2	live SRB51 + 0.5 ug IL-12	12	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice (n = 12/group) were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 3 x 10^8 CFU of live SRB51 combined with 0.5 ug of murine recombinant IL-12 administered thrice (Lee et al., 2001).
3	live SRB51 + 1.0 ug IL-12	12	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice (n = 12/group) were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 3 x 10^8 CFU of live SRB51 combined with 1.0 ug of murine recombinant IL-12, administered thrice (days 0, 5, and 21). Additional mice were vaccinated IP with 0.2 mL of saline containing 3 x 10^8 CFU of irradiated SRB51 alone, or combined with 0.5 or 1.0 ug of IL-12 administered twice (days 0 and 5) or thrice. Other mice were injected IP with 0.2 mL of saline alone or with saline containing 0.5 or 1.0 ug of IL-12 administered twice or thrice (Lee et al., 2001).
4	killed SRB51	8	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 3 x 10^8 CFU irradiated SRB51 alone (Lee et al., 2001).
5	killed SRB51 + 0.5 ug IL-12	8	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 3 x 10^8 CFU of irradiated SRB51 combined with 0.5 ug of IL-12 administered twice (days 0 and 5) or thrice (Lee et al., 2001).
6	killed SRB51 + 1.0 ug IL-12	12	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 3 x 10^8 CFU of irradiated SRB51 combined with 1.0 ug of IL-12 administered twice (days 0 and 5) or thrice (Lee et al., 2001).
7	saline	12	in volume		female	10 week	yes	Female 10-week-old BALB/c AnNHsD mice were inoculated intraperitoneally (IP) with 0.2 mL of saline alone (Lee et al., 2001).
8	saline + 0.5 ug IL-12	8	in volume		female	10 week	yes	Female 10-week-old BALB/c AnNHsD mice were inoculated intraperitoneally (IP) with 0.2 mL of saline containing 0.5 ug of IL-12 administered twice or thrice (Lee et al., 2001).
9	saline + 1.0 ug IL-12	8	in volume		female	10 week	yes	Female 10-week-old BALB/c AnNHsD mice were inoculated intraperitoneally (IP) with 0.2 mL of saline containing 1.0 ug of IL-12 administered twice or thrice (Lee et al., 2001).

Persistence: Post-vaccination antibody responses to live or killed SRB51 and clearance of live SRB51 from splenic tissue were not influenced by IL-12 treatments (Lee et al., 2001).
Challenge Protocol: Mice were challenged at 12 weeks with 4 x 10^4 CFU of B. abortus strain 2308 (S2308) and were euthanized 2 weeks later. Remaining mice (n = 8/trt) were challenged IP with 4 X 104 cfu of S2308 at 12 wk after vaccination. The time of challenge was based on data from previous studies which demonstrated that a dosage of 5 X 108 cfu of SRB51 is cleared from BALB/c mice by 12 wk after IP vaccination (Lee et al., 2001).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	40000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	12 week

Efficacy: The highest IL-12 treatment increased post-challenge antibody responses when co-administered with killed SRB51. Co-administration of 1.0 ug of IL-12 with live SRB51, but not killed SRB51, reduced S2308 colonization of splenic tissues. Following euthanasia with C02/02 at 2 wk after S2308 challenge, blood, spleens, and livers were obtained from all mice. Spleens were weighed, approximately onehalf was excised for bacteriologic examination and weighed, and remaining tissue was used to prepare spleen cell suspensions. Following weighing, the entire liver was designated for bacteriologic examination. Tissue for bacteriologic examination was stored at -69°C until processed (Lee et al., 2001).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	0.5-1.5 CFU	Co-administration of IL-12 with live SRB51, but not killed SRB51, reduced S2308 colonization of splenic tissues. Colonization of splenic and hepatic tissues as cfu (log1o) at 2 weeks after IP challenge with 4 X 10^4 cfu of S2308. Mice had been vaccinated 12 wk prior to challenge with live or killed SRB51, alone, or in combination with IL-12, or, with saline or IL-12 alone. CFU/g spleen was decreased less in mice vaccinated with live (~1 log less) or killed (0.5 log) SRB51 alone than in mice given IL-12 (~1.5 log) (Lee et al., 1999).
2	assay of CFU reduction in liver	1.5 CFU	Co-administration of IL-12 with live SRB51, but not killed SRB51, reduced S2308 colonization of hepatic tissues. Colonization of tissues as cfu (log1o) at 2 weeks after IP challenge with 4 X 10^4 cfu of S2308. Mice had been vaccinated 12 wk prior to challenge with live or killed SRB51, alone, or in combination with IL-12, or, with saline or IL-12 alone. CFU/g liver was decreased significantly in mice vaccinated with live SRB51 +/- IL-12 (~1.5 log less) but not in mice given killed SRB51 (Lee et al., 1999).

aa. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: The present study was performed to delineate cytokine induction after intraperitoneal (IP) administration of Brucella abortus strain RB51 and subsequent infection with virulent strain B. abortus S2308. Twelve- to 14-week-old BALB/c female mice were allocated to experimental groups consisting of five animals each. Mice were vaccinated IP with 0.2 ml of saline containing 2 x 10^8 CFU of RB51. Unvaccinated control animals remained untreated throughout the experiment (Pasquali et al., 2001).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	RB51	5	in volume		female	13 week	no	Twelve- to 14-week-old BALB/c female mice were vaccinated IP with 0.2 ml of saline containing 2 x 10^8 CFU of RB51 (Pasquali et al., 2001).
2	Saline control	5	in volume		female	13 week	yes	Twelve- to 14-week-old unvaccinated control BALB/c female mice were inoculated IP with 0.2 ml of saline and remained untreated throughout the experiment (Pasquali et al., 2001).

Persistence: Vaccinated mice had higher spleen weights when compared to control animals after vaccination. Vaccination of mice with live RB51 resulted in a pattern of bacterial growth in which peak numbers were seen 18 days after vaccination, followed by a progressive decline. Bacteria were absent in the spleen at 42 days postvaccination. Counts on days 6 and 18 were significantly different (Pasquali et al., 2001).
Immune Response: After vaccination, both Th1 and Th2 cytokine patterns were observed. Of those, the early production of gamma interferon seems to have the prominent role in inducing an immunologically based protection. Spleen weight in vaccinated and infected mice did not increase after challenge and were not significantly different from nonchallenged, vaccinated animals killed 42 days after vaccination. In contrast, spleen weights of unvaccinated and infected mice showed a significant enlargement as early as 6 days after infection. Vaccinated mice were almost refractory to a subsequent challenge infection with B. abortus 2308 cells, exhibiting significantly lower levels of infection compared to unvaccinated infected animals after infection. Vaccination alone induced a number of significant effects upon cytokine expression. Spleen cells from unvaccinated mice stimulated with heat-inactivated RB51 cells did not produce measurable cytokines throughout the course of the experiment. Similarly, spleen cells from vaccinated mice killed 6 and 18 days after vaccination did not produce measurable bio-active IL-12 (p70) when stimulated in vitro, but a low level of production was detectable in spleen cells from mice killed 42 days after vaccination (Pasquali et al., 2001).
Challenge Protocol: At 42 days after vaccination, unvaccinated controls and IP vaccinated mice were challenged IP with 0.2 ml of saline containing 2 x 10^4 CFU of B. abortus 2308. At 6, 18, and 42 days after vaccination and 3, 6, and 10 days after challenge, mice were euthanatized and spleens were aseptically removed. Approximately one-third of the spleen was weighed and homogenized in PBS, and an aliquot of the resulting cell suspension was plated to determine the number of CFU. The remaining 2/3 of the spleens were weighed, minced, and used to prepare spleen cell suspensions. Cytokine expression was assayed in culture supernatants of splenocytes stimulated with 10^8 heat-inactivated B. abortus RB51 or 2308 bacteria per well. Cytokines were detected by ELISA according to the manufacturer’s instructions (Pasquali et al., 2001).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	20000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	42 day

Efficacy: RB51 confers a solid immunity that protects mice against a challenge infection with virulent B. abortus 2308. After vaccination, both Th1 and Th2 cytokine patterns were observed. Protection may be more dependent upon the timing of the cytokine response rather than on the absolute level of cytokine expression. Challenge infection of vaccinated and nonvaccinated mice induced even more marked increases in cytokine expression patterns. IL-12 p40 was detectable in spleen cells from both vaccinated and unvaccinated mice after challenge infection, and there were no significant differences between vaccinated and unvaccinated mice. Similar results were seen throughout the course of the experiment for IL-12 p70 production, which was low at all times in all groups of mice. In contrast, IFN- production was detectable as early as 3 days after challenge infection in spleen cells from both vaccinated and unvaccinated mice, although levels were significantly higher in vaccinated mice. Levels of IFN in spleen cells from vaccinated, challenged mice showed no differences throughout the experiment, in contrast to spleen cells from unvaccinated, challenged mice which showed increased IFN production that reached levels seen in spleen cells from vaccinated, challenged mice 6 days after challenge. After challenge infection, low levels of IL-4 were detectable, reaching a peak in spleen cells 6 days after challenge. However, levels were not different between vaccinated and unvaccinated mice. IL-10 showed a pattern similar to that of IFN-. IL-10 was detectable in both vaccinated and unvaccinated mice after challenge infection. However, vaccinated and challenged animals did not show any differences at different times after challenge. Conversely, IL-10 production in unvaccinated, challenged mice was first detectable 6 days after challenge infection and reached a peak 10 days after challenge infection. Results of this study indicated that mice vaccinated with RB51 cells were protected as early as 3 days after a challenge infection with virulent B. abortus 2308 cells. In vaccinated mice, challenge infection resulted in high levels of IL-10 production at all times tested. In contrast, in unvaccinated mice, IL-10 production reached levels comparable to that in the vaccinated mice beginning 6 days after infection. Previous studies indicate that both IL-10 and IFN- are produced following a B. abortus infection and that IL-10 induction does not down-regulate IFN- production. This implies that in brucellosis, the effect of IL-10 on the immune response is to limit the consequences of an exaggerated proinflammatory response more than to counterbalance the production of Th1 cytokines. These findings are in agreement with others which measured IL-10 production following Brucella infection (Pasquali et al., 2001).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	1.1 CFU	At 3, 6, and 10 days after challenge, mice were euthanatized and spleens were aseptically removed and used to determine the number of CFU and cytokine expressionvia ELISA. RB51 confers a solid immunity that protects mice against a challenge infection with virulent B. abortus 2308. Both Th1 and Th2 cytokine patterns were observed. Challenge infection of vaccinated and nonvaccinated mice induced even more marked increases in cytokine expression patterns. Persistence of B. abortus S2308 in spleens of vaccinated and unvaccinated mice was also analyzed as splenic CFU decrease at 3 days (1.1 log less than unvaccinated controls), 6 days (2.2 log less), and 10 days (2.4 log) post-challenge (Pasquali et al., 2001).
2	assay of CFU reduction in spleen	2.2 CFU	At 3, 6, and 10 days after challenge, mice were euthanatized and spleens were aseptically removed and used to determine the number of CFU and cytokine expressionvia ELISA. RB51 confers a solid immunity that protects mice against a challenge infection with virulent B. abortus 2308. Both Th1 and Th2 cytokine patterns were observed. Challenge infection of vaccinated and nonvaccinated mice induced even more marked increases in cytokine expression patterns. Persistence of B. abortus S2308 in spleens of vaccinated and unvaccinated mice was also analyzed as splenic CFU decrease at 3 days (1.1 log less than unvaccinated controls), 6 days (2.2 log less), and 10 days (2.4 log) post-challenge (Pasquali et al., 2001).
3	assay of CFU reduction in spleen	2.4 CFU	At 3, 6, and 10 days after challenge, mice were euthanatized and spleens were aseptically removed and used to determine the number of CFU and cytokine expressionvia ELISA. RB51 confers a solid immunity that protects mice against a challenge infection with virulent B. abortus 2308. Both Th1 and Th2 cytokine patterns were observed. Challenge infection of vaccinated and nonvaccinated mice induced even more marked increases in cytokine expression patterns. Persistence of B. abortus S2308 in spleens of vaccinated and unvaccinated mice was also analyzed as splenic CFU decrease at 3 days (1.1 log less than unvaccinated controls), 6 days (2.2 log less), and 10 days (2.4 log) post-challenge (Pasquali et al., 2001).

ab. Mouse Response

Host Strain: Deer mouse (Peromyscus maniculatus)
Vaccination Protocol: This study was designed to determine effects of strain RB51 on deer mice (Peromyscus maniculatus), a nontarget species that could have access to treated baits in a field situation. 90 mice were orally dosed (PO) or intraperitoneally injected (IP) with 1 x 10^8 colony forming units (CFU) strain RB51, and 77 controls were similarly dosed with sterile saline. At weekly intervals for 2 months, 4-6 mice from each group were euthanized, gross necropsies performed, spleens and uteruses cultured, and tissues examined histologically (Cook et al., 2001).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	IP saline	37	in volume		female	3-5 month	yes	One hundred eighty captive raised 3–5 mo-old deer mice were randomly divided into four groups of 45 each containing approximately equal numbers of males and nonpregnant females. Mice were given a 2 wk acclimation period prior to beginning the experiment. To allow comparison of oral inoculation (PO) with intraperitoneal inoculation (IP), the standard test method in laboratory mice, both IP and PO experimental groups were established. Because some mortality occurred during the acclimation period, some groups had fewer than 45 mice remaining. One group (n = 37) of mice was injected IP with 0.2 ml of 0.85% sterile saline pH 7.0. Every week for 8 wk beginning 1 wk post inoculation (WPI) 4-6 mice were euthanized via cervical dislocation and necropsied (Cook et al., 2001).
2	PO saline	40	in volume		female	3-5 month	yes	One hundred eighty captive raised 3–5 mo-old deer mice were randomly divided into four groups of 45 each containing approximately equal numbers of males and nonpregnant females. Mice were given a 2 wk acclimation period prior to beginning the experiment. To allow comparison of oral inoculation (PO) with intraperitoneal inoculation (IP), the standard test method in laboratory mice, both IP and PO experimental groups were established. Because some mortality occurred during the acclimation period, some groups had fewer than 45 mice remaining. One group of mice (n = 40) was orally dosed with 0.2 ml of 0.85% saline via a tuberculin syringe (without a needle). Every week for 8 wk beginning 1 wk post inoculation (WPI) 4-6 mice were euthanized via cervical dislocation and necropsied (Cook et al., 2001).
3	IP RB51	45	in volume		female	3-5 month	no	One hundred eighty captive raised 3–5 mo-old deer mice were randomly divided into four groups of 45 each containing approximately equal numbers of males and nonpregnant females. Mice were given a 2 wk acclimation period prior to beginning the experiment. To allow comparison of oral inoculation (PO) with intraperitoneal inoculation (IP), the standard test method in laboratory mice, both IP and PO experimental groups were established. Because some mortality occurred during the acclimation period, some groups had fewer than 45 mice remaining. One group of mice (n = 45) was injected IP with 0.2 ml of 85% sterile saline pH 7.0 containing 1 x 10^8 colony forming units (CFU) of Brucella abortus strain RB51. Every week for 8 wk beginning 1 wk post inoculation (WPI) 4-6 mice were euthanized via cervical dislocation and necropsied (Cook et al., 2001).
4	PO RB51	45	in volume		female	3-5 month	no	One hundred eighty captive raised 3–5 mo-old deer mice were randomly divided into four groups of 45 each containing approximately equal numbers of males and nonpregnant females. Mice were given a 2 wk acclimation period prior to beginning the experiment. To allow comparison of oral inoculation (PO) with intraperitoneal inoculation (IP), the standard test method in laboratory mice, both IP and PO experimental groups were established. Because some mortality occurred during the acclimation period, some groups had fewer than 45 mice remaining. The last group of mice (n = 45) was orally dosed with 0.2 ml of 0.85% sterile saline pH 7.0 containing 1 x 10^8 CFU of RB51. Every week for 8 wk beginning 1 wk post inoculation (WPI) 4-6 mice were euthanized via cervical dislocation and necropsied (Cook et al., 2001).

Persistence: All PO inoculated mice cleared the infection by 6 weeks post-inoculation (wpi). While most of the injected mice cleared the infection by 7 wpi, a few required 9 w. With one possible exception (see below), no lesions attributable to brucellosis were noted on gross necropsy. Mice orally inoculated with RB51 developed low level splenic infections with strain RB51, but all were negative by 6 wk PI. RB51 was isolated from the uterus of one orally inoculated mouse necropsied 2 wk PI; no other orally inoculated mouse had a uterine infection. IP inoculated mice had a higher rate of splenic and uterine infections and took longer to clear the infections than orally inoculated mice with some remaining positive at 8 wk PI (Cook et al., 2001).
Immune Response: Nine of the 20 (45%) orally inoculated (PO) RB51 mice necropsied in the first 4 wk post-inoculation (WPI) had mild multifocal pleocelluar inflammatory infiltrates in the liver; 3/25 (12%) PO RB51 mice necropsied after 4 WPI had similar lesions. All 10 of the RB51 IP mice necropsied in the first 2 WPI had multifocal pleocellular inflammatory infiltrates in the liver; 2/10 (20%) RB51 IP mice necropsied 3-4 WPI had similar lesions, and only 1 necropsied after 4 WPI from this group had these lesions. Generally, lesions in the IP group were more severe (more cellular infiltrates) than in the PO RB51 group. Lesions were milder in mice at longer times PI. One PO RB51 male mouse necropsied 5 WPI had a mild lymphocytic infiltrate in the interstitium of the seminal vesicle, but no RB51 was recovered from the spleen. Culture results were usually correlated with histologic lesions. Mice with the highest number of colonies of RB51 isolated were those with the most severe lesions (Cook et al., 2001).
Side Effects: There were minimal adverse effects attributable to strain RB51. RB51 would not negatively impact P. maniculatus populations if it were used in a field situation. Incidental findings found in some mice in all groups included: mild myocarditis (19% of controls; 30% of RB51 inoculates), mild metritis (10% of controls; 5% of RB51 inoculates), mild multifocal pyogranulomatous pneumonia (8% of controls; 5% of RB51 inoculates), and nematodes in the small intestines and/or cecum (54% of controls; 33% of RB51 inoculates). In a field situation, deer mice would only be exposed to the vaccine PO and not IP. All the orally exposed animals remained clinically healthy with no evidence of illness. Orally exposed mice had fewer CFU cultured from their spleens and uteruses, cleared the vaccine more quickly, and had milder lesions than mice inoculated IP. Strain RB51, with the possible exception of one IP inoculated animal, did not cause significant morbidity or mortality (Cook et al., 2001).

ac. Mouse Response

Host Strain: Deer mice (Peromyscus maniculatus)
Vaccination Protocol: Deer mice (Peromyscus maniculatus, n = 14) were orally inoculated (PO) with Brucella abortus strain SRB51 or physiologic saline. Oral and rectal swabs and blood samples were collected for bacteriologic evaluation. Rodents were necropsied at 8-10 wk and 12-21 wk post inoculation (WPI). Spleen, liver and reproductive tissues were collected for bacteriologic and histopathologic evaluation (Januszewski et al., 2001).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	RB51	14	in volume		female	day	no	21 mature deer mice of either sex selected from a breeding colony located at the National Wildlife Research Center were maintained individually in the Animal Research Building. Deer mice were randomly divided into SRB51-inoculated (n = 14) and control (n = 7) groups. SRB51-inoculated deer mice orally (PO) received SRB51 in a 1 ml volume. Control animals were given the same oral volume of physiologic saline PO. All animals were observed daily. Oral and rectal swabs were collected from all deer mice prior to inoculation and weekly throughout the study. At necropsy, tissues were evaluated for gross lesions and bacteriologic and histologic evaluation (Januszewski et al., 2001).
2	Saline control	7	in volume		female	day	yes	21 mature deer mice of either sex selected from a breeding colony located at the National Wildlife Research Center were maintained individually in the Animal Research Building. Deer mice were randomly divided into SRB51-inoculated (n = 14) and control (n = 7) groups. SRB51-inoculated deer mice orally (PO) received SRB51 in a 1 ml volume. Control animals were given the same oral volume of physiologic saline PO. All animals were observed daily. Oral and rectal swabs were collected from all deer mice prior to inoculation and weekly throughout the study. At necropsy, tissues were evaluated for gross lesions and bacteriologic and histologic evaluation (Januszewski et al., 2001).

Persistence: No differences in clinical signs, appetite, weight loss or gain, or activity were observed between saline- and SRB51-inoculated animals. Oral and rectal swabs were negative throughout the study. In tissues obtained from SRB51-inoculated animals, the organism was isolated from 1/6 (17%) deer mice necropsied at 8 WPI. SRB51 was not recovered from deer mice necropsied 12 WPI. SRB51 was not recovered from saline-inoculated deer mice at any time. Results indicate oral exposure to SRB51 does not produce morbibity or mortality in deer mice (Januszewski et al., 2001).
Side Effects: One SRB51-inoculated mouse died immediately after inoculation, and one control mouse died at 4 days PI. Deaths were attributed to handling and probable aspiration of the inoculum. Results indicate oral exposure to SRB51 does not produce morbibity or mortality in deer mice (Januszewski et al., 2001).

ad. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Six-week-old BALB/c female mice were inoculated intraperitoneally (IP) with 4 x 10^8 CFU of Brucella abortus strains RB51 or S2308 or the same volume of saline (negative control). The mice were euthanatized at 6 weeks postimmunization (wpi) by CO2 inhalation. These mice served as splenocyte sources for CTL assays. Splenocytes from strain RB51-infected or saline-inoculated mice were resuspended in 2 ml of c-RPMI and passed through nylon wool columns to enrich for cytotoxic T lymphocytes (CTLs). After 5-day incubation, cells were collected, and live effector cells were obtained by removing dead cells by Histopaque centrifugation. CTLs were also collected and used for flow cytometric analysis, magnetic cell sorting, and colorimetric CTL assay (He et al., 2001).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	RB51	3	in volume		female	6 week	no	Six-week-old BALB/c female mice were inoculated intraperitoneally (IP) with 4 x 10^8 CFU of Brucella abortus strain RB51. The mice were euthanatized at 6 weeks postimmunization (wpi) by CO2 inhalation. These mice served as splenocyte sources for CTL assays. Splenocytes from strain RB51-infected or saline-inoculated mice were resuspended in 2 ml of c-RPMI and passed through nylon wool columns to enrich for cytotoxic T lymphocytes (CTLs). After 5-day incubation, cells were collected, and live effector cells were obtained by removing dead cells by Histopaque centrifugation. CTLs were also collected and used for flow cytometric analysis, magnetic cell sorting, and colorimetric CTL assay (He et al., 2001).
2	S2308	3	in volume		female	6 week	no	Six-week-old BALB/c female mice were inoculated IP with 4 x 10^8 CFU of S2308. The mice were euthanatized at 6 wpi by CO2 inhalation. These mice served as splenocyte sources for CTL assays. Splenocytes from strain RB51-infected or saline-inoculated mice were resuspended in 2 ml of c-RPMI and passed through nylon wool columns to enrich for CTLs. After 5-day incubation, cells were collected, and live effector cells were obtained by removing dead cells by Histopaque centrifugation. CTLs were also collected and used for flow cytometric analysis, magnetic cell sorting, and colorimetric CTL assay (He et al., 2001).
3	Saline control	3	in volume		female	6 week	yes	Six-week-old BALB/c female mice were inoculated IP with 4 x 10^8 CFU of RB51 or S2308 or the same volume of saline (negative control). The mice were euthanatized at 6 wpi by CO2 inhalation. These mice served as splenocyte sources for CTL assays. Splenocytes from strain RB51-infected or saline-inoculated mice were resuspended in 2 ml of c-RPMI and passed through nylon wool columns to enrich for CTLs. After 5-day incubation, cells were collected, and live effector cells were obtained by removing dead cells by Histopaque centrifugation. CTLs were also collected and used for flow cytometric analysis, magnetic cell sorting, and colorimetric CTL assay (He et al., 2001).

Immune Response: RB51 vaccination of mice induces specific CTLs and suggest that CD3+ CD4+ and CD3+ CD8+ T cells play a synergistic role in the anti-Brucella activity. Specifically, Brucella abortus strain RB51 vaccination of mice induced specific cytotoxic T lymphocytes (CTLs) against both RB51- and virulent strain 2308-infected J774.A1 macrophages but not against Listeria monocytogenes-infected J774.A1 cells. The antigen-specific cytotoxic activity was exerted by CTLs but not by NK cells. CD3+ CD4+ T cells secreted the highest level of gamma interferon (IFN) and were able to exert a low but significant level of specific lysis of Brucella-infected macrophages. They also exerted a low level of nonspecific lysis of noninfected macrophages. In contrast, CD3+ CD8+ T cells secreted low levels of IFN-g but demonstrated high levels of specific lysis of Brucella-infected macrophages with no nonspecific lysis (He et al., 2001).
Efficacy: RB51 vaccination of mice resulted in the development of a strong cytotoxic T-cell (CTL) response. The specific anti-Brucella cytolytic activity was mainly exerted by CD3+ CD8+ T cells. CD3+ CD4+ T cells also developed after immunization, secreted high levels of IFN, and exhibited certain levels of specific and nonspecific lytic activity against Brucella-infected target cells. NK cells appeared not to contribute significantly to the observed Brucella-specific cytotoxic activity (He et al., 2001).

ae. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: This study was designed to determine if a single 0.5 ug administration of recombinant murine interleukin-12 (IL-12) would influence immune responses of mice vaccinated with live or killed Brucella abortus strain RB51 (SRB51). A total of 180 (n = 30/treatment) female 10-week-old BALB/c AnNHsD mice were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 5 x 10^8 cfu of live or gamma-irradiated SRB51 bacteria alone, or in combination with 0.5 ug of IL-12. Control mice received saline +/- 0.5 ug of IL-12 (Lee et al., 1999).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	Saline control	30	in volume		female	10 week	yes	A total of 30 female 10-week-old BALB/c AnNHsD mice were vaccinated IP with 0.2 mL of saline (Lee et al., 1999).
2	Saline + IL-12	30	in volume		female	10 week	yes	A total of 30 female 10-week-old BALB/c AnNHsD mice were vaccinated intraperitoneally (IP) with 0.2 mL of saline + 0.5 ug of IL-12 (Lee et al., 1999).
3	Live SRB51	30	in volume		female	10 week	no	A total of 30 female 10-week-old BALB/c AnNHsD mice were vaccinated intraperitoneally (IP) with 0.2 mL of saline containing 5 x 10^8 cfu of live SRB51 bacteria alone (Lee et al., 1999).
4	Irradiated SRB51	30	in volume		female	10 week	no	A total of 30 female 10-week-old BALB/c AnNHsD mice were vaccinated IP with 0.2 mL of saline containing 5 x 10^8 cfu of gamma-irradiated SRB51 bacteria alone (Lee et al., 1999).
5	Live SRB51 + IL-12	30	in volume		female	10 week	no	A total of 30 female 10-week-old BALB/c AnNHsD mice were vaccinated IP with 0.2 mL of saline containing 5 x 10^8 cfu of live SRB51 in combination with 0.5 ug of IL-12 (Lee et al., 1999).
6	Irradiated SRB51 + IL-12	30	in volume		female	10 week	no	A total of 30 female 10-week-old BALB/c AnNHsD mice were vaccinated IP with 0.2 mL of saline containing 5 x 10^8 cfu of gamma-irradiated SRB51 bacteria in combination with 0.5 ug of IL-12 (Lee et al., 1999).

Persistence: Mice vaccinated with live SRB51 or live SRB51+IL-12 had greater serum antibody titers against SRB51 at 2, 4, 8, and 12 wpv when compared to all other treatments. When combined with live or killed SRB51, IL-12 as an adjuvant did not influence serologic responses at 2, 4, 8, or 12 wpv. In the absence of IL-12 as an adjuvant, spleen cells obtained at 12 wk after IP vaccination with live SRB51 had greater stimulation indexes against irradiated S2308 when compared to responses of spleen cells from other treatments. Administration of IL-12 as an adjuvant with live or killed SRB51 did not enhance lymphocyte proliferative responses to S2308 (Lee et al., 1999).
Challenge Protocol: Mice (n = 10/treatment) were challenged IP with 2 X 10^4 cfu of S2308 at 12 weeks post-vaccination (wpv). Blood samples and spleens were obtained from mice in all treatments after CO2/O2 euthanasia at 2, 4, 8, and 12 wpv (n = 5/treatment/time). Following C02/02 euthanasia at 2 weeks after S2308 challenge (wpc), blood and spleens were obtained from mice in all treatments (n = 10/treatment). Cells from 5 mice from each treatment were evaluated separately at 2, 4, 8, and 12 wpv. Following S2308 challenge, spleen cell suspensions from 10 mice from each treatment were combined into 5 separate suspensions (2 mice/suspension, 5 suspensions/treatment) for evaluation of lymphocyte proliferative responses. Cell proliferation results were expressed as stimulation indices (counts/min in presence of antigen divided by counts/min in medium only) (Lee et al., 1999).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	20000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	12 week

Efficacy: The clearance of SRB51 from spleens of mice vaccinated with live SRB51 alone, or in combination with IL-12, did not differ at 2, 4, 8, or 12 wk after vaccination. At 12 wk after vaccination, spleens of mice vaccinated with either live SRB51 or live SRB51+IL-12 were culture negative for SRB51. IL-12 did not influence the clearance of strain RB51 from splenic tissue. Spleen weights of mice vaccinated with live SRB51 or live SRB51+IL-12 were greater at 2, 4, 8, or 12 wpv when compared to saline controls, IL-12 controls, or mice receiving either vaccination treatment using killed SRB51. Addition of exogenous IL-12 to culture supernatants of spleen cells obtained at 4 and 8 wk, but not at 2 or 12 wpv, enhanced lymphocyte proliferative responses of all vaccine treatments. Maximal enhancement of lymphocyte response was associated with
the addition of IL-12. Mice vaccinated with live SRB51 (5 X 108 cfu) had lower spleen weights, total spleen cfu, and spleen cfu/g following challenge at 12 wk after vaccination when compared to mice receiving saline control, IL-12 control, or killed SRB51 treatments. Administration of IL-12 as an adjuvant with live or killed SRB51 did not enhance resistance against experimental challenge with S2308 (Lee et al., 1999).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	2 CFU	Colonization of splenic tissues 2 wk following IP challenge with 2 x 10^4 cfu of S2308 was analyzed via resulting CFU/g spleen +/- IL-12. Mice vaccinated with live SRB51 had lower total spleen cfu and spleen cfu/g (>2 log decreased CFU) following challenge at 12 wk after vaccination when compared to mice receiving saline control, IL-12 control (~0.5 log decreased), or killed (~1 log) SRB51 treatments. Administration of IL-12 as an adjuvant with live or killed SRB51 did not enhance resistance against experimental challenge with S2308 (Lee et al., 1999).
2	assay of CFU reduction in spleen	0.5 CFU	Colonization of splenic tissues 2 wk following IP challenge with 2 x 10^4 cfu of S2308 was analyzed via resulting CFU/g spleen +/- IL-12. Mice vaccinated with live SRB51 had lower total spleen cfu and spleen cfu/g (>2 log decreased CFU) following challenge at 12 wk after vaccination when compared to mice receiving saline control, IL-12 control (~0.5 log decreased), or killed (~1 log) SRB51 treatments. Administration of IL-12 as an adjuvant with live or killed SRB51 did not enhance resistance against experimental challenge with S2308 (Lee et al., 1999).
3	assay of CFU reduction in spleen	1 CFU	Colonization of splenic tissues 2 wk following IP challenge with 2 x 10^4 cfu of S2308 was analyzed via resulting CFU/g spleen +/- IL-12. Mice vaccinated with live SRB51 had lower total spleen cfu and spleen cfu/g (>2 log decreased CFU) following challenge at 12 wk after vaccination when compared to mice receiving saline control, IL-12 control (~0.5 log decreased), or killed (~1 log) SRB51 treatments. Administration of IL-12 as an adjuvant with live or killed SRB51 did not enhance resistance against experimental challenge with S2308 (Lee et al., 1999).

af. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Immune responses and resistance to infection with Brucella abortus 2308 (S2308) were measured in mice following oral (PO) or intraperitoneal (IP) vaccination with strain RB51 (SRB51). Female 10-week-old BALB/c AnNHsD mice were used in the following experiments. Lyophilized SRB51 reconstituted in a 0.15 M NaCl saline solution was used to vaccinate PO by placing 20 ml of saline containing 5 x 10^8 or 5 x 10^6 CFU onto the pharyngeal mucosa. Additional groups of mice were vaccinated IP with 0.2 ml of saline containing 5 x 10^8 or 5 x 10^6 CFU of SRB51. Nonvaccinated control mice were injected IP with 0.2 ml of saline alone (Stevens et al., 1996).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	PO SRB51 5 x 10^8 CFU	12	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice were vaccinated PO by placing 20 ml of saline containing 5 x 10^8 CFU onto the pharyngeal mucosa (Stevens et al., 1996).
2	PO SRB51 5 x 10^6 CFU	12	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice were given lyophilized SRB51 reconstituted in a 0.15 M NaCl saline solution PO by placing 20 ml of saline containing 5 x 10^6 CFU onto the pharyngeal mucosa (Stevens et al., 1996).
3	IP SRB51 5 x 10^8 CFU	12	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice were given lyophilized SRB51 reconstituted in a 0.15 M NaCl saline solution was used to vaccinate mice IP with 0.2 ml of saline containing 5 x 10^8 CFU of SRB51 (Stevens et al., 1996).
4	IP SRB51 5 x 10^6 CFU	12	in volume		female	10 week	no	Female 10-week-old BALB/c AnNHsD mice were given lyophilized SRB51 reconstituted in a 0.15 M NaCl saline solution and were vaccinated IP with 0.2 ml of saline containing 5 x 10^6 CFU of SRB51 (Stevens et al., 1996).
5	IP Saline control	12	in volume		female	10 week	yes	Female 10-week-old BALB/c AnNHsD mice were injected IP with 0.2 ml of saline alone (Stevens et al., 1996).

Persistence: Bacteria persisted in the parotid lymph node for 4 weeks following PO vaccination of mice with 5 x 10^8 or 5 X 10^6 CFU of SRB51. Bacteria did not appear in the spleen during 12 weeks after PO vaccination, whereas they did appear in the spleen for 8 weeks following IP vaccination of mice with SRB51. Increased resistance to S2308 infection occurred at 12-20 weeks in mice vaccinated IP with SRB51 but occurred at 12 weeks only in mice vaccinated PO with 5 x 10^8 CFU SRB51 (Stevens et al., 1996).
Immune Response: Oral SRB51 vaccination induced lower levels of antibodies to the surface antigens of intact SRB51 bacteria than did IP vaccination (Stevens et al., 1996).
Challenge Protocol: Nonvaccinated control mice and vaccinated mice at 12, 16, or 20 weeks after vaccination were challenged with S2308 by an IP injection of 2 x 10^4 CFU in 0.2 ml of 0.15 M NaCl saline solution (Stevens et al., 1996).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	S2308	20000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	12 week
2	S2308	20000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	16 week
3	S2308	20000 CFU in volume 0.2 ml	Intraperitoneal injection (i.p.)	day	20 week

Efficacy: Neither route of vaccination induced anamnestic antibody responses to the surface antigens of intact S2308 bacteria after challenge infection of the vaccinated mice with S2308. Mice vaccinated PO with SRB51 and challenged with S2308 at 12-20 weeks had lower and less persistent spleen cell proliferation and production of gamma interferon (IFN) in response to S2308 and certain immunodominant S2308 proteins (<18-32 kDa) than did mice vaccinated IP with SRB51. However, mice had similar spleen cell tumor necrosis factor alpha (TNF) production. These results indicate that PO vaccination of mice with SRB51 was effective in inducing protective immunity to S2308 infection, although the immunity was lower and less persistent than that induced by IP vaccination. The lower protective immunity induced by oral vaccination may have resulted from lower and less persistent cell-mediated immunity and IFN production in response to S2308 and S2308 proteins (Stevens et al., 1996).

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	assay of CFU reduction in spleen	2-3 CFU	Increased resistance to S2308 infection, as measured by splenic CFU reduction, occurred at 12-20 weeks in mice vaccinated IP with SRB51 but occurred at 12 weeks only in mice vaccinated PO. Resistance to infection in SRB51-vaccinated mice following challenge infection with S2308. Mice were challenged with S2308 at 12, 16, or 20 weeks after IP or PO vaccination with SRB51. CFU reduction was greatest following IP SRB51 vaccination with 5 x 10^8 CFU (2-3 log decrease at 12-20 weeks post-challenge) and with 5 x 10^6 CFU (1.5-2 log decrease). PO SRB51 vaccination led to less of a reduction, whether used at 5 x 10^8 CFU (0.3-1 log decrease) or at 5 x 10^6 CFU (0-0.3 log decrease) (Stevens et al., 1996).
2	assay of CFU reduction in spleen	1.5-2 CFU	Increased resistance to S2308 infection, as measured by splenic CFU reduction, occurred at 12-20 weeks in mice vaccinated IP with SRB51 but occurred at 12 weeks only in mice vaccinated PO. Resistance to infection in SRB51-vaccinated mice following challenge infection with S2308. Mice were challenged with S2308 at 12, 16, or 20 weeks after IP or PO vaccination with SRB51. CFU reduction was greatest following 5 x 10^6 CFU (1.5-2 log decrease). PO SRB51 vaccination led to less of a reduction, whether used at 5 x 10^8 CFU (0.3-1 log decrease) or at 5 x 10^6 CFU (0-0.3 log decrease) (Stevens et al., 1996).
3	assay of CFU reduction in spleen	0.3-1 CFU	Increased resistance to S2308 infection, as measured by splenic CFU reduction, occurred at 12-20 weeks in mice vaccinated IP with SRB51 but occurred at 12 weeks only in mice vaccinated PO. Resistance to infection in SRB51-vaccinated mice following challenge infection with S2308. Mice were challenged with S2308 at 12, 16, or 20 weeks after IP or PO vaccination with SRB51. PO SRB51 vaccination led to less of a reduction, whether used at 5 x 10^8 CFU (0.3-1 log decrease) or at 5 x 10^6 CFU (0-0.3 log decrease) (Stevens et al., 1996).
4	assay of CFU reduction in spleen	0-0.3 CFU	Increased resistance to S2308 infection, as measured by splenic CFU reduction, occurred at 12-20 weeks in mice vaccinated IP with SRB51 but occurred at 12 weeks only in mice vaccinated PO. Resistance to infection in SRB51-vaccinated mice following challenge infection with S2308. Mice were challenged with S2308 at 12, 16, or 20 weeks after IP or PO vaccination with SRB51. PO SRB51 vaccination led to less of a reduction, just a 0-0.3 log decrease at 5 x 10^6 CFU (Stevens et al., 1996).

ag. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: BALB/c mice were inoculated intraperitoneally (IP) with suspensions of Brucella abortus strains 2308 or RB51 or an htrA mutant. Spleens were examined on post-inoculation day (PID) 2, 4, 7, 10, 15, 21, 30, and 60. 132 male BALB/c mice were infected with either one of the 3 B. abortus strains or with saline as a control (Palmer et al., 1996).

Vaccination Groups:

No.	Group Name	Number of Animals	Dose	Route	Gender	Age	Control Group?	Comment	Vaccination Detail
1	S2308 group	42	in volume		male	day	yes	BALB/c mice were inoculated IP with 1 x 10^4 CFU S2308 in 0.2 ml saline (Palmer et al., 1996).
2	RB51 group	42	in volume		male	day	no	BALB/c mice were inoculated IP with RB51 (5 x 10^7 CFU) in 0.2 ml saline (Palmer et al., 1996).
3	htrA group	42	in volume		male	day	no	BALB/c mice were inoculated IP with an htrA mutant strain (5 x 10^4 CFU) in 0.2 ml saline (Palmer et al., 1996).
4	Saline control	6	in volume		male	day	yes	Control BALB/c mice were injected IP with 0.2 ml saline alone (Palmer et al., 1996).

Persistence: Brucellae were cultured in high numbers from the spleens of mice infected with strains 2308 or htrA through PID 60; however, mice infected with RB51 cleared the infection between PID 30 and 60. Histopathologic changes in spleens from 2308-infected mice were characterized by marked accumulations of macrophages, which expanded marginal zones beginning as early as PID 7 and persisting through PID 60. Morphometric analysis showed a decrease in splenic white pulp in 2308-infected mice at PID 10, which correlated with the peak of bacterial infection. Although this decrease was significant when compared with values at previous and following time periods, it was not significantly different from white pulp values noted at PID 2 or 4 or the values for control spleens (Palmer et al., 1996).
Immune Response: Spleens from RB51-infected mice showed only mild to moderate accumulations of macrophages in marginal zone areas during the peak of RB51 infection (PID 7-10). Morphometric analysis of RB51-infected spleens showed a decrease in white pulp area, which coincided with peak bacterial numbers. However, this decrease was not significant. Spleens from mice infected with htrA showed moderate to marked accumulations of macrophages in marginal zone areas, which persisted through PID 60. Multifocal necrosis in lymphoid follicles as early as PID 4 was seen in both htrA and 2308 infection (Palmer et al., 1996).
Efficacy: Morphometric analysis of htrA-infected spleens revealed no significant decrease in white pulp and no obvious correlation with bacterial numbers in the spleen. These results suggest that virulent B. abortus does not induce lymphoid depletion significantly below those values seen in noninfected mice; thus, the possible role of lymphoid depletion in the pathogenesis of brucellosis remains questionable (Palmer et al., 1996).

14. B. melitensis 16M DNA vaccine expressing Omp31

a. Vaccine Ontology ID:

VO_0000325

b. Type:

DNA vaccine

c. Antigen

The antigen for this vaccine were found in eukaryotic expression vectors called pTargeTomp31, which encoded the outer membrane protein (omp31) of B. melitensis 16M (Gupta et al., 2007).

d. Gene Engineering of Omp31

Type: DNA vaccine construction
Description: The nucleotide sequence of the gene coding for the outer membrane protein omp31 reported for B. melitensis were synthesized by Qiagen. The primers were used to amplify a target sequence of 720 bp within a gene code for the production of a 28–31 kDa outer membrane protein (omp31) specific to the B. melitensis. The omp31 gene of B. melitensis was amplified with primers 5′-TGACAGACTTTTTCGCCGAA-3′ and 5′-TATGGATTGCAGCACCGC-3′. This 720 bp B. melitensis DNA fragment encoding omp31 was cloned in pTargeT mammalian expression system vector. The resultant plasmid (pTargeTomp31) contained the omp31 gene. Competent Escherichia coli JM109 was transformed with pTargeTomp31. Ampicillin-resistant colonies were grown in Luria-Bertani medium containing 100 μg/ml of ampicillin at 37 °C with agitation at 225 rpm. Protein expression was induced by adding 1 mM isopropyl-β-d-thiogalactopyranoside and incubating transformed cells for 4 h. Bacteria were pelleted by centrifugation and frozen at −20 °C. Bacterial cells were suspended in a solution consisting of 50 mM Tris, 5 mM EDTA, and 1% Triton X-100 at a pH of 8.0 and sonicated for three 1-min cycles at 4 °C. Inclusion bodies were pelleted at 20,000 × g for 30 min at 4 °C and washed twice with suspension solution without Triton X-100. Inclusion bodies were solubilized in a solution containing 50 mM Tris, 5 mM EDTA, and 8 M urea at a pH of 8.0 at room temperature overnight with agitation. After centrifugation, soluble protein was purified by chromatography through Ni-agarose. rOmp31 was adsorbed with Sepharose-polymyxin B to eliminate LPS contamination. Plasmid DNA for in vitro transfection or mouse immunization was extracted from a 16-h culture and purified using the Endo-Free Plasmid purification kit. Plasmid DNA was adjusted to a final concentration of 1 mg/ml in PBS and stored at −80 °C (Gupta et al., 2007) .
Detailed Gene Information: Click here.

e. Vector:

pTargeT (Gupta et al., 2007)

f. Preparation

B. melitensis 16M, the virulent strain, was isolated from the stomach content of the aborted fetus of the goat. B. melitensis DNA fragment encoding omp31 was cloned in pTargeT mammalian expression system vector. The plasmid was then purified and made into a vaccine consisting of 100 μg of pTargeTomp31 in 50 μl sterile saline (Gupta et al., 2007).

g. Virulence

The strain isolated from the goat was virulent, bu the plasmid created was quite attenuated (Gupta et al., 2007).

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Specific-pathogen-free 4-week-old BALB/c female mice were obtained. 25 mice were randomly divided in to five groups of 5 mice each and received intramuscular injections in the tibialis anterior muscles with 100 μg of pTargeTomp31 in 50 μl sterile saline by using a 1-ml insulin syringe with a 28-gauge needle. Similarly, another set of 6 weeks old 25 female mice (divided in five groups of 5 mice each) were sham immunized with saline only, the control group. From both the DNA immunized and sham immunized mice, one group of 5 mice each was exclusively used in order to obtain sera to test antibody and spleen cells for cytokine production in response to omp31 or B. melitensis extract. Three vaccinations at 3-week intervals were performed (Gupta et al., 2007).
Immune Response: Mice injected with pTargeTomp31 have good IgG2a and IgG1 titers to anti-omp31 antibodies. Antibodies against omp31 could already be detected 1 week after the first pTargeTomp31 DNA injection. Immunization with pTargeT did not induce any production of anti-omp31 antibodies. Humoral response measured 18 weeks postvaccination indicates that pTargeTomp31 DNA vaccine leads to the generation of long-lived IgG1 and IgG2a responses. pTargeTomp31 DNA vaccination resulted in specific T-cell proliferation in response to omp31 or to Brucella extracts. This specific induced proliferative response was also found at 8 weeks postvaccination, although to a lesser extent. In contrast, immunization with pTargeT appeared to have no effect on the level of T-cell proliferative response. The ConA mitogen was able to induce T-cell proliferation in all cases (Gupta et al., 2007).
Challenge Protocol: Mice immunized three times with pTargeTomp31 or pTargeT were infected 9 weeks later the last DNA immunization with B. melietensis 16M. Seven, 14, 21 and 28 days after challenge, mice were killed and the number of bacteria in the spleens was quantitated (Gupta et al., 2007).
Efficacy: No significant difference in the number of the bacteria isolated from the spleens of the saline vaccinated and pTargeT-vaccinated animals was observed. The mice, which were immunized by pTargeTomp31, showed a significant level of protection at 28 days after challenge. Mice immunized with DNA vaccine made anti-Brucella serum antibody. This vaccine provided the moderate degree of protection to the mice (Gupta et al., 2007).

15. B. melitensis bp26 and TF Nasal Vaccine

a. Vaccine Ontology ID:

VO_0000411

b. Type:

Recombinant vector vaccine

c. Antigen

Purified Brucella bp26 and trigger factor (Tf) proteins, also called Tig (Yang et al., 2007).

d. Gene Engineering of Tig

Type: Recombinant protein preparation
Description: Recombinant bp26 and Tf were produced in Pichia pastoris and purified, and mixed with cholera toxin (CT) adjuvant(Yang et al., 2007).
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0000143
Description: Cholera toxin (CT) was used as the adjuvant for this vaccine (Yang et al., 2007).

f. Preparation

Recombinant bp26 and Tf were produced in Pichia pastoris and purified. Each vaccine consisted of either 50 or 100 micrograms per dose of either bp26, Tf, or both combined with the CT adjuvant (Yang et al., 2007).

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Specific pathogen-free female BALB/c mice were i.n. immunized with bp26 (50 μg/dose), Tf (100 μg/dose), or both + CT adjuvant on days 0, 7, and 14. Five μg of CT were given on day 0, and with subsequent boosts, 2 μg/dose were given. Mice were sampled for serum and fecal titers at 3–5 weeks post-immunization, before challenge (Yang et al., 2007).
Immune Response: Mice immunized with Tf alone showed reduced serum and mucosal Ab titers. Between 3 and 5 weeks post-primary immunization, mice given bp26 + Tf showed between 14- and 32-fold greater serum IgG anti-Tf Ab titers when compared to mice given only Tf. Fecal IgA titers were augmented between 24- and 128-fold in mice immunized with bp26 + Tf when compared to mice immunized with Tf alone. These results clearly show that co-immunization with bp26 enhances anti-Tf immunity. To determine whether immune responses evoked by bp26 and Tf are biased towards Th1-type, Th2-type, or a mixture of both, serum samples from bp26 + Tf-immunized BALB/c mice from day 35 were evaluated for IgG subclass responses. IgG1 was the predominant IgG subclass Ab induced by the nasal immunization regimen. IgG2a and IgG2b anti-Tf and anti-bp26 Abs were also observed, but these were significantly less than the induced IgG1 Ab titers (Yang et al., 2007).
Challenge Protocol: Immunized mice were challenged i.p. with 5 × 10^4 CFU B. melitensis strain 16 M on day 28 post-primary immunization [13]. A positive vaccination control was given i.p. 1 × 10^8 CFU of B. abortus RB51 vaccine 8 weeks prior to challenge. Four weeks post-challenge, splenic CFU and splenic weights were determined (Yang et al., 2007).
Efficacy: Mice immunized with bp26 and Tf exhibited significantly reduced B. melitensis colonization when compared to PBS-dosed control mice, the control. There was no significant difference between mice immunized with these proteins when compared to RB51-vaccinated mice. No significant differences in splenic weights were observed among any of the immunization groups. These findings show that nasal immunization with bp26 and Tf is able to reduce B. melitensis colonization, and the observed splenic inflammation may be contributed by CT immunization (Yang et al., 2007).

16. B. melitensis DNA vaccine encoding Omp31 boosted with Omp31

a. Vaccine Ontology ID:

VO_0000436

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Omp31 protein

e. Gene Engineering of omp31

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0000142
Description: Incomplete Freund's Adjuvant

g. Vector:

pCI-neo prime, recombinant protein boost (Cassataro et al., 2005)

h. Preparation

For the propagation of plasmids, Escherichia coli strain JM109 was used. For the expression of the recombinant protein, strain BL21(DE3) was employed. Bacterial strains were routinely grown, and rOmp31 was obtained and treated as described by (Estein et al., 2003). Purity was determined by Coomassie blue staining as described by (Cassataro et al., 2005). The plasmid pCIOmp31 was obtained as described in (Cassataro et al., 2005).

i. Immunization Route

Intramuscular injection (i.m.)

j. Description

A regimen of DNA prime and protein boost is followed, increasing the efficacy of the vaccine compared to DNA or protein alone (Cassataro et al., 2007).

k. Mouse Response

Vaccination Protocol: BALB/c mice was immunized with an Omp31 DNA vaccine (pCIOmp31) followed by boosting with recombinant Omp31 (rOmp31) in incomplete Freund's adjuvant (Cassataro et al., 2007).
Immune Response: Immunoglobulin G1 (IgG1) and IgG2a titers were higher in sera from pCIOmp31/rOmp31-immunized mice than in sera from mice immunized with pCIOmp31 or rOmp31 alone. Splenocytes from pCIOmp31/rOmp31-immunized mice produced significantly higher levels of gamma interferon than did those from mice given rOmp31 alone. In contrast, interleukin 2 (IL-2) production levels were comparable between the two groups of immunized mice. Cells from all immunized mice produced undetectable levels of IL-4. Notably, rOmp31 stimulated IL-10 production in the pCIOmp31/rOmp31-immunized group but not in the pCIOmp31- or rOmp31-immunized group. Although the prime-boost regimen induced specific cytotoxic responses, these responses could not reach the levels achieved by the pCIOmp31 immunization (Cassataro et al., 2007).
Challenge Protocol: Immunized mice were challenged, by intravenous inoculation, with 1x10^5 B. melitensis H38S organisms or 1x10^5 B. ovis organisms. Mice were sacrificed 30 days after the bacterial challenge, and their spleens were removed, homogenized, plated, and incubated. The number of CFU per spleen or liver was counted, and the results were given as the mean log number of CFU (Cassataro et al., 2007).
Efficacy: pCIOmp31 priming followed by rOmp31 boosting led to moderately improved protection against a challenge with B. ovis or B. melitensis (Cassataro et al., 2007).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: Cytokine secretion in culture supernatants of spleen cells from immunized mice was evaluated by ELISA 30 days after the last immunization. IFN-gamma levels were significantly higher in mice immunized with pCIOmp31 priming and rOmp31 boosting than mice immunized with PBS-, pCI-, or rOmp31 and boosted with rOmp31 (Cassataro et al., 2007).
- Detailed Gene Information: Click here.
Host Gene Response of Il10 (interleukin 10)
- Gene Response: Cytokine secretion in culture supernatants of spleen cells from immunized mice was evaluated by ELISA 30 days after the last immunization. IL-10 levels were significantly higher in mice immunized with pCIOmp31 priming and rOmp31 boosting than mice immunized with PBS-, pCI-, or rOmp31 and boosted with rOmp31 (Cassataro et al., 2007).
- Detailed Gene Information: Click here.
Host Gene Response of Il2
- Gene Response: Cytokine secretion in culture supernatants of spleen cells from immunized mice was evaluated by ELISA 30 days after the last immunization. IL-2 levels were significantly higher in mice immunized with pCIOmp31 priming and rOmp31 boosting than mice immunized with PBS-, pCI-, or rOmp31 and boosted with rOmp31 (Cassataro et al., 2007).
- Detailed Gene Information: Click here.

17. B. melitensis DNA vaccine p-ialB

a. Vaccine Ontology ID:

VO_0004397

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of IalB

Type: DNA vaccine construction
Description: Vector pCR3.1 expressed IalB (Commander et al., 2007).
Detailed Gene Information: Click here.

f. Vector:

pcDNA3 (Commander et al., 2007)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Brucella specific IFNγ was still evident at 12 weeks post-vaccination, albeit at low concentration, indicating generation of a lasting Th1 immune response (Commander et al., 2007).
Efficacy: P-ialB vaccine was very promising in terms of control of Brucella challenge, as they were unable to recover viable Brucella from the spleens of 60% (three out of five) p-ialB treated mice of a study group following challenge with ∼1 × 104 CFU B. melitensis 16M per mouse. The remaining two mice showed significantly reduced Brucella loads compared to the unvaccinated (PBS and vector control) mice. If the data is considered in terms of the % of animals without detectable Brucella in their spleens (less than 10 CFU per spleen) at 15 days post-challenge, the effect of the p-ialB vaccination is judged to be equivalent to that of the Rev.1 live attenuated vaccine, with each vaccine able to ‘protect’ 60% of the test population. Moreover, a comparison of the total quantitative data available from each sample shows the Brucella load of the p-ialB and Rev.1 vaccinated animals to be significantly lower (p < 0.05, one-way ANOVA, Dunnett's post-test) than that observed for the unprotected controls (PBS or pcDNA3.1 vector control vaccinated mice). This vaccine was shown to have a protective index of greater than 2.5 (Commander et al., 2007).

18. B. melitensis DNA vaccine p-Omp25

a. Vaccine Ontology ID:

VO_0004396

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of Omp25

Type: DNA vaccine construction
Description: Vector pCR3.1 expressed Omp25 (25 kDa Omp) (Commander et al., 2007).
Detailed Gene Information: Click here.

f. Vector:

pcDNA3.1 (Commander et al., 2007)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Brucella specific IFNγ was still evident at 12 weeks post-vaccination, albeit at low concentration, indicating generation of a lasting Th1 immune response (Commander et al., 2007).
Efficacy: P-omp25 vaccine was very promising in terms of control of Brucella challenge, as researchers were unable to recover viable Brucella from the spleens of 60% (three out of five) p-omp25 treated mice of a study group following challenge with ∼1 × 104 CFU B. melitensis 16M per mouse. The remaining two mice showed significantly reduced Brucella loads compared to the unvaccinated (PBS and vector control) mice. If the data is considered in terms of the % of animals without detectable Brucella in their spleens (less than 10 CFU per spleen) at 15 days post-challenge, the effect of the p-omp25 vaccination is judged to be equivalent to that of the Rev.1 live attenuated vaccine, with each vaccine able to ‘protect’ 60% of the test population. Moreover, a comparison of the total quantitative data available from each sample shows the Brucella load of the p-omp25 and Rev.1 vaccinated animals to be significantly lower (p < 0.05, one-way ANOVA, Dunnett's post-test) than that observed for the unprotected controls (PBS or pcDNA3.1 vector control vaccinated mice). This vaccine was shown to have a protective index of greater than 2.5 (Commander et al., 2007).

19. B. melitensis DNA vaccine pCI-Omp31

a. Vaccine Ontology ID:

VO_0004394

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of omp31

Type: DNA vaccine construction
Description: Vector pCI expressed Omp31 (hemin-binding protein) (Cassataro et al., 2005).
Detailed Gene Information: Click here.

f. Vector:

pCI (Cassataro et al., 2005)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: The Omp31 DNA vaccine induces cytotoxic responses that have the potential to contribute to protection against Brucella infection. The protective response could be related to the induction of CD8(+) T cells that eliminate Brucella-infected cells via the perforin pathway (Cassataro et al., 2005).
Efficacy: Mice given pCIOmp31 exhibited a significant degree of protection against B. melitensis and B. ovis (P < 0.001) compared with controls receiving PBS. This was determined by comparing the levels of infection in the spleen (CFU) (Cassataro et al., 2005).

20. B. melitensis DNA vaccine pCIBLSOmp31 encoding BLSOmp31 (fusion protein)

a. Vaccine Ontology ID:

VO_0004395

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of ORF

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of omp31

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Vector:

pCI-neo (Cassataro et al., 2007)

h. Immunization Route

Intramuscular injection (i.m.)

i. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: The vaccine induced a strong humoral response against the inserted peptide. It also induced peptide- and BLS-specific cytotoxic T responses. The insertion of this peptide on BLS induced stronger T helper 1 responses specific for the carrier (BLS) (Cassataro et al., 2007).
Efficacy: BLSOmp31 (pCIBLSOmp31) provided the best protection level against Brucella ovis, which was significantly higher than the given by the co-delivery of both plasmids coding for the whole proteins (pcDNABLS+pCIOmp31) and even higher than the control vaccine Rev.1. Moreover, pCIBLSOmp31 induced higher protection against Brucella melitensis than pcDNABLS+pCIOmp31 (Cassataro et al., 2007).

21. B. melitensis lipopolysaccharide (LPS) vaccine

a. Vaccine Ontology ID:

VO_0000311

b. Type:

subunit vaccine

c. Antigen

B. melitensis strain 16M lipopolysaccharide (LPS)

d. Preparation

The LPS was extracted from killed cells and purified by a modification of the method of Bundle et al (Bhattacharjee et al., 2006).

e. Virulence

None.

f. Description

LPS, an outer membrane endotoxin common to gram negative bacteria, consists of three parts: Lipid A, a core oligosaccharide, and an O-antigen. The O-antigen is found in smooth strains only.

g. Mouse Response

Vaccination Protocol: Groups of female BALB/c mice (Harlan Sprague-Dawley) were immunized by either i.n. or s.c. with purified B. melitensis LPS or LPS-GBOMP noncovalent complex vaccine. Control mice were immunized subcutaneously with sterile saline. Briefly, 25 µl of vaccine containing either 10 µg LPS or 10 µg LPS and 7.5 µg GBOMP contained in sterile saline was administered dropwise into the nostrils of anesthetized mice. Two doses of vaccine were given four weeks apart. For subcutaneous immunization, mice were given 10 µg vaccine in 200 µl sterile saline under the right hind thigh. A second dose of vaccine was given four weeks after the first dose. Blood was collected from five euthanized mice from each group four weeks after the first dose and four weeks after the second dose of vaccine. Sera were collected and stored at –20°C until analyzed for antibody. An enzyme-linked immunosorbent assay (ELISA) was used (Bhattacharjee et al., 2006).
Challenge Protocol: Groups of immunized mice (15 to 20 mice in each group) were challenged intranasally 4 weeks after the second dose of vaccine with 1x10^4 CFU of B. melitensis 16M suspended in 30 µl phosphate-buffered saline (PBS) (0.01 M sodium phosphate, 0.14 M sodium chloride; pH 7.5) as described previously (21). Blood, spleens, lungs, and livers were aseptically collected from anesthetized mice 8 weeks postchallenge. The numbers of Brucella CFU in organs were determined by dilution and culture on brucella agar as described previously (17). Serum was separated and stored at –20°C until it was used (Bhattacharjee et al., 2006).
Efficacy: Mice immunized subcutaneously with LPS vaccine showed significant protection against infection of the spleen (P < 0.001), liver (P < 0.001), and lungs (P < 0.05).

22. B. melitensis LPS-GBOMP

a. Vaccine Ontology ID:

VO_0000312

b. Type:

Subunit vaccine

c. Antigen

The antigens used in this vaccine were purified Brucella melitensis lipopolysaccharide (LPS) as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (GBOMP) (Bhattacharjee et al., 2002).

d. Preparation

To create the vaccine, the LPS was extracted from killed B. melitensis cells and purified. N. meningitidis group B strain 8047 bacteria were grown in a synthetic medium, and outer membrane protein (GBOMP) was extracted. The B. melitensis LPS-GBOMP noncovalent complex vaccine was prepared with purified B. melitensis LPS dissolved in 42 ml of TEEN buffer. This mixture was added to the LPS solution and kept at 5°C for 30 min. The detergent was removed, and buffer was exchanged with sterile 0.9% NaCl solution. The final product was filtered and the LPS content was determined (Bhattacharjee et al., 2002).

e. Storage

The vaccines were stored at −20°C until use (Bhattacharjee et al., 2002).

f. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Each mouse was given an intramuscular injection of 0.3 mg of xylazine hydrochloride and 1.0 mg of ketamine hydrochloride in 50 μl of sterile saline prior to immunization. The mice were then immunized by administration of 25 μl of vaccine containing 10 μg of LPS slowly into the nostrils with a micropipette, with a second dose of vaccine was given 4 weeks after the initial dose (Bhattacharjee et al., 2002).
Immune Response: Anti-B. melitensis LPS IgG titers were significantly increased two weeks after i.n. immunization with B. melitensis LPS-GBOMP vaccine. The pattern of IgG1 response closely resembled that of total IgG, but IgG2a and IgG2b responses were blunted compared to the IgG1 response,and the IgG3 response was also blunted compared to that of IgG1(Bhattacharjee et al., 2002).
Challenge Protocol: Groups of immunized and control mice were challenged intranasally at various times with 10^4 CFU of B. melitensis 16 M suspended in 30 μl of phosphate-buffered saline. In one experiment, mice were challenged with 10^5 CFU of bacteria (Bhattacharjee et al., 2002).
Efficacy: I.n. immunization with B. melitensis LPS-GBOMP subunit vaccine significantly protects mice against intranasal challenge with virulent B. melitensis. Vaccination reduces spleen and liver bacterial dissemination but has no effect on the course of lung infection (Bhattacharjee et al., 2002).

23. B. melitensis P39 deletion vaccine

a. Vaccine Ontology ID:

VO_0000633

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Preparation

A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the p39 gene deletion (Tibor et al., 1998).

e. Immunization Route

Intramuscular injection (i.m.)

24. B. melitensis P39 protein vaccine

a. Vaccine Ontology ID:

VO_0000412

b. Type:

Subunit vaccine

c. Antigen

Brucella melitensis 16M P39, a putative periplasmic binding protein (Al-Mariri et al., 2001).

d. Gene Engineering of B. melitensis M5 P39

Type: recombinant protein
Description: The bfr gene of Brucella melitensis 16M was subcloned into a pET-15b expression vector that contains a polyhistidine tag, and the resulting plasmid pET-15b-bfr was introduced in E. coli BL21(DE3). After 2 to 4 of induction with 1 mM IPTG (isopropyl-β-d-thiogalactopyranoside), bacterial cells from a 100-ml culture were washed once and then sonicated. The lysate was centrifuged for 10 min at 9,000 × g at 4°C. The pellet was kept frozen at −70°C. After it had thawed, the pellet was resuspended in a lysis buffer. The resulting lysate was centrifuged at 9,000 × g for 20 min at 4°C (Al-Mariri et al., 2001). P39 was then purified based on metal chelate affinity chromatography as described previously (Letesson et al., 1997).
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0001237
Description: The adjuvant is a synthetic phosphorothioate oligodeoxynucleotide containing an unmethylated, consensus immunostimulatory CpG motif (5′-purine-purine-CpG-pyrimidine-pyrimidine-3′ oligodeoxynucleotide [CpG ODN]). Specifically, the immunostimulatory CpG 1826 (5′-TCCATGACGTTCCTGACGTT-3′) was used (Al-Mariri et al., 2001).

f. Preparation

The bfr gene of Brucella melitensis 16M was subcloned and expressed in an expression vector. The protein was purified and mixed with the CpG ODN as the vaccine (Al-Mariri et al., 2001).

g. Virulence

Not reported.

h. Description

P39 has been found to be a Brucella protective antigen (Al-Mariri et al., 2001).

i. Mouse Response

Host Strain: Balb/c mice
Vaccination Protocol: Female BALB/c mice at 4 weeks of age were separated into nine groups of 12 mice. Groups 1, 2, and 3 received PBS, CpG ODN, and non-CpG ODN, respectively, and served as negative controls. Groups 4 and 5 were injected with the purified P39 and bacterioferrin (BFR) alone, respectively. Groups 6 and 7 were injected with the recombinant protein with CpG ODN adjuvant. Finally, groups 8 and 9 received the recombinant antigens with the non-CpG ODN. Vaccines were prepared in PBS and contained combinations of the following: 20 μg of recombinant protein and/or 20 μg of oligonucleotides when needed. Vaccines were given intramuscularly (i.m.) into the left tibial anterior muscles in a total volume of 50 μl three times at 3-week intervals (Al-Mariri et al., 2001).
Persistence: Not reported.
Side Effects: None reported.
Challenge Protocol: Three weeks after the last injection, the remaining mice of each group were challenged by the intraperitoneal route (i.p.) with 5 × 10^4 CFU of B. abortus strain 544 in 100 μl of PBS. An additional group of eight mice vaccinated i.p. with B19 (1x10^5 CFU) was challenged 4 weeks later in the same way and served as a vaccinated control. Spleen colonization with the challenge strain was determined at 4 and 8 weeks postinfection (Al-Mariri et al., 2001).

25. B. melitensis strain VTRM1

a. Vaccine Ontology ID:

VO_0000300

b. Type:

attenuated live vaccine

c. Preparation

VTRM1 was obtained from B. melitensis 16M by allelic exchange of the rfbU gene encoding mannosyltransferase with a Tn5-disrupted rfbU gene (Winter et al., 1996).

d. Virulence

VTRM1, like RB51, is a stable rough form of B. melitensis that does not revert during passage in mice (Winter et al., 1996).

e. Description

Vaccination with the rough strain VTRM1 induces protection against virulent strains of B. abortus (2308), B melitensis (16M), B. suis biovar 1 (750), B. suis biovar 4 (2579), and B. ovis (Winter et al., 1996).

f. Mouse Response

Host Strain: VTRM1
Vaccination Protocol: Five groups of mice, (eight to nine weeks old), were vaccinated with the following live organism vaccines. These included: VTRM1, VTRS1, and Rev 1 (5 x 10^4 CFU); strain 19 (S19) (5 x 10^3 CFU); and RB51 (3 x 10^8 CFU). Each vaccine was delivered intravenously except RB51 which was administered intraperitoneally. All vaccines except RB51 were obtained directly from frozen stock cultures. Large doses of RB51 were required, therefore stock cultures were inoculated onto plates. After three days of culture and growth after 3 days was diluted to the appropriate concentration (Winter et al., 1996).
Challenge Protocol: Eight weeks after the initial vaccination, mice were injected IV with 5x10^4 CFU of Brucella. The time interval between IV injection and euthanasia was two weeks for all Brucella strains with the exception of B abortus 8-954 and 2-1230; for these strains, a one-week time interval was chosen. Mice were euthanized by CO2 asphyxiation. Individual spleens were homogenized, the homogenate diluted serially, and plated on Schaedler blood agar. B abortus, B melitensis, or B suis colonies were counted after three days of incubation; B. ovis colonies were counted after four to five days of incubation at 37 C under 10% CO2 (Winter et al., 1996).
Efficacy: Strains VTRM1 and VTRS1 were effective in inducing protection against virulent strains of heterologous, and homologous, Brucella spp. Vaccination with either strain conferred substantial protection against exposure to virulent laboratory strains of B melitensis, B abortus, and B suis of biovars 1 and 4. VTRM1 provided protection against B. ovis (Winter et al., 1996).

26. B. melitensis vaccine strain Rev. 1

a. Vaccine Ontology ID:

VO_0000710

b. Type:

Attenuated live vaccine

c. Status:

Licensed

d. Antigen

Rev.1 is a live attenuated Brucella melitensis strain derived from a virulent B. melitensis isolate.

e. Gene Engineering of RpsL

Type: Recombinant protein preparation
Description: The gene rpsL of B. melitensis reference strain 16 M encodes for ribosomal protein S12. This gene was mutated in the vaccine strain Rev. 1 during its natural selection process. Nucleotide sequencing has revealed that a mutation in the rpsL gene of vaccine strain Rev . 1 compared to that of reference strain 16M leading to an amino acid Pro- to -Leu change at codon position 91 ( Pro91Leu ) (Cloeckaert et al., 2002).
Detailed Gene Information: Click here.

f. Preparation

Rev . 1 vaccine, obtained in the 1950s by a two-step selection involving firstly, a streptomycin resistance and/or dependence, and secondly, a reversion of dependence but maintaining streptomycin resistance (ELBERG and FAUNCE, 1957). Acquired chromosomal streptomycin resistance is frequently due to mutations in the gene encoding for ribosomal protein S12, rpsL (Cloeckaert et al., 2002).

g. Virulence

Whether Rev. 1 is virulent is unclear. A Rev. 1-like strain was isolated from the membranes of an aborted fetus at an intensively managed farm that had complied with the vaccination regimen, i.e. ewelambs were vaccinated between two and six months. When the whole flock (410 ewes) was serologically tested, 34 animals showed a positive complement fixation test. The ewes were slaughtered and attempts to culture additional isolates from milk, major lymph nodes, and mammary glands were unsuccessful. A few months later , the flock owner contracted brucellosis and Brucella was cultured from his blood (Banai, 2002).

h. Storage

The vaccine was kept on plates at 5 degrees celsius (ELBERG and FAUNCE, 1957).

i. Description

The live attenuated strain of B melitensis Rev . 1 is considered the best vaccine available for the prophylaxis of brucellosis in sheep and goats (Cloeckaert et al., 2002).

j. Mouse Response

Vaccination Protocol: Several groups of 10 (or eight mice in the assay after storage or passage) were vaccinated subcutaneously with Rev. 1 strains. Control unvaccinated mice received BSS alone (Bosseray, 1991).
Challenge Protocol: Vaccinated and control mice were challenged intraperitoneally 30 or 45 days after vaccination with The virulent B. abortus 544 CO2-dependent reference challenge strain (Bosseray, 1991).

k. Sheep Response

Vaccination Protocol: Seven groups, 22 sheep/group were either vaccinated subcutaneously (SC) or conjunctivally (CJ) (right eye) at the age of four months with the following actual doses, Rev.1, 1.1 × 10^9 CFU (SC) and 1.33 × 10^9 CFU (CJ); CGV26, 1.25 × 10^9 CFU (SC) and 1.22 × 10^9 cfu (CJ); CGV2631, 1.11 × 10^9 cfu (SC) and 1.30 × 10^9 cfu (CJ). The vaccine doses (<1 mL) were utilized where administered SC and 30 uL where administered CJ (Jacques et al., 2007).
Challenge Protocol: One week before challenge, of 154 ewes, 99 of whiche were pregnant assesd by progesterone levels were were kept in a high security pen. Each ewe was challenged CJ (left eye) with 5.1 × 10^7 CFU of B. melitensis strain H38 after 76 days of pregnancy. Each animal was submitted to periodic immunological, clinical, and bacteriological tests and sacrificed 4–6 weeks after delivery. To follow cellular response, six ewes from each group were selected for further investigation (Jacques et al., 2007).
Efficacy: Regardless of the route of administration of Rev.1 vaccine (SC or CJ), the results obtained agreed with those of previous studies [35], Rev.1 effectively protected ewes challenged at middle of pregnancy with 5 × 10^7 CFU of strain H38. In the control group (unvaccinated ewes), 100% aborted (Jacques et al., 2007).

l. Goat Response

Host Strain: Angora
Vaccination Protocol: Four to five-year-old goats were used. Each goat received 1.5 x 10^9 cells of the bacteria subcutaneously in the left prescapular region. At 2,4,5,7,10,11, and 14 weeks the goats were sacrificed and tested for the presence of brucellae (ELBERG and FAUNCE, 1957).
Persistence: At the third week organisms from the spleen, bone marrow, left and right prescapular regions, left and right supramammary nodes, right precrural and the mediastinal nodes were detected. By the fourteenth week, the infection in the single goat sacrificed was isolated to the left prescapular node. It was assumed that at this point the animals were free from infection (ELBERG and FAUNCE, 1957).
Immune Response: The mutant strain stimulated an antibody-producing mechanism within the first ten days of vaccination. The antibody titers were highest at about 20 days postinfection (ELBERG and FAUNCE, 1957).
Challenge Protocol: The challenge consisted of 33 ID doses of B. melitensis. It was administered 90 days after vaccination (ELBERG and FAUNCE, 1957).
Efficacy: The vaccine was proven to be an effective immunizing agent for the host species tested (ELBERG and FAUNCE, 1957).

27. B. melitensis with deleted bp26 (CGV26)

a. Vaccine Ontology ID:

VO_0000338

b. Type:

Live, attenuated vaccine

c. Antigen

The antigen for this vaccine is Brucella melitensis containing a deletion of the bp26 gene, a strain called CGV26 (Guilloteau et al., 2006).

d. Gene Engineering of RL3382

Type: Recombinant protein preparation
Description: The CGV26 and CGV2631 strains were engineered with Brucella melitensis Rev.1 mutant strains containing deletions in the bp26 gene or both bp26 and omp31 genes (Guilloteau et al., 2006).
Detailed Gene Information: Click here.

e. Preparation

Mutants were kept freeze-dried. Bacteria were rehydrated in sterile buffered saline solution, seeded on Trypticase Soy Agar, supplemented with yeast extract and incubated at 37 °C. Fresh bacterial suspensions were harvested in BSS from 24 h cultures and spectrophotometrically adjusted. Each suspension used was always checked for purity and dissociation and the exact doses were assembled (Guilloteau et al., 2006).

f. Virulence

The virulence of the CGV26 mutant was similar to that of the parental Rev.1 strain (Guilloteau et al., 2006).

g. Sheep Response

Host Strain: Préalpes
Vaccination Protocol: 42 Brucella-free Préalpes females of 3–4 months of age were randomly allotted into seven groups of six animals. Six groups were inoculated either by CJ or SC route with 1 × 10^9 cfu of CGV26 mutant or the Rev.1 vaccine as a vaccinated control group. The vaccine suspension was administered conjunctivally with a calibrated dropper by depositing 33 μl on the surface of the right eye or subcutaneously with a needle by injecting 1 ml just behind the left elbow joint. One group remained as a separate uninfected control group. Swabs were taken from the conjunctiva and nostrils in groups inoculated by CJ route for bacteriological analyses. At regular intervals after inoculation, blood samples were collected for analysis of the immune response induced (Guilloteau et al., 2006).
Persistence: The local persistence of the CGV26 mutant was not statistically different from the Rev.1 strain (Guilloteau et al., 2006).
Immune Response: The results together showed that the CGV26 mutant was able to induce both specific antibody response and systemic lymphoproliferation in sheep. Specific systemic antibody response to S-LPS of Brucella was induced after inoculation of the mutant and the Rev.1 strain. The intensity of this response was much higher and earlier after SC vaccination (1 week) than that after CJ vaccination (second week) (Guilloteau et al., 2006).
Efficacy: This mutant induced significant specific antibody and cell-mediated immunity in sheep (Guilloteau et al., 2006).

28. B. melitensis WR201 (16MΔpurEK)

a. Vaccine Ontology ID:

VO_0000345

b. Type:

Live, attenuated vaccine

c. Antigen

This vaccine is an live, attenuated purine-auxotrophic mutant strain of Brucella meletensis, WR201 (Hoover et al., 1999).

d. Gene Engineering of purK

Type: Recombinant protein preparation
Description: The B. melitensis strain WR201 (or called delta purE201) was created through the deletion of the gene purE and the deletion of the first seven bases of purK (Drazek et al., 1995; Hoover et al., 1999). Specifically, B. melitensis 16M was electroporated with suicide plasmids containing a kanamycin resistance cassette that replaced 226 bp at the carboxyl end of purE, the intergenic region, and 18 bases of the purK open reading frame. Recombinant B. melitensis delta purE201 required exogenous purines for growth on minimal media. This mutant failed to grow in human monocyte-derived macrophages, while the growth of wild-type 16M and the complemented strain, delta purE201 (pSD5), increased by nearly two logs (Drazek et al., 1995).
Detailed Gene Information: Click here.

e. Gene Engineering of purE

Type: Gene mutation
Description: This purE mutant is from Brucella melitensis (Crawford et al., 1996).
Detailed Gene Information: Click here.

f. Preparation

The WR201 strain was procured and the bacterial cells were killed by treatment for 16 h with 0.5% phenol. These cells were then washed and pelleted several times, eventually leading to a product containing approximately 3.0 mg of protein per ml (Hoover et al., 1999).

g. Virulence

The antigens for this vaccine were severely attenuated. The strain WR201 fails to replicate in cultured human monocyte-derived macrophages (Hoover et al., 1999).

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: The mice were immunized by intraperitoneal administration of vaccine. Each vaccine contained approximately 10^5 WR201 cells Nonimmunized, control mice received 0.9% NaCl intraperitoneally (Hoover et al., 1999).
Immune Response: After mice were innoculated, they were found to have made serum antibody to non-O-polysaccharide and lipopolysaccharideantigens. The splenocytes from the immunized animals were found to have released interleukin-2, gamma interferon, and IL-10 when cultured with Brucella antigens (Hoover et al., 1999).
Challenge Protocol: Nine weeks post immunization, animals were innoculated intranasally with 10^4 CFU of B. melitensis 16M in 30 μl of 0.9% NaCl. The vaccine was administered dropwise into the external nares with a micropipette (Hoover et al., 1999).
Efficacy: Immunization of the mice led to protection from disseminated infection. Immunization had only a slight effect on the clearance of the challenge inoculum from the lungs (Hoover et al., 1999).
Description: This study suggests that WR201 may be a good vaccine candidate for the prevention of human brucellosis (Hoover et al., 1999).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: Spleen cells obtained 9 weeks after inoculation of mice with WR201 produced more IFN-gamma than non-immunized, non-infected control mice. These results were significant (Hoover et al., 1999).
- Detailed Gene Information: Click here.
Host Gene Response of IgG
- Gene Response: Sera obtained from immunized animals from 1 to 8 weeks after intraperitoneal administration of WR201 showed a rise in anti-protein IgG by week 4 (Hoover et al., 1999).
- Detailed Gene Information: Click here.
Host Gene Response of Il10 (interleukin 10)
- Gene Response: Spleen cells obtained 9 weeks after inoculation of mice with WR201 produced more IL-10 than non-immunized, non-infected control mice. These results were significant (Hoover et al., 1999).
- Detailed Gene Information: Click here.
Host Gene Response of Il2
- Gene Response: Spleen cells obtained 9 weeks after inoculation of mice with WR201 produced more IL-2 than non-immunized, non-infected control mice. These results were significant (Hoover et al., 1999).
- Detailed Gene Information: Click here.

i. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Mice were first orally administered 0.2 ml of sterile 2.5% sodium bicarbonate, then they were administered 0.2 ml of the bacterial suspension which had been standardized to 5 × 10^11 cells/ml. In designated experiments, bacteria were further diluted to provide an inoculum of 1010 or 109 CFU, then administered. In another experiment, strain WR201 was killed by treatment overnight at room temperature with 0.8% (vol/vol) formaldehyde prior to administration to mice (Izadjoo et al., 2004).
Persistence: No bacteria were recovered from the spleens of 54 mice eight weeks post-vaccination, while no bacteria were recovered from the iguinal lymph nodes of 15 mice at this time either. Strain WR201 was progressively lost from the feces following oral administration (Izadjoo et al., 2004).
Immune Response: When grown in cultures with Brucella antigens, splenocytes from immunized animals released interleukin-2 and gamma interferon. Immunized mice made serum antibody to lipopolysaccharide and non-O-polysaccharide antigens (Izadjoo et al., 2004).
Challenge Protocol: For virulent strain 16M i.n. challenge, 30 μl of bacterial suspension adjusted to contain 104 CFU of bacteria. This was administered with a micropipette into the external nares of mice (Izadjoo et al., 2004).
Efficacy: The mice that were immunized had protection from infection and better clearance of the challenge inoculum from the lungs. The best protection was found with the administration of live bacteria with the inclusion of a booster dose. The results suggest that strain WR201 may be a candidate for a vaccine to prevent human brucellosis (Izadjoo et al., 2004).

29. B. suis strain 2

a. Vaccine Ontology ID:

VO_0000722

b. Type:

Live, attenuated vaccine

c. Status:

Licensed

d. Location Licensed:

China

e. Immunization Route

Intramuscular injection (i.m.)

f. Description

An orally administrable brucellosis vaccine that was was developed in China. It is effective for oral vaccination of sheep, goats, cattle and pigs (Xin, 1986).

30. B. suis strain VTRS1

a. Vaccine Ontology ID:

VO_0000303

b. Type:

Attenuated live vaccine

c. Preparation

The rough mutant VTRS1 was obtained from B. suis 2579 by allelic exchange of the rfbU gene encoding mannosyltransferase with a Tn5-disrupted rfbU gene (Winter et al., 1996).

d. Virulence

VTRS1, like RB51, is a stable rough form of the bacterium. It does not manifest evidence of reversion during passage in mice (Winter et al., 1996).

e. Description

Vaccination with the rough strain VTRS1 induces protection against virulent strains of B. abortus (2308), B melitensis (16M), B. suis biovar 1 (750), B. suis biovar 4 (2579) (Winter et al., 1996).

f. Mouse Response

Vaccination Protocol: Mice, (eight to nine weeks old), in experimental groups of five, were vaccinated with live vaccines: VTRM1, VTRS1, and Rev 1 with 5 x 10^4 CFU (IV); strain 19 (S19) 5 x 10^3 CFU given IV; and RB51, 3 x 10^8 CFU given i.p. All vaccines except RB51 were obtained from frozen stock cultures. The large dose of RB51 administered required that stock cultures be cultured on plates, and after three days diluted to the appropriate concentration (Winter et al., 1996).
Challenge Protocol: Eight weeks after the initial vaccination, mice were challenged IV with 5x10^4 CFU of Brucella. From challenge exposure to euthanasia was 2 weeks for all Brucella strains except B abortus 8-954 and 2-1230. For these strains a 1-week interval was used. Mice were euthanized with CO2. Individual spleens were homogenized, diluted serially, and plated on Schaedler blood agar. Colonies were counted after incubation for 3 days (B. abortus, B. melitensis, and B. suis) or 4 to 5 days (B. ovis) at 37 C under 10% CO2 (Winter et al., 1996).
Efficacy: VTRM1 and VTRS1 were effective in inducing protection against virulent strains of heterologous, as well as the homologous, Brucella spp. Vaccination with either strain conferred protection against challenge exposure with virulent laboratory strains of B. abortus, B. melitensis, and B. suis of biovars 1 and 4. VTRM1 also provided protection against B. ovis (Winter et al., 1996).

31. Brucella abortus bacA mutant

a. Vaccine Ontology ID:

VO_0000347

b. Type:

Live, attenuated vaccine

c. Antigen

The antigen for this vaccine is a bacA deletion mutant of Brucella abortus, known as KL7 (bacAmut-KL7) (Parent et al., 2007).

d. Preparation

The bacA mutant strain designated as bacAmut-KL7 was produced by deleting a portion of the bacA gene from the parent strain, B. abortus 2308. The vaccines were produced, each dose containing 5 × 10^4 bacterial colony forming units per dose (Parent et al., 2007).

e. Mouse Response

Host Strain: BALB/c, C57BL/6 and C57BL/6 IFNγ−/− mice
Vaccination Protocol: Eight to 12-week-old mice were infected intra-peritoneally with 5 × 10^4 bacterial colony forming units of B. abortus 2308, bacAmut-KL7 or hfq3 (Parent et al., 2007).
Persistence: IFNγ-activated macrophages equivalently controlled strains 2308 and bacAmut-KL7. The bacAmut-KL7 organism and its LPS induced greater amounts of pro-inflammatory cytokines than 2308 (Parent et al., 2007).
Immune Response: The C57BL/6 mice mounted a strong TH1 immune response to infection with B. abortus which was characterized by continuous IFNγ production. At 4 weeks post-infection, a time corresponding to the plateau phase of infection, there was no significant difference in the number of 2308 and bacAmut-KL7 CFU recovered from C57BL/6 mice. BacAmut-KL7 was significantly attenuated in BALB/c mice during this time. During the clearance phase of the infection bacAmut-KL7 did show significant attenuation in C57BL/6 mice relative to 2308 although it was much less than that observed in BALB/c mice (Parent et al., 2007).
Side Effects: The bactAmut-KL7 mutant was more pathogenic in C57BL/6 interferon-γ-deficient mice than 2308 causing abscesses and wasting even though the splenic loads of bacAmut-KL7 were significantly lower (Parent et al., 2007).
Challenge Protocol: No challenge was conducted, but it is known that the mutant created, bacAmut-KL7, has protected against challenge in previous experiments (Parent et al., 2007).

32. Brucella abortus exsA mutant vaccine

a. Vaccine Ontology ID:

VO_0002812

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of exsA

Type: Gene mutation
Description: This exsA mutant is from Brucella abortus (Rosinha et al., 2002a).
Detailed Gene Information: Click here.

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Persistence: Brucella DeltaexsA mutant showed decreased survival in mice compared to the survival of parental strain S2308 (Rosinha et al., 2002a).
Efficacy: Challenge experiments revealed that the exsA mutant strain induced superior protective immunity in BALB/c mice compared to the protective immunity induced by strain S19 or RB51 (Rosinha et al., 2002a).

33. Brucella abortus pgk mutant vaccine

a. Vaccine Ontology ID:

VO_0002818

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of pgk

Type: Gene mutation
Description: This pgk mutant is from Brucella abortus strain 2308 (Trant et al., 2010).
Detailed Gene Information: Click here.

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Persistence: A pgk mutant is attenuated in mice (Trant et al., 2010).
Efficacy: A pgk mutant induces significant protection from challenge with wild type B. abortus (Trant et al., 2010).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: In IRF-1 KO mice, significantly increased levels of IFN-gamma were produced after vaccination with a pgk mutant as compared to medium. Animals immunized with strain RB51 showed reduced production of IFN-γ compared to mice vaccinated with the Δpgk mutant and S19, but it was not a statistically significant difference (Trant et al., 2010).
- Detailed Gene Information: Click here.

34. Brucella abortus pgm mutant vaccine

a. Vaccine Ontology ID:

VO_0002819

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of pgm

Type: Gene mutation
Description: This pgm mutant is from Brucella abortus (Ugalde et al., 2003).
Detailed Gene Information: Click here.

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Persistence: A pgm mutant is attenuated in mice (Ugalde et al., 2003).
Efficacy: A pgm mutant induces significant protection in mice from challenge with wild type B. abortus (Ugalde et al., 2003).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: Spleen cells from Δpgm-vaccinated mice were induced to secrete high levels of IFN-γ 8 weeks after immunization after stimulation with heat-inactivated B. abortus S2308 whole cells. The levels were compared to a positive control, the nonspecific mitogen ConA, and were significant (Ugalde et al., 2003).
- Detailed Gene Information: Click here.

35. Brucella abortus S19 vjbR mutant vaccine

a. Vaccine Ontology ID:

VO_0004283

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of vjbR

Type: Gene mutation
Description: The vjbR was mutated in Brucella abortus strain 19 (Arenas-Gamboa et al., 2009).
Detailed Gene Information: Click here.

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Persistence: An encapsulated vjbR mutant is attenuated in mice (Arenas-Gamboa et al., 2009).
Efficacy: A single dose of an encapsulated vjbR mutant induced protection in mice from challenge with wild type Brucella (Arenas-Gamboa et al., 2009).
Host Gene Response of Ighg1
- Gene Response: Mouse immunization with encapsulated S19 ΔvjbR::Kan induced higher IgG1 and IgG2a levels compared to the nonencapsulated S19 ΔvjbR::Kan mutant 3 weeks post vaccination and significantly higher levels than naive mice (Arenas-Gamboa et al., 2009).
- Detailed Gene Information: Click here.
Host Gene Response of Ighv1-9
- Gene Response: Mouse immunization with encapsulated S19 ΔvjbR::Kan induced higher IgG1 and IgG2a levels compared to the nonencapsulated S19 ΔvjbR::Kan mutant 3 weeks post vaccination and significantly higher levels than naive mice (Arenas-Gamboa et al., 2009).
- Detailed Gene Information: Click here.

36. Brucella Abortus Strain 19, Live Culture Vaccine (USDA: 1251.01)

a. Manufacturer:

Colorado Serum Company

b. Vaccine Ontology ID:

VO_0001575

c. Type:

Live vaccine

d. Status:

Licensed

e. Location Licensed:

USA

f. Host Species for Licensed Use:

Cattle

37. Brucella Abortus Strain 19, Live Culture, Reduced Dose Vaccine (USDA: 1251.02)

a. Manufacturer:

Colorado Serum Company

b. Vaccine Ontology ID:

VO_0001576

c. Type:

Live vaccine

d. Status:

Licensed

e. Location Licensed:

USA

f. Host Species for Licensed Use:

Cattle

38. Brucella Abortus Strain RB-51, Live Culture Vaccine (USDA: 1261.00)

a. Manufacturer:

Colorado Serum Company

b. Vaccine Ontology ID:

VO_0001577

c. Type:

Live vaccine

d. Status:

Licensed

e. Location Licensed:

USA

f. Host Species for Licensed Use:

Cattle

39. Brucella DNA vaccine encoding chimera BLSOmp31

a. Vaccine Ontology ID:

VO_0001144

b. Type:

DNA vaccine

c. Antigen

Brucella outer membrane protein and lumazine synthase from Brucella spp. (BLS) (Cassataro et al., 2007).

d. Vector:

pCI-neo (Cassataro et al., 2007)

e. Preparation

To develop the chimerical plasmid, the BLSOmp31 DNA sequence was amplified by PCR using pETBLSOmp31 as template and sub-cloned in the pCI-neo vector (Promega, Madison, WI). The following oligonucleotides were constructed including restriction sites at the 5

f. Virulence

None.

g. Description

Brucella outer membrane protein and lumazine synthase from Brucella spp. (BLS) induce protection against Brucella spp. A novel mode of delivering these antigens was devised as a DNA vaccine (Cassataro et al., 2007).

h. Mouse Response

Vaccination Protocol: Mice were anaesthetized and immunized by the intramuscular route with 100 ug of pcDNABLS, pCIOmp31, pCIBLSOmp31, pcDNABLS + pCIOmp31 (100
Challenge Protocol: Thirty days after the last DNA injection, mice were challenged with 1 ×10^4 CFU of B. melitensis H38S or B. ovis (i.v.). Thirty days post challenge the animals were sacrificed and their spleens aseptically removed.
Efficacy: Vaccinationof BALB/c mice with pCIBLSOmp31 provided optimal protection level against B. ovis (3.14 log), a value significantly higher than the protection elicited by the co-delivery of two plasmids (pCIOmp31+pcDNABLS) (2.20log) or by the Rev.1 vaccine (2.42 log). Mice vaccinated with pCIOmp31 exhibited a significant protection (2.24 log) against B. ovis; pcDNABLS induced 1.94log units of protection. pCIBLSOmp31 induced significantly higher protection (1.77log) against B. melitensis than pCIOmp31 plus pcDNABLS (1.09log) and similar protection than Rev.1 (2.30 log). Mice given pCIOmp31 exhibited a significant degree of protection(1.44 log) against B. melitensis as was against B. melitensis (1.44 log), while pcDNABLS induced 1.22 log protection. Together these results show that the chimera significantly increases protection elicited against B. ovis with respect to either pcDNABLS, pCIOmp31 or Rev.1 and induces a similar degree of protection against B. melitensis infection than Rev.1 vaccination.

40. Brucella melitensis bp26 mutant vaccine

a. Vaccine Ontology ID:

VO_0004000

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of bp26

Type: Gene mutation
Description: This bp26 mutant is from Brucella melitensis (Cloeckaert et al., 2004).
Detailed Gene Information: Click here.

f. Immunization Route

subcutaneous injection

g. Mouse Response

Persistence: A bp26 mutant is attenuated in mice (Cloeckaert et al., 2004).
Efficacy: A bp26 mutant induces significant protection in mice from challenge with wild type B. melitensis (Cloeckaert et al., 2004).

41. Brucella melitensis mucR mutant vaccine

a. Vaccine Ontology ID:

VO_0004277

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

mouse

e. Gene Engineering of mucR

Type: Gene mutation
Description: This gene is mutated in the B. melitensis 16M mucR mutant (Arenas-Gamboa et al., 2011).
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Persistence: A mucR mutant has a significantly reduced degree of colonization in mice (Arenas-Gamboa et al., 2011).
Efficacy: A mucR mutant of 16M protected against challenge with wild type B. melitensis 16M (Arenas-Gamboa et al., 2011).

42. Brucella melitensis omp25 mutant vaccine

a. Vaccine Ontology ID:

VO_0004001

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of Omp25

Type: Gene mutation
Description: This omp25 mutant is from Brucella melitensis (Edmonds et al., 2002).
Detailed Gene Information: Click here.

f. Immunization Route

Intravenous injection (i.v.)

g. Mouse Response

Persistence: An omp25 mutant is attenuated in mice (Edmonds et al., 2002).
Efficacy: An omp25 mutant induces protection from challenge with wild type Brucella melitensis (Edmonds et al., 2002).

43. Brucella melitensis omp31 mutant vaccine

a. Vaccine Ontology ID:

VO_0004002

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of omp31

Type: Gene mutation
Description: This omp31 mutant is from Brucella melitensis (Cloeckaert et al., 2004).
Detailed Gene Information: Click here.

f. Immunization Route

subcutaneous injection

g. Mouse Response

Persistence: An omp31 mutant is attenuated in mice (Cloeckaert et al., 2004).
Efficacy: An omp31 mutant induces significant protection in mice from challenge with wild type B. melitensis (Cloeckaert et al., 2004).

44. Brucella ovis Microparticle Subunit Vaccine

a. Vaccine Ontology ID:

VO_0004146

b. Type:

Subunit vaccine

c. Antigen

A high hydrophobic antigenic complex taken from Brucella ovis (HS) (Estevan et al., 2006).

d. Adjuvant:

VO ID: VO_0000181

e. Preparation

The antigenic extract (HS) was obtained from B. ovis REO 198 cells. The bacterial cells were cultured, suspended in distilled water, and heat-killed in flowing steam. Following centrifugation, the supernatant was dialyzed against deionized water. The dialyzed material was ultracentrifuged, and the pellet (HS) was washed in dH₂O and freeze-dried. The batch of antigen used to prepare the vaccine formulation contained 48.7 ± 5.0% protein and 41.7 ± 4.7% rough lipopolysaccharide (R-LPS). The vaccine consisted of F68–CD–MP microparticles suspended in saline. F68,CD, and MP are different excipients that were used in order to facilitate the encapsulation and conserve the bioactivity of the encapsulated antigenic complex (HS) (Estevan et al., 2006).

f. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Five groups of five female BALB/c mice, 9 weeks old, were immunized subcutaneously with one of the following treatments: (i) F68–CD–MP microparticles containing 20 μg of HS per mouse in 0.1 mL saline; (ii) free HS (20 μg/mouse); (iii) empty TROMS microparticles; (iv) 5 × 10^4 CFU/mouse of the living attenuated B. melitensis Rev1 reference vaccine strain; or (v) sterile buffered saline solution, the unvaccinated control group (Estevan et al., 2006).
Challenge Protocol: Eight weeks after vaccination, the mice were challenged by the intraperitoneal route with 1 × 10^5 CFU of B. melitensis H38 virulent strain. Two weeks after the challenge, the animals were euthanatised by cervical dislocation. The spleens of the animals were aseptically removed, individually homogenized in BSS, properly diluted, and plated in Blood Agar Base medium for viable counts (Estevan et al., 2006).
Efficacy: A single dose administered s.c. 8 weeks before infection produced significant protection with respect to unvaccinated control mice. Moreover, this protection was similar to that conferred by B. melitensis Rev1 reference vaccine. In contrast, no significant protection was obtained when non-encapsulated HS was given to mice (Estevan et al., 2006).

45. Brucella recombinant SurA protein vaccine

a. Vaccine Ontology ID:

VO_0000358

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

The antigen for this vaccine is SurA protein from B. abortus strain 2308, B. abortus strain S19, and Brucella melitensis strain H38 (Delpino et al., 2007).

e. Gene Engineering of SurA

Type: Recombinant protein preparation
Description: Mice given rSurA with adjuvant exhibited a significant degree of protection against B. abortus infection (Delpino et al., 2007b).
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0000139
Description: Two different adjuvants were used in these vaccines: Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA). CFA was administered on day 0 and IFA was administered on day 15 (Delpino et al., 2007).

g. Adjuvant:

VO ID: VO_0000142
Description: Two different adjuvants were used in these vaccines: Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA). CFA was administered on day 0 and IFA was administered on day 15 (Delpino et al., 2007).

h. Preparation

The PCR primers for cloning SurA gene from B. abortus were as follows: sense 5′AGAAAGCATATGTTTGCAAGACCTCTT3′ (NdeI) and antisense 5′TCTTCGGGATCCTCAACGATTGACGATGGT3′ (BamHI). B. abortus genomic DNA was used as template for PCR with Pfu DNA polymerase (Stratagene). The surA gene was cloned to plasmid Pet17b and then transformed to E. coli JM19 and then BL21(DE3) competent cells. Recombinant proteins were adsorbed with Sepharose-polymyxin B (Sigma, St. Louis, MO) to eliminate lipopolysaccharide contamination. The antigen and PBS were administered mixed with Complete Freund's Adjuvant (CFA) (Sigma) on day 0 and with Incomplete Freund's Adjuvant (IFA) on day 15 (Delpino et al., 2007).

i. Immunization Route

Nasal spray, Intraperitoneal injection (i.p.)

j. Mouse Response

Host Strain: Balb/c
Vaccination Protocol: Female BALB/c mice of 6 to 8-weeks old were used for the testing of these vaccines. Mice were anaesthetized with methoxyfuorane and immunized by the intraperitoneal route with (i) 30 μg of rSurA, (ii) 30 μg of rDnaK, (iii) rSurA + rDnaK (30 μg + 30 μg) or iv) PBS, which was the negative control. Antigens and PBS were administered mixed with Complete Freund's Adjuvant (CFA) on day 0 and with Incomplete Freund's Adjuvant (IFA) on day 15. A fifth group of mice was immunized i.p with 30 μg rDnaK in PBS without no adjuvant on days 0 and 15. As reference vaccinated controls other groups were immunized once (i) by the subcutaneous route at day 0 with 8 × 10^8 formalin-killed B. melitensis H38S in IFA or (ii) i.p with 1 × 10^4 live B. abortus S19. Two separate assays of immunization were performed. The first experiment included groups immunized with rDnaK plus adjuvant, rDnaK without adjuvant, rSurA, and the negative (PBS) and reference (H38) control groups. The second experiment included groups immunized with rDnaK, rSurA, and rDnaK + rSurA, all with adjuvant, and the negative (PBS) and reference (B. abortus S19) control groups. Sera for antibody detection were obtained by retro-orbital bleeding under anaesthesia at 15, 30, 45 and 75 days after the first immunization (Delpino et al., 2007).
Immune Response: Immunization with rSurA elicited a vigorous IgG response that was detectable after the first immunization, increased further after the second Ag injection. PBS-immunized animals challenged with B. abortus 2308 developed antibodies against rSurA at 1 month after infection. Anti-rSurA IgG2a titers were higher than IgG1 titers during the whole immunization. rSurA stimulated significant production of IFN-γ, IL-2, IL-4 and IL-5 in spleen cells from rSurA-immunized animals but not from the PBS control group. All animals immunized with rDnaK alone elicited a humoral immune response that was detectable 15 days after the first immunization and increased further after the second injection to reach an IgG mean titer of 217,000 at day 30 post-vaccination. Immunization with rDnaK plus adjuvant induced similar anti-rDnaK IgG titers than immunization with rDnaK alone. None of the animals inoculated with PBS showed specific anti-rDnaK Abs at the time of challenge but notably, 30 days after infection all of them produced anti-rDnaK. Stimulation with rDnaK induced a significant production of IFN-γ and IL-2 in spleen cells from all mice immunized with rDnaK plus adjuvant Cells from rDnaK alone- or PBS-immunized mice were unable to stimulate the secretion of IFN-γ, IL-2, IL-4, IL-5 or IL-10 in response to rDnaK (Delpino et al., 2007).
Challenge Protocol: Immunized mice were challenged by i.p. injection with 1 × 10^4 B. abortus 2308 (Delpino et al., 2007).
Efficacy: Mice given rSurA or rDnaK plus adjuvant exhibited a significant degree of protection against B. abortus when compared with controls receiving PBS. Formalin-killed B. melitensis H38S, the control vaccine, induced 2.19 units of protection against B. abortus. Immunization with rDnaK alone induced a low but still significant level of protection. In a second experiment, both evaluated vaccines (rDnaK or rSurA plus adjuvant) induced significant protection against B. abortus infection. There was no additive protection by the simultaneous immunization with both rDnaK and rSurA. All evaluated vaccines induced less protection than H38 or B. abortus strain 19 control vaccines. Altogether these results indicate that rSurA or rDnaK in adjuvant induce partial protection against B. abortus infection (Delpino et al., 2007).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: Spleen cells from mice were used to determine cytokine levels 1 month after last immunization. Mice immunized with rSurA and stimulated with SurA had significantly higher levels of IFN-gamma than did mice immunized with PBS and stimulated with SurA (Delpino et al., 2007b).
- Detailed Gene Information: Click here.
Host Gene Response of Il2
- Gene Response: Spleen cells from mice were used to determine cytokine levels 1 month after last immunization. Mice immunized with rSurA and stimulated with SurA had significantly higher levels of IL-2 than did mice immunized with PBS and stimulated with SurA (Delpino et al., 2007b).
- Detailed Gene Information: Click here.
Host Gene Response of Il4 (interleukin 4)
- Gene Response: Spleen cells from mice were used to determine cytokine levels 1 month after last immunization. Mice immunized with rSurA and stimulated with SurA had significantly higher levels of IL-4 than did mice immunized with PBS and stimulated with SurA (Delpino et al., 2007b).
- Detailed Gene Information: Click here.
Host Gene Response of Il5
- Gene Response: Spleen cells from mice were used to determine cytokine levels 1 month after last immunization. Mice immunized with rSurA and stimulated with SurA had significantly higher levels of IL-5 than did mice immunized with PBS and stimulated with SurA (Delpino et al., 2007b).
- Detailed Gene Information: Click here.

46. CGV2631

a. Product Name:

B. melitensis Rev. 1 with bp26 and omp31 deletions

b. Vaccine Ontology ID:

VO_0001171

c. Type:

Live, attenuated vaccine

d. Status:

Research

e. Antigen

B. melitensis Rev. 1 with bp26 and omp31 deletions (Jacques et al., 2007).

f. Immunization Route

Intramuscular injection (i.m.)

g. Sheep Response

Vaccination Protocol: Sheep were conjunctivally or subcutaneously vaccinated at 4 months old (Jacques et al., 2007).
Challenge Protocol: Sheep were challenged with B. melitensis H38 at the middle of the first pregnancy following vaccination (Jacques et al., 2007).
Efficacy: eletion of bp26 and omp31 genes did not significantly affect the well recognised capacity of Rev.1 to protect sheep against B. melitensis challenge. However, the protection conferred by the CGV2631 mutant was significantly lower than that conferred by the CGV26 mutant or the Rev.1 strain (Jacques et al., 2007).

47. Divalent DNA B. abortus Vaccine pcDNA3.1-L7/L12-Omp16

a. Vaccine Ontology ID:

VO_0000374

b. Type:

DNA vaccine

c. Antigen

Brucella abortus L7/L12 protein and Omp16 protein were the antigens used in this vaccine. The vaccine was designated as pcDNA3.1-L7/L12-Omp16 (Luo et al., 2006b).
divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein) and Omp16 protein (outer membrane lipoprotein), designated pcDNA3.1-L7/L12-Omp16.

d. Gene Engineering of L7/L12

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Gene Engineering of omp16

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

pcDNA3.1(+) (Luo et al., 2006b)

g. Preparation

Full-length open reading frames of the L7/L12 gene and Omp16 gene were amplified with PCR from the genome of B. abortus strain RB51. The gene amplified with L7/L12 primers and/or the gene amplified with Omp16 primers were inserted into pcDNA3.1(+) vector (Invitrogen) (Luo et al., 2006b).

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Female BALB/c mice were distributed into two groups: each mouse in one group was inoculated intramuscularly with 100 μg of pcDNA3.1-L7/L12-Omp16, pcDNA3.1-L7/L12, or pcDNA3.1-Omp16 in 100 μl of PBS. A control group was also used in this group, and these mice were infected with PBS or the pcDNA3.1 expression vector alone. Each mouse in the other group was injected with 10 μg of rL7/L12-Omp16 in 100 μl PBS according to the same schedule. Every mouse in this group was injected on weeks 0, 2, and 4. The mice used as positive controls were inoculated intraperitoneally on day 0 with 2× 10^8 CFU of B. abortus strain RB51 in 0.2 ml of PBS (Luo et al., 2006b).
Immune Response: The results showed that the total IgG titer of the hyperimmune sera from mice immunized with pcDNA3.1-L7/L12-Omp16, pcDNA3.1-L7/L12, or pcDNA3.1-Omp16 reached 1:1,000, 1:800, or 1:600, respectively. Immunization with rL7/L12 and live RB51 strain elicited much higher humoral immune responses in mice, with IgG titers reaching 1:25,600 and 1:50,000, respectively. The analysis of IgG subtypes showed a significant increase in IgG1 and IgG2a from the DNA vaccine group, fusion protein vaccine group, and live RB51 group compared with the pcDNA3.1 vector control (Luo et al., 2006b).
Challenge Protocol: Five mice from each group were challenged intraperitoneally 14 days after initial immunization. These mice were given a higher dose of strain 544, 5 × 10^5 CFU (Luo et al., 2006b).
Efficacy: Immunization with any type of DNA vaccine resulted in a significantly higher degree of protection than the controls that received only PBS. Within the three recombinant DNA vaccines, the divalent DNA vaccine provided a higher protection level than either of the univalent DNA vaccines. Immunization with the recombinant fusion protein rL7/L12 also created significant protection. This protective effect was significantly lower than that created by theimmunization with the DNA vaccines (Luo et al., 2006b).

48. E. coli Escheriosome-mediated Cytosolic Delivery of recombinant Brucella rL7/L12 Protein

a. Vaccine Ontology ID:

VO_0000423

b. Type:

Subunit vaccine

c. Antigen

The vaccine antigen is Brucella L7/L12 protein, which was delivered by an E. coli lipid liposome (escheriosome)-mediated cytosolic delivery system (Mallick et al., 2007).

d. Adjuvant:

VO ID: VO_0000139

e. Preparation

The rL7/L12 proteins were purified and introduced into Escherischia coli lipid liposome, allowing for escheriosome-mediated cytosolic delivery of the antigen, recombinant rL7/L12 protein. Combinations containing rL7/L12 protein and different adjuvants were formed for vaccination (Mallick et al., 2007).

f. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Four-to-six-week-old female Balb/c mice were randomly distributed into eight experimental groups so that each group consisted of 20 animals. Each group consisted of 20 animals. Various groups of mice were injected separately through subcutaneous route, on days 0,21, and 28 with escheriosome entrapped rL7/L12 (E-Lip-L7), egg PC/Chol liposome entrapped rL7/L12 protein (P-Lip-L7), rL7/L12 protein with Complete Freund’s adjuvant (IFA-L7), rL7/L12 protein alone (free form; F-L7), E. coli lipid sham liposome and sham escheriosome mixed with free rL7/L12 protein, a physical mixture (EL + L7). The positive control in this study were mice vaccinated with about 5 x 10^6 cfu of Brucella S-19. The negative control for this study received only PBS. Each animal was immunized with a priming dose of 50 micrograms of rL7/L12 protein per animal (day 0) and boosted with 30 micrograms per animal (days 21 and 28) (Mallick et al., 2007).
Immune Response: Analysis of the mouse sera revealed non-signiﬁcant antibody titre up to day 14 post-immunization in various groups of immunized mice. Signiﬁcantly higher titre of IgG was detected on day 21 post-immunization in sera of animals which were primed with E-Lip-L7 form of the antigen as compared with the P-Lip-L7. Antibody titre was signiﬁcantly less in the animals immunized with S-19 or IFA-L7 combination. High antibody response was maintained in E-Lip-L7 immunized mice following each booster with maximum antibody level on seventh day after the last immunization as compared with P-Lip-L7 group which was unable to rise to that extent. The antibody response evoked by S-19 or IFA-L7 was signiﬁcantly less as compared to E-Lip-L7 immunized group. It was observed that E-Lip-L7 maintained signiﬁcantly higher titer of IgG1 and IgG2a as compared with P-Lip-L7-immunized group. Both S-19 as well as IFA-L7 combination failed to induce signiﬁcant level of IgG1 and IgG2a titre in the serum after 42 days post-ﬁrst immunization and the trend was maintained even after day 60 post-immunization (Mallick et al., 2007).
Challenge Protocol: One week after the final immunization, the mice belonging to various groups were challenged with 2 x 10^5 cfu of a virulent culture of B. abortus 544 intraperitoneally in 0.2ml
of saline solution. After 7, 15 and 30 days post-challenge, four mice from each group were euthanatized and their spleens were analyzed (Mallick et al., 2007).
Efficacy: Escherischia coli escheriosome-mediated cytosolic delivery of recombinant rL7/L12 protein can elicit strong immunological responses in the Balb/c mice. However, egg PC/Chol liposome entrapped rL7/L12 was found to impart relatively poor immune response. Escheriosome-entrapped rL7/L12 protein elicited high IgG2a isotype response, suggestive of its relevance in imparting protection against brucellosis in mice(Mallick et al., 2007).

49. Live attenuated B. abortus with deletion of znuA

a. Vaccine Ontology ID:

VO_0000386

b. Type:

Live, attenuated vaccine

c. Antigen

The antigen for this vaccine is live, attenuated B. abortus strain 2308 with a znuA knockout mutation (Yang et al., 2006).

d. Gene Engineering of znuA

Type: Gene mutation
Description: A suicide plasmid and a B. abortus mutant were constructed, then plasmids from transformants were isolated and analyzed by agarose gel electrophoresis after restriction digestion. B. abortus ΔznuA was electroporated with pBznuA to finalize the mutation (Yang et al., 2006).
Detailed Gene Information: Click here.

e. Preparation

ΔznuA mutant, RB51strains were grown overnight in Brucella broth at 37°C. Cells were pelleted, washed twice in sterile phosphate-buffered saline, and diluted to 1 × 10^8 cells/200 μl in sterile PBS. The actual viable inoculum CFU was confirmed by serial dilution tests on Bacto Potato Infusion Agar. Each vaccine consisted of 0.2 ml of this suspension (Yang et al., 2006).

f. Virulence

The znuA-deleted mutant is very attenuated (Yang et al., 2006).

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Experiments were conducted with 7- to 9-week-old age-matched mice. 0.2 ml of vaccine was administered to mice via intraperitoneal injection (Yang et al., 2006).
Persistence: Compared to wild-type strain 2308, splenic CFU in B. abortus ΔznuA-dosed mice were significantly decreased at weeks 1, 4, and 8. Importantly, by week 8, in three of the five B. abortus ΔznuA-dosed mice, splenic CFU could not be detected (Yang et al., 2006).
Challenge Protocol: For challenge study, B. abortus 2308 was diluted in sterile PBS, in which 100 μl of bacterial suspension contained 5 × 10^4 CFU bacteria, and immunized and naive mice were subsequently challenged intraperitoneally. The challenge dose was confirmed by plating B. abortus on PIA (Yang et al., 2006).
Efficacy: The results showed that the ΔznuA mutant was mostly cleared by 8 weeks postinfection. Splenic CFU detected 4 weeks postchallenge were all wild type, and none were from the ΔznuA mutant. Protection against wild-type B. abortus 2308 challenge was as effective as that obtained with the RB51 or S19 vaccine strain, so this mutant is a potential live vaccine (Yang et al., 2006).

50. Live, Attenuated Rifampin-Resistant Rough Mutants of Brucella melitensis

a. Vaccine Ontology ID:

VO_0004147

b. Type:

Live, attenuated vaccine

c. Antigen

This vaccine contains rifampin-resistant rough mutants of Brucella melitensis (Adone et al., 2005).

d. Preparation

The vaccines were made through suspensions of B. melitensis mutant strains at a concentration of 5 × 10^8 CFU/ml (Adone et al., 2005).

51. Microencapsulated B. melitensis vjbR mutant vaccine

a. Vaccine Ontology ID:

VO_0000398

b. Type:

Live, attenuated vaccine

c. Antigen

An attenuated mutant of Brucella meletensis called vjbR::Tn5 (BMEII1116) is the antigen used in this vaccine (Arenas-Gamboa et al., 2008).

d. Gene Engineering of VjbR

Type: Gene mutation
Description: Live B. melitensis attenuated mutant vjbR::Tn5 was generated by mutation of the vjbR gene through interruption with a Tn5 (Arenas-Gamboa et al., 2008).
Detailed Gene Information: Click here.

e. Preparation

6 x 10^6 CFU of the live B. melitensis mutant bjvR::Tn5 was suspended in 1ml of MOPS buffer (buffer containing MOPS and NaCl) and mixed with 5 ml of alginate solution. Spheres were obtained by extruding the suspension through a 200 micron nozzle into a 100 mM calcium chloride solution and stirred for 15 minutes. After extrusion of the bacteria-alginate mixture into the CaCl2, the capsules were washed twice with MOPS for 5 minutes and further crosslinked with 0.05% poly-L-lysine for 10 minutes. Following two successive washes, the beads were stirred for five minutes in a solution of 0.03% (w/v) alginate to apply a final outer shell and washed twice with MOPS (Arenas-Gamboa et al., 2008).

f. Virulence

B. melitensis mutant bjvR::Tn5 is an attenuated live strain.

g. Storage

The vaccine was stored at 4°C (Arenas-Gamboa et al., 2008).

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Sixty female BALB/c mice were randomly distributed into groups of 10 for intraperitoneally (IP) vaccination. Each animal was given a single dose of microcapsules containing 1 x 10^5 CFU of either: encapsulated B. melitensis mutant vjbR::Tn5 in alginate (vjbR::Tn5/alginate), encapsulated vjbR::Tn5 in alginate with VpB inside the capsule (vjbR::Tn5/VpB core), or encapsulated vjbR::Tn5 in alginate with VpB in the shell of the sphere (vjbR::Tn5/VpB shell). The control groups received 1 x 10^5 CFU of either nonencapsulated vjbR::Tn5, empty capsules (no bacteria entrapped), or two hundred microliters of MOPS buffer (Arenas-Gamboa et al., 2008).
Persistence: There appears to be a brief period between week one and two during which the organism replicates and the numbers of B. melitensis vjbR::Tn5 in the spleen increase, but by three weeks post-inoculation the number of organisms in the spleen exhibits a drastic decline and drops below the level of detection by four weeks post-infection (Arenas-Gamboa et al., 2008).
Immune Response: Immunization with BM vjbR::Tn5 elicited an IgG response that was clearly detectable after 2 weeks post-vaccination for either encapsulated or nonencapsulated vaccines. In mice vaccinated with the nonencapsulated BM vjbR::Tn5 vaccine, IgG levels peaked at 8 weeks post-immunization, whereas IgG responses in mice immunized with the BM vjbR::Tn5 with VpB in the shell, levels increased steadily and reached a maximum after 18 weeks post immunization. In this case, an induction of higher and sustained antibody levels correlated with enhanced protection for both BM vjbR::Tn5 in alginate and vjbR::Tn5 in VpB shell formulations. Mice vaccinated with the encapsulated vjbR::Tn5 revealed elevated secretion from spleen cells of INF-γ, IL-12, but no IL-4. These suggested an induction of a T helper 1 (Th1) response reflecting the enhanced immunity associated with microencapsulation (Arenas-Gamboa et al., 2008).
Challenge Protocol: At certian times after vaccination, mice were challenged IP using 1 x 10^5 CFU/mouse of B.melitensis wild-type 16M. One week post challenge, mice were euthanizediation and their spleens were removed .
Efficacy: A single immunization dose in BALB/c mice with the encapsulated vjbR mutant improved protection against wild-type B. melitensis 16M challenge compared to the nonencapsulated vaccine strain (P<0.05) .
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: Cytokine secretion from spleen cells of mice vaccinated with the encapsulated vjbR::Tn5 revealed significantly elevated secretion of gamma interferon compared to non-vaccinated mice 10 and 30 weeks post vaccination (Arenas-Gamboa et al., 2008).
- Detailed Gene Information: Click here.
Host Gene Response of Il12b
- Gene Response: Cytokine secretion from spleen cells of mice vaccinated with the encapsulated vjbR::Tn5 revealed significantly elevated secretion of interleukin-12 compared to non-vaccinated mice 10 and 30 weeks post vaccination (Arenas-Gamboa et al., 2008).
- Detailed Gene Information: Click here.

52. NPAP Brucella vaccine

a. Product Name:

Brucella vaccine using nonpathogenic alphaproteobacteria

b. Vaccine Ontology ID:

VO_0000450

c. Type:

Inactivated or "killed" vaccine

d. Antigen

The angtiens for this vaccine were Ochrobactrum anthropi, Sinorhizobium meliloti, Mesorhizobium loti, Agrobacterium tumefaciens, or Brucella melitensis H38. These were used because provious findings indicate that Brucella antigens and those from Nonpathogenic Alphaproteobacteria (NPAP) are cross-recognized by the immune system (Delpino et al., 2007a).

e. Adjuvant:

VO ID: VO_0000133

f. Preparation

Bacterial cultures were grown on plates, then centrifuged at 15,000 x g. Bacterial pellets were washed with PBS, then the bacteria were heat-killed. These suspensions were centrifuged at 15,000 x g again, then washed with Tris buffer. The cells were suspended in Tris buffer , then disrupted with a French press. Bacterial cells were broken by two passages and then digested for 1 hour with D. Nase and R. Nase. Unbroken cells were seperated by centrifugation. Particulate matter was pelleted by centrifugation, and the resulting supernatent was stored for vaccine (Delpino et al., 2007a).

g. Virulence

Not noted.

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Mice were immunized with 3 doses (at 2 week intervals) of heat-killed bacteria (1 x 10^9 CFU per dose) mixed with adjuvant and administered subcutaneously in the back or with 3 doses of CYTs administered intraperitoneally. Control groups received PBS. The Brucella group was immunized with B. Melitensis H38 (Delpino et al., 2007a).
Persistence: Not noted.
Immune Response: Subcutaneous immunization with with heat-killed bacteria elicited a strong antobody response against CYT antigens. Antibody levels were highest after the second immunization, in most cases. In mice immunized with nonpathogenic species. Anti-Brucella antibody levels were augmented in all groups compared to preimmunization levels (Delpino et al., 2007a).
Challenge Protocol: One month after the final immunization, mice were challenged intravenously with 1.3 x 10^4 CFU of live B. abortus 2308. The mice were killed 30 days later and had their spleens analyzed and plated (Delpino et al., 2007)
Efficacy: Cross-reacting anibodies were detected in serum samples obtained at the moment of challenge in all groups of mice. Spleen counts were significantly lower in immunized mice than in mice injected with PBS. Protection levels for nonpathogenic bacteria were lower than that obtained with Brucella immunization . Counts of CFU in mice immunized with B. melitensis were significantly lower than those of mice immunized with any other bacteria. Anti-brucella antibodies were detected in all groups 30 days postchallenge at levels similar to those found at the moment of challenge (Delpino et al., 2007a).

i. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Two separate experiments of oral immunization were performed. Mice were inoculated intragastrically at weekly intervals with three doses of live NPAP(1 x 10^8 CFU) or heat-killed B. abortus (HKBA) strain 2308 (1 x 10^8 CFU)or PBS by an intragastric feeding tube (Delpino et al., 2007a).
Persistence: Not noted.
Immune Response: Anti-Brucella IgG levels were significatly higher than preinfection levels in all groups of mice infected with NPAP. Mice infected with HKBA exhibited a significant rise in anti-Brucella IgG in serum. No significant increase in IgA was detected at the time of challenge for mice immunized with HKBA or infected with NPAP (Delpino et al., 2007a).
Challenge Protocol: Twenty days after the last infecting dose, mice were challenged by the same route with live B. abortus 2308 (Delpino et al., 2007a).
Efficacy: Serum levels of anti-Brucella IgA increased significantly in mice previously infected with O. anthropi and in mice orally infected with HKBA. Fecal levels of anti-Brucella IgA also increased after challenge (Delpino et al., 2007a).

53. Porin and S-LPS Extracted from Virulent Brucella abortus 2308

a. Vaccine Ontology ID:

VO_0000403

b. Type:

Subunit vaccine

c. Antigen

The antigen for this vaccine is a complex of porin and smooth lipopolysaccharide (S-LPS) extracted from virulent Brucella abortus 2308 (Winter et al., 1988).

d. Adjuvant:

VO ID: VO_0001250
Description: The porin-S-LPS was given without adjuvant or in several adjuvants: trehalose dimycolate and muramyl dipeptide; the pluronic polymer L-121 and muramyl dipeptide; or complexed with Quil A in immunostimulating complexes (Winter et al., 1988).

e. Preparation

The S-LPS was produced from smooth strain 2308 by extraction in hot phenol followed by treatment with guanidinium thiocyanate. Inocula were prepared from a freshly thawed vial which was diluted in sterile phosphate buffered saline to yield an infecting dose of 5 x 10^4 bacteria per 0.1 ml. Each dose was mixed with its appropriate adjuvant (Winter et al., 1988).

f. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Five week-old female mice were used. The mice were vaccinated subcutaneously. Blood samples were taken on one or more occasions during the course of some experiments. Quantitative cultures for viable B. abortus were performed on spleens at 1 and 4 weeks postinfection. Each mouse was vaccinated with 30 micrograms of porin-S-LPS (Winter et al., 1988).
Immune Response: Protective vaccines caused the formation of increased concentrations of circulating O-polysaccharide-specific antibodies, although there were individual exceptions to the quantitative associatiQn between O-polysaccharide-specific antibodies and protection. Antibodies specific for porin or R-LPS were found in negligible quantities in vaccinated mice (Winter et al., 1988).
Challenge Protocol: B. abortus smooth strain 2308 of known virulence was used for challenge infections. In some experiments, vaccination or challenge was performed with vaccine strain 19. Animals were challenged 4 weeks postinfection with approximnately 5 x 10^4 CFU of live B. abortus cells (Winter et al., 1988).
Efficacy: Vaccination with porin-S-LPS conferred significant protection against challenge infections with either B. abortus 2308 or 19 at both 1 and 4 weeks postinfection. The magnitude of protection was not significantly enhanced at either time period by the inclusion of TDM and MDP adjuvant in the vaccine. In contrast, vaccination with the same quantity of porin-R-LPS with or without adjuvant provided no significant protection against either challenge strain (Winter et al., 1988).

54. Recombinant B. abortus AsnC protein with CFA/IFA adjuvant

a. Vaccine Ontology ID:

VO_0004286

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

Recombinant B. abortus AsnC protein (Fu et al., 2012)

e. Gene Engineering of AsnC

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0000133
Description: CFA and IFA were used.

g. Immunization Route

Intramuscular injection (i.m.)

55. Recombinant B. abortus CobB protein with CFA/IFA adjuvant

a. Vaccine Ontology ID:

VO_0004285

b. Type:

Subunit vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

mouse

e. Antigen

Recombinant Brucella abortus CobB (Fu et al., 2012)

f. Gene Engineering of cobB

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

g. Immunization Route

Intramuscular injection (i.m.)

56. Recombinant B. abortus RB51SOD

a. Vaccine Ontology ID:

VO_0000720

b. Type:

Live attenuated B. abortus strain

c. Gene Engineering of SodC from B. abortus strain 2308

Type: Protein overexpression
Description: B. abortus Cu/Zn SOD is over-expressed in recombinant strain RB51SOD using the broad-range plasmid pBBR1MCS (Vemulapalli et al., 2000a).
Detailed Gene Information: Click here.

d. Preparation

The gene for B. abortus Cu/Zn SOD (sodC) along with its own promoter was initially obtained from a genomic library of B. abortus strain 2308, and later subcloned into pBBR1MCS, a broad-host-range plasmid. The resulting plasmid pBBSOD was transformed into E. coli DH5a, confirmed, purified, and then electroporated into B. abortus strain RB51. Strain RB51 containing the plasmid pBBSOD was designated RB51SOD (Vemulapalli et al., 2000a).

e. Virulence

RB51SOD is not more virulent than RB51 (Vemulapalli et al., 2004).

f. Storage

RB51SOD does not increase virulence compared to RB51.

g. Description

RB51SOD is a recombinant strain of B. abortus cattle vaccine strain RB51. RB51SOD overexpresses B. abortus Cu/Zn superoxide dismutase (SOD). Overexpression of this enzyme significantly increases vaccine efficacy against strain 2308 challenge (Vemulapalli et al., 2004).

h. Mouse Response

Host Strain: BALB/c mice
Vaccination Protocol: RB51SOD was used to vaccinate mice with a dose of ~4 x 10^8 cfu per mouse.
Persistence: The presence of the Cu/Zn SOD plasmid in strain RB51 does not alter its vaccine efficacy. Overexpression of SOD does not alter the attenuation characteristic of strain RB51 (Vemulapalli et al., 2000a).
Vaccine Immune Response Type: VO_0003068
Side Effects: None observed.
Efficacy: Recombinant strain RB51SOD in mice induces better protection against virulent B. abortus infection compared to B. abortus vaccine strain RB51 (Vemulapalli et al., 2000a).
Description: Mice vaccinated with RB51SOD, but not RB51, develop antibodies and cell-mediated immune responses to Cu/Zn SOD (Vemulapalli et al., 2000a).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: Mice vaccinated with strain RB51SOD developed a Th1 immune response to the CuZn SOD, indicated by specific induction of serum IgG2a antibodies, but not IgG1 antibodies. IFN-gamma , but not IL -4 is secreted by CuZn SOD-stimulated splenocytes (Vemulapalli et al., 2000a). The enhanced protective immunity conferred by strain RB51SOD my be attributed to the specific cell-mediated responses, especially IFN-gamma secretion (Vemulapalli et al., 2000a).
- Detailed Gene Information: Click here.

57. Recombinant B. abortus RB51WboA

a. Vaccine Ontology ID:

VO_0000404

b. Type:

Live attenuated B. abortus strain

c. Preparation

RB51WboA is a recombinant Brucella strain that complements RB51 with a functional wboA gene. Rough Brucella abortus RB51 is a stable, attenuated mutant vaccine generated strain derived from virulent strain 2308. The wboA gene in RB51 is disrupted by an IS711 element. Abrogation of the wboA gene in smooth , virulent B. abortus, B. melitensis , and B. suis results in rough , attenuated mutants which fail to produce O polysaccharide (O antigen) (Vemulapalli et al., 2000).

d. Virulence

RB51WboA is not more virulent than RB51 (Vemulapalli et al., 2000b).

e. Mouse Response

Vaccination Protocol: Groups of 13 mice each were vaccinated by intraperitoneal (i.p.) inoculation of viable strains RB51 (3 × 10^8 CFU/mouse), RB51SOD (5 × 10^8 CFU/mouse), RB51WboA (2.5 × 10^8 CFU/mouse) and RB51SOD/WboA (2.8 × 10^8 CFU/mouse) (Vemulapalli et al., 2004).
Persistence: No bacteria were isolated from the strain RB51WboA- and RB51SOD/WboA vaccinated mice at the time of challenge (Vemulapalli et al., 2004).
Challenge Protocol: Seven weeks after vaccination, five mice from each group were challenged i.p. with 3 × 10^4 CFU/mouse of virulent B. abortus 2308, and the remaining five mice were challenged i.p. with 2.4 × 10^4 CFU/mouse of virulent B. melitensis 16 M. Two weeks after challenge, the mice were euthanized and the number of CFUs in their spleens were determined (Vemulapalli et al., 2004).
Efficacy: Mice vaccinated with strains RB51 and RB51SOD showed significant protection in comparison to control. Mice vaccinated with strain RB51SOD showed a significantly better protection (mean reduction in CFU/spleen = 2.9 logs) than the mice vaccinated with strain RB51 (mean reduction in CFU/spleen = 1 log) (P = 0.02). No bacteria were isolated from the strain RB51WboA- and RB51SOD/WboA vaccinated mice, indicating that these mice developed a superior immunity that prevented the infection of B. abortus 2308 (Vemulapalli et al., 2004).

58. Recombinant Brucella DnaK protein vaccine

a. Vaccine Ontology ID:

VO_0000373

b. Type:

Subunit vaccine

c. Antigen

The antigen for this vaccine is rDnaK protein from B. abortus strain 2308, B. abortus strain S19, and Brucella melitensis strain H38 (Delpino et al., 2007).

d. Adjuvant:

VO ID: VO_0000139
Description: Two different adjuvants were used in these vaccines: Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA). CFA was administered on day 0 and IFA was administered on day 15 (Delpino et al., 2007).

e. Adjuvant:

VO ID: VO_0000142
Description: Two different adjuvants were used in these vaccines: Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA). CFA was administered on day 0 and IFA was administered on day 15 (Delpino et al., 2007).

f. Preparation

The open reading frame of DnaK was cloned in the Pet17b vector (Novagen, Madison, WI, USA). The specific primers for B. abortus DnaK contain with XbaI and BamHI restriction sites at the 5′ ends: sense 5′ GCAGTTTCTAGAATGGAGAGAAATA 3′, antisense 5′ TAAAAGGATCCAATTACGACGAC 3′. B. abortus genomic DNA was used as template for PCR with Pfu DNA polymerase (Stratagene). Plasmid Pet17b was digested with BamHI and NheI. After ligation, the mix was used to transform E. coli JM109 competent cells. The plasmid DNA of a clone containing the insert was purified and used to transform E. coli strain BL21 (DE3) competent cells. Upon induction with 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG), recombinant DnaK (rDnaK) was successfully expressed, and purified using a Mono Q column in an AKTA apparatus (Amersham Pharmacia, Uppsala, Sweden). Recombinant proteins were adsorbed with Sepharose-polymyxin B (Sigma, St. Louis, MO) to eliminate lipopolysaccharide contamination (Delpino et al., 2007).

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Female BALB/c mice of 6 to 8-weeks old were used for the testing of these vaccines. Mice were anaesthetized with methoxyfuorane and immunized by the intraperitoneal route with (i) 30 μg of rSurA, (ii) 30 μg of rDnaK, (iii) rSurA + rDnaK (30 μg + 30 μg) or iv) PBS, which was the negative control. Antigens and PBS were administered mixed with Complete Freund's Adjuvant (CFA) on day 0 and with Incomplete Freund's Adjuvant (IFA) on day 15. A fifth group of mice was immunized i.p with 30 μg rDnaK in PBS without no adjuvant on days 0 and 15. As reference vaccinated controls other groups were immunized once (i) by the subcutaneous route at day 0 with 8 × 10^8 formalin-killed B. melitensis H38S in IFA or (ii) i.p with 1 × 10^4 live B. abortus S19. Two separate assays of immunization were performed. The first experiment included groups immunized with rDnaK plus adjuvant, rDnaK without adjuvant, rSurA, and the negative (PBS) and reference (H38) control groups. The second experiment included groups immunized with rDnaK, rSurA, and rDnaK + rSurA, all with adjuvant, and the negative (PBS) and reference (B. abortus S19) control groups. Sera for antibody detection were obtained by retro-orbital bleeding under anaesthesia at 15, 30, 45 and 75 days after the first immunization (Delpino et al., 2007b).
Immune Response: Immunization with rSurA elicited a vigorous IgG response that was detectable after the first immunization, increased further after the second Ag injection. PBS-immunized animals challenged with B. abortus 2308 developed antibodies against rSurA at 1 month after infection. Anti-rSurA IgG2a titers were higher than IgG1 titers during the whole immunization. rSurA stimulated significant production of IFN-γ, IL-2, IL-4 and IL-5 in spleen cells from rSurA-immunized animals but not from the PBS control group. All animals immunized with rDnaK alone elicited a humoral immune response that was detectable 15 days after the first immunization and increased further after the second injection to reach an IgG mean titer of 217,000 at day 30 post-vaccination. Immunization with rDnaK plus adjuvant induced similar anti-rDnaK IgG titers than immunization with rDnaK alone. None of the animals inoculated with PBS showed specific anti-rDnaK Abs at the time of challenge but notably, 30 days after infection all of them produced anti-rDnaK. Stimulation with rDnaK induced a significant production of IFN-γ and IL-2 in spleen cells from all mice immunized with rDnaK plus adjuvant Cells from rDnaK alone- or PBS-immunized mice were unable to stimulate the secretion of IFN-γ, IL-2, IL-4, IL-5 or IL-10 in response to rDnaK (Delpino et al., 2007b).
Challenge Protocol: Immunized mice were challenged by i.p. injection with 1 × 104 B. abortus 2308 (Delpino et al., 2007b).
Efficacy: Mice given rSurA or rDnaK plus adjuvant exhibited a significant degree of protection against B. abortus when compared with controls receiving PBS. Formalin-killed B. melitensis H38S, the control vaccine, induced 2.19 units of protection against B. abortus. Immunization with rDnaK alone induced a low but still significant level of protection. In a second experiment, both evaluated vaccines (rDnaK or rSurA plus adjuvant) induced significant protection against B. abortus infection. There was no additive protection by the simultaneous immunization with both rDnaK and rSurA. All evaluated vaccines induced less protection than H38 or B. abortus strain 19 control vaccines. Altogether these results indicate that rSurA or rDnaK in adjuvant induce partial protection against B. abortus infection (Delpino et al., 2007b).

59. Recombinant chimera vaccine BLSOmp31

a. Vaccine Ontology ID:

VO_0000413

b. Type:

Subunit vaccine

c. Antigen

The antigen used in this vaccine is a chimerical protein containing parts of Brucella Lumazine Synthase (BLS) and an outer membrane protein of 31 kDa (Omp31).

d. Preparation

Recombinant BLS (rBLS), rOmp31 and rBLSOmp31 were expressed in E. coli and purified as previously described (Laplagne et al., 2004). Purity was assessed by Coomassie blue stain, and recombinant proteins were adsorbed with Sepharose-polymyxin B to eliminate LPS contamination. The peptide was further purified by HPLC using a C-18 reverse phase column and the molecular weight was confirmed by mass spectroscopy (Laplagne et al., 2004).

e. Virulence

None.

f. Description

The chimerical protein BLSOmp31 is synthesized using parts of Brucella Lumazine Synthase (BLS) and an outer membrane protein of 31 kDa (Omp31), which have given limited protection in mouse models (Cassataro et al., 2007).

g. Mouse Response

Vaccination Protocol: Mice (eight/group) were anaesthetized with methoxyfuorane and immunized by the intraperitoneal route with 30
Immune Response: Immunization with recombinant BLSOmp31 elicited a strong specific IgG response that was detectable after the first immunization, increased after the second boost and reached IgG mean titers of 78,400 or 26,000 (anti-rOmp31 and anti-Omp31(48–74) , respectively) at the time of bacterial challenge. Immunizatio with rBLSOmp31 elicited high levels of anti-Omp31 IgG1 as well as IgG2a antibodies (IgG1 mean titer: 17,600; IgG2a mean titer: 5300). IgG1 titers predominated over IgG2a titers during the whole immunization schedule for both recombinant antigens. The elicited anti-peptide antibodies recognized the recombinant Omp31 as well as the native membrane protein, as demonstrated by the reactivity of the sera against whole rough B. ovis bacteria. These antibodies also produced complement mediated B. ovis cells lysis (Cassataro et al., 2007).
Challenge Protocol: Immunized mice were challenged, by intravenous injection, with 1×10^4 B. melitensis H38S or 1×10^4 B. ovis. Mice were killed by cervical dislocation 30 days after being challenged and their spleens were removed aseptically. Each spleen was homogenized in a stomacher bag, serially diluted, plated on supplemented TSA yeast extract (TSA-YE) and incubated (Cassataro et al., 2007).
Efficacy: The chimera significantly increases the protection elicited against B. ovis with respect to either BLS or Omp31. In fact, rBLSOmp31 induced the highest protection level (2.45 log) against B. ovis, which was only comparable with that induced by the control vaccine (2.42 log), but significantly higher (P < 0.01) than the vaccination with rBLS plus Omp31(48–74) (1.08 log) (Cassataro et al., 2007).

60. Recombinant O. anthropi 49237SOD

a. Vaccine Ontology ID:

VO_0000407

b. Type:

Recombinant vector vaccine

c. Adjuvant:

VO ID: VO_0001237

d. Preparation

Ochrobactrum anthropi strain 47237 was originally isolated from soil. Plasmids pBBSOD and pBBR1MCS were electroporated into electrocompetent O. anthropi strain 49237 using a protocol described previously for Brucella. Colonies of the O. anthropi strain 49237 containing pBBSOD or pBBR1MCS (designated O. anthropi strain 49237SOD or 49237pBB, respectively) were selected from TSA plates containing chloramphenicol at a concentration of 30 μg/ml (He et al., 2002)

e. Virulence

O. anthropi strains are rarely pathogenic to humans (He et al., 2002)

f. Description

Ochrobactrum anthropi is very closely related to Brucella, and has been used as a vaccine or vaccine vector for Brucellosis (He et al., 2002).

g. Mouse Response

Vaccination Protocol: Experiment 1 (Exp. 1):
Groups of eight mice were inoculated (i.p.) with either saline (negative control), B. abortus strain RB51 (2×10^8 CFU/mouse; positive control), recombinant B. abortus strain RB51SOD (2×108 CFU/mouse; positive control), O. anthropi 49237 (5×10^8 CFU/mouse), O. anthropi 49237pBB (5 × 108 CFU/mouse), or O. anthropi 49237SOD (5×10^8 CFU/mouse). At 2, 4, and 6 weeks after inoculation, three mice from each group were bled retroorbitally. The sera obtained were stored at −40°C until use in an enzyme-linked immunosorbent assay (ELISA) or for Western blot analysis.

In a second experiment (Exp. 2) whether multiple injections were required for protection was asessed . Groups of five mice were immunized i.p. with either saline, B. abortus strain RB51, or O. anthropi 49237SOD at the doses described above. After two weeks, mice inoculated with O. anthropi 49237SOD were reimmunized with O. anthropi 49237/SOD (5×10^8 CFU/mouse). To determine whether different doses influenced the results of protection, four groups of five mice each were inoculated with O. anthropi 49237 at four different doses: 5×10^8, 5×10^7, 5×10^6, and 5×10^5 CFU/mouse. A fifth group (five mice) was inoculated i.p. with saline as negative control. Synthetic CpG-containing oligodeoxynucleotides (CpG-ODN) were administered to group four as an immunostimulatory adjuvant. One group (eight mice) was inoculated i.p. with O. anthropi strain 49237 (5×10^8 CFU/mouse); one group with strain 49237 (5×10^8 CFU/mouse) and CpG adjuvant, one group with strain 49237SOD alone (5×10^8 CFU/mouse), and one group with strain 49237SOD (5×10^8 CFU/mouse) and CpG adjuvant. The CpG adjuvant (10 nmol) was administered i.p. 4 h before inoculation and again at the time of inoculation of the bacterial strains. Three groups of mice (eight/group) served as controls and were inoculated with saline alone, CpG-ODN alone, or E. coli DH5α (10^6 CFU/mouse) and CpG-ODN. The mice were bled at 2, 4, and 6 weeks after inoculation (He et al., 2002).
Challenge Protocol: Six weeks after inoculation, mice (5) from each group were challenged i.p. with 2×10^4 CFU of virulent B. abortus 2308/mouse. The mice were sacrificed after two weeks. Their spleens were homogenized, and spleens from the dilutions were plated to determine the numbers of Brucella CFU per spleen. The remaining unchallenged mice (each group) were sacrificed 6 to 8 weeks postinoculation, and spleen cells collected for cell culture in vitro (He et al., 2002).

V. References

1. Abtahi et al., 2008: Abtahi H, Salmanian AH, Rafati S, Nejad GB, Saffari M, Ghazavi A, Mosayebi G. The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene. Pakistan journal of biological sciences: PJBS. 2008; 11(21); 2472-2477. [PubMed: 19205266].

2. Adone et al., 2005: Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G, Pasquali P. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infection and immunity. 2005; 73(7); 4198-4204. [PubMed: 15972510].

3. Al-Mariri et al., 2001: Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infection and immunity. 2001 Aug; 69(8); 4816-22. [PubMed: 11447155 ].

4. Al-Mariri et al., 2001: Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godfroid J, Walravens K, Letesson JJ. Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infection and immunity. 2001; 69(10); 6264-6270. [PubMed: 11553569].

5. Al-Mariri et al., 2002: Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson JJ. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infection and immunity. 2002; 70(4); 1915-1923. [PubMed: 11895955].

6. Arenas-Gamboa et al., 2008: Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection Against Wild-type Challenge. Infection and immunity. 2008; ; . [PubMed: 18362129].

7. Arenas-Gamboa et al., 2009: Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Wong-Gonzalez A, Rice-Ficht AC. Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres. Journal of wildlife diseases. 2009; 45(1); 165-173. [PubMed: 19204345].

8. Arenas-Gamboa et al., 2009: Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC. The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infection and immunity. 2009; 77(2); 877-884. [PubMed: 19047401].

9. Arenas-Gamboa et al., 2011: Arenas-Gamboa AM, Rice-Ficht AC, Kahl-McDonagh MM, Ficht TA. The protective efficacy and safety of 16M{Delta}mucR against intraperitoneal and aerosol challenge in BALB/c mice. Infection and immunity. 2011; ; . [PubMed: 21708998].

10. Banai, 2002: Banai M. Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: laboratory aspects and field observations. Veterinary microbiology. 2002 Dec 20; 90(1-4); 497-519. [PubMed: 12414167].

11. Bhattacharjee et al., 2002: Bhattacharjee AK, Van de Verg L, Izadjoo MJ, Yuan L, Hadfield TL, Zollinger WD, Hoover DL. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infection and immunity. 2002; 70(7); 3324-3329. [PubMed: 12065469].

12. Bhattacharjee et al., 2006: Bhattacharjee AK, Izadjoo MJ, Zollinger WD, Nikolich MP, Hoover DL. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infection and immunity. 2006 Oct; 74(10); 5820-5. [PubMed: 16988260].

13. Blasco et al., 1993: Blasco JM, Gamazo C, Winter AJ, Jimenez de Bagues MP, Marin C, Barberan M, Moriyon I, Alonso-Urmeneta B, Diaz R. Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. Veterinary immunology and immunopathology. 1993 Aug; 37(3-4); 257-70. [PubMed: 8236802].

14. Bosseray, 1991: Bosseray N. Brucella melitensis Rev. 1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice. Biologicals : journal of the International Association of Biological Standardization. 1991 Oct; 19(4); 355-63. [PubMed: 1797046].

15. Cassataro et al., 2002: Cassataro J, Velikovsky CA, Giambartolomei GH, Estein S, Bruno L, Cloeckaert A, Bowden RA, Spitz M, Fossati CA. Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA. Vaccine. 2002; 20(11-12); 1660-1669. [PubMed: 11858876].

16. Cassataro et al., 2004: Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA, Baldi PC. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clinical and diagnostic laboratory immunology. 2004 Jan; 11(1); 111-4. [PubMed: 14715555].

17. Cassataro et al., 2005: Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infection and immunity. 2005 Oct; 73(10); 6537-46. [PubMed: 16177328].

18. Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A DNA vaccine coding for the quimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine. 2007 Jun 12; ; . [PubMed: 17600596].

19. Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine. 2007 May 30; 25(22); 4437-46. [PubMed: 17442465].

20. Cassataro et al., 2007: Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clinical and vaccine immunology : CVI. 2007; 14(7); 869-874. [PubMed: 17428946].

21. Cheville, 2000: Cheville NF. Development, testing and commercialization of a new brucellosis vaccine for cattle. Annals of the New York Academy of Sciences. 2000; 916; 147-53. [PubMed: 11193615].

22. Cloeckaert et al., 2002: Cloeckaert A, Grayon M, Grepinet O. Identification of Brucella melitensis vaccine strain Rev.1 by PCR-RFLP based on a mutation in the rpsL gene. Vaccine. 2002 Jun 7; 20(19-20); 2546-50. [PubMed: 12057611].

23. Cloeckaert et al., 2004: Cloeckaert A, Jacques I, Grilló MJ, Marín CM, Grayon M, Blasco JM, Verger JM. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis. Vaccine. 2004; 22(21-22); 2827-2835. [PubMed: 15246618].

24. Colby et al., 2002: Colby LA, Schurig GG, Elzer PH. An indirect ELISA to detect the serologic response of elk (Cervus elaphus nelsoni) inoculated with Brucella abortus strain RB51. Journal of wildlife diseases. 2002; 38(4); 752-759. [PubMed: 12528442].

25. Commander et al., 2007: Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine. 2007; 25(1); 43-54. [PubMed: 17049676].

26. Cook et al., 2001: Cook WE, Williams ES, Thorne ET, Taylor SK, Anderson S. Safety of Brucella abortus strain RB51 in deer mice. Journal of wildlife diseases. 2001; 37(3); 621-625. [PubMed: 11504238].

27. Corbel, 1997: Corbel MJ. Recent advances in brucellosis. Journal of medical microbiology. 1997 Feb; 46(2); 101-3. [PubMed: 9060868 ].

28. Crawford et al., 1996: Crawford RM, Van De Verg L, Yuan L, Hadfield TL, Warren RL, Drazek ES, Houng HH, Hammack C, Sasala K, Polsinelli T, Thompson J, Hoover DL. Deletion of purE attenuates Brucella melitensis infection in mice. Infection and immunity. 1996; 64(6); 2188-2192. [PubMed: 8675325].

29. Delpino et al., 2007a: Delpino MV, Estein SM, Fossati CA, Baldi PC. Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria. Clinical and vaccine immunology : CVI. 2007; 14(10); 1296-1301. [PubMed: 17715332].

30. Delpino et al., 2007b: Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine. 2007; 25(37-38); 6721-6729. [PubMed: 17686554].

31. Drazek et al., 1995: Drazek ES, Houng HS, Crawford RM, Hadfield TL, Hoover DL, Warren RL. Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages. Infection and immunity. 1995; 63(9); 3297-3301. [PubMed: 7642258].

32. Edmonds et al., 2002: Edmonds MD, Cloeckaert A, Elzer PH. Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Veterinary microbiology. 2002; 88(3); 205-221. [PubMed: 12151196].

33. ELBERG and FAUNCE, 1957: ELBERG SS, FAUNCE K Jr. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. Journal of bacteriology. 1957; 73(2); 211-217. [PubMed: 13416171].

34. Estein et al., 2003: Estein SM, Cassataro J, Vizcaino N, Zygmunt MS, Cloeckaert A, Bowden RA. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes and infection / Institut Pasteur. 2003 Feb; 5(2); 85-93. [PubMed: 12650766].

35. Estevan et al., 2006: Estevan M, Gamazo C, Grilló MJ, Del Barrio GG, Blasco JM, Irache JM. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine. 2006; 24(19); 4179-4187. [PubMed: 16481077].

36. Fernandes et al., 1996: Fernandes DM, Jiang X, Jung JH, Baldwin CL. Comparison of T cell cytokines in resistant and susceptible mice infected with virulent Brucella abortus strain 2308. FEMS immunology and medical microbiology. 1996 Dec 31; 16(3-4); 193-203. [PubMed: 9116636 ].

37. Fu et al., 2012: Fu S, Xu J, Li X, Xie Y, Qiu Y, Du X, Yu S, Bai Y, Chen Y, Wang T, Wang Z, Yu Y, Peng G, Huang K, Huang L, Wang Y, Chen Z. Immunization of Mice with Recombinant Protein CobB or AsnC Confers Protection against Brucella abortus Infection. PloS one. 2012; 7(2); e29552. [PubMed: 22383953].

38. Galindo et al., 2009: Galindo RC, Muñoz PM, de Miguel MJ, Marin CM, Blasco JM, Gortazar C, Kocan KM, de la Fuente J. Characterization of possible correlates of protective response against Brucella ovis infection in rams immunized with the B. melitensis Rev 1 vaccine. Vaccine. 2009; 27(23); 3039-3044. [PubMed: 19428917].

39. Gee et al., 2005: Gee JM, Valderas MW, Kovach ME, Grippe VK, Robertson GT, Ng WL, Richardson JM, Winkler ME, Roop RM 2nd. The Brucella abortus Cu,Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice. Infection and immunity. 2005 May; 73(5); 2873-80. [PubMed: 15845493].

40. Geong et al., 2000: Geong M, Robertson ID. Response of Bali cattle (Bos javanicus) to vaccination with Brucella abortus strain 19 in West Timor. Preventive veterinary medicine. 2000 Nov 16; 47(3); 177-86. [PubMed: 11058778].

41. Goldbaum et al., 1999: Goldbaum FA, Velikovsky CA, Baldi PC, Mortl S, Bacher A, Fossati CA. The 18-kDa cytoplasmic protein of Brucella species --an antigen useful for diagnosis--is a lumazine synthase. Journal of medical microbiology. 1999 Sep; 48(9); 833-9. [PubMed: 10482294 ].

42. Guilloteau et al., 2006: Guilloteau LA, Laroucau K, Olivier M, Grillo MJ, Marin CM, Verger JM, Blasco JM. Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination. Vaccine. 2006; 24(17); 3461-3468. [PubMed: 16519974].

43. Gupta et al., 2007: Gupta VK, Rout PK, Vihan VS. Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16M. Research in veterinary science. 2007; 82(3); 305-313. [PubMed: 17014873].

44. Hamdy et al., 2002: Hamdy ME, El-Gibaly SM, Montasser AM. Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3. Veterinary microbiology. 2002; 88(1); 85-94. [PubMed: 12119140].

45. He et al., 2001: He Y, Vemulapalli R, Zeytun A, Schurig GG. Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. Infection and immunity. 2001 Sep; 69(9); 5502-8. [PubMed: 11500423 ].

46. He et al., 2002: He Y, Vemulapalli R, Schurig GG. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infection and immunity. 2002 May; 70(5); 2535-43. [PubMed: 11953393].

47. Hemmen et al., 1995: Hemmen F, Weynants V, Scarcez T, Letesson JJ, Saman E. Cloning and sequence analysis of a newly identified Brucella abortus gene and serological evaluation of the 17-kilodalton antigen that it encodes. Clinical and diagnostic laboratory immunology. 1995 May; 2(3); 263-7. [PubMed: 7664168 ].

48. High et al., 2007: High KP, Prasad R, Marion CR, Schurig GG, Boyle SM, Sriranganathan N. Outcome and immune responses after Brucella abortus infection in young adult and aged mice. Biogerontology. 2007; 8(5); 583-593. [PubMed: 17653832].

49. Hoover et al., 1999: Hoover DL, Crawford RM, Van De Verg LL, Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Warren RL, Nikolich MP, Hadfield TL. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK). Infection and immunity. 1999; 67(11); 5877-5884. [PubMed: 10531243].

50. Hu et al., 2010: Hu XD, Chen ST, Li JY, Yu DH, Yi-Zhang, Cai H. An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response. Vaccine. 2010; 28(12); 2408-2415. [PubMed: 20064480].

51. Izadjoo et al., 2004: Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M. Infection and immunity. 2004; 72(7); 4031-4039. [PubMed: 15213148].

52. Jacques et al., 2007: Jacques I, Verger JM, Laroucau K, Grayon M, Vizcaino N, Peix A, Cortade F, Carreras F, Guilloteau LA. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep. Vaccine. 2007 Jan 15; 25(5); 794-805. [PubMed: 17070627].

53. Januszewski et al., 2001: Januszewski MC, Olsen SC, McLean RG, Clark L, Rhyan JC. Experimental infection of nontarget species of rodents and birds with Brucella abortus strain RB51 vaccine. Journal of wildlife diseases. 2001; 37(3); 532-537. [PubMed: 11504226].

54. Jensen and Halling, 2008: Jensen AE, Halling SM. Effect of polymyxin B and environmental conditions on isolation of Brucella species and the vaccine strain RB51. Comparative immunology, microbiology and infectious diseases. 2008; ; . [PubMed: 18814911].

55. Jiménez et al., 1994: Jiménez de Bagüés MP, Elzer PH, Jones SM, Blasco JM, Enright FM, Schurig GG, Winter AJ. Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis. Infection and immunity. 1994; 62(11); 4990-4996. [PubMed: 7927779].

56. Kahl-McDonagh and Ficht, 2006: Kahl-McDonagh MM, Ficht TA. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infection and immunity. 2006; 74(7); 4048-4057. [PubMed: 16790778].

57. Kahl-McDonagh et al., 2007: Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infection and immunity. 2007; 75(10); 4923-4932. [PubMed: 17664263].

58. Ko et al., 2002: Ko J, Gendron-Fitzpatrick A, Ficht TA, Splitter GA. Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice. Infection and immunity. 2002; 70(12); 7004-7012. [PubMed: 12438380].

59. Kohler et al., 2002: Kohler S, Foulongne V, Ouahrani-Bettache S, Bourg G, Teyssier J, Ramuz M, Liautard JP. The analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell. Proceedings of the National Academy of Sciences of the United States of America. 2002 Nov 26; 99(24); 15711-6. [PubMed: 12438693 ].

60. Kurar and Splitter, 1997: Kurar E, Splitter GA. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine. 1997; 15(17-18); 1851-1857. [PubMed: 9413093].

61. Laplagne et al., 2004: Laplagne DA, Zylberman V, Ainciart N, Steward MW, Sciutto E, Fossati CA, Goldbaum FA. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins. 2004 Dec 1; 57(4); 820-8. [PubMed: 15390265].

62. Leclerq et al., 2002: Leclerq S, Harms JS, Rosinha GM, Azevedo V, Oliveira SC. Induction of a th1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene. Journal of medical microbiology. 2002; 51(1); 20-26. [PubMed: 11803949].

63. Lee et al., 1999: Lee IK, Olsen SC, Kehrli M, Bolin CA. The adjuvant effect of a single dose of interleukin-12 on murine immune responses to live or killed Brucella abortus strain RB51. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1999; 63(4); 284-287. [PubMed: 10534009].

64. Lee et al., 2001: Lee IK, Olsen SC, Bolin CA. Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2001; 65(4); 223-228. [PubMed: 11768128].

65. Letesson et al., 1997: Letesson JJ, Tibor A, van Eynde G, Wansard V, Weynants V, Denoel P, Saman E. Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay. Clinical and diagnostic laboratory immunology. 1997 Sep; 4(5); 556-64. [PubMed: 9302205].

66. Li, 1991: Li HZ. [A pathohistological study on experimental brucellosis in inbred mice]. Zhonghua bing li xue za zhi Chinese journal of pathology. 1991 Jun; 20(2); 134-6. [PubMed: 1914022 ].

67. Longo et al., 2009: Longo M, Mallardo K, Montagnaro S, De Martino L, Gallo S, Fusco G, Galiero G, Guarino A, Pagnini U, Iovane G. Shedding of Brucella abortus rough mutant strain RB51 in milk of water buffalo (Bubalus bubalis). Preventive veterinary medicine. 2009; 90(1-2); 113-118. [PubMed: 19362381].

68. Luo et al., 2006a: Luo DY, Li P, Xing L, Zhao GY, Shi W, Zhang SL, Wang XL. DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chinese medical journal. 2006 Feb 20; 119(4); 331-4. [PubMed: 16537031].

69. Luo et al., 2006b: Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, Mao L, He Y, Wu Y, Wang X. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infection and immunity. 2006; 74(5); 2734-2741. [PubMed: 16622210].

70. Makar et al., 1975: Makar AB, McMartin KE, Palese M, Tephly TR. Formate assay in body fluids: application in methanol poisoning. Biochemical medicine. 1975; 13(2); 117-126. [PubMed: 1].

71. Mallick et al., 2007: Mallick AI, Singha H, Khan S, Anwar T, Ansari MA, Khalid R, Chaudhuri P, Owais M. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine. 2007; 25(46); 7873-7884. [PubMed: 17931756].

72. Martins et al., 2009: Martins H, Garin-Bastuji B, Lima F, Flor L, Pina Fonseca A, Boinas F. Eradication of bovine brucellosis in the Azores, Portugal-Outcome of a 5-year programme (2002-2007) based on test-and-slaughter and RB51 vaccination. Preventive veterinary medicine. 2009; 90(1-2); 80-89. [PubMed: 19439382].

73. Montaraz et al., 1986: Montaraz JA, Winter AJ. Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice. Infection and immunity. 1986 Aug; 53(2); 245-51. [PubMed: 3089933 ].

74. Moriyon et al., 2004: Moriyon I, Grillo MJ, Monreal D, Gonzalez D, Marin C, Lopez-Goni I, Mainar-Jaime RC, Moreno E, Blasco JM. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Veterinary research. 2004 Jan-Feb; 35(1); 1-38. [PubMed: 15099501].

75. Munoz-Montesino et al., 2004: Munoz-Montesino C, Andrews E, Rivers R, Gonzalez-Smith A, Moraga-Cid G, Folch H, Cespedes S, Onate AA. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infection and immunity. 2004 Apr; 72(4); 2081-7. [PubMed: 15039330].

76. Nol et al., 2009: Nol P, Olsen SC, Rhyan JC. Experimental infection of Richardson's ground squirrels (Spermophilus richardsonii) with attenuated and virulent strains of Brucella abortus. Journal of wildlife diseases. 2009; 45(1); 189-195. [PubMed: 19204348].

77. Oliveira et al., 1994: Oliveira SC, Zhu Y, Splitter G. Sequences of the rplJL operon containing the L10 and L7/L12 genes from Brucella abortus. Gene. 1994 Mar 11; 140(1); 137-8. [PubMed: 8125331 ].

78. Oliveira et al., 1996: Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine. 1996 Jul; 14(10); 959-62. [PubMed: 8873388 ].

79. Olsen et al., 2004: Olsen SC, Rhyan J, Gidlewski T, Goff J, Stoffregen WC. Safety of Brucella abortus strain RB51 in black bears. Journal of wildlife diseases. 2004; 40(3); 429-433. [PubMed: 15465709].

80. Olsen et al., 2007: Olsen SC, Waters WR, Stoffregen WS. An aerosolized Brucella spp. challenge model for laboratory animals. Zoonoses and public health. 2007; 54(8); 281-285. [PubMed: 17894637].

81. Olsen et al., 2009: Olsen SC, Boyle SM, Schurig GG, Sriranganathan NN. Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes. Clinical and vaccine immunology : CVI. 2009; 16(4); 535-540. [PubMed: 19176693].

82. Onate et al., 2003: Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, Folch H, Andrews E. A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infection and immunity. 2003 Sep; 71(9); 4857-61. [PubMed: 12933826].

83. Palmer et al., 1996: Palmer MV, Cheville NF, Tatum FM. Morphometric and histopathologic analysis of lymphoid depletion in murine spleens following infection with Brucella abortus strains 2308 or RB51 or an htrA deletion mutant. Veterinary pathology. 1996; 33(3); 282-289. [PubMed: 8740701].

84. Paranavitana et al., 2005: Paranavitana C, Zelazowska E, Izadjoo M, Hoover D. Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice. Cytokine. 2005; 30(2); 86-92. [PubMed: 15804600].

85. Parent et al., 2007: Parent MA, Goenka R, Murphy E, Levier K, Carreiro N, Golding B, Ferguson G, Roop RM 2nd, Walker GC, Baldwin CL. Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain. Microbes and infection / Institut Pasteur. 2007; 9(1); 55-62. [PubMed: 17196866].

86. Pasquali et al., 2001: Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F. Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection. Infection and immunity. 2001; 69(10); 6541-6544. [PubMed: 11553603].

87. Pasquali et al., 2003: Pasquali P, Rosanna A, Pistoia C, Petrucci P, Ciuchini F. Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. Infection and immunity. 2003; 71(5); 2326-2330. [PubMed: 12704101].

88. Pasquevich et al., 2009: Pasquevich KA, Estein SM, García Samartino C, Zwerdling A, Coria LM, Barrionuevo P, Fossati CA, Giambartolomei GH, Cassataro J. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infection and immunity. 2009; 77(1); 436-445. [PubMed: 18981242].

89. Poester et al., 2006: Poester FP, Gonçalves VS, Paixão TA, Santos RL, Olsen SC, Schurig GG, Lage AP. Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. Vaccine. 2006; 24(25); 5327-5334. [PubMed: 16713034].

90. Rajasekaran et al., 2008: Rajasekaran P, Seleem MN, Contreras A, Purwantini E, Schurig GG, Sriranganathan N, Boyle SM. Brucella abortus strain RB51 leucine auxotroph as an environmentally safe vaccine for plasmid maintenance and antigen overexpression. Applied and environmental microbiology. 2008; 74(22); 7051-7055. [PubMed: 18836016].

91. Ramamoorthy et al., 2007: Ramamoorthy S, Sanakkayala N, Vemulapalli R, Duncan RB, Lindsay DS, Schurig GS, Boyle SM, Kasimanickam R, Sriranganathan N. Prevention of lethal experimental infection of C57BL/6 mice by vaccination with Brucella abortus strain RB51 expressing Neospora caninum antigens. International journal for parasitology. 2007; 37(13); 1521-1529. [PubMed: 17568587].

92. Roop et al., 2004: Roop RM 2nd, Bellaire BH, Valderas MW, Cardelli JA. Adaptation of the Brucellae to their intracellular niche. Molecular microbiology. 2004 May; 52(3); 621-30. [PubMed: 15101970 ].

93. Rosinha et al., 2002a: Rosinha GM, Freitas DA, Miyoshi A, Azevedo V, Campos E, Cravero SL, Rossetti O, Splitter G, Oliveira SC. Identification and characterization of a Brucella abortus ATP-binding cassette transporter homolog to Rhizobium meliloti ExsA and its role in virulence and protection in mice. Infection and immunity. 2002; 70(9); 5036-5044. [PubMed: 12183550].

94. Rosinha et al., 2002b: Rosinha GM, Myioshi A, Azevedo V, Splitter GA, Oliveira SC. Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation. Journal of medical microbiology. 2002; 51(8); 661-671. [PubMed: 12171297].

95. Schurig et al., 1991: Schurig GG, Roop RM 2nd, Bagchi T, Boyle S, Buhrman D, Sriranganathan N. Biological properties of RB51; a stable rough strain of Brucella abortus. Veterinary microbiology. 1991 Jul; 28(2); 171-88. [PubMed: 1908158].

96. Schurig et al., 2002: Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Veterinary microbiology. 2002 Dec 20; 90(1-4); 479-96. [PubMed: 12414166].

97. Sislema-Egas et al., 2012: Sislema-Egas F, CÃ©spedes S, FernÃ¡ndez P, Retamal-DÃaz A, SÃ¡ez D, OÃ±ate A. Evaluation of protective effect of DNA vaccines encoding the BAB1_0263 and BAB1_0278 open reading frames of Brucella abortus in BALB/c mice. Vaccine. 2012; 30(50); 7286-7291. [PubMed: 23026687].

98. Stevens et al., 1994a: Stevens MG, Olsen SC, Pugh GW Jr. Lymphocyte proliferation in response to Brucella abortus 2308 or RB51 antigens in mice infected with strain 2308, RB51, or 19. Infection and immunity. 1994; 62(10); 4659-4663. [PubMed: 7927736].

99. Stevens et al., 1994b: Stevens MG, Olsen SC, Pugh GW Jr, Palmer MV. Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308. Infection and immunity. 1994 Aug; 62(8); 3206-12. [PubMed: 8039890].

100. Stevens et al., 1995a: Stevens MG, Olsen SC, Pugh GW Jr. Comparison of spleen cell proliferation in response to Brucella abortus 2308 lipopolysaccharide or proteins in mice vaccinated with strain 19 or RB51. Infection and immunity. 1995; 63(8); 3199-3205. [PubMed: 7622248].

101. Stevens et al., 1995b: Stevens MG, Olsen SC, Pugh GW Jr, Brees D. Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. Infection and immunity. 1995; 63(1); 264-270. [PubMed: 7806364].

102. Stevens et al., 1996: Stevens MG, Olsen SC, Palmer MV, Pugh GW Jr. Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51. Infection and immunity. 1996; 64(11); 4534-4541. [PubMed: 8890203].

103. Stoffregen et al., 2006: Stoffregen WC, Olsen SC, Bricker BJ. Parenteral vaccination of domestic pigs with Brucella abortus strain RB51. American journal of veterinary research. 2006; 67(10); 1802-1808. [PubMed: 17014337].

104. Suryanarayana et al., 2016: Suryanarayana N, Verma M, Thavachelvam K, Saxena N, Mankere B, Tuteja U, Hmuaka V. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model. Applied microbiology and biotechnology. 2016; 100(19); 8439-8451. [PubMed: 27364624].

105. Tibor et al., 1998: Tibor A, Jacques I, Guilloteau L, Verger JM, Grayon M, Wansard V, Letesson JJ. Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice. Infection and immunity. 1998; 66(11); 5561-5564. [PubMed: 9784574].

106. Tobias et al., 1992: Tobias L, Schurig GG, Cordes DO. Comparative behaviour of Brucella abortus strains 19 and RB51 in the pregnant mouse. Research in veterinary science. 1992; 53(2); 179-183. [PubMed: 1439207].

107. Trant et al., 2010: Trant CG, Lacerda TL, Carvalho NB, Azevedo V, Rosinha GM, Salcedo SP, Gorvel JP, Oliveira SC. The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice. Infection and immunity. 2010; 78(5); 2283-2291. [PubMed: 20194591].

108. Ugalde et al., 2003: Ugalde JE, Comerci DJ, Leguizamón MS, Ugalde RA. Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. Infection and immunity. 2003; 71(11); 6264-6269. [PubMed: 14573645].

109. Velikovsky et al., 2002: Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, Bruno L, Fossati CA, Spitz M. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infection and immunity. 2002 May; 70(5); 2507-11. [PubMed: 11953389 ].

110. Vemulapalli et al., 2000a: Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infection and immunity. 2000 Jun; 68(6); 3286-9. [PubMed: 10816475].

111. Vemulapalli et al., 2000b: Vemulapalli R, He Y, Buccolo LS, Boyle SM, Sriranganathan N, Schurig GG. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. Infection and immunity. 2000 Jul; 68(7); 3927-32. [PubMed: 10858205].

112. Vemulapalli et al., 2004: Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Veterinary microbiology. 2004 Sep 8; 102(3-4); 237-45. [PubMed: 15327798].

113. Wang et al., 2011: Wang Y, Bai Y, Qu Q, Xu J, Chen Y, Zhong Z, Qiu Y, Wang T, Du X, Wang Z, Yu S, Fu S, Yuan J, Zhen Q, Yu Y, Chen Z, Huang L. The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. Veterinary microbiology. 2011; ; . [PubMed: 21530111].

114. Winter et al., 1988: Winter AJ, Rowe GE, Duncan JR, Eis MJ, Widom J, Ganem B, Morein B. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infection and immunity. 1988; 56(11); 2808-2817. [PubMed: 2844673].

115. Winter et al., 1996: Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, Elzer PH, Kopec JD. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. American journal of veterinary research. 1996 May; 57(5); 677-83. [PubMed: 8723881].

116. Xin, 1986: Xin X. Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine. Vaccine. 1986; 4(4); 212-216. [PubMed: 3541425].

117. Yang et al., 2006: Yang X, Becker T, Walters N, Pascual DW. Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge. Infection and immunity. 2006; 74(7); 3874-3879. [PubMed: 16790759].

118. Yang et al., 2007: Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine. 2007; 25(12); 2261-2268. [PubMed: 17239499].

119. Yu et al., 2007: Yu DH, Hu XD, Cai H. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA and cell biology. 2007 Jun; 26(6); 435-43. [PubMed: 17570767].

120. Yu et al., 2007: Yu DH, Li M, Hu XD, Cai H. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine. 2007; 25(37-38); 6744-6754. [PubMed: 17681650].